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Parallel increases in many inflammatory diseases including atopy over the last 40 years suggest 
that  common  environmental  changes  may  be  promoting  inflammatory  immune  responses. 
Modern diets have become increasingly rich in n-6 polyunsaturated fatty acids (PUFAs) and 
relatively  deficient  in  n-3  PUFAs.  These  dietary  changes  are  believed  to  promote  a  pro-
sensitisation,  pro-allergic  and  pro-inflammatory  environment.  Exposure  to  such  an 
environment during pregnancy and in the very early life period is considered to influence 
subsequent patterns of the immature and developing neonatal immune system, and this may 
contribute  to  the  increase  in  allergic  disease  in  early  life.  As  allergic  diseases  often  first 
manifest  in  infancy,  prevention  strategies  need  to  be  targeted  early,  even  in  utero. 
Epidemiologic and experimental data provide a plausible link between dietary changes and 
increased incidence of childhood atopic disease. Although there have been studies examining 
the potential benefits of giving n-3 PUFA-rich fish oil supplements during pregnancy, there are 
no  studies  examining  the  effects  of  increased  consumption  of  oily  fish  in  pregnancy  on 
neonatal immune responses and subsequent clinical outcomes.  
The Salmon in Pregnancy Study (SIPS) is the first randomised controlled trial of oily 
fish intervention during pregnancy. The hypotheses being investigated in SIPS is that increased 
intake of salmon, a source of long chain (LC) n-3 PUFAs (eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA)), in pregnancy will a) increase maternal LC n-3 PUFA intake, b) 
increase maternal and infant blood LC n-3 PUFA status, c) modulate fetal/neonatal immune 
responses and d) lower the risk of infant atopy determined at 6 months of age. The primary 
outcome measures of SIPS were the clinical signs of atopy in the offspring. 
Pregnant women (n=123) at high risk of having atopic offspring, and with low habitual 
intake of oily fish (≤ 2/month) were randomised at 20 weeks of pregnancy to either consuming 
2 portions/week of farmed salmon (n=62) or continuing their habitual diet (n=61) until the end 
of pregnancy. The woman attended a clinic at 20 (n=123), 34 (n=110) and 38 (n=91) weeks of 
gestation at which fasting blood was collected and a food frequency questionnaire (FFQ) was 
administered (at 20 and 34 weeks). At delivery umbilical cord blood was collected (n=101) for 
fatty acid and immunological analysis. Infants attended a clinic at 6 months of age (n=86) for 
assessment of allergic sensitisation by skin prick testing (SPT) using various allergen extracts 
and of atopic dermatitis (SCORAD index). 
Maternal  and  cord  plasma  and  cord  blood  mononuclear  cell  (CBMC)  fatty  acid 
compositions were determined by gas chromatography. Neonatal (cord) immune cell subsets 
were identified by  flow cytometry. Ex-vivo cytokine production by CBMC in response to 
stimulants  (allergen,  mitogen,  and  toll-like  receptor  (TLR)  ligands)  was  determined  by 
cytometric bead array and flow cytometry. Ex-vivo prostaglandin E2 production by CBMC was 
determined  by  enzyme-linked  immunosorbent  assay.  Immunoglobin  E  concentration  was 
measured in cord blood plasma and in 6 month infant blood plasma.  
Eating oily fish twice a week during pregnancy resulted in a higher maternal intake of 
LC n-3 PUFAs (both EPA and DHA) and in higher maternal and cord blood plasma status of 
LC n-3 PUFAs (both EPA and DHA). LC n-3 PUFA content of CBMC was not significantly 
affected. CBMC production of interleukins-2, -4, -5, and -10 and tumour necrosis factor-α was 
lower in the salmon group. There was no effect of salmon on the atopic outcomes assessed at 6 
months.   XIV 
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1  General Introduction   2 
 
1.1  Fatty acids 
1.1.1  Terminology of fats and lipids 
 
Like other organic compounds, all lipids are composed of a carbon skeleton with hydrogen 
and  oxygen  substitutions.  Nitrogen,  sulphur  and  phosphorus  are  also  present  in  some 
lipids. Water insolubility is a characteristic distinguishing most lipids from proteins and 
carbohydrates. There are some exceptions to this general rule, since short- to medium- 
chain fatty acids, soaps, and some complex lipids are soluble in water.  There are four 
general categories of lipids: simple, complex, derived and miscellaneous (1). Simple lipids 
are  esters  of  fatty  acids  with  various  alcohols.  They  include  triglycerides,  waxes, 
cholesteryl esters and vitamin A and D esters. Complex lipids are esters of fatty acids in 
combination with both alcohols and other groups. They include phospholipids, glycolipids, 
lipoproteins and lipopolysaccharides. Derived lipids are hydrolysis products of simple or 
compound lipids, including fatty acids, monoglycerides and diglycerides, straight-chain 
and ring-containing alcohols, sterols and steroids. Miscellaneous lipids include some wax 
lipids, carotenoids, vitamins E and K (1).  
 
Table 1.1: Classification of lipids (1) 
 
LIPID CATEGORY  EXAMPLES 
Simple (Fatty acids esterified with alcohols)  .  Fats (fatty acids esterified with glycerol) 
.  Waxes (true waxes, sterol esters, vitamin A and D esters) 
Complex (Fatty acids esterified with alcohols plus other groups) 
.  Phospholipids (contain phosphoric acid and usually a 
nitrogenous base) 
.  Glycolipids (lipids containing a carbohydrate and nitrogen 
but no phosphate and no glycerol) 
.  Sulpholipids (lipids containing a sulphur group) 
.  Lipopoteins (lipids attached to plasma or other proteins) 
.  Lipopolysaccharides (lipids attached to polysaccharides) 
Derived (obtained by hydrolysis of simple or complex lipids) 
.  Fatty acids (saturated, monounsaturated or polyunsaturated) 
.  Monoglycerides and diglycerides 
.  Alcohols (include sterols, steroids, vitamin A and D) 
Miscellaneous 
.  Straight chain hydrocarbons 
.  Carotenoids 
.  Squalene 
.  Vitamins E and K   3 
 
1.1.2  Structure and types of fatty acids 
Saturated and unsaturated fatty acids 
The main components of dietary lipids are fatty acids which may vary in length from one 
to greater than thirty carbons. They are carboxylic acids with the structure RCOOH, where 
R is hydrogen in formic acid, CH3 in acetic acid, or else a chain of one to over thirty CH2 
groups terminated by a CH3 group.  
Fatty acids having their full complement of hydrogen atoms are termed saturated. These 
usually  exist  as  straight  chains.  The  most  abundant  saturated  fatty  acid  (SFA)  in  the 
context of the human diet is palmitic acid, a 16-carbon fatty acid. 
If two hydrogen atoms are removed from the chain, a carbon-to-carbon double bond or 
point of unsaturation is created and the molecule bends. This bending causes the molecule 
to occupy more space and become more fluid. The presence of one or more double bonds 
in  a  fatty  acid  defines  it  as  unsaturated.  Fatty  acids  with  one  double  bond  are  called 
monounsaturated. The most common monounsaturated fatty acid (MUFA) is oleic acid, an 
18-carbon  fatty  acid  with  its  double  bond  nine  carbons  from  the  methyl  end  of  the 
hydrocarbon  chain  (Table  1.2).  Oleic  acid  is  the  major  fatty  acid  in  olive  oil. 
Polyunsaturated fatty acids (PUFAs) have two or more double bonds and include both 
omega-6 and omega-3 families. For example, linoleic acid (LA) is an 18-carbon omega-6 
fatty acid, with two double bonds. It is abundant in plants and seed oils. Its counterpart in 
the  omega-3  family  is  alpha-linolenic  acid  (ALA),  an  18-carbon  fatty  acid  with  three 
double bonds, also found in plant lipids and oils.  
1.1.3  Physicochemical properties of fatty acids 
In general, SFAs have a higher melting point than unsaturated fatty acids, and unsaturated 
fatty acids with a greater degree of unsaturation have a lower melting point than those with 
fewer double bonds. Also, fatty acids with a longer hydrocarbon chain usually have a 
higher melting point. Therefore, PUFAs are usually more easily liquefied than SFAs or 
MUFAs.  Unsaturation  results  in  structural  variety  in  fatty  acids  and  allows  for 
isomerisation. A SFA occupies, in general, less space than an unsaturated fatty acid of the 
same length. This is because the insertion of double bonds increases the curvature of the 
unsaturated fatty acid causing it to occupy a greater area. When the two hydrogens at the 
double bond are on the same side of the molecule the bond is termed cis-unsaturated and 
when the hydrogens are on the opposite side of the double bond the bond is termed trans-  4 
unsaturated. This leads to different orientation of the adjoining carbons across the double 
bond. A cis-fatty acid molecule has a curved structure whereas a trans-fatty acid does not. 
Thereby the physicochemical properties of a trans-fatty acid are closer to those of a SFA. 
Lastly, most naturally occurring PUFAs have a methylene (CH2) group between the two 
double bonds. This methylene interruption of the double bonds can be lost when bonds 
move  one  carbon  closer  as  a  result  of  food  processing.  These  isomers  are  termed 
conjugated.  
1.1.4  Nomenclature of fatty acids 
Individual fatty acids have both common and systematic names, as well as a shorthand 
notation that reflects the number of carbons, the number of double bonds and the position 
of the first double bond from the methyl-terminus. Because of the methylene interruption 
of the double bonds in PUFAs, the position of the rest of the double bonds is assumed and 
not referred to in the shorthand notation. The n- notation is also referred to as ω or omega. 
For example, the shorthand notation 18:1n-9 refers to the common MUFA oleic acid which 
has 18 carbons and one double bond at the ninth carbon from the methyl-terminus. Table 
1.2 presents the nomenclature and sources of common fatty acids and Figure 1.1 shows the 
chemical structures of selected PUFAs.   5 
 
Table 1.2: Fatty acid nomenclature and sources (2) 
 
SYSTEMATIC NAME  COMMON NAME  SHORTHAND 
NOTATION 
SOURCES 
Saturated fatty acids 
.  Dodecanoic  .  Lauric  .  12:0  .  Coconut oil,  milk 
.  Tetradecanoic  .  Myristic  .  14:0  .  Coconut oil, milk 
.  Hexadecanoic  .  Palmitic  .  16:0  .  Milk, eggs, animal fats, meat, 
fish, some vegetable oils (e.g. 
palm oil) 
.  Octadecanoic  .  Stearic  .  18:0  .  Milk, eggs, animal fats, meat, 
cocoa butter 
Monounsaturated fatty acids 
.  9-Hexadecanoic  .  Palmitoleic  .  16:1n-7  .  Animal fats, vegetable oils, fish, 
fish oils 
.  9-Octadecanoic  .  Oleic  .  18:1n-9  .  Animal fats, olive oil 
Polyunsaturated fatty acids 




.  α-Linolenic  .  18:3n-3  .  Vegetable oils, seeds, nuts, green 
leaves 
.  6,9,12-Octadecatrienoic  .  γ-Linolenic  .  18:3n-6  .  Synthesised from linoleic acid, 
evening primrose oil 
.  5,8,11-Eicosatrienoic  .  Mead  .  20:3n-9  .  Synthesised from oleic acid 
.  8,11,14-Eicosatrienoic  .  Dihomo-γ-linolenic  .  20:3n-6  .  Synthesised from linoleic acid 
.  5,8,11,14-
Eicosatetraenoic  
.  Arachidonic  .  20:4n-6  .  Synthesised from linoleic acid, 
eggs, meat, marine algae 
.  5,8,11,14,17-
Eicosapentaenoic 
.  Eicosapentaenoic  .  20:5n-3  .  Fish, fish oils, marine algae 
.  4,7,10,13,16,19-
Docosapentaenoic 
.  Docosapentaenoic  .  22:5n-3  .  Fish, fish oils, marine algae 
.  4,7,10,13,16,19-
Docosahexaenoic 
.  Docosahexaenoic  .  22:6n-3  .  Fish, fish oils, marine algae   6 
  
 
Figure 1.1: Chemical structures of linoleic acid (LA), alpha-linolenic acid (ALA), arachidonic acid 
(ARA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (3) 
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1.1.5  Long-chain PUFAs - Essential fatty acids - Sources 
By definition, long-chain PUFAs (LC PUFAs) are those with 20 or more carbon atoms; the 
precursor fatty acids, LA and ALA are not included when using this term. The major LC 
PUFAs of the n-6 family are arachidonic acid (ARA; 20:4n-6) and docosapentaenoic acid 
(22:5n-6).  The  latter  accumulates  in  brain  and  retinal  membranes  when  n-3 
docosahexaenoic acid (DHA; 22:6n-3) is inadequate, as happens in ALA deficiency. Both 
LC n-6 PUFAs are synthesized from linoleic acid.  
In the n-3 family, the major LC PUFAs are eicosapentaenoic acid (EPA; 20:5n-3) and 
DHA. Both are synthesized from ALA. EPA and DHA can be interconverted in the body 
via another fatty acid, docosapentaenoic acid (DPA; 22:5n-3).  
By definition, essential fatty acids (EFAs) cannot be synthesized in the body, and because 
they are required for optimal health, must be obtained from the diet. In classical nutrition, a 
nutrient  is  considered  essential  if  its  removal  from  the  diet  leads  to  symptoms  of 
deficiency, which often include impaired growth, development and immune function. LA 
is considered essential because its absence from the diet is associated with the loss of 
dermal integrity (4), as it is an essential component of complex lipids, sphingolipids, in 
skin (5;6). LA deficiency is associated with lower growth and reduced tissue accumulation 
of ARA. LA is also essential as the precursor of ARA (Figure 1.2), which is important in 
brain  development  and  function  and  as  a  precursor  for  the  production  of  eicosanoids, 
which are potent regulatory substances. LA is widespread in plants and seed oils, whereas 
ARA is found mainly in meats, egg yolk, and some fish.  
 
Scientific consensus on the question of the essentiality of n-3 fatty acids was achieved 
recently. Initially, because ALA did not fully ameliorate the symptoms of EFA deficiency 
in laboratory animals, it was not considered an EFA. Studies by Bjerve et al. in Europe and 
Holman  et  al.  in  the  U.S.  provided  evidence  for  the  essentiality  of  n-3  fatty  acids  in 
humans, although deficiency experiments in people cannot be undertaken (7;8). ALA is 
considered essential as it is the precursor of DHA; a vital fatty acid in the structural lipids 
of  brain  and  other  nervous  tissues  (Figure  1.2).  Cunnane  (9)  and  Carlson  (10)  have 
suggested  that  DHA  be  considered  as  a  "conditionally  essential  nutrient"  in  human 
nutrition because its production from ALA may be inadequate to meet needs for brain 
growth in early human development and it confers some functional benefit even when 
ALA is present in the diet. For this reason, provision of preformed DHA is considered   8 
optimal, especially early in life. Both DHA and ARA are present in breast milk and in 
many infant formulas in developed countries. ALA is found in plants, particularly flax seed 
and oil, canola and soybean oils, and English walnuts. It is also abundant in perilla seeds 
and oils and in purslane, a vegetable used in the Middle East. DHA, while present in all 
fish, is found in abundance in fatty fish such as salmon, tuna, trout, sardines, and mackerel 
(1). The dietary sources of n-3 and n-6 PUFAs are summarised in section 1.1.6. 
 
  




Figure 1.2 shows the metabolic steps (desaturation plus elongation reactions) by which LA 
is converted to ARA and by which ALA is converted to EPA and DHA. Further details on 
fatty acid metabolism are given in later sections. It is noted in Figure 1.2 that elevations of 
EPA and DHA in human cells and tissues can be readily provided for by the direct dietary 
consumption of EPA and DHA (11). Unlike LA, which is present at considerable levels in 
most cellular lipids (particularly membrane phospholipids) throughout various tissues and 
cells,  ALA  does  not  usually  accumulate  to  particularly  high  concentrations  in 
cellular/tissue lipids/phospholipids even when ingested at relatively high dietary levels. 
This  is  partly  due  to  the  fact  that  much  of  the  ALA  which  is  consumed  in  the  diet 
undergoes beta oxidation in the mitochondria and only a limited amount is available for the   9 
very limited conversion to EPA plus DHA (11). Figure 1.2 also indicates that dietary DHA 
has the potential to undergo some reverse metabolism (retroconversion) back to EPA.  
1.1.6  Dietary Sources of n-3 and n-6 PUFAs 
Table 1.3 and Table 1.4 show the contents of LA and ALA in nuts, seeds and oils and of 
various  fatty  acids  in  fish  and  fish  products,  respectively.  LA  is  found  in  abundance 
vegetable  oils  (corn,  safflower,  sunflower,  soybean),  some  which  contain  significant 
amounts of ALA (Table 1.3). The LC n-3 PUFAs EPA and DHA are found in oily fish and 
fish oils  (12;13). White fish, like cod, have flesh  that is  very low in  fat  as  these fish 
accumulate fat in their liver. Oily fish have fat in their flesh and its amount is related to 
their breeding cycle. After breeding the fat content falls significantly. Oily fish contain 5-
20% fat as opposed to white fish which contain only 1-2% fat. Oily fish include sardines, 
salmon, pilchards, mackerel, herring, and trout, whether fresh, frozen or canned. Fresh tuna 
is also included, but unlike other canned oily fish, canned tuna is not considered as oily, 
because the processing of tuna during canning reduces its fat content to the levels of non-
oily/white fish (Table 1.4). 
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Table 1.3: LA and ALA contents of selected nuts, seeds and oils (14) 
 
FOOD 
POLYUNSATURATED FATTY ACIDS 
(G PER 100 G TOTAL FATTY ACIDS)
1 
α-Linolenic acid 
 (ALA; 18:3n-3) 
Linoleic acid  
(LA; 18:2n-6) 
Nuts and Seeds 
.  Almonds  0.27  10.19 
.  Brazil nuts  0  25.43 
.  Hazelnuts  0.12  6.50 
.  Peanuts  0.35  12.75 
.  Poppy seeds  0.45  27.20 
.  Pumpkin seeds  0.13  21.58 
.  Sesame seeds  0.15  25.35 
.  Sunflower seeds  0.09  28.06 
.  Walnuts  7.47  39.29 
Vegetable/Plant Oils 
.  Corn oil  0.90  50.40 
.  Evening primrose oil  0.12  68.81 
.  Peanut oil  0  31.00 
.  Rapeseed oil  9.60  19.70 
.  Safflower oil  0.10  73.90 
.  Sesame oil  0.30  43.10 
.  Soya oil  7.30  51.50 
.  Sunflower oil  0.10  63.20 
.  Walnut oil  11.5  58.40   11 
Table 1.4: Total fat, SFA, MUFA and PUFA content of fish and fish products (12;13) 
 
  TOTAL FAT, SATURATED, MONOUNSATURATED AND POLYUNSATURATED FATTY ACIDS (G PER 100 G) 
Food  Total 



















Cod, raw  0.7  0.13  0.08  0.28  0.02  0.26  Tr  0.02  Tr  0.08  0.16 
Haddock, raw  0.6  0.12  0.09  0.20  0.03  0.17  0.01  0.01  Tr  0.05  0.10 
Plaice, raw  1.4  0.23  0.39  0.35  0.01  0.32  0  0  0  0.16  0.10 
Sea Bass, raw  2.5  0.4  0.6  0.6  0.1  0.5  Tr  Tr  0  0.1  0.4 
Fatty fish 
Eel, jellied   7.1  1.89  3.50  0.96  0.32  0.64  0.15  0.10  0.12  0.19  0.15 
Herring, raw  13.2  3.65  5.98  2.17  0.32  1.83  0.29  0.04  0.18  0.51  0.69 
Kippers, raw  17.7  2.76  9.26  3.86  0.24  3.52  0.18  0.03  0.24  1.15  1.34 
Mackerel, raw  16.1  3.23  7.87  3.27  0.51  2.78  0.30  0.07  0.22  0.71  1.10 
Pilchards, canned in tomato   8.1  1.71  2.22  3.36  0.28  2.97  0.12  0.07  0.07  1.17  1.20 
Salmon, raw  11.0  1.9  4.4  3.1  0.5  2.4  0.3  0.2  0.2  0.5  1.3 
Salmon, canned in brine   7.8  1.38  3.29  2.24  0.27  1.85  0.13  0.11  0.08  0.55  0.86 
Sardines,  raw   9.2  2.7  2.5  2.7  0.2  2.2  0.1  0.1  0.1  0.9  1.1 
Sardines, canned in tomato   9.9  2.79  2.90  3.22  1.04  2.11  0.96  0.04  0.16  0.89  0.68 
Sprats, raw  11.0  2.15  4.67  3.04  0.31  2.68  0.11  0.07  0.08  0.93  1.35 
Trout, rainbow, raw   5.2  1.1  1.85  1.73  0.41  1.32  0.34  0.03  0.06  0.23  0.83 
Tuna, raw   4.6  1.2  1.2  1.6  0.2  1.5  0.1  0.1  0  0.3  1.1 
Tuna, canned in brine   0.6  0.23  0.10  0.21  0.04  0.17  0.01  0.02  0  0.02  0.14 
Crustacea and mollluscs 
Crab, boiled  5.5  0.68  1.55  1.36  0.24  1.10  0.02  0.12  0.02  0.47  0.45 
Mussels, boiled  2.7  0.52  0.40  0.76  0.08  0.68  0.02  0.05  0.02  0.41  0.16 
Oysters, raw  1.3  0.26  0.14  0.41  0.05  0.37  0.02  0.01  0.01  0.14  0.16 
Prawns, frozen, raw  0.6  0.13  0.15  0.13  0.03  0.11  0.01  0.01  0  0.06  0.04 
Squid, raw  1.7  0.35  0.22  0.61  0.16  0.45  0.12  0.01  0  0.13  0.29 
Fish products and dishes 
Fish cakes, frozen, raw   3.9  0.59  1.43  0.93  0.60  0.33  0.58  0.01  0.18  0.05  0.09 
Fish fingers cod, frozen, raw   7.8  1.81  1.99  1.38  1.28  0.17  1.21  0  0.10  0.04  0.03 
Roe, cod, raw   1.9  0.41  0.37  0.55  0.05  0.49  0.02  0.04  0.01  0.16  0.30 
Scampi, breaded, cooked   0.9  0.07  0.34  0.20  0.14  0.06  0.14  0  0.06  0  0 
Taramasalata  52.9  3.90  27.71  15.14  10.81  5.00  10.52  0  4.43  0.14  0 
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1.1.7  Triglycerides and triglyceride metabolism  
Fatty  acids  are  rarely  found  “free”  in  the  body.  They  are  most  commonly  found  as 
components  of  triglycerides  (TAGs)  also  known  as  triacylglycerols.  TAGs  are  three-
carbon alcohols to which are attached three fatty acids as esters (Figure 1.3). 
 
Figure 1.3: Triglyceride structure 
 
In vegetable oils, PUFAs are most frequently found in positions one and three in the TAG. 
In fish oils and animal fats, the LC PUFAs are usually located in the central sn-2 position. 
TAGs are the storage form of fatty acids in adipose tissue, food fats, and oils. In order to 
be digested in the gut they need to be emulsified or made soluble, then hydrolysed to 
remove the fatty acids from the glycerol backbone. Emulsification is accomplished in the 
small intestine by bile salts, while cleavage of the fatty acids is achieved by the action of 
the enzyme pancreatic lipase, also released into the intestine. Pancreatic lipase removes 
fatty acids from the 1 and 3 positions to generate free fatty acids and a TAG remnant with 
one fatty acid in the 2-position, a monoglyceride (2-acylglycerol). Monoglycerides may be 
further broken down by the enzyme phospholipase A2 into free fatty acids and glycerol. 
Fatty acids and monoglycerides form complexes with bile salts called micelles, which are 
absorbed passively into the intestinal cell or enterocyte. Once inside the enterocyte, fatty 
acids  are  re-esterified  into  TAGs  and  packaged  with  cholesterol,  phospholipods  and 
proteins in a type of lipoprotein called chylomicrons. These large complexes are released 
into the lymph system and then into the blood circulation. Certain free fatty acids are also 
transported directly to the liver via the portal vein.  
Once in the blood stream, chylomicrons acquire additional proteins and interact with the 
enzyme lipoprotein lipase found in endothelial cells lining the blood vessels. This enzyme 
removes some of the fatty acids, which are then taken up by tissues and resynthesized into 
TAGs for storage, export, oxidation, or further metabolism. The chylomicron remnants and   13 
glycerol backbone are removed by the liver, while the remaining lipids and proteins are 
transferred to high density lipoproteins in the blood.  
The liver is a primary site for fatty acid metabolism. Fatty acids are removed from the 
circulation,  synthesized  into  TAGs,  and  packaged  with  proteins,  cholesterol,  and  other 
lipids  into  very  low  density  lipoproteins  (VLDLs).  Released  back  into  the  circulation, 
VLDLs are the primary vehicle for delivering TAGs to tissues, particularly adipose tissue 
and skeletal muscle. In the circulation, TAGs are removed from VLDLs through the action 
of  the  enzyme  lipoprotein  lipase,  leaving  intermediate-sized  particles  and  low  density 
lipoproteins (LDLs) as products. LDLs are rich in cholesterol which is made available for 
membrane structure and intracellular storage (1).  
 
1.1.8  Fatty Acid Metabolism 
Fatty acid metabolism is a complex combination of different pathways which act to derive 
energy  from  the  fatty  acids  via  oxidation  or  to  convert  the  fatty  acids  into  active 
derivatives.  
Β-oxidation is the process by which fatty acids are utilized for energy generation and 
occurs largely within mitochondria. B-oxidation of SFAs appears to be simpler than that of 
unsaturated  fatty  acids.  However,  abundant  in  vivo  and  in  vitro  research  shows  that 
unsaturated fatty acids with one to three double bonds are more readily β-oxidised than 
SFAs of equivalent chain length (1).  
Ketogenesis and ketosis: Large amounts of fatty acids inhibit glycolysis and thereby the 
production of oxaloacetate in the Krebs Cycle. This situation favours the production of 
ketones (acetoacetate and acetone) from fatty acids. When glucose is limiting, ketones are 
an alternative source of energy for certain organs, particularly the brain. They are also 
efficient substrates for lipid synthesis during early postnatal development.  
Carbon recycling and peroxidation: Carbon recycling (i.e. conversion of fatty acids to 
other fatty acids via simple units such as acetate) appears to be a ubiquitous feature of the 
metabolism of PUFAs, although its biological significance is still unclear (1). PUFAs are 
particularly vulnerable to peroxidation (autooxidation) at the double bonds. This process 
can produce free radicals which abstract further hydrogens from the same or different fatty 
acids and propagate the peroxidation process. Peroxidation of PUFAs is a potential hazard 
facing  lipoproteins,  membranes  and  dietary  lipids.  Antioxidants  such  as  vitamin  E  are   14 
usually present in sufficient amounts to prevent or block peroxidation in living cells and 
tissues.  However  lipid  peroxidation  is  an  important  part  of  many  necessary  biological 
processes such as activating the immune response. 
Desaturation, chain elongation and shortening: Desaturation is the insertion of a double 
bond into a fatty acid chain. Elongation is the extension of the carbon chain (usually by 
two carbon units), while shortening is the opposite. 
Hydrogenation:  This  is  opposite  to  the  desaturation  process  i.e.  it  is  the  removal  of 
unsaturated bonds in lipids. 
Eicosanoid synthesis: Eicosanoids are a family of highly active substances derived from 
ARA, dihomo-γ-linolenic acid or EPA that affect immune and inflammatory responses, 
amongst other processes. They include prostaglandins (PGs), thromboxanes (TXs), and 
leukotrienes  (LTs).  Eicosanoids  are  considered  to  be  fast-acting  local  hormones,  the 
presence of which in the plasma and urine is largely a spillover from localized production, 
in response to an injury, or a stimulus that releases the free precursor, most commonly, 
ARA. Those made from ARA are generally pro-inflammatory, whereas those from EPA 
are less inflammatory or may even be anti-inflammatory. Four important characteristics of 
eicosanoid  action  should  be  noted.  Firstly,  individual  eicosanoids  often  have  biphasic 
actions. Secondly, several abundant eicosanoids that arise from the same precursor fatty 
acid (i.e. ARA) have opposite actions to each other. Thirdly, eicosanoids derived from 
dihomo-γ-linolenic acid and from EPA often have effects that oppose those derived from 
ARA. Fourthly, varying the ratio of the precursor fatty acid in the diet is an effective way 
to modulate eicosanoid production (1). 
1.1.9  Metabolic fate of LA, ALA, and LC n-3 PUFAs 
 
As described earlier, LA and ALA can be elongated and desaturated to form the long-chain 
derivatives ARA, and EPA and DHA, respectively (Figure 1.4). Conversion of LA to ARA 
occurs more readily than that of ALA to DHA.    15 
 
 
Figure 1.4: Metabolic competition between n-3 and n-6 fatty acids (15) 
Most ALA and much LA is consumed in energy production via -oxidation.
 More than 
80% of dietary ALA may be used by this pathway (16). As a result, little ALA remains for 
conversion to long-chain derivatives and synthesis into other fatty acids and lipids.  
LC PUFAs have several destinies in vivo: 
- Incorporation into phospholipids in membranes  
- Eicosanoid synthesis – conversion to prostaglandins, thromboxanes, leukotrienes 
- Oxidation to provide energy 
- Incorporation into TAG and tissue storage.  
Using isotope tracer and other methods, Cunnane's laboratory has shown that membrane 
lipids in brain and liver preferentially use exogenous or dietary LC PUFAs rather than 
those  produced  endogenously  (16).  ARA  not  incorporated  into  membranes  may  be 
consumed by eicosanoid metabolism which requires a readily available supply at all times 
(16). 
LC PUFAs are present in cell membrane phospholipids and are stored in small amounts in 
TAG in  adipose tissue.  LA  and ALA in  adipose tissue have been used as  markers of 
dietary intake (17).   16 
As structural components of membranes, ARA, EPA and DHA influence the functional 
characteristics  of  certain  tissues,  particularly  neural  and  immune  tissues.  For  example, 
DHA is highly concentrated in the outer segment of the rods in the retina of the eye. The 
presence of DHA is related to light activation and visual processing (18). ARA is the major 
precursor  for  the  synthesis  of  eicosanoids  involved  in  platelet  aggregation,  T-cell 
proliferation,  lymphocyte  migration,  vasoconstriction  and  dilation,  and  inflammatory 
processes (19;20). In the presence of EPA, alternative eicosanoids can also be produced, 
and these attenuate or inhibit the action of the ARA-derived eicosanoids. Those derived 
from EPA also have weaker biological activity than those from ARA. Competition from n-
3 fatty acids for the same eicosanoid synthesizing enzymes may reduce the production of 
ARA-derived eicosanoids. Thus, the presence of EPA can moderate the production and 
activity  of  ARA-derived  eicosanoids.  It  is  believed  by  some  researchers  that  the 
predominance of eicosanoids derived from ARA contributes to the development of several 
chronic human diseases, including heart disease (21;22). 
1.1.10  Nutritional regulation of long-chain fatty acid profiles 
Phospholipids of all cellular and subcellular membranes contain a diverse range of long-
chain fatty acids, the profile of which is subject to both dietary influence and endogenous 
control. Usually, the fatty acid profile of most organs is responsive to changes in dietary 
fatty acid composition and other nutritional variables. When changes in dietary fat change 
fatty acid profiles, appropriate membrane fluidity can be maintained by the addition or 
removal of other lipids such as cholesterol. Insufficient energy intake and the presence of 
disease  have  important  consequences  for  fatty  acid  synthesis,  desaturation  and  chain 
elongation and eventually tissue fatty acid profiles (1). 
1.1.11  LC n-3 PUFA intakes, recommended intakes & 
contaminants 
 
Typical  daily  intakes  of  EPA  plus  DHA  in  adult  individuals  in  the  UK  who  do  not 
regularly consume either oily fish or fish oil capsules are quoted as less that 0.25 g (23). 
One  portion/serving  of  oily  fish  (140  g)  such  as  salmon,  trout,  pilchards,  sardines, 
mackerel or kippers will provide between 1.5 g and 3.5 g EPA plus DHA (24;25). Data 
from the last National Diet and Nutrition Survey (26) of adults aged 19-64 years showed 
that most people in UK consume very little fish. Mean consumption of white fish per week 
was 103 g and of oily fish 50 g per week (23). This low intake of fish explains the low 
intake of EPA plus DHA. Data (27) from the Australian National Nutrition Survey in 1995 
showed that the average daily intakes of EPA and DHA acids were 0.056 and 0.106 g,   17 
respectively, and LC n-3 PUFA intake (EPA plus DPA plus DHA) was 0.189 g, similar to 
the above data for the UK. However, median intakes were considerably lower (0.008 g 
EPA, 0.015 g DHA, and 0.029 g LC n-3 PUFA) (27). Thus 50% of the adult Australian 
population was consuming < 0.03 g LC n-3 PUFA/day. Similar low intakes seem likely in 
the UK. 
 
Recommended intakes for n-3 PUFAs are not uniform. In 2000, Simopoulos recommended 
a daily intake for EPA plus DHA of 650 mg, with at least 222 mg for both EPA and DHA, 
and 2.22 g/d for ALA (28). The American Heart Association recommends adults to eat fish 
(in particular fatty fish) at least two times per week (29). The guidelines proposed by the 
US Food and Nutrition Board established adequate intakes for ALA at 1.6 g/d and 1.1 g/d 
for adult men and women, respectively, and that EPA plus DHA could account for up to 
10% of the total n-3 fatty acid intake as a contribution toward the adequate intake for ALA 
(30). 
 
Current UK recommendations by the Scientific Advisory Committee on Nutrition (SACN) 
propose that people should eat at least 2 portions of fish, of which one should be oily, per 
week and agree that this recommendation should also apply to pregnant women (23). This 
was equated to a daily intake of at least 450 mg of LC n-3 PUFAs. There are several 
published recommendations concerning the intake of n-3 fatty acids during pregnancy and 
lactation  listed  below.  Dietary  Reference  Intakes  (DRI)  suggest  that  the  recommended 
daily dosage for ALA be 1.4 g/day for pregnant women and 1.3 g/day for lactating women 
(31)  and  recommend  a  DHA  dosage  of  100  mg/day  (plus  50-60  mg/day  in  the  third 
trimester)  in  pregnant  women;  Makrides  &  Gibson  (32)  suggest  an  intake  of  LC  n-3 
PUFAs of 0.2-0.4 g/day in pregnant and lactating women; European Food Safety Authority 
(EFSA) suggests intake of 250 mg/day DHA during pregnancy and lactation (33).  
 
Despite fish being the best source of preformed LC n-3 PUFAs, because of concern about 
contaminants such as methylmercury, dioxins and dioxin like PCBs in some species of oily 
fish, the UK Foods Standards Agency (FSA) has advised that pregnant women, women 
intending to  become pregnant  and girls under 16  years old  should avoid  eating shark, 
marlin  and  swordfish  (21).  The  Committee  on  Toxicology  advises  that  women  of 
reproductive age and girls should aim to consume within the range of one to two portions 
of oily fish per week, based on maintaining consumption of dioxins and dioxin like PCBs 
below the TDI of 2 pg WHO-TEQ/kg bodyweight per day (21). Women past reproductive 
age, boys and men should aim to consume within the range of one to four portions of oily   18 
fish a week, based on maintaining consumption of dioxins and dioxin-like PCBs below the 
guideline value of 8 pg WHO-TEQ/kg bodyweight per day (23). 
 
The demand for LC PUFAs for the development of the mammalian brain is high (34). 
Preformed LC PUFAs, particularly DHA, but also EPA, may need to be provided in the 
diets of infants to meet the high requirements of rapidly growing tissues and organs (23). 
The mother is the primary source of these fatty acids for the fetus and breast-fed infant. 
 
According to data reviewed by the Scientific Advisory Committee on Nutrition in 2004 
(23), there is some evidence that for many women there is a marginal status for LC n-3 
PUFAs during pregnancy and lactation. However, there is a lack of agreed markers which 
are  suitable  for  defining  LC  n-3  PUFA  status.  The  markers  usually  reported  relate  to 
concentrations of fatty acids within the circulation. They may be expressed as a percentage 
of  total  fatty  acids  or  as  their  absolute  concentrations  in  different  circulating  pools. 
Concentrations of fatty acids in maternal or umbilical blood have been used as measures of 
LC n-3 PUFA status during pregnancy. These measures have been related to maternal 
dietary intake (35) and to pregnancy outcomes (gestation duration, infant growth) (36-39). 
What is more, during pregnancy a woman must also meet the additional demands related to 
the accretion of maternal, placental, and fetal tissues. Although, the formation of DHA and 
EPA appears to be tightly regulated, a marginal state for many women during pregnancy 
and lactation cannot be excluded. The additional demands for EPA and DHA or other fatty 
acids during a normal pregnancy have not been adequately defined. It was concluded that 
the extent of dietary dependence on increased levels of consumption of n-3 PUFAs, or 
specifically DHA, to improve pregnancy outcome needs to be demonstrated (23). 
 
Since eating fish is advised, but fish are also a source of contaminants, aquaculture of 
fish  to  have  low  contaminant  levels  could  be  an  ideal  solution  to  enable  oily  fish 
consumption by pregnant women and possibly the intake of the recommended amounts 
of LC n-3 PUFAs without the concern about contaminants. In this way, consumption of 
tailor-made salmon by pregnant women could prevent the depletion of the mother and 
could improve fetal and neonatal status of EPA and DHA.    19 
 
1.2  Immune system 
 
The role of the immune system is to achieve a balance between “protection against 
threats”  including  infectious  agents  that  exist  in  the  environment  (bacteria,  viruses, 
fungi,  parasites)  and  other  noxious  insults  and  maintaining  “tolerance  to  harmless 
things” such as “self” proteins and cells and harmless environmental factors, including 
those  from  the  diet.  The  following  sections  will  give  an  overview  of  the  key 
components of the immune system, and more specifically the immunology of the atopic 
disease and how the environment encountered during pregnancy and fetal life may play 
a role in the predisposition to atopy (40). 
 
1.2.1  Innate immunity 
 
The  immune  system  has  two  functional  divisions:  the  innate  (or  natural)  immune 
system and the acquired (specific or adaptive) immune system. The immune response, 
in most cases requires the coordination of the two types of immunity. All cells of the 
immune system originate in the bone marrow and result from the differentiation of stem 
cells (41;42). 
 
Innate  immunity  consists  of  physical  barriers  (skin,  mucous  membranes,  lysozyme, 
stomach acid, commensal bacteria), soluble mediators (macrophage derived cytokines), 
circulating  molecules  (complement),  phagocytic  cells  which  include  granulocytes 
(neutrophils,  basophils,  eosinophils),  monocytes  and  macrophages  and  natural  killer 
cells.  Innate immunity  has  no memory and is  therefore not  influenced by the prior 
exposure to an antigen-bearing organism (43). Phagocytic cells, the main effectors of 
innate  immunity,  express  surface  receptors  specific  for  bacterial  surface  structures. 
Binding of microbes to these receptors triggers phagocytosis and subsequent destruction 
of  the  pathogenic  microorganism  by  complement  or  by  toxic  chemicals,  such  as 
superoxide  radicals  and  hydrogen  peroxide  (44).  Bacterial  lipopolysaccaride  (LPS; 
known also as endotoxin) is an important exogenous trigger. LPS is a component of the 
cell wall of gram-negative bacteria. Natural killer cells also possess surface receptors 
and destroy pathogens by the release of cytotoxic proteins  (45). In this way, innate 
immunity provides a first line of defense against invading pathogens (40). 
   20 
1.2.2  Acquired immunity 
 
This type of immunity involves the specific recognition of antigens on an invading 
pathogen  which  distinguish  it  as  being  foreign  to  the  host.  The  components  of  the 
acquired immune immune system also consist of physicochemical barriers (cutaneous 
and  mucosal  immune  systems,  antibodies  in  mucosal  secretions),  soluble  mediators 
(lymphocyte  derived  cytokines),  circulating  molecules  (antibodies)  and  cells 
(lymphocytes). Lymphocytes, which are subdivided into T- and B-lymphocytes, effect 
this form of immunity. All lymphocytes originate in the bone marrow. B-lymphocytes 
undergo further development and maturation in the bone marrow before being released 
into the circulation, while T-lymphocytes mature in the thymus. From the bloodstream 
lymphocytes can enter peripheral lymphoid organs, including lymph nodes, the spleen, 
mucosal lymphoid tissue, tonsils and gut-associated lymphoid tissue. Immune responses 
occur  largely  in  these  lymphoid  organs,  which  are  designed  to  promote  interaction 
between cells and invading pathogens (43). 
 
The characteristics of the acquired immune response are that is specific, diverse, has 
memory and is self-regulated (46).The acquired immune system is highly specific, since 
each  lymphocyte  carries  surface  receptors  for  a  single  antigen.  However  acquired 
immunity is extremely diverse, recognizing approximately 10
11 antigens, meaning that 
only a small number of lymphocytes will be able to recognize any given antigen. For 
that reason the acquired immune system involves clonal expansion that involves the 
proliferation of a lymphocyte after an interaction with its specific antigen has occurred, 
so that a single lymphocyte gives rise to a clone of lymphocytes, all of which have the 
ability to recognize and destroy the source of the antigen causing the initial response 
(47).  The  acquired  immune  response  becomes  effective  over  several  days  after  the 
initial activation, but it also persists for some time after the removal of the initiating 
agent,  giving  rise  to  another  characteristic  of  acquired  immunity,  immunological 
memory (40). Figure 1.5 depicts the coordinated actions of both innate and acquired 
immunity. The last feature of the acquired immune system, self-regulation, reflects its 
ability to re-establish homeostasis through communication between cells (48).   21 
 
 
Figure 1.5: A general overview of the immune system (21) 
 
1.2.3  B- and T-Lymphocytes 
 
B-lymphocytes  have  the  ability  to  produce  antibodies  (immunoglobulins  which  are 
specific for individual antigens). This form of protection is named humoral immunity 
and  is  conducted  exclusively  by  B-lymphocytes.  B-lymphocytes  carry 
immunoglobulins  that  bind  with  an  antigen  on  their  cell  surfaces.  This  attachment 
causes  proliferation  of  B-lymphocytes  and  induces  their  transformation  into  plasma 
cells, which secrete large amounts of antibody with the same specificity as the parent 
cell. There are 5 major classes of immunoglobulin, IgA, IgD, IgG, IgM, and IgE, each 
of  which  elicits  different  components  of  the  humoral  immune  response.  Antibodies 
work in  several  ways  to combat invading pathogens. They  can neutralize toxins  or 
microorganisms by binding to them and preventing their attachment to host cells and   22 
they can activate complement proteins in plasma, which in turn promote the destruction 
of bacteria by phagocytes. Since antibodies have binding sites for both antigen and for 
receptors on phagocytic cells, antibodies can also promote the interaction of the two 
components  by  forming  physical  „bridges‟  a  process  known  as  opsonisation.  The 
antibody  class  determines  the  antibody  bound  on  the  type  of  phagocytic  cell,  for 
example  eosinophils  are  specific  for  IgE.  In  this  way  antibodies  are  a  form  of 
communication  between  the  acquired  and  the  innate  immune  responses;  they  are 
elicited through highly specific mechanisms, but are ultimately translated to a form that 
can be interpreted by the innate immune system, enabling it to destroy the pathogen 
(47). 
 
Humoral immunity deals with extracellular pathogens, but viruses and some bacteria 
infect individuals by entering cells. These pathogens will be dealt with cell mediated 
immunity, which is conferred by T-lymphocytes which express antigen-specific T-cell 
receptors (TCR) on their surface. T-lymphocytes are only able to recognize antigens 
that are presented to them on a cell surface of an antigen presenting cell (APC), which 
ingest  the  pathogen  proteins  and  digest  them  into  small  peptides.  This  is  the 
distinguishing feature of cell mediated immunity.  
 
The peptide fragments derived from the pathogen are transported to the surface of the 
APC  and  expressed  there  in  conjunction  with  proteins  termed  histocompatibility 
complex (MHC), after migration of the cells to the regional lymph nodes; in man MHC 
is  termed  human  leucocyte  antigen  (47).  The  combination  of  the  pathogen  peptide 
fragment  with  the  MHC  is  recognised  by  T-lymphocytes.  There  are  two  classes  of 
MHC (MHC class I and MHC class II). MHC I binds peptides that are produced within 
the  host  cell  cytosol  originating  from  pathogen  proteins  (viruses,  certain  bacteria) 
whereas  MHC  II  binds  peptides  that  originate  from  pathogens  that  have  been 
phagocytosed by macrophages or endocytosed by APCs (macrophages, dendritic cells, 
B-lymphocytes). MHC I bound peptides are recognised by T-lymphocytes expressing 
CD8, whereas MHC II bound peptides are recognised by T-lymphocytes expressing 
CD4 (49). 
 
Activation of the TCR results in the entry of T-lymphocytes into the cell cycle and 
ultimately  proliferation.  Activated  T-lymphocytes  secrete  interleukin  (IL)-2,  which 
promotes further proliferation and differentiation of T-lymphocytes. The expanded T-
lymphocytes have the ability to migrate to sites of infection, injury or tissue damage.   23 
Cytotoxic (CD8
+) T-lymphocytes are stimulated by intracellular pathogens and secrete 
cytotoxic  enzymes  which  lyse  the  target  cell,  or  secrete  the  antiviral  cytokine 
interferon-γ  (IFN-γ)  or  induce  apoptosis  of  target  cells  (50).  Helper  T-lymphocytes 
(CD4
+)  are  stimulated  by  extracellular  pathogens  and  they  induce  the  phagocytic 
activity  of  macrophages,  and  also  proliferation  of  B-lymphocytes  and  antibody 
secretion from them (51). The secretion of cytokines by antigen activated CD4
+ T-
lymphocytes causes recruitment of neutrophils and monocytes from the blood stream to 
the  site  of  infection  and  also  activation  of  monocytes.  This  type  of  cell-mediated 
immunity is  called delayed-type hypersensitivity  (DTH) and is  the primary  defence 
against  intracellular  bacteria.  DTH  may  be  caused  by  contact  with  chemicals  and 
environmental antigens. Intradermal injection of microbial antigens also leads to DTH 
and has been used as a rapid in vivo marker of cell-mediated immunity (46). 
 
While effective immune responses are highly desirable some aspects of immunity have 
undesirable consequences, such as toxicity to host tissues caused by mediators secreted 
by macrophages. For this reason immune responses need to be tightly controlled and the 
self-regulatory properties of the immune system are normally effective (52). 
 
1.2.4  Cytokines, Th1, Th2 and T-reg cells 
 
Communication  between  acquired  and  innate  immune  system  as  well  as  within  the 
acquired  immune  system  is  achieved  by  adhesion  molecules  and  by  production  of 
chemical messengers, which send signals from one cell to another. Chief amongst these 
messengers are proteins called cytokines which act to regulate the activity of the cell 
that  produced  the  cytokine  or  of  other  cells.  Cytokines  act  by  binding  to  specific 
receptors on the cell surface and thereby induce changes in the growth, development or 
activity of the target cell (53). Tumour necrosis factor-α (TNF-), IL-1 and IL-6 are 
among the most important cytokines produced by monocytes and macrophages. These 
cytokines  activate  neutrophils,  monocytes  and  macrophages  to  initiate  bacterial  and 
tumour cell killing, increase adhesion molecule expression on the surface of neutrophils 
and endothelial cells, stimulate B and T cell lymphocyte proliferation and initiate the 
production of other pro inflammatory cytokines (e.g. TNF induces production of IL-1 
and IL-6, and IL-1 induces production of IL-6). The actions of inflammatory cytokines 
are opposed by anti-inflammatory cytokines such as IL-10 and by receptor antagonists 
such as IL-1 receptor antagonist.   24 
Thus TNF, IL-1 and IL-6 are mediators of both natural and acquired immunity and are 
an important link between them (54). In addition these cytokines mediate the systemic 
effects of inflammation such as fever, weight loss and acute-phase protein synthesis in 
the liver. Production of appropriate amounts of TNF, IL-1 and IL-6 is clearly important 
in  response  to  infection  but  overproduction  can  be  dangerous  and  these  cytokines, 
particularly  TNF  are  implicated  in  causing  some  of  the  pathological  responses  that 
occur  in  chronic  inflammatory  conditions  (e.g.  rheumatoid  arthritis,  inflammatory 
bowel disease and psoriasis) (54).  
 
T-cells that have not previously encountered antigen produce mainly IL-2 upon the 
initial encounter with an antigen. These cells may differentiate into a population, Th0 
cells which differentiate further into either Th1 or Th2 cells. This differentiation is 
regulated by cytokines: Th1 cells produce IL-2 and IFN-γ, which activate macrophages, 
natural killer cells and cytotoxic T-lymphocytes and are the principal effectors of cell-
mediated immunity. Interactions with bacteria, viruses and fungi tend to induce Th1 
activity.  Since  Th1  cytokines  activate  monocytes  and  macrophages,  these  cytokines 
may also be regarded as proinflammatory (55). Inflammatory conditions are frequently 
associated with Th1 responses (56). 
 
Th2  cells  produce  IL-4,  IL-5  and  IL-13.  IL-4  stimulates  IgE  production  by  B-cells 
(antibody responses) and IL-5 activates eosinophils. IL-4 also suppresses cell-mediated 
immune responses by Th1 cells, and thus these cytokines may be regarded as anti-
inflammatory (52). On the other hand, cytokines produced by Th1 cells, suppress Th2 
cell activity. Th2 responses induce IgE-mediated activation of mast cells and basophils 
to eliminate helminthic parasites and are associated with allergy and asthma (57).  
 
Cells with typical Th1 and Th2 profiles have been demonstrated in mice. In humans, 
although some cells might have typical responses, there is no discrete division between 
the two types of cells. Helper T-cells most of the time produce a mixture of Th1 and 
Th2 cytokines in various proportions (55). Consequently, helper T-lymphocytes can be 
„Th1  dominant‟  (inflammatory  conditions)  or  „Th2  dominant‟  (allergy),  and  the 
dominant activity antagonises the non-dominant one, leading to polarisation towards the 
dominant phenotype. Figure 1.6 represents Th1 and Th2 immune responses (48;58).  
 
More recently a novel helper T-cell subset which produces IL-17 has been identified as 
a different population from Th1 and Th2. These cells have been termed Th17 and are   25 
the result of naïve T-cell differentiation through the effect  of  IL-1,  IL-6 and  IL-23 
(59;60). These cells provided new insight into the molecular mechanisms involved in 
immune responses and/or disease development, and their discovery has led to revision 
of  the  classic  Th1/Th2  paradigm  in  such  settings.  Likewise,  new  T  cell  subsets, 
particularly  Th17  cells,  may  also  contribute  to  the  pathogenesis  of  classically 
recognized  Th2  mediated  allergic  disorders.  Oboki  et  al.  reviewed  that  IL-17 
production by Th17 cells may contribute to the pathogenesis of non-atopic and/or non-
eosinophil/neutrophil dominant asthma, and may be a new marker for classification of 
such non-Th2 type asthma (60). 
 
Regulatory T cells (T-reg cells) control peripheral immune responses and are likely to play 
a central role in determining the incidence and severity of several immune pathologies, 
including autoimmune, infectious, allergic, and asthmatic diseases (52;61). There are two 
major  categories  of  T-reg  cells  described  to  date.  The  first  is  the  naturally  occurring, 
thymically derived CD4
+CD25
+T-reg cells  that  express  high levels  of the transcription 
factor FOXP3, which is essential for their development and function. The other category is 
the antigen-specific T-reg cells, which can be induced in vitro and in vivo under particular 
conditions  of  antigenic  stimulation.  These  antigen-specific  T-reg  cells  secrete  anti-
inflammatory cytokines  such as  IL-10 and/or transforming growth factor (TGF)-, and 
regulate immune responses and inflammatory pathologies. Induced T-reg cells that secrete 
IL-10 are often referred to as IL-10–T-reg cells, or Tr1 cells; those that secrete TGF-β have 
been referred to as Th3 cells. However, it is likely that both categories of T-reg cells 
require one or both of these cytokines to evoke their suppressive functions during different 
stages or types of inflammatory responses (61). 
 
Figure 1.6: Schematic representation of the roles of helper T cells in regulating immune responses and 
in physiological and pathological responses (58) 
APC, antigen presenting cell; B, B cell; E, eosinophil; IFN, interferon; MC, mast cell; N, neutrophil; TGF, 
transforming growth factor; Th1, type 1 helper T cell; Th2, type 2 helper T cell; T-reg, regulatory T cell    26 
 
1.2.5  Inflammation 
 
Inflammation is the body‟s immediate response to infection or injury. It is typified by 
redness,  swelling,  heat  and  pain.  These  occur  as  a  result  of  increased  blood  flow, 
increased permeability across blood capillaries which permits large molecules to leave 
the blood stream and cross the endothelial wall and increased movement of leukocytes 
from the bloodstream into the surrounding tissue. Thus inflammation is an integral part 
of the innate immune response (62). 
 
1.2.6  The immune system in health and disease 
 
Some of the undesirable features of the immune response are described below: 
Firstly, the immune system is responsible for the rejection of transplanted tissues, which 
occurs because of the ability of the immune system to recognize and eliminate foreign 
antigens effectively. 
 
Secondly,  the  ability  to  discriminate  between  „self‟  and  „non-self‟  is  an  essential 
requirement of the immune system and is normally achieved by the destruction of self-
recognising T-and B-lymphocytes before their maturation. However, since lymphocytes 
are unlikely to be exposed to all possible self-antigens in this way, a second mechanism 
termed clonal anergy exists, which ensures that an encounter with a self-antigen induces 
tolerance. In some individuals there is a breakdown of the mechanisms that normally 
preserve  tolerance;  a  number  of  factors  contribute  to  this,  including  a  range  of 
immunological abnormalities and a genetic predisposition in some individuals. As a 
result, an inappropriate immune response to host tissues is generated and this leads to 
autoimmune  and  inflammatory  diseases,  which  are  typified  by  ongoing  chronic 
inflammation  and  a  dysregulated  Th1  response.  Examples  of  this  type  of  disease 
include psoriasis, multiple sclerosis and rheumatoid arthritis (63). 
 
Thirdly,  the  immune  system  of  some  individuals  can  become  sensitized  to  usually 
„innocent‟  antigens  from  the environment  and can respond inappropriately  to  them. 
Such antigens include components of food or of so-called allergens (e.g. cat or dog fur, 
house dust mite, some pollens), such that this response can lead to allergies, asthma and 
related atopic diseases (63;64). These diseases are often termed chronic inflammatory 
diseases but have a different immune basis from the diseases described above.   27 
 
1.2.7  Immunology of atopic disease 
 
Atopy (a derivation of the Greek word "atopos" which means out of place) is defined by a 
familial and/or personal predisposition to develop IgE antibodies to environmental (e.g. 
inhaled) antigens (65), which has a genetic background. The sensitization process, i.e. the 
generation of allergen specific IgE antibodies, is driven by interactions between antigen 
presenting  cells  (APCs,  particularly  dendritic  cells)  and  T-lymphocytes.  It  involves 
multiple mechanisms that are influenced by the genetic background, allergen exposure and 
co-factors. In genetically susceptible individuals, dendritic cells activated by the allergen in 
a pro-inflammatory milieu in the airways, the intestinal mucosa or the skin instruct T cells 
to polarize into Th2 cells, which produce a specific set of cytokines, including IL-4, IL-5, 
IL-9 and IL-13. These cytokines drive B cell switching to IgE production (IL-4, IL-13), 
basophil/mast cell development (IL-4, IL-9), eosinophil accumulation (IL-5, IL-9) as well 
as  epithelial  mucus  production  (IL-9,  IL-13),  all  of  which  are  hallmarks  of  allergic 
inflammation.  
 
The Th2 bias in allergy could either relate to a defective stimulation of Th1 and/or Treg 
immunity. The number  and/or function of Treg cells  that control  immune tolerance to 
allergens  (and  self-antigens),  might  be  deficient  in  allergic  individuals  (61).  This 
regulatory T-cell subset includes natural FOXP3
+ Treg cells, which exert their suppressive 
effects on effector T cells probably through TGF-ß signalling and membrane mechanisms, 
and  IL-10  producing  CD4
+CD25
+  Tr1  cells.  Tissue  macrophages  could  also  play  an 
important suppressive role, notably in the lung (66), while the role of other cells in allergy, 
including the recently described Th17 cells still need to be investigated.  
 
The  epithelium  could  also  play  a  key  primary  role  during  sensitization.  Functional 
dysregulation of the so-called epithelial-mesenchymal trophic unit has been suggested to 
play  an  important  role  in  asthma  (67)  as  well  as  atopic  dermatitis.  Resulting  from  a 
deficient  barrier  function,  these  changes  would  favour  Th2-type  allergic  inflammation 
towards  allergens  and  lead  to  abnormal  repair  processes.  The  epithelium  can  release 
various  mediators  regulating  the  induction  and  fate  of  the  immune  response,  such  as 
chemokines, cytokines and destructive proteins. Several cofactors probably influence the 
sensitization processes, including products of commensal (and pathogenic) microbes that 
may act by activating APCs and epithelial receptors of innate immunity (e.g. Toll-like 
receptors),  and  the  involvement  of  the  environment  is  increasingly  recognized  with  a   28 
complex role of combined exposure to allergens, pollutants and microbes which will be 
described further in section 1.3. 
 
In  summary,  atopy  is  the  genetic  predisposition  for  mounting  an  immunoglobin 
(predominantly IgE) dominated response by B-lymphocytes in response to exposure to an 
antigen for the first time, such as components in foods, pollen or dust. Binding of IgE to 
specific receptors on the surfaces of the mast cells and basophils occurs and is termed 
sensitization. If an antigen is reintroduced it will interact with the bound IgE, leading to 
activation  of  the  cells  and  the  release  of  both  preformed  and  newly  synthesized 
inflammatory  mediators,  particularly  histamine  and  Th2  cytokines,  like  IL-4  and  IL-5. 
Atopy  is  associated  with  increased  levels  of  IgE  in  the  circulation  and  tissues  and  is 
believed to play a central role in the pathogenesis of the allergic diseases which include: 
  Asthma 
  Atopic dermatitis (eczema) 
  Seasonal rhinitis (hay fever) 
  Perennial rhinitis (all year round symptoms like hay fever) 
  Urticaria (hives or nettle rash) 
  Acute Urticaria - short lived / chronic urticaria lasting six weeks or more - not 
necessarily  on  a  daily  basis.  The  majority  of  chronic  urticarias  are  not  IgE 
mediated. 
However, not everyone who has inherited the tendency to be atopic will necessarily go on 
to develop an allergic disorder. Nevertheless this inherited tendency or disposition could 
result in the development of symptoms later in life. Atopy may remain clinically silent in a 
good number of subjects and is only detected through a positive skin prick test (SPT) or 
serum  IgE  to  specific  allergens.  Factors  enhancing  the  translation  of  atopic  status  to 
clinically allergic syndromes remain unknown. 
1.2.8  International data of allergy prevalence 
 
Chronic inflammatory diseases (allergies/autoimmune diseases) are highly prevalent in 
Western  and  industrialised  countries  (Figure  1.7).  Large  increases  in  incidence  and 
prevalence of these disorders were observed during the last 4 decades or so (68-72). 
Among  these  diseases,  allergies  represent  an  immunologic  disorder  strongly 
exemplifying the interaction between genetic and environmental conditions especially 
in childhood (73;73).   29 
 
Figure 1.7: Data on changing incidene of immune disorders over time (72) 
 
Systematic  international  comparisons  of  the  prevalences  of  asthma  and  other  allergic 
disorders in children are needed for better understanding of their global epidemiology so as 
to generate new hypotheses, and to assess existing hypotheses of possible causes. The 
International Study for Asthma and Allergy in Childhood (ISAAC) investigated worldwide 
prevalence  of  asthma,  allergic  rhinoconjunctivitis,  and  atopic  dermatitis.  They  studied 
463,801 children aged 13-14 years in 155 collaborating centres in 56 countries. Children 
self-reported symptoms  of three atopic disorders.  The  researchers  found differences  of 
between 20-fold and 60-fold between centres in the prevalence of symptoms of asthma, 
allergic  rhinoconjunctivitis,  and  atopic  eczema,  with  four-fold  to  12-fold  variations 
between the 10th and 90th percentiles for the different disorders. For asthma symptoms, 
the highest 12-month prevalences were from centres in the UK, Australia, New Zealand, 
and Republic of Ireland, followed by most centres in North, Central, and South America; 
the lowest prevalences were from centres in several Eastern European countries, Indonesia, 
Greece,  China,  Taiwan,  Uzbekistan,  India,  and  Ethiopia.  The  centres  with  the  lowest 
prevalences were similar to those for asthma symptoms. For atopic dermatitis, the highest 
prevalences came from scattered centres, including some from Scandinavia and Africa that 
were not among centres with the highest asthma prevalences; the lowest prevalence rates 
of  atopic  dermatitis  were  similar  to  those  for  asthma  symptoms.  The  variation  in  the 
prevalences of asthma, allergic rhinoconjunctivitis, and atopic dermatitis symptoms was 
striking between different centres throughout the world. These findings formed the basis of 
further studies to investigate factors that potentially lead to these  international patterns 
(74).   30 
Figure  1.8  shows  the  positive  correlation  between  the  gross  national  product  and  the 
incidence of asthma in 12 European countries, emphasising the effect of western lifestyle 
and better living on the prevalence of asthma (72). 
 
 
Figure 1.8: The frequency of asthma in 12 European countries according to 
the gross national product per capita (American dollars) (72) 
 
The European Community Respiratory Health Survey (ECRHS) was a multi centre survey 
of  the  prevalence,  determinants  and  management  of  asthma.  This  study  presented  a 
description of the variation in self-reported attacks of asthma and asthma symptoms across 
Europe. A screening questionnaire, including seven questions relating to the 12 month 
prevalence of symptoms of asthma, was distributed to representative samples of 20–44 
year old men and women in 48 centres, predominantly in Western Europe. The prevalence 
of all symptoms varied widely. Although these were generally lower in northern, central 
and southern Europe and higher in the British Isles, New Zealand, Australia and the United 
States,  there  were  wide  variations  even  within  some  countries.  Centres  with  a  high 
prevalence  of  self-reported  attacks  of  asthma  also  reported  high  prevalences  of  nasal 
allergies and of waking at night with breathlessness. The use of asthma medication was 
more common where wheeze and asthma attacks were more frequent. In most centres in 
The Netherlands, Sweden, New Zealand and the UK over 80% of those with a diagnosis of 
asthma were currently using asthma medication. In Italy, France and Spain the rate was 
generally less than 70%. These data are the best cross-sectional evidence indicating that 
geographical differences in asthma prevalence exist (71). 
 
In addition, there has been a worldwide increase in allergic disease (75) with as many as 
40%  of  children  in  industrialized  countries  developing  allergic  sensitization.  Recent 
Australian figures estimated that 20% of school-aged children experienced wheezing in the 
previous 12 months and that prevalences of eczema and rhinitis were roughly 17% and 
13%, respectively, in this age group (76). In the UK, as in most prosperous industrialized 
western countries, there are well documented increases in the prevalence of asthma and the   31 
atopic diseases hay fever, eczema, and food allergy (77). Data from the Office for National 
Statistics published in 2004 shows that between 1995 and 1997, the prevalence of asthma 
symptoms  and  diagnosis  among  children  aged  5  to  15  years,  in  England,  varied  little 
between the parental social classes. However, the prevalence was slightly higher among 




Figure 1.9: Prevalence of symptoms and diagnosis of asthma, hayfever and eczema, by age and social 
class of head-of-household, 1995-1997 in England (78) 
 
The  rapid  rate  of  this  rise  suggests  that  environmental  factors,  perhaps  including 
alterations  in  diet,  may  be  responsible  (79;80).  Those  environmental  factors  and 
especially  their  effect  during  the  critical  period  of  pregnancy  and  infancy  will  be 
explored in section 1.3. 
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1.3  Atopy in infancy: Maternal influence, infant immune origins 
and responses 
1.3.1  Infant immune system  
 
Up until recently, it was considered that the neonate was immunologically naive and that 
the  development  of  specific  immune  responses  was  restricted  to  the  postnatal  period. 
However, it is now recognised that infants are born with the capacity to mount a specific 
immune response that can only have developed in utero, often to common environmental 
antigens.  A  number  of  studies  have  shown  cord  blood  mononuclear  cell  (CBMC) 
sensitivity to allergens exists at birth (81;82) and, by studying the CBMC responses from 
fetuses through gestation, it has been possible to establish that specific allergen-induced 
responses  can  occur  from  as  early  as  22  weeks  gestation  (83).  These  responses  are 
modified by events after birth and allergens, infections, diet, and microbial gut flora have 
all been implicated in the development, or not, of subsequent allergy (58). However, the 
mechanisms  put  in  place  during  gestation  may  well  be  the  starting  point  for  eventual 
disease. This is consistent with the “early life origins of health and disease” hypothesis. 
 
Stem  cells  are  present  in  the  human  yolk  sac  at  21  days  of  gestation  with  the  first 
lymphocytes seen in the thymus at the end of the 9th week of gestation. B lymphocytes can 
be seen in a range of organs including the lungs and gut from 14 weeks and by 19-20 
weeks  circulating  B  cells  have  detectable  surface  IgM.  This  implies  that  the  full 
sensitization  process  must  have  occurred  from  antigen  presentation  through  T-cell 
proliferation to B-cell stimulation and antibody production (84). 
 
The culture of fetal blood collected by fetoscopy at 12-19 weeks of gestation yields high 
levels  of  both  erythroid  and  granulocytic/monocytic  progenitor  cells;  monocytes 
comprising 42-68%, neutrophils 27-41%, and eosinophils 5-30%. Despite this high number 
of granulocyte progenitors in the circulation at this time, granulocytes are not formed in 
large numbers until after birth, neutrophils being the last population to appear in the blood 
during early life. What follows is a summary of the development of the cell populations 
which play different roles in the allergic response (85).   33 
 
1.3.1.1 Macrophages and dendritic cells 
 
Macrophages and dendritic cells, which have a central role in the generation of an antigen- 
specific immune response, process and present antigens to T cells. Although dendritic cells 
are considered professional antigen presenting cells because they can prime naive T cells, 
very little is  known about  them in  the fetal period. The major population of  yolk  sac 
macrophages is MHC class II-negative, and there is a minor population that is MHC class 
II-positive (85). 
1.3.1.2 T cells 
 
Putative prothymocytes can be identifed in the fetal liver from 7 weeks of gestation as 
highly proliferative cells that are positive for CD7, CD45, and cytoplasmic CD3. From 18-
24 weeks of gestation, the mesenteric lymph nodes have a high percentage of CD45RA
+ T 
cells but very few B cells or monocytes. The fetal spleen at this time has equal numbers of 
T  cells,  B  cells,  and  monocytes/macrophages.  The  spleen  is  considered  already  fully 
immunocompetent by 18 weeks of gestation, having sufficient accessory cells to ensure T-
cell  activation,  whereas  the  mesenteric  lymph  nodes  are  deficient  in  accessory  cells 
numerically or functionally. There are few memory T cells (CD45RO
+) in the blood and 
spleen of the newborn, whereas half the T cells in adult tissues have this phenotype. This 
low memory cell number is consistent with limited antigen exposure in early life. CD3
+ T 
cells are detectable in the fetal circulation at about 15-16 weeks of gestation, at which time 
they  also  express  CD2  and  CD5.  Proliferation  in  response  to  the  mitogen 
phytohaemaggluttinin (PHA) is first seen at 17 weeks of gestation (85). 
 
The question is how early antigen-specific responses occur. Umbilical CBMC collected at 
full term exhibit antigen-specific reactivity to allergens, including those of house-dust mite 
and cows‟ milk (81;82). One of the frequently observed properties of neonatal T cells is 
their poor cytokine production in comparison to the adult (86), particularly in relation to 
Th1  cytokines.  The  underlying  mechanisms  that  account  for  this  deficiency  are 
incompletely understood, but appear to derive in part from the secretory functions of the 
placenta, which are discussed below. The relatively poor capacity of neonatal T cells to 
produce cytokines is thought to contribute to the impaired responses of other neonatal cell 
populations that rely on these factors for their functions.   34 
 
1.3.1.3 B cells  
 
The percentage of pre-B cells in the fetal omentum and liver is similar over 8-12 weeks 
gestation, but the percentage of these cells decreases during weeks 13-23 in the omentum, 
remaining the same in the liver. The proportion of immature B cells in the bone marrow 
decreases with age, and cells expressing maturity markers increase. B cells in the spleen 
are diffusely distributed at 22 weeks, and then form primary nodules around 24 weeks. The 
liver, spleen and lymph nodes are important sites of B-cell differentiation in mammals. B 
cells emerge into the peripheral circulation at 12 weeks of gestation, and they are positive 
for CD19, CD20, CD21, CD22, HLA-DR, IgM, and IgD. The percentage of CD5
+ B cells 
is higher in the fetal circulation than the adult, and declines with increasing gestational age, 
yet even at birth most cord-blood B cells are CD5
+ (B-1 B cells), in contrast to the adult, 
where few peripheral blood B cells express this molecule. 
1.3.1.4 Immunoglobulin production 
 
Early IgG and IgM synthesis occurs primarily in the spleen, large amounts of both being 
produced by the spleen as early as 10 weeks of gestation, although levels are maximal at 
17-18 weeks of gestation. IgG traverses the placenta throughout gestation with a marked 
upregulation in the transfer rate occurring from 20 weeks, and this upregulation is maximal 
from 32 weeks of gestation. IgE synthesis was observed at 11 weeks of gestation in fetal 
liver and lung, and by 21 weeks in the spleen. Despite this early burst of production in fetal 
life, the production of Ig isotypes at birth is impaired. Neonates have very low serum IgM 
and even lower IgA and IgE levels, and the IgG present is essentially of maternal origin.  
Neonatal B cells are mature in their capacity to switch to IgE-producing cells if they are 
given exogenous IL-4, although they require higher levels of IL-4 than required by adult B 
cells to switch to IgE production. Thus, the minimal production of IgE is not due to the 
immaturity  of  the  B  cells  but  to  the  lack  of  IL-4  produced  by  fetal  cells,  i.e.,  to  the 
immature helper T-cell function. As IgE has a central role in the allergic response, it is 
worth noting that despite the low levels of total IgE detectable in the circulation, specific 
IgE (either allergen or parasite) is detectable in cord plasma from some neonates (87). 
1.3.1.5 Mucosal immunity 
 
A functioning mucosal immune system is essential for survival in infancy and beyond. IgA 
and IgM are important in the first line of defence. In the fetal parotid gland (20-40 weeks),   35 
occasional IgM and IgA-producing cells were observed, but no cells producing IgD, IgG, 
or IgE isotypes were seen. 
1.3.1.6 Eosinophils 
 
Eosinophil  granulopoiesis  occurs  in  the  fetal  liver,  and  eosinophilic  granulocytes  are 
evident for the first time at 5 weeks in the hepatic laminae. Numbers at this site increase 
gradually over gestation, and then, after 20 weeks of gestation, they appear in the portal 
areas. The eosinophil population in the portal areas comprises a greater number of mature 
cells than is seen in the hepatic laminae. This was postulated to reflect increasing activity 
in  the  portal  areas  by  the  component  cells  that  are  also  developing  and  beginning  to 
provide growth factors. Although eosinophilia at 3 months of age has been associated with 
a greater risk of the development of atopic disease at 18 months of age, there are no studies 
of eosinophil numbers and/or function at birth with regard to the development of allergic 
disease (85). 
 
1.3.2  Events after birth 
 
The areas currently most discussed in relation to the influences on the developing immune 
response in early life are: (i) the hygiene hypothesis; (ii) gut microbial flora; and (iii) 
allergen exposure. It seems likely that they may all have a role to play in determining 
whether the events set up during pregnancy result in the development of allergic disease 
and they will be considered in the following section. 
 
1.3.2.1 The hygiene hypothesis 
 
In 1989, Strachan demonstrated an inverse relationship between birth order in families and 
the prevalence of hay fever. He proposed that infections in early infancy brought home by 
older  siblings  might  prevent  sensitization  (88).  There  is  clearly  a  quite  convincing 
biological explanation to support this hypothesis. Early infection, whether with viruses or 
bacteria, will tend to stimulate a Th1 immune response, which, if early enough postnatally, 
will  switch  any  Th2  biased  allergic  immune  responses  to  common  allergens  to  a  Th1 
immunising pattern (89). It must, however, be noted that there are some anomalies to this 
hypothesis, in that some infections, for example respiratory syncytial virus, are actually 
associated with more, rather than less, allergy, and immunisation with altered organisms 
does not have the same effect as active infection (84).   36 
 
1.3.2.2 Gut microbiota 
 
It has been reported that allergic children are more likely to have a low colonisation of 
lactobacilli in their gut than non-allergic children. Also, children in Estonia, where the 
prevalence of allergies is low, have a very different gut flora to those in Sweden where the 
prevalence of allergy is higher  (90). Allergic children tended to have higher counts of 
aerobic  micro-organisms  such  as  coliforms  and  Staphylococcus  aureus.  A  number  of 
groups have questioned whether this might explain the remarkable observation that there is 
a much lower risk of asthma amongst children of farmers who have been born on farms. 
Ingestion of higher quantities of raw and sometimes unpasteurised milk containing a higher 
microbial  load,  particularly  of  lactobacilli,  may  well  have  been  protective  (91).  This 
observation may, however, also be explained by a greater exposure to infecting organisms 
and particularly their products such as LPS which would be consistent with the earlier 
hygiene hypothesis (92). LPS-induced immune responses are primarily mediated via the 
receptor CD14. It is likely that the early switch from a Th2 to a Th1 biased response 
postnatally is a consequence of postnatal microbial exposure as described above. Those 
infants with an intact response to microbial antigens such as LPS will have a very rapid 
switch  orchestrated  through  the  CD14  molecule  once  the  gut  becomes  colonised  with 
organisms. Those infants with abnormalities in this response and those who have already 
had significant over commitment to a Th2 response as a result of antenatal factors, will not 
be so easily switched and have a higher probability of having a persistent response going 
on to atopic disease. 
1.3.2.3 Allergen exposure 
 
There is a good correlation between early high level exposure to house dust mite and the 
subsequent increase in prevalence and severity of asthma. Indeed, high level exposure to a 
number of indoor allergens is strongly associated with sensitisation in the first 3 years (93) 
and early sensitisation is associated with greater probability of persistence of bronchial 
hyper-responsiveness and symptoms of asthma in late childhood and adolescence (94). The 
main difficulty in  employing allergen avoidance strategies is  that techniques to  reduce 
exposure to the commonest allergen, the house dust mite, are far from satisfactory. Indeed, 
meta-analysis of trials published in 1998 suggested that it was not likely to be effective 
(95).  The  studies  that  have  attempted  allergen  avoidance  in  high  risk  infants  with  or 
without  pre-existing  evidence  of  sensitisation  but  not  yet  disease  have  yielded  very   37 
disappointing  outcomes.  Some  interventions  have  even  commenced  antenatally.  The 
attitude to antenatal dietary avoidance has been formed on the basis of one study where 
elimination  of  egg,  milk,  fish  and  nuts  from  the  maternal  diet  in  the  last  trimester  of 
pregnancy had no impact  on outcome in  relation to  disease. Furthermore, the mothers 
gained less weight during pregnancy as a consequence of the diet (96). However, perhaps 
the intervention was started too late, as it is now known that sensitisation might have 
occurred at an earlier stage in the pregnancy.  
 
Postnatal avoidance has again tended to focus on diet with promotion of breast feeding. 
Many  studies  have  been  performed  with  very  diverse  results  extending  from  reduced 
prevalence of food associated atopic disease, through no effect, to some studies showing a 
higher prevalence of atopy in intervention groups. Importantly, however, only one of many 
studies  has  demonstrated  any  long-term  effects  of  early  dietary  manipulation  on  the 
prevalence of asthma (97). Where studies have demonstrated benefits these have been to 
reduce  prevalence  of  food-associated  atopic  disease  in  infancy  but  with  no  long-term 
impact on any atopic problems and no effect on asthma (98). 
 
1.3.3  Factors affecting the development of atopic disease  
 
As  said  before,  global  increases  in  the  incidence  and  prevalence  of  many  chronic 
inflammatory conditions, including autoimmune diseases, allergies, asthma and atopy, and 
inflammatory  bowel  diseases,  have  been  observed  over  the  last  sixty  years  or  so, 
particularly  in  Westernized  and  industrialized  countries  (72).  Genetic  studies  have 
documented the risk of developing atopy based on family history. Development of atopic 
disease has a strong familial component and as a result much research has focused on 
interventions in infants and children with an increased risk of atopy. Children born into 
atopic families have a 50-80% risk of developing atopic diseases; children from families 
with no history of atopy have approximately a 20% risk. Risk of allergy appears to be 
higher if both parents are allergic (versus only one parent) and if the mother (versus the 
father)  has  allergic  disease  (99).  Although  there  are  genetic  predispositions  to  these 
diseases (100), the presence of certain gene polymorphisms alone is unlikely to explain the 
shift in disease prevalence. Thus, in addition to genetics, environmental factors must be 
taken into consideration; these are listed for atopic disease in Table 1.5. Epidemiological 
investigations  have  identified  that  early  exposure  to  microbes  may  be  an  important 
protective factor for allergy and asthma, perhaps acting as an „immune educator‟. This is 
the so called „hygiene hypothesis‟ (101), which suggests that the absence of early exposure   38 
to certain types of microbes as a result of modern hygienic and medical practices removes 
the drive to mature Th1 cell effector responses and so allows the dominant early Th2 cell 
responses to continue unchecked. The role of microbial exposure in educating the immune 
system away from Th2 predominance may explain why certain probiotic strains of bacteria 
appear to have a protective role in atopic diseases  (102). It is also speculated that the 
different  gut  flora  present  in  infants  born  by  caesarean  section,  or  other  factors,  like 
antibiotics given to the mother, may put the child at risk for allergic sensitization (103). 
 
Epidemiology has also identified that early exposure to certain nutrients, including LC n-3 
PUFAs may be protective (25;104). LC n-3 PUFA status in relation to developing atopic 
disease is discussed in section 1.4. 
 
Table 1.5: Potential determinants of atopic disease (58) 
 
POTENTIAL FACTORS AFFECTING ATOPY 
Genetics 
Family history 
Low birth weight 
Exposure to pets 
Exposure to allergens 
Infections/Microbial stimulation/Gut microflora 
Exposure to parasites 
Obesity 
Dietary fatty acids 
Dietary antioxidants 
Exposure to tobacco smoke 
Exposure to air pollutants-indoor/outdoor 
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1.3.4  Early origins of atopic disease-summary 
 
 
Figure 1.10: Schematic representation of the development of clinical tolerance through the pre- and 
postnatal periods and of how this relates to the risk of allergy (58) 
 
A characteristic action of immune system is tolerance to self, to food, to environmental 
components  and to  commensal bacteria. The development  of tolerance  is  the result of 
active immune mechanisms  requiring antigen-contact  and acting in  a T cell dependent 
fashion (105). However, as described in section 1.3.1, both development and maintenance 
of tolerance are lifelong processes which start very early in life, even prenatally. In this 
regard early „education‟ of the immune system seems to begin in utero  (106;107) and 
continues after birth, particularly during the first 2 years of life (Figure 1.10). Moreover, it 
is  now  recognized  that  profound  immunologic  changes  occur  in  the  mother  during 
pregnancy.  These  changes  involve  a  polarization  of  T  helper  (Th)  cells  towards  a 
dominance of Th2 and T-reg cell effector responses (108). The fetal immune response 
shows the same polarization and this  phenomenon has  been  considered as  a Th2/Treg 
default pathway early in life (82). The default pathway is important to maintain pregnancy, 
through suppression and avoidance of the rejection of the immunologically incompatible 
fetus (108). Th2-driven IgE and IgA responses allow the recognition of ultra-low antigen 
doses  (109).  Since  there  is  significant  uptake  and  transfer  of  food-derived  and 
environmental antigens via the placental barrier into amniotic fluid (106), the ability to 
recognize low antigen doses may be important in order to develop early specific T cell 
responses against such antigens. Thus, the formation of antigen-specific IgE (and IgA) 
starts prenatally (110), and this pattern of Ig production is heavily driven through the Th2-
biased environment. Mature CD4
+ and CD8
+ T cells can be detected in the fetus as early as 
around  week  20  in  human  pregnancy  (107).  Therefore,  particularly  during  the  third   40 
trimester of human pregnancy, the fetal T cell compartment is ready and able to mount 
antigen-specific T cell responses to environmental and food-derived antigens. Indeed, such 
T  cells  are  detectable  in  cord  blood  in  virtually  all  newborns  indicating  in  utero 
sensitization  (83).  This  seems  to  be  a  normal  phenomenon  although  its  functional 
consequences  are  not  clear.  One  idea  is  that  this  is  designed  as  a  route  to  the  early 
development of antigen-specific tolerance, particularly to food-derived antigens. However, 
if the neonatal immune system is not able to effectively down-regulate the pre-existing Th2 
dominance and overcome the presence of low levels of allergen-specific IgE antibodies 
then an allergic phenotype may develop.  
 
Although  the  fetus  at  term  may  be  sensitized  to  certain  antigens,  it  does  lack  a  fully 
functional immune system and has a sterile gastrointestinal tract. Changes occur at, and 
soon after, birth in order that the immune system of the neonate becomes competent and 
functional and that the gut becomes colonized with bacteria (84). Exposure to bacteria 
during birth and from the mother‟s skin and the provision of immunologic factors in breast 
milk  are amongst  the key  events that promote  maturation of the infant‟s  gut  and  gut-
associated and systemic immune systems. The introduction of formula and of solid foods 
exposes the infant to novel food antigens and also affects the gut flora. The nature of the 
infant‟s environment (e.g. the presence of older siblings or of pets, the use of nurseries) 
will determine exposure to novel bacterial and environmental antigens to which it must 
respond in an appropriate manner (111;112). Thus, pregnancy, the suckling period, and the 
periods during which formula and solid foods are introduced offer windows during which 
nutrition might affect the immunologic development of the fetus and young infant. In this 
way, nutrition may: 
  be the source of antigens to which the immune system must become tolerant; 
  provide  factors,  including  nutrients,  that  themselves  might  modulate  immune 
maturation and responses; 
  provide  factors  that  influence  intestinal  flora,  which  in  turn  will  affect  antigen 
exposure, immune maturation and immune responses. 
Through  these  mechanisms  it  is  possible  that  nutrition  early  in  life  might  affect  later 
immune competence, the ability to mount an appropriate immune response upon infection, 
the ability to develop a tolerogenic response to „self‟ and to benign environmental antigens, 
and the development of atopic disease (58).   41 
 
1.4  Long-chain n-3 PUFAs and atopy in early life 
 
This section will describe and discuss the current evidence linking LC n-3 PUFA intake or 
status to the immune response, especially as it relates with atopic disease in early life. 
There have been many studies conducted, both human and animal, in vivo and in vitro, 
looking at the effect of long chain n-3 PUFAs on production of inflammatory mediators of 
allergy, eicosanoids, T cell proliferation, cytokine production and IgE production. 
1.4.1  Eicosanoids 
 
As described in the section 1.1, eicosanoids are a group of mediators whose precursors are 
20-carbon  PUFAs  (ARA  and  EPA).  These  PUFAs  are  contained  in  the  phospholipid 
bilayer of cell membranes, with ARA being present in most cell membranes in relatively 
large amounts. Eicosanoid synthesis involves PUFA mobilisation from the cell membrane 
by various phospholipase enzymes,  most  notably  phospholipase A2. The free PUFA is 
converted by cyclooxygenase (COX) enzymes into PGs, TXs and related compounds, or 
by lipoxygenase (LOX) enzymes into LTs and related compounds. Figure 1.11shows the 
synthesis of eicosanoids from ARA (48). 
 
 
Figure 1.11: Generalized pathway for the conversion of arachidonic acid to eicosanoids  
(104) 
COX, cyclooxygenase; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; 
LOX, lipoxygenase; LT, leukotriene; PG, prostaglandin; TX, thromboxane   42 
 
ARA is the principal precursor of eicosanoids because it is present in greater amounts than 
other precursors. However, different cell types produce different compounds belonging to 
each class of eicosanoids. Monocytes and macrophages produce large amounts of PGE2 
and PGF2, neutrophils produce moderate amounts of PGE2 and mast cells produce PGD2. 
The LOX enzymes have a tissue-specific distribution. The 5-LOX enzyme is mainly found 
in  mast  cells,  monocytes,  macrophages,  and  granulocytes,  and  12-  and  15-LOX  in 
epithelial cells. 
Eicosanoids  are  the  key  link  between  fatty  acids  and  the  immune  system.  They  are 
involved in modulating the intensity and duration of inflammatory and immune responses 
(113). The effects of eicosanoids may vary even if these have the same precursor, and in 
addition, a single eicosanoid may have opposing effects. The overall physiological effect 
of eicosanoids will be determined by the nature of cells producing them, the nature of the 
stimulus, their concentrations, the timing of their production, and the sensitivities of target 
cells. For example, ARA is the precursor of different mediators (PGE2, LTB4) which may 
have opposing effects to one another. PGE2 has various proinflammatory effects (increases 
vascular  permeability,  vasodilatation,  pain,  oedema),  but  at  the  same  time  exhibits 
immunosuppressive and anti-inflammatory effects (suppresses lymphocyte proliferation, 
inhibits IFN-, TNF-α and IL-1 production). Recent studies have shown that PGE2 inhibits 
5-LOX leading to decreased production of 4-series LTs, and induces 15-LOX promoting 
the formation of lipoxins (114) which have been shown to have anti-inflammatory effects. 
LTB4  also  has  proinflammatory  effects  such  as  increasing  vascular  permeability  and 
enhancing  the  production  of  inflammatory  cytokines,  but  it  also  inhibits  lymphocyte 
proliferation. Table 1.6 lists the anti- and pro-inflammatory effects of these two different 
eicosanoids (48). 
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Table 1.6: Pro- and anti-inflammatory effects of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4). 
(Adapted from (48)) 
EICOSANOID  PRO-INFLAMMATORY EFFECTS  ANTI-INFLAMMATORY EFFECTS 
PGE2 
Induction of fever 
Increase of vascular permeability  
Increase of vasodilatation  
Cause of pain 
Enhancement of pain caused by other 
agents  
Increased production of IL-6 
Inhibition of production of TNF and IL-1 
Inhibition of 5-LOX leading to decreased 
4-series LT production 
Induction of 15-LOX leading to 
increased lipoxin production  
LTB4 
Increase of vascular permeability 
Enhancement of local blood flow 
Chemotactic agent for leukocytes 
Induction of release of lysosomal 
enzymes 
Induction of release of reactive oxygen 
species by granulocytes 
Increased production of TNF, IL-1, IL-6 
 
LOX, lipoxygenase; LT, leukotriene; IL, interleukin; TNF, tumour necrosis factor 
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1.4.2  Arachidonic acid and eicosanoids 
The amount of ARA in immune cells can be increased by including ARA in the diet of rats 
(115), or by increasing its intake from the diet in humans (116). Increasing the dietary 
intake of linoleic acid (18:2n-6) may also increase the amount of ARA in immune cells 
although this is not well defined in humans and studies are contradictory (48;117). 
Animal feeding studies have shown that increasing the amount of ARA in immune cells is 
related to increased production of eicosanoids, such as PGE2, by these cells (115). The 
effects of increased dietary ARA intake on immune processes have been little investigated 
in humans. It has been shown that modest increase of ARA intake in humans results in 
increased production of proinflammatory eicosanoids (PGE2 and LTB4) by LPS-stimulated 
PBMCs  (118).  However,  it  was  shown  that  the  production  of  inflammatory  cytokines 
(TNF-α, IL-1β, IL-6) by these cells was not affected (118;119). Furthermore ARA intake 
did  not  affect  T-cell  responses,  generation  of  reactive  oxygen  species  (superoxide)  by 
neutrophils and monocytes, or the concentrations of adhesion molecules in plasma (119). 
 
1.4.3  Long-chain n-3 PUFAs and eicosanoid production 
 
Increased dietary intake of EPA and DHA results in increased proportions of these fatty 
acids in immune cell membrane phospholipids (117). The incorporation of LC n-3 PUFAs 
occurs in a dose-response fashion and leads to decreased levels of ARA in immune cell 
membranes (120). Consequently, there is less substrate available for the synthesis of ARA-
derived eicosanoids (121;122)). Furthermore, EPA can be converted to 3-series PGs and 
TXs,  and  5-series  LTs,  by  COX  and  5-LOX  respectively  (Figure  1.12).  Fish  oil 
supplementation of the human diet has been shown to result in increased production of 
LTB5, LTE5 and 5-hydroxyeicosapentaenoic acid (5-HEPE) by inflammatory cells (123). 
EPA-derived eicosanoids have a slightly different structure and are less biologically potent 
than their ARA-derived analogues, and some of them exhibit anti-inflammatory effects 
(PGE3, LTB5). The decreased production of ARA-derived  eicosanoids, followed by an 
increase in EPA-derived eicosanoids as a result of fish oil consumption, has led to the idea 
that fish oil may have anti-inflammatory effects and may influence the function of the 
immune system.   45 
 
Figure 1.12: Generalized pathway for the conversion of eicosapentaenoic acid (EPA)  
to eicosanoids (104) 
COX, cyclooxygenase; HEPE, hydroxyeicosapentaenoic acid; HPEPE, hydroperoxyeicosapentaenoic acid; 
LOX, lipoxygenase; LT, leukotriene; PG, prostaglandin; TX, thromboxane 
 
 
Recent studies have demonstrated the production of a novel group of mediators, termed E-
series resolvins. These compounds are produced when EPA acts as a substrate for COX-2 
and they have anti-inflammatory actions (124-126). Moreover, DHA also competitively 
inhibits ARA metabolism acting as a substrate for COX-2, giving rise to DHA-derived 
mediators termed D-series resolvins, docosatrienes and neuroprotectins, that appear to be 
anti-inflammatory. These novel inflammatory mediators may be of great importance for a 
variety of conditions (127;128).    46 
 
1.4.4  Clinical applications  
 
LC  n-3  PUFAs  from  oily  fish  and  fish  oils  decrease  the  production  of  inflammatory 
eicosanoids,  cytokines  and  adhesion  molecules  (19;21;48).  They  act  both  directly,  by 
replacing ARA as an eicosanoid substrate, by inhibiting ARA metabolism and by giving 
rise  to  anti-inflammatory  resolvins,  and  indirectly,  by  altering  the  expression  of 
inflammatory  genes  through  effects  on  transcription  factor  activation.  Thus,  LC  n-3 
PUFAs are potentially useful anti-inflammatory agents (Figure 1.13). The recognition that 
the LC n-3 PUFAs have anti-inflammatory actions has led to the ideas that an absolute or 
relative lack of these fatty acids might contribute causally to inflammatory conditions and 
that supplementation of the diet of patients with inflammatory diseases may bring about 
clinical  benefit.  Possible  therapeutic  targets  for  LC  n-3  PUFAs  include  rheumatoid 
arthritis, Crohn‟s disease, ulcerative colitis, lupus, type-1 diabetes, cystic fibrosis, asthma, 
allergic  disease,  chronic  obstructive  pulmonary  disease,  psoriasis,  multiple  sclerosis, 
atherosclerosis,  acute  cardiovascular  events,  neurodegeneration  and  the  systemic 
inflammatory response to surgery, trauma and critical illness (25). Supplementation trials 
with long chain n-3 PUFAs have been conducted in most of these conditions. In most cases 
these  demonstrate  anti-inflammatory  effects,  as  indicated  by  changes  in  circulating 
concentrations or ex vivo production of inflammatory mediators.  
 
Figure 1.13: Representation of the cellular mechanisms by which long chain n-3 PUFAs result in 
decreased inflammation (48)   47 
 
Effects of LC PUFA intake in pregnancy 
 
Prescott (112) has described that newborns who subsequently develop allergic diseases 
have a number of changes in immune function at birth such as allergen-specific immune 
responses.  Jones  et  al.  have  noted  that  neonates  at  high  risk  of  atopy  already  had 
differences in vitro T-cell responses at birth (83). Evidence coming from several studies 
suggests that there are differences in LC PUFA profiles in neonates at high risk of 
allergic  disease  compared  with  low  risk  newborns,  although  the  findings  are  not 
consistent (129;130). Despite speculation about biochemical alterations  or metabolic 
abnormalities  which  could  contribute  to  the  development  of  atopy,  specific 
relationships have not been confirmed.  
 
1.4.5  Potential pathways during early immune programming 
 
Although there is debate about when immune programming first occurs, it is clear that this 
occurs in the neonatal period, if not before. For this reason, the capacity for LC PUFAs to 
influence immune function during this period is of central interest. A complex series of 
events occur during the programming of antigen-specific immune responses (as illustrated 
in Figure 1.14). This typically begins in local tissues where antigen (allergen) proteins are 
first encountered by surveying antigen presenting cells (APCs), such as tissue dendritic 
cells  (DCs),  which  ingest  the  proteins  and  digest  them  into  small  peptides.  These  are 
expressed  on  the  cell  surface  with  MHC  class  II  receptors  to  effector  T  cells,  after 
migration to the regional lymph nodes. The local tissue conditions play an important part 
in determining the maturation and activity of APCs. This in turn has a significant effect on 
down-stream  T  cell  programming  (below).  Local  inflammation  has  a  direct  effect  on 
increasing the expression of MHC class II, cytokines (such as IL-12) and co-stimulatory 
molecules on APCs, which all act to promote an effector response. In contrast, the absence 
of inflammation is more likely to lead to T cell apoptosis, anergy and tolerance. Once 
activated, the pattern of APC cytokine production also determines the pattern of T helper 
cell differentiation. Th1 cells develop under the influence of IL-12, whereas Th2 cytokine 
responses develop in the relative absence of IL-12 (or the presence of pro-Th2 factors such 
as PGE2). These differences in T cell cytokine production determine the pattern of B-cell 
antibody production, with Th2 cytokines (IL-4, IL-5 and IL-13) promoting IgE production 
and allergic inflammation while Th1 cytokines (IFNγ) largely inhibit this in favour of low 
level  IgG  production  (Figure  1.14).  Tissue  factors  are  again  important  in  determining   48 
whether  these  immune  responses  result  in  clinically  relevant  disease  (such  as  asthma, 
allergic  rhinitis  or  atopic  dermatitis)  although  this  is  still  not  well  understood.  More 
recently there has been growing recognition of the role of specialized „„regulatory‟‟ cells in 
immune  programming  and  subsequent  immune  regulation.  This  encompasses  a  broad 
range of cells that regulate effector T cell responses through direct cell contact and/or 
production of regulatory cytokines such as IL-10 and TGF- (Figure 1.14). Variations in 
LC PUFA composition of neonatal cell membranes have the potential to influence immune 
programming at many levels during this complex process (131). 
 
 
Figure 1.14: Potential pathways of influence of long-chain (LC) PUFA  
on immune development (131) 
 
   49 
 
1.4.5.1 Effects on Local Tissue Inflammation in Neonates 
 
Higher  levels  of  the  LC  n-6  PUFA  ARA  lead  to  preferential  production  of  the  pro-
inflammatory  2-series  PGs  (such  as  PGE2)  and  the  4-series  LTs  (LTB4).  In  contrast 
eicosanoids (PGE3 and LTB5) produced from the LC n-3 PUFA EPA are less potent. In the 
pregnancy intervention trial conducted in Australia by Dunstan et al. (132;133) neutrophils 
isolated from umbilical cord blood were used to test the hypothesis that maternal fish oil 
supplementation  would  alter  the  pattern  of  neonatal  LTB4  and  LTB5  production. 
Neutrophil samples were available from 30 neonates whose mothers had received a daily 
dose of 4 g of fish oil (containing 3.7 g LC n-3 PUFAs as 56% DHA and 27% EPA) and 
34 neonates whose mothers received the same amount of olive oil for the last 20 weeks of 
pregnancy. Following stimulation with calcium ionophore, production of pro-inflammatory 
LTB4  was  significantly  lower  in  the  fish  oil  group  (p=0.03).  This  confirms  that  the 
maternal  diet  can  have  effects  on  the  propensity  of  neonatal  neutrophils  to  generate 
inflammatory  products.  Secondly,  they  examined  the  effects  of  maternal  fish  oil 
supplementation on neonatal oxidative stress. Excessive oxidative stress may play a role in 
inflammation and tissue damage. It has been demonstrated that changes in oxidative status 
can influence APCs during T cell programming by altering cytokine production. Improved 
oxidative balance can promote pro-Th1 signalling by APCs, by enhancing IL-12 (134) 
(135).  In contrast, adverse oxidative balance (oxidative stress and reduced glutathione) 
promotes CD4
+ T cell Th2 differentiation (134) and the production of IL-4 and IL-5 which 
contribute  to  allergic  inflammation.  So,  they  assessed  the  effects  of  fish  oil 
supplementation on oxidative stress, using plasma F2-isoprostanes as a measure of lipid 
peroxidation. Maternal fish oil supplementation resulted in significantly lowered plasma 
(p<0.001) F2-isoprostanes (136). Of note, there was a significant relationship between F2-
isoprostanes  and  APC  (monocyte)  MHC  Class  II  (HLA-DR)  expression  (p=0.007), 
although  HLA-DR  expression  was  not  different  between  the  groups.  This  shows  that 
maternal  supplementation  with  fish  oil  can  attenuate  neonatal  lipid  peroxidation,  and 
suggests  potential  effects  on  APC  function.  Thus,  neonatal  LC  PUFA  status  has  the 
potential  to  influence  both  the  oxidative  balance  and  the  production  of  inflammatory 
mediators in local tissues.  
1.4.5.2 Effects on neonatal antigen presenting cells 
 
APC function is impaired in the neonatal period (137;138), and neonatal APCs appear to 
lack the capacity to deliver important Th1 polarising signals to T-cells (138). This may   50 
contribute  to  an  increased  susceptibility  to  infection  and  tolerance  induction,  and  a 
predisposition  to  Th2  responses  in  early  life.  There  are  differences  in  APC  function 
between atopic and non-atopic adults (139). However, it is not clear whether altered APC 
function preceeds sensitisation and the onset  of allergic disease, or whether functional 
differences  arise  secondary  to  allergic  inflammation.  This  can  only  be  addressed  by 
examining APC function in early life, prior to allergic sensitisation. Increasing the content 
of LC n-3 PUFAs in APC cell membranes reduces the capacity of APCs to present antigen 
to T cells by inhibiting the upregulation of MHC class II receptors, cytokine production 
and expression of co-stimulatory molecules  (140). A study in  mice showed that DHA 
inhibited the IFN--induced MHC class II expression on neonatal APCs (141).  
1.4.5.3 Effects on Regulatory Pathways 
 
This  is  another potential  pathway through which  LC PUFAs could  mediate effects  on 
immune function. Because the role of specialised Treg cells  has  only  been recognised 
recently  there  are  still no  studies  examining  the  effects  of  PUFAs  on  these  pathways. 
However, there are a number of potential pathways through which PUFAs could exert an 
immune  effect  through  actions  on  these  cells.  Firstly,  studies  have  shown  that  PGE2 
induces Treg cell function (and FOXP3 gene expression) (142) and so it is possible that LC 
n-3 PUFAs could work by altering PGE2 associated pathways. However, if this is the case 
it might be expected that n-3 PUFAs (which inhibit PGE2 production) may also inhibit 
Treg function, which would not explain the immunomodulatory effects of these fatty acids. 
Alternatively, PUFAs could have effects through microbial recognition molecules (Toll-
like receptors (TLRs)) that are found on both Treg cells and APCs, and are important for 
activation of these cells. One study (140) has shown that the immunomodulatory actions of 
LC n-3 PUFAs are mediated through TLR pathways on APCs. It is possible, but not yet 
explored if these effects are also relevant on other TLR expressing cells, such as Treg cells.   51 
 
1.4.5.4 Effects on Neonatal Effector T Cell Function 
 
Effects of modifying PUFA composition on T cell function have been extensively studied 
in  adults.  Many  studies  have  demonstrated  that  dietary  LC  n-3  PUFAs  reduce  T 
lymphocyte proliferation to mitogens in both humans (116;118) and rodents (143). In vitro 
studies in which PBMCs were incubated with fatty acids, have also generally shown a 
decrease in T cell responses to mitogens (144). There are only two studies to examine this 
phenomenon in human neonates: the Australian fish oil supplementation study by Dunstan 
et al. (35;132) and an observational study which examined the relationship between cord 
blood fatty acid levels and immune function in a Boston cohort by Gold et al. (145). 
 
In  the  Dunstan  et  al.  study,  they  looked  at  (a)  the  effects  of  maternal  fish  oil 
supplementation on T cell cytokine levels in cord blood, (b) the effects on in vitro T cell 
responses to specific stimuli, and (c) the relationship between fatty acid levels and T cell 
cytokine responses (in vivo and in vitro). Firstly, there were significantly (65%) lower 
circulating Th2 IL-13 levels in the fish oil group (35). There were no differences in the 
levels of other cytokines (including Th1 IFN-γ which was present only at very low levels). 
Secondly, there was a consistent trend for all cytokine responses studied (IL-5, IL-13, IL-
10, IFN-γ) to be lower in the fish oil group (although this was statistically significant only 
for IL-10 responses to cat allergen) (35). Thirdly, there were statistically significant inverse 
relationships between the the n-3 PUFA content of neonatal erythrocytes and cytokine 
responses (132). The Boston observation study examined the relationship between LC n-3 
PUFA  levels  in  cell  membranes  and  in  vitro  immune  responses.  Consistent  with  the 
Dunstan  et  al.  findings,  they  found  that  EPA  levels  were  associated  with  reduced 
lymphocyte proliferation and reduced IFN-γ production (145) They also noted that LA 
levels  were  associated  with  higher  Th2  IL-13  responses  (to  house  dust  mite  and 
cockroach). The findings suggest that LC PUFA exposures in pregnancy affect neonatal 
immune  function.  The  MUFA  oleic  acid  (18:1n-9)  is  also  recognised  to  have  anti-
inflammatory properties although these are generally thought to be less potent than those 
of n-3 PUFAs. In the Australian fish oil supplementation study described above, there was 
a significant inverse association between oleic acid in neonatal erythrocytes and allergen-
specific  (IL-5,  IL-10,  IL-13,  IFN-γ)  cytokine  responses.  Mitogen  or  bacterial  LPS 
stimulated responses were not associated with oleic acid levels. In a previous study in 
adults, olive oil supplementation had little effect on immune responses (146). However in 
animals,  high-level  oleic  acid  supplementation  results  in  inhibition  of  lymphocyte   52 
proliferation,  IL-2  responses,  and  NK  cell  function  (147).  No  previous  studies  have 
examined oleic acid and neonatal immune response or allergen specific responses in adults.  
1.4.5.5 Effects on Infant B Cell Function and Subsequent IgE Production 
 
There have not been any studies to directly assess the relationship between neonatal PUFA 
status  and  B  cell  function  directly.  However,  there  are  several  logical  pathways  of 
influence.  Firstly,  variations  in  PGE2  production  could  have  a  direct  effect  on  B  cell 
maturation as PGE2 is known to synergise with IL-4 to promote IgE switching in B cells. 
Secondly, the documented effects on neonatal T cell cytokine production are likely to have 
secondary effects on B cell function during T cell B cell interaction (Figure 1.14). In the 
Dunstan et al. study, children in the fish oil group were three times less likely to have egg-
specific IgE (a positive skin prick test to egg) at 1 year of age (132), although this could 
result  from  an  effect  at  one  or  more  steps  that  ultimately  lead  to  IgE  production  and 
response to IgE. 
1.4.5.6 Observational Studies 
 
A number of early observational studies suggested a link between cord blood n-6: n-3 fatty 
acid ratios and allergy risk (129;148). However, these studies were too small (less than 60 
subjects) to look at clinical outcomes definitively. They also only examined cord blood 
PUFAs in relation to family allergy (129) or very early outcomes (149), which are also not 
definitive. There has been one published study to address this in a large population with 
long-term follow up (150). This UK-based observational study (n=1238) examined the 
relationship between cord red blood cell fatty acids and clinical allergy outcomes at 3.5 
years of age (150). Although they found that a higher cord red cell n-3:n-6 fatty acid ratio 
was  associated  with  an  increased  risk  of  eczema  (p=0.04)  and  late-onset  wheeze  (p 
=0.019),  none  of  these  relationships  was  significant  after  adjusting  for  multiple 
comparisons (150). They concluded that PUFAs are unlikely to be a major determinant of 
allergy and asthma risk. 
 
1.4.6  Relationship between early long-chain n-3 PUFA status and 
subsequent atopic disease - conclusion 
 
It is now recognized that sensitization to allergens occurs early in life and it is considered 
that PUFAs might affect aspects of sensitization. Thus, the LC n-3 PUFA status of the 
mother and the newborn may be very important in determining predisposition to atopy and 
studies addressing this question need to be performed in pregnant women. Τhere is limited   53 
data on the relationship between neonatal LC n-3 PUFA status and subsequent risk of 
allergic disease. Existing data derived from both observational and intervention studies are 
limited (largely because of small sample sizes) and not definitive at this stage. In the study 
described in this thesis, the effect of early consumption of oily fish as a source of LC n-3 
PUFAs on factors related to offspring allergic disease will be investigated. Thus, the next 
two  sections  will  review  the  available  literature  based  on  epidemiological  studies  and 
intervention trials that relate n-3 fatty  acids  during pregnancy and infancy  with  atopic 
outcomes in infancy and early childhood.   54 
 
1.5  Review of epidemiological and supplementation studies 
 
In section 1.4 the potential for PUFAs, especially LC n-3 PUFAs to influence aspects of 
immune function related to allergic sensitisation was described. This understanding has 
lead to epidemiological studies looking at the association between early fish exposure, as a 
source of long-chain n-3 PUFAs, and later atopy outcomes and to intervention studies with 
fish oil again looking at later atopy outcomes. This section reviews the published studies 
on the effects of fish intake and fish oil supplementation during pregnancy and lactation on 
immune and atopy outcomes on the offspring of those mothers, as well as the effects of 
fish intake and fish oil supplementation during infancy and childhood on immune and 
atopy outcomes on those infants/children.  
1.5.1  Epidemiological studies 
The  aim  of  this  section  is  to  review  the  epidemiological  evidence  available  on  the 
association  of  maternal  fish  intake  during  pregnancy/lactation  with  atopic/allergic 
outcomes in the offspring of those mothers, as well as the association of fish intake during 
infancy/childhood with atopic/allergic outcomes in those infants/children. 
1.5.1.1 Studies investigating the association of maternal fish intake 
during perinatal life with atopic/allergic outcomes in infants or 
children of those pregnancies 
 
Table  1.7  includes  all  studies  published  to  the  time  of  writing  that  investigate  the 
association between maternal fish intake in perinatal life and atopic/allergic outcomes in 
the offspring of those mothers. The studies were identified through Ovid Medline (1950-
2008) and Embase (1980-2008) databases performing and combining searches with the 
following  keywords:  fish  intake,  oily  fish  intake,  maternal,  pregnancy,  atopy,  allergy, 
asthma, eczema, childhood, infancy. Five studies were identified investigating maternal 
fish  intake  during  pregnancy  and  one  study  investigating  maternal  fish  intake  during 
lactation in relation to atopic outcomes in infants or children.   55 
1.5.1.2 Studies investigating the association of maternal fish intake 
during pregnancy with atopic/allergic outcomes in infants or 
children of those pregnancies 
Study design 
The studies included in Table 1.7 had different study designs; three of them are prospective 
longitudinal cohort studies (151-153), one is retrospective cohort study (154) and one is 
nested case control (155). The prospective study design is superior to a retrospective or a 
cross sectional/case-control design for studying cause-effect relations. In general, all the 
studies were well powered, with the largest being the two prospective birth cohort studies 
conducted by Sausenthaler  et  al. (152) and Willers  et  al. (153). The age range of the 
offspring that were followed up or participated in the cohort studies varied from 2 to 6.5 
years.  In  Table  1.7,  only  the  statistically  significant  results  which  relate  maternal  fish 
intake with atopic outcomes on the infants/children of those mothers are presented. 
Exposure measures 
Regarding the quality and the method of assessing fish intake during pregnancy, three of 
the five studies used a food frequency questionnaire (FFQ) (151;154;155) and two used a 
semi-quantitative FFQ (152;153). FFQs varied in frequency categories and also in time 
point  of  administration  [during  pregnancy  (153),  shortly  after  birth  (151;152)  or 
retrospectively  a  long  time  after  birth  (154;155)]  and  way  of  administration  [self-
administered (153) or interviewer-administered (151;152;155)]. 
Two of the studies examined only the effect of total fish consumption during pregnancy on 
childhood/infancy atopic outcomes  (152;154;155). Three studies  included different  fish 
categories  in  their  questionnaires  (151;153;155),  and  two  of  them  found  statistically 
significant results for oily fish (153;155). It has to be pointed out that although Romieu et 
al. (151) found a statistically significant lower allergy risk of total fish intake, they did not 
assess the impact of different types of fish because of the small number of participants 
reporting  intake  of  oily  fish  only.  Analysing  different  types  of  fish  and  consumption 
frequencies  could  possibly  explain  the  heterogeneity  in  the  extent  of  the  suggested 
protective effect between the studies. For example, Salam et al. (155) observed statistically 
significant results when comparing the effects of „monthly intake‟ versus „never‟ whereas 
the other four studies (151-154) observed statistically significant results when comparing 
the effects of weekly consumption frequencies. Also, the latter four studies reported results 
only on total fish consumption, with the exception of Willers et al. (153) who reported the 
effect of oily fish consumption.    56 
The  smallest  decreases  in  childhood/infancy  atopic  risk  were  found  in  those  studies 
comparing  the  effect  of  two  different  weekly  consumption  frequencies  of  total  fish 
(151;152). On the contrary, studies observing a greater decrease in risk made comparisons 
between  the  effect  of  weekly  versus  „less  than  monthly‟  or  „never‟  consumption 
frequencies (153;154). 
Moreover, in some of the studies oily fish were better defined that in other studies. For 
example, Salam et al. (155) defined oily fish as those with > 2% fat specifying which types 
of fish are included in this category. Other studies which gave a definition of oily fish were 
those of Romieu et al. (151) and Willers et al. (153). A major issue in epidemiological 
studies  is  misclassification  of  dietary  exposure  and  this  should  always  be  taken  into 
account when interpreting data. 
Using  a  FFQ  is  an  effective  method  of  assessing  total  or  oily  fish  intake  in  the  diet, 
although  it  is  not  always  possible  to  have  a  complete  picture  of  the  rest  of  the  diet 
(depending on the food items included in the questionnaire) in order to identify other food 
categories/items related to the outcome measure or that could be possible confounding 
factors. A FFQ reflecting total and oily fish intake during the second and third trimester of 
pregnancy and which is not administered retrospectively (in order to reduce bias resulting 
from poor memory) nor is self-administered would be ideal. Also, apart from including 
fish  categories  it  is  important  to  include  other  major  food  categories  so  as  to  enable 
adjustment for other components of the diet, such as antioxidants, total energy intake and 
dietary fat composition. 
 
Confounding factors 
Romieu et al. (151) included type of fish as a confounding factor and Sausenthaler et al. 
(152)  adjusted  for  all  dietary  variables  included  in  their  FFQ.  Three  of  the  studies 
controlled  for  breastfeeding  (152;153;155).  All  five  studies  controlled  for  maternal 
atopy/asthma and all, apart from Salam et al. (155), controlled for maternal smoking. It is 
worth mentioning that fish consumption might be a marker of a specific lifestyle, so it is 
important to adjust for socio-economic factors such as social class and parental education, 
as well as smoking. Each of the studies in Table 1.7 adjusted for most of these confounding 
factors. 
   57 
Outcome measures 
Referring  to  the  outcome  measures  and  their  assessment,  there  seems  to  be  a  great 
heterogeneity between the five studies. Salam et al. (155) focused on asthma, Calvani et al. 
(154) focused on allergic sensitisation, while Sausenthaler et al. (152), Romieu et al. (151) 
and Willers et al. (153) included various outcome measures such as eczema, atopic wheeze 
allergic sensitisation, or hay-fever. Also, all of the studies assessing clinical outcomes used 
a parental questionnaire which most of the time asked for doctor-diagnosis and gave clear 
definitions  of  each  outcome.  Although  doctor-diagnosed  atopic  diseases  may  be  more 
valid,  limited  access  to  health  care  may  result  in  under-diagnosis  of  atopic  disease 
especially when these are in mild or primary stages (155). 
 
Results 
There is consistency between the findings of the five studies of maternal diet since all of 
them identified beneficial associations between maternal fish intake during pregnancy and 
atopic or allergic outcomes in children. However, in the study of Salam et al. (155) the 
association between maternal oily fish intake and children‟s risk of developing asthma was 
greater in children whose mothers were asthmatic compared to children of non-asthmatic 
mothers (p-interaction = 0.02). Also, for children born to mothers with asthma, the allergy 
risk reduction after oily fish intake was greater for early persistent and late-onset asthma 
(p-trend = 0.06 and 0.01, respectively). On the contrary, Calvani et al. (154) observed 
stronger, and with higher significance, beneficial associations of increased oily fish intake 
during  pregnancy  for  children  of  non-allergic  mothers  compared  to  those  of  allergic 
mothers. It is not clear why these findings are different.  
Moreover, in the prospective cohort study conducted by Romieu et al. (151), although a 
beneficial association was observed initially for the whole population, after stratifying by 
breast-feeding, the risk of persistent wheeze at 6 years of age decreased among the non-
breastfed infants whereas no decreased risk was observed among the breastfed infants. 
The large cohort studies conducted by Sausenthaler et al. (152) and Willers et al. (153) 
concluded similar associations. High (≥ 1 time/week) vs. low maternal fish intake during 
pregnancy was associated with decreased doctor-diagnosed eczema. However the decrease 
in the study of Willers et al. (153) was greater than that in the study of Sausenthaler et al. 
(152)  (43%  vs.  25%  respectively).  This  might  be  related  to  the  fact  that  the  study  of 
Willers et al. (153) followed-up children for a longer period, allowing for signs of atopy to   58 
develop and enabling doctor diagnosis. Willers et al. (153) also showed that there was a 
72% decrease in doctor-diagnosed hay-fever in children born to mothers with higher oily 
fish intake during pregnancy, an association which was not significant for total fish intake.  
In summary 
Fish  consumption  in  pregnancy  was  associated  with  decreased  risk  of  atopy  and  its 
manifestations in the infants born of those pregnancies; this was seen in all five studies. 
However, the extent of the reduction of atopy risk was highly heterogeneous. The decrease 
in childhood or infant atopy ranged between 25-95% in relation to fish intake. However, 
most decreases in atopic risk ranged between 40-80%. Although these five studies provide 
strong evidence of a beneficial effect of maternal fish intake during pregnancy, they are 
characterised by inconsistency in the extent of the decrease in atopy risk observed, which 
may be due to differences in their study design, such as differences in: confounding factors 
controlled for, statistical analysis, definition of atopic outcome in infants/children and their 
mothers, method of assessing atopy, method of collecting dietary information, oily and/or 
total  fish  definition  as  well  as  categories  of  consumption  frequencies  used  to  make 
comparisons. 
 
1.5.1.3 Studies investigating the association of maternal fish intake 
during lactation with atopic outcomes in the offspring of those 
pregnancies 
The last study of Table 1.7 conducted by Hoppu et al. (156) assessed maternal dietary 
intake one month after birth (during lactation). This was not the primary exposure measure 
of this study, which was set up to examine the effect of breast milk fatty acid composition 
on atopic dermatitis during the first year of life. Although a high percentage of EPA in 
breast  milk  was  related to  lower risk of atopic dermatitis,  fish consumption frequency 
during lactation was not associated with breast milk EPA content. This may be attributed 
to the fact that breast milk fatty acid composition is determined by fatty acids accumulated 
in the maternal adipose tissue during pregnancy [(157); (158) cited in (156)]. Maternal fish 
intake during pregnancy in relation to breast milk composition would have been more 
appropriate to investigate (156). 
Conclusion 
Epidemiological studies investigating the effect of maternal fish intake during pregnancy 
have differences in exposure and outcome measure definition and assessment. However,   59 
all  of  them  identified  beneficial  associations  between  maternal  fish  intake  during 
pregnancy and atopic or allergic outcomes in infants/children of those pregnancies. The 
extent of lowering the atopy risk ranged between 25-95%. The one study looking at the 
effects of maternal fish intake during lactation did not observe any significant associations, 
suggesting that altered exposure during pregnancy is more likely to alter atopic outcomes 
in the offspring, as this is more likely to determine fatty acid composition of breast milk 
and thus provision of n-3 PUFAs to the infant. 
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Table 1.7 Maternal fish intake during perinatal life and atopic/allergic outcomes in infants and children of those mothers 
 
Study  Study population and 
design 
Exposure measures and 
exposure assessment 
Outcome measures and 
confounding factors 
Results  
Salam et al 2005 
(155) 





th  grade) and 
their mothers/ guardians 
 
Nested case-control 
study in the Children‟s 
Health Study 
 
Public schools in 
southern California, 
USA 




oily fish (> 2% fat) 
non-oily fish (≤ 2% fat) 








at least 1/month 
Parental report of physician-
diagnosed by age 5 years: 
any asthma, early transient 
asthma, early persistent 





race/ethnicity, maternal age, 
maternal education, 
gestational age, number of 
siblings, exclusive breast 
feeding for four months, 
other fish categories 
 Asthmatic mothers: at least monthly oily fish consumption during 
pregnancy vs. never decreased risk of any asthma in children (OR 
0.20; 95% CI 0.06-0.65, p-trend 0.006).  
 
 Asthmatic and non-asthmatic mothers together: maternal oily fish 
consumption at least monthly was protective for early persistent 
asthma in children (OR 0.45; 95% CI 0.23-0.91, p-trend 0.04) 
 
Fish fingers consumption increased risk of any asthma (OR 2.04; 95% CI 
1.18-3.51, p-trend 0.01) 
 
 Children of non-asthmatic mothers were not benefited from maternal 
oily fish consumption during pregnancy. 
 
No associations were found for the rest of the fish categories 
Calvani et al 2006 
(154) 
295 allergic and 693 
non-allergic mothers 
and their children 
(median age 5 years, 






General Hospitals in 
Rome, Italy 
Maternal intake of fish, butter, 
margarine during pregnancy 
 
Retrospectively assessed by 
parental report via standardised 
questionnaire  
 
1 time/month or less 
1 time/week 
2-3 times/week or more 
 
 
Atopy in children: SPT to 
inhalant and food allergens 
(at hospital)  
 
Confounding factors: age, 
gender, oculorhinitis, 
eczema, age of gestation, 
maternal smoking, paternal 
atopy, maternal occupation, 
butter and margarine intake  
 
 Non-allergic mother group:  
-There was a reduction in risk of food sensitisations in offspring to 
mothers with fish intake during pregnancy „1 time/week‟ (OR 0.22; 95% 
CI 0.08-0.55, p-trend 0.002) and „2-3 times/week or more‟(OR 0.23; 95% 
CI: 0.08-0.69, p-trend 0.002) compared to 1 time/month or less 
 
-Intake of fish „1 time/week‟ and „2-3 times/week or more‟ reduced milk 
sensitisation (OR 0.15; 95% CI 0.04-0.59 and OR 0.05; 95% CI 0.00-0.54 
respectively) and egg sensitisation (OR 0.26; 95% CI 0.09-0.76 and OR 
0.33; 95% CI 0.10-1.07 respectively) 
 
-No associations with inhalant sensitisation 
 
 Allergic mother group: no associations between maternal intake of fish 
during pregnancy and children food or inhalant sensitisation 
 
 Whole study population (adjusted also for maternal atopy):  
-Trend between increased consumption of fish and decreased prevalence 
of positive  SPT for foods (p-trend= 0.008) 
 
-Fish intake „1 time/week‟ vs ≤1 time/month decreased risk of food 
sensitisation (OR 0.34; 95% CI 0.15-0.75, p= 0.007) 
   61 
 
Study  Study population and 
design 
Exposure measures and 
exposure assessment 
Outcome measures and 
confounding factors 
Results  
Romieu et al 
2007 (151) 
462 pregnant women 
and their offspring 





Antenatal Clinics in 
Manorca, Spain 
Maternal dietary intake during 






Interviewer administered FFQ; 
3 months after delivery 
 




diagnosed eczema (at age 1 
year), atopic wheeze and 
persistent wheeze (at age 6 
year) 
SPT (at age 6 years) 
IgE (at age 4 years) 
 
Confounding factors: 
maternal asthma, type of 
fish, smoking during 
pregnancy, maternal atopy, 
gender, maternal social class, 
gestational age 
For an increase in maternal fish intake during pregnancy from once per 
week to 2.5 times per week the risk of having the followings decreased: 
eczema at age 1 year (OR 0.73; 95% CI 0.55-0.98, p= 0.036) , positive 
SPT for HDM at 6 years (OR 0.68; 95% CI 0.46-1.01, p= 0.058) and 
atopic wheeze at age 6 years (OR 0.55; 95% CI 0.31-0.96, p= 0.034)  
 
Weekly maternal fish intake during pregnancy was lower for infants with: 
eczema at 1 year (p= 0.050), positive SPT for HDM at 6 yr (p= 0.048), 
atopic wheeze at 6 years (p= 0.028) 
 
Stratification by breastfeeding: for an increase in fish intake during 
pregnancy from 1 time/week to 2.5 times/week the risk of persistent 
wheeze at 6 years decreased by 90% (OR 0.10; 95% CI 0.02-0.69, 
p<0.05) only among the non-breastfed infants. 
Sausenthaler et al 
2007 (152) 
2641 mothers and their 
infants followed up to 
age 2 years  
 
Prospective cohort in 
the Influences of 
Lifestyle Factors on the 
Immune System and the 
Development of 
Allergies in Childhood 
Study (LISA)  
 
Newborns from 4 
German cities 
 
Maternal diet during the last 4 





administered shortly after 
delivery  
 
high (1-2 times/week) 
low (<1 time/week) 
Parental report of lifetime 
doctor-diagnosed eczema at 
age 2 years  
 
Allergic sensitisation (IgE)  
 
Confounding factors: study 
area, sex, maternal age at 
delivery, smoking during 2
nd 
or 3
rd trimester of pregnancy, 
parental education, exclusive 
breastfeeding for ≥4 months, 
family history of atopy, 
season of birth, all dietary 
variables from FFQ 
High maternal fish intake vs low was associated with decreased doctor-
diagnosed eczema risk in children at 2 years (OR 0.75; 95% CI 0.57-0.98, 
p<0.05) 
Willers et al 2007 
(153) 
1212 pregnant women 
and their children 
followed up to age 5 
years  
 




Maternal diet during pregnancy 
including fish; reflecting intake 2-3 
months prior to 32 weeks gestation  
 
total fish 
oily fish  
 
Semi-quantitative FFQ:  
 
Version 5.4 of the Scottish 
Collaborative Group FFQ; sent by 







Parental report of asthma, atopic 
eczema, wheezing, hay-fever in 
children at 5 years (ISAAC core 
questions) 
 
Spirometry and SPT (only on 
small number of children)  
 
Confounding factors: maternal 
age of leaving full-time 
education, paternal social class, 
maternal age, maternal smoking 
during pregnancy, smoking in 
the home during childhood, 
energy intake, maternal asthma, 
maternal atopy, birth weight, 
presence of older siblings, 
child‟s gender, breastfeeding. 
Beneficial associations (p-trend):  
Maternal total fish intake ≥1/week vs never decreased risk of: doctor-
diagnosed eczema (OR 0.57; 95% CI 0.35-0.92, p-trend= 0.008), current 
treated eczema (OR 0.58; 95% CI 0.32-1.06, p-trend= 0.028), and ever 
having eczema (OR 0.68; 95% CI 0.43-1.10, p-trend= 0.050) 
 
Maternal oily fish intake ≥1/week vs never decreased risk of doctor-
diagnosed hay-fever (OR 0.28; 95% CI 0.06-1.19, p-trend= 0.043)   62 
 
Study  Study population and 
design 
Exposure measures and 
exposure assessment 
Outcome measures and 
confounding factors 
Results  
Hoppu et al 2005 
(156) 
34 atopic mothers and 
their infants followed 
up to age 1 year 
 
Finland  
Breast milk fatty acids; 
samples taken 1 month 
postpartum when infants were 
exclusively or predominantly 
breastfed  
 
Maternal atopic disease 
(asthma, allergic rhinitis, atopic 
dermatitis) assessed with 
questionnaire and SPT; 35-36 
weeks of gestation 
 
Maternal dietary intake (4-
consequative-day food records) 
and questionnaire on maternal 
dietary habits including fish 
consumption frequency; 1 
month postpartum reflecting 




> 1 time/week 
Clinical examination at ages 
1, 3, 6, 12 months and SPT 
at 12 months  
 
Atopic dermatitis during the 
1
st year of life (Hanifin 
criteria) 
Maternal frequency of fish consumption during pregnancy was not related 
to breast milk EPA content. 
 
The ratio SFA/PUFA was higher in breast milk consumed by infants 
developing atopic dermatitis compared to those remaining healthy (4.3 vs 
3.1; p=0.05) 
 
Total n-3 PUFA (% of total fatty acids) was lower in the breast milk of 
mothers whose infants developed atopic dermatitis than of those whose 
infants remained healthy (1.61% vs 2.17%; p=0.05) 
 
EPA (% of total fatty acids) was lower in breast milk consumed by 
infants who developed atopic dermatitis during the 1
st yr of life compared 
to those who did not (0.10 vs 0.15; p=0.02) 
  
OR, odds ratio; CI, confidence interval; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; HDM, house dust mite; FFQ, food frequency questionnaire; 
ISAAC;  International  Study  of  Asthma  and  Allergies  in  Childhood;  SPT,  skin  prick  testing;  DHA,  docosahexaenoic  acid;  EPA,  eicosapentaenoic  acid;  Ig, 
immunoglobulin; vs, versus.   63 
 
1.5.1.4 Studies investigating the association of fish intake during infancy 
or childhood with atopic/allergic outcomes in those 
infants/children 
Table 1.8 summarises the characteristics and results of published observational studies that 
investigate the association between fish intake during infancy or childhood and atopic or 
allergic  outcomes  in  those  infants  or  children.  Studies  were  identified  through  Ovid 
Medline  (1950-2008)  and  Embase  (1980-2008)  databases  performing  and  combining 
searches with the following keywords: fish intake, oily fish intake, childhood, infancy, 
atopy,  allergy,  asthma,  eczema.  Fourteen  epidemiological  studies  were  identified.  The 
evidence provided by these studies is less consistent and there is a greater heterogeneity in 
study designs, exposure, outcome measures and results compared to the epidemiological 
studies of Table 1.7.  
A  total  of  14  studies  were  identified.  Eight  studies  observed  a  beneficial  association 
between fish intake during childhood/infancy and atopic outcomes in those children/infants 
(159-166). Three of the studies observed an adverse effect of fish intake on childhood 
atopy (167-169), and three studies observed no associations (170-172). All studies were 
well powered, with large enough sample sizes, although was a wide range of sample size 
amongst the studies.  
The studies of Table 1.8 will be discussed according to whether they observed a protective, 
adverse or a null effect. 
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Table 1.8: Fish intake during infancy/ childhood and atopic or allergic outcomes in those infants/ children 
 
Study  Study population and 
design 
Exposure measures and 
exposure assessment 
Outcome measures and 
confounding factors 
Results  
Hodge et al 1996 
(163) 






Dietary intake of children 
including fish (reflecting intake 
over the last year) 
 
total fish (all categories) 
fish fingers 
canned fish 
total fresh fish 
fresh oily fish (>2% fat) 
fresh non-oily fish (≤2% fat)  
 
FFQ completed by parents 






Assessed 6 months before 
dietary information was 
collected: AHR (by 




Current asthma: presence of 
both recent wheeze and AHR  
 
Confounding factors: Sex, 
ethnicity, country of birth, 
atopy, respiratory infection 
in the first 2 years of life, 
parental smoking or asthma 
history 
Children who ate any fresh (OR 0.52; 95% CI 0.24-1.15) or oily fresh fish 
vs none had reduced risk of current asthma (OR 0.26; 95% CI 0.09-0.72, 
p< 0.01) 
Hijazi et al 2000 
(171) 
114 asthmatic and 202 
non-asthmatic children; 
aged 12 years (from a 





Saudi Arabia (rural and 
urban areas) 
Dietary intake including fish; at 
age 12 years 
 
-Maternal completion of  
semi-quantitative FFQ 
-Questionnaire on food types 






Asthma ever, wheeze in the 
last 12 months (ISAAC 




Cases: both asthma and 
wheeze 
 
Confounding factors: social 
class, place of residence, 
nationality, sex, maternal 
education, family history of 
asthma or allergy, positive 
SPT 
Univariate analysis:  
The frequency of eating fish was not significantly related to ever having 
asthma or wheezing in the last 12 months 
 
There was no association between PUFA intake and asthma or wheeze     65 
 
Dunder et al 2001 
(162) 
1. Retrospective case-
control nested in the 9-year 
follow-up (1980-1989): 60 
atopic and 1293 non-atopic 
children aged 3, 6, 9, 12, 
15, 18 years.  
 
2. Case-control: 
231 atopic and 231 non-
atopic children (1980); 
mean age 10.3 years  
 
154 atopic and 154 non-
atopic children (1986) 
 
(pairs matched for age, sex 
and place of residence) 
 
Finland (rural and urban areas) 
Dietary intake including fish 
intake (standardised to energy 
intake); in 1980 and 1986 
 
48-h recall administered by 
nutritionists 
 
gr/1000 Kcal energy 
 
 
Serum fatty acids 
 
Physician diagnosed: allergic 
rhinitis, allergic dermatitis, 
asthma (parental 
questionnaires in 1980, 
1986, 1989) 
 
Atopic disease: one or more 
of the above diseases 
 
Confounding factors: age, 
sex, region, maternal 
education 
  Follow-up: children who developed atopic diseases in 1989 had 
consumed less fish in 1980 compared to those who remained healthy 
(3.2 vs 6.6 g/1000 Kcal; p< 0.001) 
 
  Cross-sectional data in 1980: fish consumption was not associated with 
atopic disease, atopic dermatitis, allergic rhinitis, or asthma  
 
  Serum EPA and DHA were lower in children with atopic dermatitis in 
1980 (1.11 vs 1.22; p=0.01 and 0.64 vs 0.69; p=0.01 respectively) and 
1986 (0.91 vs 1.02; p=0.02 and 0.55 vs 0.61; p=0.01 respectively) 
  
 
Huang et al 2001 
(168) 






st Nutrition and 
Health Survey in Taiwan 
 
 
Dietary intake including fish 





other seafood  
 
24-h recall and FFQ; 
administered to children  
 
Quartiles of intake 
Physician-diagnosed: 
allergic rhinitis, asthma; 
(questionnaire to children) 
 
Confounding factors: levels 
of urbanisation 
  Univariate analysis: Higher intake of oily fish (1
st vs 4
th quartile of 
intake) was associated with higher prevalence (1.5% vs 4.9%) of 
doctor diagnosed asthma (p=0.01) 
 
  Multivariate analysis: total and oily fish intake were not associated 
with asthma or allergic rhinitis  
 
  There was no association between any fish category intake and 
allergic rhinitis 
 
  No associations found for shellfish and other seafood and outcome 
measures 
Takemura et al 
2002 (169) 
Children aged 6-15 years: 
1673 currently asthmatic 





Childhood Asthma and 
Pollinosis Study, Japan 
Questions on consumption 








Parental FFQ (Japanese 
Ministry of Health and 
Welfare) 
Current asthma (parental 
questionnaire of the American 
Thoracic Society and Division 
of Lung Diseases adopted by the 
Japan Environment Agency) 
 
Current asthma: doctor-
diagnosed asthma with 
symptoms and treatment during 
the past 2 years 
 
Confounding factors: age, 
gender, parental history of 
asthma, vegetable and fruit 
intake 
Higher prevalence of asthma among subjects who ate fish 1-2 times/wk 
compared to those who ate fish 1-2 times/month (OR 1.117; 95% CI 
1.005-1.241, p= 0.041).  
 
The risk of current asthma increased gradually with increasing frequency 
of fish intake (p-trend= 0.0349)   66 
 
Study  Study population and 
design 
Exposure measures and 
exposure assessment 
Outcome measures and 
confounding factors 
Results  
Antova et al 2003 
(167) 





25 areas in 6 Central 





Dietary intake of fish, fresh 
fruit and fresh vegetable 
(parental FFQ; redesigned 




Winter cough , persistent 




Confounding factors: age, 
sex, area, pets, indoor 
moisture, gas oven for 
heating, additional gas 
heating, passive smoking, 
maternal education, paternal 
occupation, parental allergy, 
respondent, overcrowding, 
all tested nutritional factors 
Low fish intake (<1/month) compared with higher (≥1/month) was 
associated with increased risk of persistent cough (OR 1.18; 95% CI 1.04-
1.34, p=0.01), wheeze ever (OR 1.14; 95% CI 1.03-1.34, p=0.01), and 
current wheeze (OR 1.21; 95% CI 1.06-1.39, p=0.01)  
Farchi et al 2003 
(170) 
4104 children aged 6-7 
years, followed-up for 
one year 
 
Prospective cohort  
 
Italian Studies on 
Respiratory Disorders 
in Children and the 
Environment (SIDRIA), 
part of the ISAAC 
Dietary intake including fish 
(at 1 year follow-up) 
 
pasta with fish: tuna, mackerel, 
sardines, salmon, anchovies 
 
oily („blue‟) fish: tuna, 
mackerel, sardines, salmon, 
anchovies 
 






12 month occurrence of: 
wheeze, shortness of breath 
with wheeze, allergic rhinitis 
symptoms (parental 
completion; ISAAC 
questions at baseline and 
questionnaire at 1 year 
follow-up) 
 
Confounding factors: sex, 
study area, paternal 
education, household 
crowding, maternal or 
paternal smoking, dampness 
or mould, parental asthma 
In the univariate analysis: neither oily fish nor „pasta with fish‟ were 
associated with 12 month occurrence of wheeze, shortness of breath with 
wheeze or allergic rhinitis (p-trend not significant)   67 
 
Study  Study population and 
design 
Exposure measures and 
exposure assessment 
Outcome measures and 
confounding factors 
Results  
Nafstad et al 2003 
(166) 
2531 infants followed 
up to age 4 years  
 
Prospective cohort  
 
Oslo Birth Cohort 
Study, Norway 
Introduction of various kinds of 
food including fish into diet 
during the year 1 of life 
 
 
Parental questionnaires at age 1  
year (no quantitative 
information)  
 




asthma and allergic rhinitis 
(parental questionnaire 
administered at 4 years) 
 
Confounding factors: parental 
atopy, atopic eczema at 0-6 
months of age, gender, parity, 
birth weight, maternal age at 
delivery, birth order, uterus-
related pregnancy complications, 
keeping pets at home when child 
was born, episode of lower 
respiratory tract infections 
during year 1 of life, maternal 
education, family income per 
year, maternal smoking at the 
end of pregnancy, length of 
breastfeeding. 
The risk of allergic rhinitis was lower in children who had fish during the first year 
of life compared to children who had fish later in life (OR 0.45; 95% CI 0.28-0.74) 
 
Among children who were breastfed for >6 months, those who had fish during year 
1 of age had lower asthma risk (OR 0.56; 95% CI 0.36-0.87) and allergic rhinitis 
risk (OR 0.28; 95% CI 0.15-0.52) compared to those who had none (respective 
risks 0.073 and 0.058). 
 
Among children without parental hay fever or asthma, those who had fish during 
year 1 of age had lower asthma risk (OR 0.50; 95% CI 0.30-0.83) and allergic 
rhinitis risk (OR 0.47; 95% CI 0.25-0.86) compared to those who had none  
 
Among children with early life atopic eczema, there was a decreased risk of asthma 
(OR 0.47; 95% CI 0.23-0.97) and allergic rhinitis (OR 0.32; 95% CI 0.15-0.69) 
with any fish consumption during year 1  
 
Among children without an episode of lower respiratory tract infection during the 
first year of life, those who had fish during year 1 of age had lower allergic rhinitis 
risk (OR 0.39; 95% CI 0.24-0.66) compared to those who had none  
 
The risk of having doctor-diagnosed atopic eczema with symptoms during the 4
th 
year of age was reduced in children who consumed fish during year 1 of life 
compared to those who did not (OR 0.66; 95% CI 0.52-0.84, p=0.001) 
Wijga et al 2003 
(172) 
2978 children, aged 2 





The Prevention and 
Incidence of Asthma 
and Mite Allergy 
(PIAMA) birth cohort 
study, Netherlands 
Dietary intake including fish 
during the previous month; at 




Rarely: <1 time/week 
Regularly: 1-5 times/week 
Daily: 6-7 times/week 
Doctor-diagnosed ever 
asthma, doctor-diagnosed 
recent asthma (last 12 
months), recent wheeze 
(parental questionnaire based 
on ISAAC); posted at age 3 
years 
 
Confounding factors: sex, 
birth weight, presence of 
older siblings, parental 
allergy, maternal level of 
education, breastfeeding for 
at least 8 weeks, smoking in 
the home and during 
pregnancy, region, parental 
asthma  
In the univariate analysis eating fish at least once a week was not 
associated with ever asthma, recent asthma or recent wheeze 
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Andreasyan et al 
2005 (160) 











Children‟s total fish intake at 





SPT, asthma, hay-fever, 
wheeze, eczema (ISAAC 
questionnaire to parents)  
 
Confounding factors: 
sheepskin and plastic 
mattress use during infancy, 
sex, number of siblings at 8 
years, bottle feeding at 1 
month, any maternal 
smoking during pregnancy 
Fish intake was associated with decreased risk of ryegrass-pure 
sensitisation (OR 0.37; 95% CI 0.15-0.90, p= 0.03). 
 
Fish intake was associated with decreased risk of asthma linked to 
ryegrass-pure sensitisation (OR 0.20; 95% CI 0.04-0.90, p= 0.04), and the 
risk of hey-fever linked to ryegrass-pure sensitisation (OR 0.25; 95% CI 
0.08-0.78, p= 0.02). 
 
Fish consumption was associated with a greater reduction in risk for 
ryegrass-pure sensitisation in comparison to the risk reduction for HDM-
pure sensitisation (OR 0.20; 95% CI 0.05-0.79) 
Kim et al 2005 
(164) 





All primary schools in 
Knivsta, Sweden 
Dietary intake of specific food 
categories including fish 
(parental completion in co-












Assessment of allergens in the 
school environment  
Doctor-diagnosed asthma, 
current asthma (last 12 
months), wheeze, daytime 
breathlessness, night-time 
breathlessness, self-reported 
atopic sensitisation to cat, 
dog, pollen, food  
 
Questions obtained from the 
European Community 
Respiratory Health Survey; 
parental completion in co-
operation with the child 
 
Confounding factors: age, 
gender, and all other dietary 
factors 
For an increase of fish intake by one frequency category there was a 
decreased risk of doctor-diagnosed asthma (OR 0.54; 95% CI 0.35-0.84, 
p<0.01), current asthma (OR 0.51; 95% CI 0.31-0.84, p<0.01), and night-
time breathlessness (OR 0.36; 95% CI 0.17-0.78, p<0.05) 
 
 
Kull et al 2006 
(165) 
3619 infants followed 






frequency and time of 
introducing fish during the 1
st 
year of life  
 







>1 time/ week 
 
Regular fish consumption 
defined as ≥2-3 times/week 
Assessed at age 4 years 
(occurrence during last 1-2 
years): asthma, eczema, 
allergic rhinitis, persistent 
allergic disease, sensitisation 
(IgE) 
 
Any allergic disease: at least 
one of asthma, eczema, 
allergic rhinitis 
 
Multiple allergic diseases: 
more than two 
 
Confounding factors: 
parental allergic disease, 
maternal age, maternal 
smoking, breastfeeding 
Dose-dependent reduced risk for asthma (p-trend= 0.03), eczema, allergic rhinitis 
and sensitisation (p-trend< 0.001) with increased in fish consumption frequency 
 
Introducing fish at age 3-8 months reduced risk for asthma (OR 0.73; 95% CI 0.55-
0.97), eczema (OR 0.77; 95% CI 0.64-0.92), allergic rhinitis (OR 0.77; 95% CI 
0.60-0.97) and sensitisation (OR 0.78; 95% CI 0.64-0.95) compared to introducing 
fish at or after age 9 months. 
  
  Among children without eczema and /or recurrent wheeze during the 1
st year of 
life: fish consumption ≥2 times/month compared to ≤1 time/month during the first 
year of life was associated with reduced risk of any allergic disease (OR 0.76; 
95% CI 0.61-0.94), eczema (OR 0.78; 95% CI 0.60-1.00), rhinitis (OR 0.60; 95% 
CI 0.43-0.83), sensitisation (OR 0.76; 95% CI 0.57-1.00), persistent eczema (OR 
0.48; 95% CI 0.32-0.68), persistent rhinitis (OR 0.43; 95% CI 0.23-0.79) and 
multiple allergic disease (OR 0.56; 95% CI 0.35-0.89) at 4 yr 
 
  Fish consumption ≥2 times/month compared to ≤1 time/month during the first 
year of life was associated with reduced risk of sensitisation (OR 0.52; 95% CI 
0.35-0.76, p< 0.01) only in children without parental allergy   69 
 
Study  Study population and 
design 
Exposure measures and 
exposure assessment 
Outcome measures and 
confounding factors 
Results  
Chatzi et al 2007 
(161) 











fried/ coated fish 
seafood 
 
Parental completion of semi-
quantitative FFQ (modified 




Current wheeze, atopic 





Confounding factors: gender, 
maternal and parental 
asthma, maternal and 
paternal atopy, maternal 
smoking, BMI at 6.5 years, 
maternal and paternal 
education and social class, 
breastfeeding, fish intake 
during pregnancy, number of 
siblings 
There was inverse association between children‟s total fish intake ≥ 60 
gr/day and atopy (OR 0.43; 95% CI 0.21-0.90, p< 0.05) 
 




Alm et al. 2009 
(159) 
4921 infants aged 1year 
 
Prospective Cohort 




Food frequency data collected 




A few times per year 
1-3 times per month 
1-3 times per week 





Mackerel or herring 
Paternal reported prevalence of 
eczema and food allergy 
diagnosed by a physisian at 6 
and 12 months of age. 
 
Significant risk factors (p<0.01): 
maternal eczema, a sibling with 
eczema, a bird in the home, the 
introduction of fish before 9 
months of age and cows‟ milk 
allergy. 





In the multivariate analysis: familial occurrence of eczema, especially in 
siblings (OR 1.87; 95% confidence interval (CI) 1.50 to 2.33) or the 
mother (OR 1.54; 95% CI 1.30 to 1.84), remained an independent risk 
factor.  
Introducing fish before 9 months of age (OR 0.76; 95% CI 0.62 to 0.94) 
and having a bird in the home (OR 0.35; 95% CI 0.17 to 0.75) were 
beneficial. 
At 1 year of age, 20.9% of the infants had previous or current eczema. 
Median age at onset was 4 months. 
In the univariate analysis: eating fish never vs 3times/week increases the 
risk of eczema  at 1 year of age (OR=2.73;95%CI 1.80 to 4.13,p<0.001) 
and  never vs usually eating lean fish reduces the risk for eczema at 1 year 
(OR=0.81;CI 0.68 to 0.97) 
OR, odds ratio; CI, confidence interval; PUFA, polyunsaturated fatty acids; HDM, house dust mite; FFQ, food frequency questionnaire; ISAAC; International Study of 
Asthma and Allergies in Childhood; SPT, skin prick testing; DHA, hocosahexaenoic acid; EPA, eicosapentaenoic acid; Ig, immunoglobulin; AHR, airway hyper-
responsiveness; vs, versus. 
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Studies showing a protective effect of fish 
Of  the  studies  that  found  a  beneficial  association  between  fish  intake  during 
infancy/childhood  and  atopic/allergic  outcomes,  three  were  prospective  cohort 
(159;165;166),  two  were  case-control  (162;163),  and  three  were  cross-sectional 
(160;161;164) studies. Although cross-sectional studies are able to identify associations, 
they  are  weak  designs  in  assessing  causal  associations.  In  contrast,  retrospective  case-
control studies and prospective cohort studies are stronger in design and better able to 
identify association. 
The age range of children taking part in these studies was between 1-18 years (at the time 
point  that  outcomes  were  measured).  Because  of  the  wide  age  range  of  the  study 
population differences in the extent of the beneficial effect can be expected. Some of the 
studies measured exposure and outcome at a much older age (160;162-164) than others 
(159;161;165;166). The two prospective cohort studies followed-up infants to age 4 years 
(165;166) whereas the „Infants of Western Sweden‟ study followed up infants up to one 
year. 
The reduction in atopy/allergy risk associated with fish intake ranged between 22-80%. 
However,  the  risk  reduction  in  most  cases  was  between  50-60%,  providing  consistent 
evidence for suggesting a protective effect of fish consumption during childhood/infancy 
on atopy/allergy.  
However, studies were inconsistent as far as exposure assessment is concerned. All three 
prospective cohort studies (159;165;166) determined the time point of fish introduction 
during the first year of life using a parental questionnaire. In addition Kull et al. (165) 
collected information on fish consumption frequencies. Alm et al. collected food frequency 
data at two different time points (159). The cross-sectional study of Kim et al. (164) used a 
parental FFQ, that of Chatzi et al. (161) used a semi-quantitative FFQ and the other cross-
sectional study used parental report of fish consumption without frequencies (160). The 
retrospective case-control study of Dunder et al. (162) used a 48-hour recall of intake and 
the case-control study of Hodge et al. (163) used a parental FFQ (although consumption 
frequency categories were not used in their analysis). 
The ideal method of collecting information on fish consumption would be a FFQ with 
various food categories/items reflecting intake during the past 12 months, including time of 
introduction of fish into diet and different types of fish consumed (oily, non-oily). Also,   71 
ideally the questionnaire should be administered to the children in collaboration with their 
parents and also repeated at different time points in the case of prospective cohort studies 
which have a long period of follow-up. 
Oily fish consumption was recorded in the studies of Hodge et al. (163), Chatzi et al. (161) 
and  Alm  et  al.  (159).  The  rest  of  the  studies  recorded  only  total  fish  intake  without 
specifying the types of fish. In the study of Hodge et al. (163) fresh oily fish consumption 
had  a  greater  protective  effect  on  current  asthma  than  total  fish  consumption  (74% 
reduction versus 48%, respectively). However, in the „Infants of Western Sweden‟ study 
information was collected on type of fish usually ingested split into 2 different kinds of 
fish (lean/white or fat/oily) and no influence was found of any type of fish on eczema. 
Chatzi et al. (161) did not identify any significant association for any of the subgroups of 
fish included in their FFQ.  
Regarding the outcomes, in the study of Nafstad et al. (165;166), introduction of fish early 
into diet suggested a protective effect on allergic rhinitis which was observed for the whole 
study  population  initially.  When  analysing  the  results  for  different  subgroups,  the 
protective effect on asthma and/or allergic rhinitis remained significant only among the 
following groups of children: breastfed for more than 6 months, without parental hay-fever 
or asthma, with early life atopic eczema, without an episode of lower respiratory tract 
infection during the first year of life. Similarly, in the prospective cohort study of Kull et 
al. (165), although there was a dose-dependent reduction in risk of atopic outcomes with 
increased  fish  consumption  frequency,  when  conducting  the  analysis  for  different 
subgroups, the suggested protective effect remained significant only for children without 
parental allergy. In contrast to the study of Nafstad et al. (166), in the study of Kull et al. 
(165) the results remained significant only for children without eczema and/or recurrent 
wheeze during the first year of life. Interestingly, introducing fish early during the first 
year of life (age 3-8 months) was more beneficial than introducing fish later on (age ≥ 9 
months) and this was associated with a lower risk of eczema at four years of age (165). 
This is compatible with the findings of Alm et al. (159) who found that the introduction of 
fish before nine months of age lowered eczema risk in infants at one year (by 24%), when 
the prevalence of eczema at 12 months on the population was reported to be 20.9%. All the 
rest of the studies which suggested a protective effect, conducted their analysis for the 
study population as a whole.  
As discussed for Table 1.7, atopic outcome definitions and assessment methods differed 
between  studies.  Three  of  the  studies  performed  SPT  (160;161;163)  and  one  study   72 
determined specific IgE to identify sensitisation (165). In the study of Alm et al. no clinical 
test or biochemical measurement of allergy was conducted. Clinical outcomes measured in 
all of the studies were assessed with parental questionnaires which included questions on 
atopic  outcomes.  However  parents  were  not  always  asked  for  doctor-diagnosis  [for 
example self-reported atopic sensitisation or eczema (159)]. Clinical outcomes in all of the 
studies were generally well defined. 
As far as confounding factors are concerned, the only studies which adjusted for all other 
dietary information collected were those of Kim et al. (164) and Alm et al (159). The study 
of Chatzi et al. (161) controlled for total energy intake and for maternal fish intake during 
pregnancy  which  was  recorded  using  the  Spanish  version  of  the  validated  European 
Prospective  Investigation  into  Cancer  and  Nutrition  (EPIC)-Norfolk  FFQ.  Maternal 
smoking was  controlled  for  in  the studies  of Hodge  et  al. (163), Nafstad  et  al.  (166), 
Andreasyan et al. (160), Kull et al. (165) and Alm et al. (159). Parental history of atopy 
and breastfeeding were controlled for in the studies of Nafstad et al. (166), Kull et al. 
(165), Alm et al. (159) and Chatzi et al. (161). Hodge et al. (163) and Nafstad et al. (166) 
adjusted for atopy/respiratory infection in early life. It should be emphasised that issues 
related to the methods of collecting the information about confounding factors and the 
validity of this information need to be considered when interpreting the results of these 
studies. 
Studies showing a harmful effect of fish 
Three studies were identified that found a negative association of fish consumption with 
atopic/allergic  outcomes  in  children/infants  (167-169).  All  three  studies  had  a  cross-
sectional  study  design,  measuring  exposure  and  outcome  at  the  same  time  point.  As 
mentioned previously, this study design is not strong enough to infer causality. All sample 
sizes can be considered as large enough. Compared to the studies that suggested a lowering 
atopic risk, these studies were conducted in older children. Also, the increase in risk was 
not of great magnitude (12-21%). 
All three studies used a FFQ. The FFQs in the studies of Takemura et al. (169) and Antova 
et al. (167) were completed by parents. The study of Huang et al. (168), apart from the 
FFQ, also used a 24-h recall and compared the effect between quartiles of intake rather 
than consumption frequencies. The study conducted by Huang et al. was the only one 
which included oily fish in the questionnaire.   73 
As far as the atopic outcome measures are concerned, in the studies of Takemura et al. 
(169)  and  Antova  et  al.  (167)  questionnaires  about  atopy  were  answered  by  parents 
whereas in the study of Huang et al. (168) questionnaires were answered by children. All 
of  the  studies  were  focused  on  clinical  outcomes.  Also,  all  three  studies  included  a 
component of doctor-diagnosis of atopic outcomes in their questionnaires. The study of 
Huang  et  al.  (168)  excluded  subjects  with  atopic  symptoms  who  were  not  doctor-
diagnosed.  This  could  potentially  lead  to  misclassification  of  atopy  since  some  of  the 
subjects may not have access to the health care system or may have a mild or premature 
form of the disease. 
Two of the studies adjusted for parental atopy and for children‟s fruit and vegetable intake 
(167;169). The studies of Huang et al. (168) and Takemura et al. (169) did not adjust for 
socio-economic  factors.  As  mentioned  previously,  these  are  very  important  since  fish 
intake may be associated with a specific lifestyle. 
In the study of Takemura et al. (169), although there was a trend of increasing risk of 
current asthma with increasing fish intake, the increase in risk was significant only when 
comparing the effect of fish intake 1-2 times/month with that of fish intake 1-2 times/week, 
but not when comparing the effect of fish intake 1-2 times/month with never or ≥ 3-4 
times/week.  Also,  in  this  study  the  validation  of  the  FFQ  was  done  using  four  7-day 
records of dietary intake (from 102 males and 113 females).  
In the study of Antova et al. (167), although the results were significant when comparing 
the effect of fish intake once a month or more vs. less than once a month, the significance 
of the results reduced when comparing the effect of more frequent fish consumption (> 2 
times/week, 1-4 times/month, never or < 1 time/month). 
Studies showing no effect of fish 
 
Of the three studies that did not identify any significant association between fish intake and 
atopic or allergic outcomes in infants/children, two were prospective cohort (170;172) and 
one was case-control (not retrospective design) (171). It has to be mentioned that the cross-
sectional data taken from the case-control study nested in the follow-up study of Dunder et 
al. (162) identified a null association between fish consumption and any atopic diseases (in 
1980).  However,  as  mentioned  above,  the  retrospective  follow-up  showed  beneficial 
associations. In the same study the cross-sectional data of 1986 was not presented.   74 
All three studies used a parental/maternal FFQ. The study of Farchi et al. (170) was the 
only one including oily fish (mentioned as „blue fish‟) and „pasta with oily fish‟. The other 
two studies  collected information  only on  consumption  frequencies of  total  fish. Also, 
frequency categories (often, sometimes, rarely, never) in the study of Hijazi et al. (171) 
were not clearly defined in the questionnaire. What is more, the two prospective cohort 
studies (170;172) did not include monthly fish consumption frequencies in their analysis. 
In  contrast,  they only  compared weekly  consumption  frequencies which may not  have 
allowed for significant associations to be identified. 
All studies were conducted in children older than 1 year of age. Hijazi et al. (171) collected 
fish intake data at age 12 years, Farchi et al. (170) at age 6-7 years and Wijga et al. (172) 
at age 2 years.  
As  far  as  the  outcome  measures  are  concerned,  the  two  prospective  cohort  studies 
(170;172)  assessed  atopic  outcome  based  on  the  ISAAC  questionnaires  completed  by 
parents. The ISAAC questions were also used in the study of Hijazi et al. (171), however, 
they were answered by the children themselves. Two of the studies (171;172) reported 
results  of  univariate  analysis  (i.e.  not  controlling  for  possible  confounders).  Lastly, 
although the two prospective cohort studies had a large sample size, their follow-up lasted 
only for 1 year which may not have been long enough to allow for allergy/atopy outcomes 
to appear.  
Conclusion 
The  evidence  from  epidemiological  studies  investigating  the  association  of  fish  intake 
during  infancy  and  childhood  with  atopic  outcomes  in  those  infants  or  children  is 
inconsistent. However, the majority of the studies (8/14) proposed a protective association 
between  fish  intake  during  infancy  or  childhood  and  atopic  outcomes  in  those 
infants/children.  The  reduction  in  atopy/allergy  risk  ranged  between  22  and  80%. 
Nevertheless, studies differed in study design, exposure and outcome measure assessment. 
Three studies did not observe any association and three studies observed increased risk of 
atopy (12-21%) with higher fish consumption. Therefore, based on the evidence available 
from epidemiological studies, it cannot be concluded whether fish consumption during 
infancy  or  childhood  can  be  recommended  in  order  to  protect  from  atopic  disease 
development.    75 
1.5.2  Randomised controlled trials (RCTs) and mechanistic studies 
 
In general, randomised controlled trials (RCTs) are study designs that provide the highest 
level of evidence of cause and effect. This section reviews the literature on RCTs of fish 
oil supplementation in pregnancy, lactation or infancy/childhood and allergic outcomes in 
infants/children of those pregnancies or those infants/children (Table 1.9, Table 1.10). The 
studies  were  identified  through  Ovid  Medline  (1950-2008)  and  Embase  (1980-2008) 
databases by performing and combining searches with the following keywords: fish oil, 
EPA, DHA, fish oil trial, fish supplements, maternal, pregnancy, lactation, atopy, allergy, 
asthma, eczema, childhood, infancy. 
 
1.5.2.1 Randomised controlled trials looking on the effects of fish oil 
supplementation during pregnancy or lactation on allergic 
outcomes in the offspring of those pregnancies 
 
Table  1.9  summarizes  RCTs  of  maternal  fish  oil  supplementation  during  early  life 
(pregnancy  and  lactation)  and  allergic  outcomes  in  the  offspring  during  infancy  or 
childhood;  five  such  studies  have  been  published  at  the  time  of  writing.  One  study 
investigated the effects  of LC n-3 PUFA supplementation during pregnancy and many 
scientific papers have been published on this study (35;132;133;136;173-176), of which six 
(35;132;133;136;173;176) refer to clinical allergic outcomes in the offspring or immune 
markers that may modulate these outcomes (Table 1.9). A second study, also investigating 
the effects of fish oil supplementation during pregnancy on the immune system of the 
mother and the offspring, has recently published two papers (177;178) of which one (178) 
is included in Table 1.9. The third study was conducted on lactating women and associated 
the maternal fish oil intervention with allergic biomarkers, but not with clinical outcomes 
in the children (179). The fourth trial, conducted by Olsen et al. (180) investigated the 
effects of fish oil intake in the last trimester of pregnancy and followed up the children to 
assess asthma-related diagnosis at 16 years of age. The fifth study investigated the effects 
of n-3 fatty acid supplementation both during pregnancy and lactation, on infant allergy 
risk.  This  trial  has  published  two  relevant  papers,  one  looking  on  the  effects  of  the 
supplementation on the offspring during the first year of life (181) and the other looking on 
the effects of the supplementation during pregnancy on the immune system of the mother 
(182). 
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Study design 
The study by Dunstan et al. (35;132;133;136;173-176) was conducted in Australia and it 
was  a  double-blinded  RCT  starting  at  week  20  of  pregnancy.  The  study  of  Krauss-
Etschmann et al. (178) was a European multicenter (Germany, Spain, Hungary) 2-factorial 
double-blinded  RCT  starting  at  week  22  gestation.  This  study  was  conducted  by  the 
Nutraceuticals for Healthier Life (NUHEAL) study group. The study by Lauritzen et al. 
(179) was conducted in Denmark and it was also a double-blinded parallel group RCT 
including women from The Danish National Birth Cohort. In this study, the women were 
supplemented during lactation and their children were followed up to 2.5 years of age. The 
study by Furuhjelm et al. (181) was conducted in Sweden and was a RCT as well starting 
at 25
th week of gestation up to 3-4 months of breastfeeding. The study of Olsen et al. 
(180), conducted in Denmark, was a double blinded RCT with stratification by maternal 
fish intake at baseline (low/medium/high), conducted from week 30 gestation to delivery, 
and children were followed up at 16 years of age.  
Furuhjelm et al. (181) compared marine n-3 fatty acid supplementation with soy oil as 
placebo. The studies of Dunstan et al. (35;132;133;136;173-176), Lauritzen et al. (179), 
and Olsen et al. (180) compared marine n-3 fatty acid supplementation with olive oil as 
placebo. However, in the study of Lauritzen et al. (179) there was a third group of women 
which was a high-fish-intake reference group and did not receive any supplement. In the 
study of Olsen et al. (180) there was also a third group which was a control group and 
which received no oil capsules. Krauss-Etschmann et al. (178) included four groups: DHA-
rich fish oil, 5-methyl-tetra-hydrofolic acid (5-MTHF, 400 μg/day), both, or placebo. All 
were provided in a milk-based drink. The placebo was a plain milk-based supplement of 
minerals and vitamins recommended for pregnancy. For the intervention groups, fish oil 
and/or 5-MTHF were added into the placebo supplement. All groups received supplement 
with similar energy value, protein, fat and carbohydrate content, and identical content in 
rest of vitamins and minerals. Detailed analysis of individual fatty acids of the placebo and 
fish oil supplement was provided by the authors, and there were not significant differences 
in linoleic and α-linolenic acid between them.  
The main inclusion criterion for the women who participated in the study by Dunstan et al. 
(132) was the presence of atopy. All women had a history of physician diagnosed allergic 
rhinitis and/or asthma and one or more positive skin prick tests (SPT) to six common 
allergens. What is more, the subjects‟ habitual dietary intake did not exceed two fish meals 
per week. This was assessed using a semi-quantitative FFQ prior to the study. On the other   77 
hand, in the study of Krauss-Etschmann et al. (178) subjects were healthy pregnant women 
(including both atopic and non-atopic subjects). Only women who did not use fish oil, 
folate or vitamin B12 supplementation after week 16 gestation were included in the study. 
Mothers  that  took  part  in  the  Danish  study  (179)  were  healthy  and  non-atopic.  The 
estimation of their habitual LC n-3 PUFA (g/day) intake was conducted using a semi-
quantitative 300 item  FFQ. As mentioned above, randomization was  based on  LC n-3 
PUFA intake, and women with an intake below the population median (< 0.4 g/day) were 
randomized to one of the intervention groups. Women with an intake in the upper quartile 
(> 0.8 g/day) were used as a reference group. In the study of Olsen et al. (180) the women 
were  healthy  at  study  entry  (atopic  and  non-atopic),  and  those  with  fish  allergy  were 
excluded. Food intake was assessed at baseline by a simple FFQ that categorised women in 
low, medium and high habitual intake of fish. In the study of Furuhjelm et al. (181) both 
atopic  (55%)  and  non-atopic  women  (30%)  were  included  (family  history  of  allergy 
assessed by interview and doctor diagnosis and IgE positive test) and those with fish or soy 
allergy  were  excluded.  For  the  purposes  of  the  study,  only  women  that  planned  to 
breastfeed their offspring were included. At baseline (25 weeks of gestation) 3-day dietary 
diaries were conducted and PUFA intakes were calculated. In both groups EPA and DHA 
intakes were 0.2g/day and 0.1 g/day respectively, while in the placebo group the LA intake 
was about 7 g/day (181). 
Although the window of early life that the intervention took place differed between the five 
studies (pregnancy and/or lactation), the duration of intervention period prenatally was 
similar for the three studies: week 20 of gestation to delivery (132), week 22 of gestation to 
delivery (132), and week 30 of gestation to delivery (180). For one study supplementation 
occurred only postnatally, during the first 4 months of lactation (179) and for the study 
conducted by Furuhjelm et al. supplementation occurred perinatally, started in pregnancy 
(25
th week) and finishing in lactation (average 3-4 months of breastfeeding) (181).  
It has to be noted that the fish oil supplements used contained high amounts of long chain 
n-3 PUFAs and supplementation dosages differed between the three studies. Women in the 
fish oil group in the study of Dunstan et al. (132) received 3.7 g/day of LC n-3 PUFAs 
with 56% as DHA and 28% as EPA. The control group received 4 g/day of olive oil, 
containing  67%  n-9  MUFAs  and  less  than  1%  n-3  PUFAs.  In  the  study  of  Krauss-
Etschmann et al. (178) women received a lower dose of fish oils: 0.5 g/day DHA and 0.15 
g/day EPA. Mothers in the study of Olsen et al. (180) received 2.7 g/day EPA and DHA (4 
x 1g capsules; each capsule containing 32% EPA, 23% DHA with 2 mg tocopherol), while 
the placebo group (one of the 2 control groups) received 4 g/day olive oil (72% oleic acid,   78 
12% linoleic acid). In the trial of Furuhjelm et al. (181) the pregnant women assigned in 
the intervention group consumed 4.5 g/day of marine n-3 capsules containing 1.6 g/d EPA 
and 1.1 g/d DHA (35% EPA, 25% DHA with 23 mg α-tocopherol) while the placebo group 
consumed 4.5 g/day soy oil containing mainly linoleic acid (58%; 2.5 g/day), α-linolenic 
(6%;  0.28  g/day)  mixed  with  36  mg  α-tocopherol.  A-tocopherol  was  used  for  its 
antioxidant properties, to assure the durability of the fish oil products. Mothers in the study 
of Lauritzen et al. (179), were supplemented with 4.5 g/day of fish oil which provided 1.5 
g/day  of  LC  n-3  PUFAs  or  with  4.5  g/day  of  olive  oil.  It  has  to  be  noted  that  the 
supplementation in the studies of Dunstan et al. (132), Furuhjelm et al. (181), and Olsen et 
al. (180) was in the form of capsules, in the study of Krauss-Etschmann et al. (178) in the 
form of powder stirred into a milk-based drink, whereas in the study of Lauritzen et al. 
(179) the fish oil was incorporated into muesli bars, home-made cookies and capsules.  
Follow up and compliance 
 
In  the  study  of  Dunstan  et  al.,  85%  of  the  women  that  took  part  in  the  intervention 
completed the study. Compliance was monitored by measuring the incorporation of DHA 
and EPA into the cell membranes of erythrocytes (174). 
In the European multicenter study (178), there is no reference to subject compliance rates. 
However, this trial has published results on DHA and EPA incorporation in the mother and 
offspring (177). In this paper it is mentioned that left over sachets of the supplement were 
asked to be returned. Also, compliance was assessed in standardised questionnaires at 30 
weeks gestation, and at delivery by asking each subject how many days of dosing they had 
missed.  The  drop-out  rate  was  13.18%  (270  of  the  311  recruited  pregnant  women 
completed the study) (177).  
In the study conducted by Furuhjelm et al. (181) the overall dropout from gestation week 
25 till delivery was 17%, and the dropout was higher in the fish oil group (23%) than in the 
control group (12%). After birth, 52 infants were followed up in the fish oil group and 65 
infants in the control group. This means that the dropout in the fish oil group was 25% and 
in  the  control  group  13%,  while  overall,  the  attrition  rate  was  19%.  Authors  did  not 
comment anything special on method of compliance, apart from the fact that the research 
nurses contacted the mothers twice during the last part of pregnancy to remind them of the 
supplementation (181).   79 
In the study of Olsen et al. (180) children were followed up and assessed in terms of 
asthma and other related allergic symptoms at 16 years of life. The follow up rate was 
extremely  high,  as  522  were  included  in  analyses  16  years  after  the  intervention. 
According to the authors compliance was optimised by returning and weighing the empty 
boxes  of  capsules  at  3  times,  so  that  the  researchers  estimated  amounts  of  capsules 
consumed (180). 
Lauritzen  et  al.  (179)  stated  that  the  overall  self-reported  compliance  with  exclusive 
breastfeeding in both groups was on average 91% (range 67-100%, n=64). The follow-up 
rates at 2.5 years of age in the randomized groups and in the high-fish-intake reference 
group were 72 and 58%, respectively but in total the follow up rate at 2 1/2  years of 
infants‟ age in comparison to the baseline subjects‟ recruitment was 48% (101 infants out 
of  211  pregnant  women).  However,  the  follow-up  women  had  significantly  better 
compliance  with  exclusive  breastfeeding  in  the  intervention  groups  compared  to  the 
follow-up women in the reference group (89 versus 85%, p=0.020) (179). 
Confounding factors 
In the Dunstan study so as to minimise potential confounding factors at randomization the 
groups  were  stratified  by  parity  (no  previous  term  birth  child  vs.  one  or  more),  pre-
pregnancy  BMI,  age  and  maternal  allergy  (allergic  rhinitis  or  asthma).  Results  were 
adjusted for gender, parity and method of delivery (35). Dunstan et al. (132) reported that 
background  maternal  dietary  intake  of  fatty  acids  assessed  by  FFQ  was  not  different 
between the two groups at study entry or at 30 weeks gestation. 
In the study of Krauss-Etschmann et al. (178), after randomization the women in different 
groups did not differ significantly in parity, height, weight at study entry, smoking habits, 
and social demographic characteristics. Also, data on dietary habits were obtained at study 
entry (177) but no dietary data was presented nor controlled for. The neonates did not 
differ significantly in sex, birth weight, length, Apgar score, and parental history of allergy. 
For  the  purposes  of  analysis  only  158  mother-child  pairs  were  available.  Their 
characteristics did not differ from those of the main trial (n=311). The analysis of this 
study was adjusted for study centre (177) and maternal percentage weight/weight DHA at 
week  20  gestation  (baseline).  Confounding  factors  controlled  for  were  gravity,  parity, 
delivery mode, and maternal smoking at 20 and 30 weeks gestation.  
Olsen  et  al.  (180)  did  not  control  for  any  factors  but  randomisation  was  stratified  by 
maternal habitual fish intake (low, medium and high).   80 
Furuhjelm et al. (181) made adjustments in their analysis for allergic symptoms in children 
for  the  following  factors:  ARA  and  LA  levels  in  maternal  phospholipids  at  inclusion, 
breastfeeding  fully  until  6  months,  number  of  siblings,  exposure  to  tobacco  smoke, 
maternal allergic symptoms and eczema in family (181). 
Lauritzen et al. (179), although not controlling for confounding factors in their analysis, 
assessed subjects‟ compliance with exclusive breastfeeding, and they found no differences 
in  characteristics  of children (2.5  years) between the groups (sex, parity, birth  weight, 
duration and degree of breastfeeding, age, height, weight, family history of atopy, eczema, 
wheezing, food allergy, plasma IgE). 
Outcome measures and results in the Australian ‘pregnancy supplementation 
study’ (35;132;133;136;173;175;176) 
 
Plasma  (cord  blood)  and  urinary  F2-isoprostanes  were  measured  as  markers  of  lipid 
peroxidation.  Barden  et  al.  (136)  associated  urinary  markers  of  cord  blood  and  cord 
erythrocyte fatty acids with neonatal lipid peroxidation suggesting that maternal fish oil 
supplementation during pregnancy might be protective against oxidative stress in the infant 
of atopic mothers soon after birth. It was concluded that supplementation with fish oil 
during pregnancy significantly alters early post-partum breast milk fatty acid composition, 
and it was suggested that there is a relationship between fatty acid status and mucosal 
immune function, potentially influencing infant immune development. In accordance with 
this, a more recent analysis (175), showed that breast milk from women who received fish 
oil had proportionally higher EPA and DHA levels at 3 days and 6 weeks after delivery, 
but not at 6 months. Also, infant DHA status at 1 year of age was directly related to DHA 
levels at 3 days, 6 weeks and 6 months postpartum, but not to antenatal supplementation.  
 
Dunstan et al. (133) examined the relationships between PUFA levels and immunological 
parameters  in  breastmilk,  such  as  sCD14,  IgA  and  a  range  of  cytokines,  suggesting  a 
further pathway of maternal diet effect on the post-natal infant immune development. 
 
Dunstan et al. (35) observed that maternal dietary supplementation with LC n-3 PUFA was 
associated  with  significantly  lower  IL-13  levels  in  cord  plasma,  supporting  a  relation 
between dietary n-3 PUFA and neonatal immune function.  
 
Dunstan et al. (132) provided evidence that fish oil supplementation in pregnancy achieved 
a significant increase in LC n-3 PUFAs in neonatal red blood cell membranes compared 
with the control group which was associated with a general trend for decreased neonatal   81 
immune responses to allergens and reduced expression of allergic disease at 1 year of age. 
This is the only intervention study to publish evidence that fish oil might offer potential 
clinical benefits in reducing the risk of allergic disease. However it should be noted that the 
children were too young to study a diagnosis of asthma reliably. In this regard, further 
analysis at 2.5 and 5 y of age would provide a more reliable assessment of such clinical 
outcomes.  In  addition,  the small sample size makes  this  study  an “exploratory” study. 
Larger scale studies  are needed  for neonatal clinical  assessment and to investigate the 
effects  of n-3 PUFA supplementation during pregnancy and/or early life in  relation  to 
allergy prevention in children of those pregnancies. 
 
Denburg et al (173) showed that dietary LC n-3 PUFA supplementation during pregnancy 
in atopic mothers altered infant cord blood hemopoietic progenitor phenotype, that favours 
the development of allergic disease. It was shown that fish oil supplementation resulted in 
increased numbers of cord blood CD34
+ progenitors and their increased responsiveness to 
IL-5 in cord blood eosinophil/basophil colony forming units (Eo/B-CFU). The numbers of 
CD34
+  cells  in  cord  blood  increased  significantly  the  risk  of  atopic  eczema/dermatitis 
syndrome  (AEDS)  in  infants  at  1  year  of  age,  and  cord  blood  progenitor  IL-5 
responsiveness  increased  the  risk  of  AEDS  and  recurrent  wheeze  significantly.  These 
results support that fish oil supplementation during pregnancy may have an impact on 
development of atopic disease in the offspring. 
 
Finally, Prescott et al (176) showed that maternal fish oil supplementation in pregnancy 
modifies  neonatal  neutrophil  function,  which  has  implications  for  early  immune 
programming  and  provides  another  mechanism  through  which  LC  n-3  PUFAs  may 
influence early immune development. Specifically, it was shown that the production of 
LTB4  from  neutrophils was  significantly lower  in  neonates born to  mothers who were 
supplemented with fish oil during pregnancy as can be seen on Table 1.9. There was a 
trend for lower production of 5-HETE by neutrophils in the fish oil group. There was also 
a trend for higher levels of less inflammatory products (LTB5) in the fish oil group. Also, 
LTB5 levels were positively correlated with n-3 PUFAs levels in maternal and neonatal 
erythrocytes (particularly EPA), and negatively correlated with n-6 PUFAs. 
Outcome  measures  and  results  from  the  European  multicenter  pregnancy 
supplementation study (177;178) 
The European multicenter study measured the effects of fish oil supplementation during 
pregnancy on maternal and cord blood plasma concentrations of EPA and DHA. It was   82 
shown  that  fish  oil  supplementation  with  or  without  5-MTHF  resulted  in  increased 
proportion of DHA in cord blood plasma, and DHA and EPA in maternal plasma at 30 
weeks of gestation and at delivery compared with placebo or 5-MTHF (177). 
Outcomes on immune markers in the study are presented on Table 1.9. It was shown that 
fish  oil  supplementation  during  pregnancy  was  associated  with  decreased  mRNA 
expression of IL-4, IL-13 and CCR4 in cord blood. Also, fish oil supplementation was 
related to decreased frequencies of cord blood NK cells and CCR3
+ CD8
+ T cells. It has to 
be mentioned that the data on cord blood lymphocyte subsets were analysed only for the 
German arm of the study (n= 30), where facilities were available. Moreover, mRNA levels 
of  IL-1  and  IFN-γ  in  maternal  blood  at  delivery  were  decreased  after  fish  oil 
supplementation. On the contrary, mRNA levels of the regulatory cytokine TGF-β were 
increased  in  both  maternal  blood  at  delivery  and  in  cord  blood  following  maternal 
supplementation.  Thus,  it  was  shown  that  fish  oil  supplementation  during  pregnancy 
downregulates Th1 responses in the mother and Th2 responses in the fetus. These results 
are in line with the observations made by Dunstan et al. (35) who also showed a reduction 
in  cord  blood  IL-13  levels,  a  Th2  marker.  In  addition,  Krauss-Etschmann  et  al.  (178) 
showed that the decrease in cord blood IL-13 mRNA levels was more pronounced in non-
allergic mothers. Their study showed that Th2 responses are decreased in neonates of both 
allergic and non-allergic mothers, as opposed to the Australian study which focused on 
allergic mothers. The authors suggested as a clinical implication of their study that fish oil 
supplementation of pregnant women might be an option for primary allergy prevention.  
Outcome measures and results from the Danish follow up study (180) 
 
Olsen et al. (180) conducted the supplementation trial in 1992 and related late pregnancy 
fish  oil  supplementation  to  prolonged  gestation.  Fish  oil  supplementation  had  no 
detrimental effects on the course of the labour or on the growth of the fetus. The dose of 
the supplementation was 2.7 g/day EPA and DHA, equal to 10 times the average intake 
(180). After 16 years, they followed up the offspring of those mothers who participated in 
the  trial  and  assessed  the  prevalence  of  asthma-related  diagnosis,  as  well  as  atopic 
dermatitis or allergic rhinitis in those children after obtaining information on occurrences 
of  those  allergic  diagnoses  from  the  Danish  patient  registry.  The  hazard  rate  ratio  of 
asthma  (all  types)  and  allergic  asthma  decreased  significantly  (by  63%  and  87% 
respectively)  in  the  fish  oil  group  in  comparison  to  the  olive  oil  group  (control). 
Interestingly, the risk of asthma (all types) was decreased in the no oil group as well,   83 
compared  with  the  olive  oil  group,  but  not  significantly.  There  was  a  decrease  in  the 
prevalence of asthma (all types), atopic dermatitis or allergic rhinitis (by 57%) and in the 
prevalence of allergic asthma, atopic dermatitis or allergic rhinitis (by 69%) in the fish oil 
group compared to control. Surprisingly a similar decrease in risk was observed for both of 
the above diagnoses in the no oil group compared with the olive oil group. The authors 
speculated that this would be attributed to contamination bias (taking part in that study, 
study fish oil available in the market, public awareness about potential health benefits of 
consuming  marine  foods  or  fish  oils  such  as  heart  disease).  Finally,  stratification  by 
maternal fish intake at baseline (low/medium/high) resulted in small number of cases and 
did not have any significant effect on the hazard rate ratio of asthma (all types) and allergic 
asthma between the 3  groups  (fish  oil/  olive oil/ no oil), using the olive oil  group  as 
reference (180).  
Outcome measures and results from the Swedish pregnancy and lactation study 
(181;182) 
 
The paper of Warstedt et al. (182) associated fish oil supplementation during pregnancy 
(25 weeks till delivery) with plasma fatty acid composition and with maternal immune 
function at 1 week post-partum. This is the second study investigating immune function in 
pregnant women after LC n-3 PUFA supplementation after Krauss-Etschmann et al. (177). 
In terms of phospholipid fatty acid changes, it was shown that the maternal serum/plasma 
ratio of ARA/EPA was decreased in the fish oil group. Also, in the control group plasma 
phospholipid %ARA increased, whereas %EPA and %DHA increased in the intervention 
group. These results were similar in both atopic and non-atopic mothers. Moreover LPS-
induced PGE2 secretion from whole blood cultures was decreased in the majority of the 
fish oil group. However, the mean decrease in the fish oil group was not significant, in 
contrast to the PGE2 production in the control group that increased significantly. The non-
significant decrease of PGE2 secretion in the intervention group was probably due to the 
observation of higher LPS-induced PGE2 secretion at baseline from the mothers that were 
randomized to the fish oil group compared to those allocated in the placebo group. The 
change in PGE2 production differed significantly between the 2 groups and the decrease in 
PGE2  secretion  in  the  LC  n-3  PUFA  group  was  more  pronounced  among  non-atopic 
women (not significant). The researchers tried to explain this tendency of reduction of 
PGE2 in the non-atopic women, but it was not possible as no differences in fatty acid 
profile  were  observed  between  atopic  and  non-atopic  women.  Secretion  of  LTB4, 
chemokines and cytokines were not affected by fish oil.  Krauss-Etschmann et al. reported   84 
no data on eicosanoid secretion (177). Finally, Warstedt et al. showed that the changes in 
LPS-induced PGE2 production in the intervention group correlated positively with changes 
in plasma phospholipid ARA% and negatively with changes in EPA%, which was even 
stronger among the non-atopic (182). 
 
The paper published by Furuhjelm  et  al. (181) associated  the fish oil supplementation 
during pregnancy and lactation (25 weeks gestation to 3-4 months lactation) with atopic 
outcomes in the offspring at 6 months and 1 year of age. Regarding allergic sensitization, 
the prevalence of any positive SPT during the first year of life was significantly lower in 
the fish oil group compared to the placebo. More specifically, the prevalence of positive 
SPT to egg was lower in the fish oil group at 12 months. Moreover, in terms of clinical 
symptoms IgE associated eczema (eczema in the presence of detectable IgE antibodies or 
positive SPT towards egg, milk or wheat) and food allergy (reaction to egg or milk) during 
the first 12 months of life were significantly higher in the placebo group. IgE associated 
eczema was higher in the placebo group at 6 months of age as well but not significantly. In 
the regression analysis, after controlling for the confounding factors described above, it 
was found that the risk of developing any positive SPT, a positive SPT to egg or IgE 
associated eczema was 3-4 times less in the fish oil group compared to the placebo. The 
risk  of  developing  food  allergy  was  reduced  10  times  in  the  LC  n-3  PUFA  group  in 
comparison to the control. The researchers also found that these significant relations for 
any  positive SPT, food  allergy and  IgE mediated eczema  were reserved after separate 
analysis for the non-allergic mothers but not for the allergic mothers. One disadvantage of 
the  study  was  the  incomplete  blinding  because  of  belching  with  fishy  taste  that  some 
mothers in the fish oil group reported. Nevertheless, the examiners were blinded. The study 
had enough power to detect significant differences in the incidence of egg sensitization and 
IgE-mediated symptoms but not in sensitization to milk as the incidence was very low 
(181).  
Outcome measures and results in the ‘Danish National Birth Cohort’(179) 
 
Erythrocyte LC n-3 PUFAs at 4 months were higher in infants from the mothers in the fish 
oil group compared with the olive oil control group. These differences were no longer 
evident at 2.5 years of age. The study was not powered to look at clinical outcomes i.e. 
atopic sensitization and no differences in atopy and plasma IgE were observed between the 
groups. No association was found between in vitro cytokine production and plasma IgE 
levels and there was no significant association as well between plasma IgE and eczema, 
wheezing  or  food  allergy,  although  both  associations  tended  to  be  positive.  Cytokine   85 
responses and erythrocyte fatty acid composition in children of mothers with a high fish 
intake  (reference  group)  were  intermediate  in  comparison  to  those  in  the  randomized 
groups. However, the subjects were healthy children in the sense that were not selected to 
have a high risk of atopy. Furthermore, plasma IgE is a very crude measure of atopy and 
does  not  give  an  indication  of  allergen  sensitization.  Lauritzen  et  al.  (179)  stated  that 
because of the immunomodulatory and anti-inflammatory properties that olive oil has the 
differences between the fish oil and the control group may have been larger if they had 
chosen  a  more  „neutral‟  oil.  On  the  other  hand,  in  the  Australian  pregnancy 
supplementation trial, the amount given (4 g of olive oil /day) did not significantly alter the 
average daily intake of oleic acid (26 g/day) in Australian diets. 
Conclusion 
The studies of Dunstan et al. and Krauss-Etschmann et al. (132;178) both investigated the 
effects of maternal fish oil supplementation during pregnancy on blood immune markers in 
the offspring. It is clearly evident from the Australian study of Dunstan et al. (35) that 
maternal fish oil supplementation resulted in higher LC n-3 PUFA status (higher EPA and 
DHA in cord blood erythrocytes) and lower n-6 PUFA status in the neonates. What is 
more, in relation to immune markers, fish oil supplementation resulted in lower cytokine 
levels  in  cord  blood  plasma  (IL-13),  lower  cytokine  production  from  cord  blood 
mononuclear cells (IL-10), and lower leukotriene production from cord blood neutrophils 
(LTB4).  In  addition,  fish  oil  significantly  altered  cord  blood  hemopoietic  progenitor 
phenotype which may impact on the development of atopic disease. Lastly, although the 
study was not designed to assess clinical outcomes, at 1 year of age there were signs of 
beneficial  effects  on  atopic  outcomes  as  a  result  of  maternal  fish  oil  supplementation 
during pregnancy (less severe atopic dermatitis, lower risk of positive SPT to egg). 
The  study  of  Krauss-Etschmann  et  al.  (178),  also  demonstrated  that  fish  oil 
supplementation during pregnancy results in higher levels of DHA in maternal and cord 
blood.  The  intervention  resulted  in  differential  affects  on  maternal  and  fetal  immune 
parameters. There was a significant decrease in maternal Th1-related cytokines (IL-1, INF-
γ) at birth, and in fetal Th2-related cytokines (IL-13, IL-4, CCR4). The latter results are in 
accordance with those from the Australian study. However results in the study of Krauss-
Etschmann et al. (178) were significant irrespective of the atopy status of the mothers. The 
effects observed might be mediated through TGF-β, which mRNA levels were increased in 
both maternal blood at birth and in cord blood.    86 
The Danish study of Olsen et al. (180) conducted in late pregnancy (week 30-delivery), 
supplemented  pregnant  women  with  either  fish  oil  (2.7g/day),  olive  oil  or  no  oil  and 
assessed asthma and other allergic manifestations on the children of those pregnancies 16 
years later. They observed a large reduction of asthma and allergic asthma by 60-80% in 
the fish oil group (comparison to olive oil group). The trial had a large sample size (522 
children identified at 16 years of age), with a follow up rate of 97%. 
The  study  conducted  in  Sweden  (181;182)  is  the  first  study  to  present  with  fish  oil 
supplementation  in  both  pregnancy  and  lactation.  The  results  presented  referred  to 
outcomes in the mothers (plasma fatty acid composition and immune outcomes relevant to 
allergies at 1week post partum) (182) and in the infants (clinical outcomes on infant allergy 
during the first year of life) (181). LC n-3 PUFA supplementation decreased the ARA/EPA 
ratio and this was associated with reduced LPS-induced PGE2 secretion, which is related 
with the Th2 polarization in the mother and subsequently less allergic inflammation in the 
mother and probably less allergic inflammation in the immunologically naïve offspring. 
Clinical outcomes suggest that the infants from mothers in the fish oil group had reduced 
risk of developing allergic sensitization to egg, IgE associated eczema and food allergy 
during the first year of life. However, repeatability of such observations is essential in 
order to draw more definite conclusions about the benefit of LC n-3 PUFA towards allergic 
manifestations. 
The study of maternal fish oil supplementation during lactation (179) is also the only one 
to date investigating outcomes on immune markers in the offspring. As in the previous 
study, infants of lactating mothers who received fish oil supplementation had a higher n-3 
PUFA status at 4 months of age. What is more, IFN-γ production at 2.5 years of age 
increased  significantly  in  the  fish  oil  group,  an  observation  which  may  reflect  faster 
maturation  of  the  immune  system.  This  study  was  also  not  powered  to  assess  clinical 
outcomes. 
In  conclusion,  the  evidence  available  supports  that  fish  oil  supplementation  during 
pregnancy  and  lactation  results  in  higher  provision  of  n-3  PUFAs  to  the  offspring 
perinatally, and thus, it can increase LC n-3 PUFA status in the offspring. The increase in 
LC n-3 PUFA status of the offspring may potentially affect immune markers in early life 
indicating  a  possible  protective  effect  of  maternal  fish  oil  supplementation  during 
pregnancy or lactation on atopic disease in the offspring. The study of Krauss-Etschmann 
et al. (178) points out the clinical implications of their study: „fish oil supplementation of 
pregnant women might be an option for primary allergy prevention‟. The follow-up of the   87 
European multicenter study and its effects on incidence of allergic diseases in the offspring 
of fish oil supplemented mothers are anticipated. The follow up study by Olsen et al. (180) 
suggests  the  importance  of  fish  oil  supplementation  in  early  life,  particularly  during 
pregnancy, as the results were observed in adolescence. However, interpretation of such 
results should be done with caution especially when the follow up of the study is of long 
duration and not controlled for confounding factors such as lifestyle (physical activity), 
gender, weight, and most importantly diet (fish, fruit, vegetable intake) of the children. The 
unique Swedish supplementation study in pregnancy and lactation implies protective effect 
and clinical signs of reducing the allergic sensitisation in the infants at 6 months and 1 year 
of age (181;182). 
Well designed maternal fish oil supplementation trials would possibly be more effective 
during pregnancy. The observations of these studies need to be confirmed by future trials 
powered adequately to examine clinical outcomes in the offspring later on in life in order 
to be able to draw more definite conclusions and form recommendations.    88 
Table 1.9: Maternal fish oil supplementation during pregnancy or lactation and allergic outcomes in infants/ children of those pregnancies 
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n= 40 FO  
n= 43 Control  



















Lipid peroxidation: CB 
plasma and infant urinary F2-
isoprostanes 
 
CB erythrocyte membranes 
FA levels 
 
Markers of APC function 
(HLA-DR expression and 
cytokine responses) 
Maternal fish oil supplementation lowered CB 
plasma (p< 0.0001) and urinary F2-isoprostanes 
(p= 0.06) 
 
HLA-DR expression on APC was not different 
between the groups 
 
28.8% of the variance in CB plasma F2-
isoprostanes was explained by positive 
relationships with erythrocyte ARA and monocyte 
HLA-DR expression and a negative relationship 
with erythrocyte EPA 
This study shows 
that maternal 
supplementation 














Same as above  Same as 
above 




CB plasma total IgE 
 
CB erythrocyte membranes 
FA levels 
Maternal fish oil supplementation resulted in : 
increased total n-3 PUFA, EPA and DHA levels, 
and decreased n-6 ARA levels in CB erythrocyte 
membranes (p< 0.001) 
 
Significantly lower CB plasma IL-13 levels (p< 
0.05) in neonates from intervention group 
compared to control 
 
Significant inverse relationship between n-3 




PUFA levels with 
maternal fish oil 
supplementation 














Same as above  Same as 
above 
CB erythrocyte membranes 
FA levels 
 
CBMNC cytokine responses 
to allergen and mitogen (IL-
5, IL-10, IL-13, INF-γ) 
 
SPT of infants at 1 year of 
age 
 
Symptoms of allergic disease 
(asthma, wheeze, food 
allergy, atopic dermatitis) 
Fish oil supplementation resulted in higher 
proportions of total n-3 PUFAs in CB erythrocyte 
membranes (17.75% ﾱ 1.85%) compared with 
control group (13.69% ﾱ 1.22%, p< 0.001), and 
lower proportions of total n-6 PUFA (p< 0.001) 
 
CBMNC cytokine (IL-5, IL-13, IL-10, and INF-γ) 
responses tended to be lower in the fish oil group 
(statistically significant only for IL-10 in response 
to cat allergen, p= 0.046) 
 
Amongst subjects with atopic dermatitis, those in 
the FO group were 10 times less likely to have 
severe disease (SCORAD>25) (OR 0.09, 95% CI 
0.01-0.94, p= 0.045) 
Infants in the fish oil were 3 times less likely to 
have a positive SPT to egg at 1 year of age (OR 








supplementation.   89 
 
Study and study 
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period 
Outcome measures  Results  Conclusions 








Same as above  Same as above  Same as 
above 
Immunomodulatory 
factors in breast milk 
collected 3 days post-
partum: sCD14, IgA, 
cytokines (IL-5, IL-6, IL-
10, TNF-α and INF-γ) 
 
Breast milk FA levels 
 
DHA and EPA were in higher proportions in 
breast milk from women supplemented with 
fish oil (DHA 1.15% ﾱ 0.47%, EPA 0.16% ﾱ 
0.07%) than in samples from the control group 
(DHA 0.50% ﾱ 0.17%, EPA 0.05% ﾱ 0.02%, 
p< 0.001) 
 
Breast milk ARA levels were significantly 
lower (p= 0.045) in the fish oil group (mean 
0.55%, SD 0.12%) compared with the control 
group (mean 0.61%, SD 0.14%) 
 
Breast milk IgA was positively correlated with 
DHA (p= 0.046) and 22:5n-3 (p= 0.003), but 
inversely correlated with linoleic acid (p= 
0.034) 
 
No differences were observed in breast-milk 
IgA, sCD14, and cytokines between the groups 
Supplementation 




breast milk fatty 
acid composition. 
n-3 PUFA levels 
were positively 
associated with 
IgA and sCD14 
levels, suggesting 
a relationship 
between fatty acid 
status and mucosal 
immune function. 
















expression of cytokine 




CB cells were also 
cultured for Eo/BCFU 
 
Clinical assessment of 
infants for atopic disease/ 
SPT at 1 year of age  
Percentages of CB CD34
+ cell numbers were 
higher after n-3 PUFA than placebo (p< 0.002) 
 
CB CD34
+ cell expression of cytokine and 
chemokine receptors was not different between 
groups 
 
There were significantly more IL-5 responsive 
CB Eo/BCFU in the fish oil, compared to the 
control group (p< 0.003) 
 
Overall, there was a positive association 
between the percentage of CD34
+ cells, and the 
number of IL-5 responsive Eo/BCFU in CB, 
and 1 year clinical outcomes, including atopic 
dermatitis and wheeze (p< 0.05) 
Dietary n-3 PUFA 
supplementation 
during pregnancy 
in atopic mothers 





















Same as above  Same as above  Same as 
above 
Leuktriene production by 
CB neutrophils after 
stimulation 
 





production (IL-5, IL-10, 
IL-13, INF-γ) 
CB neutrophil LTB4 (isomer 2) production 
reduced in FO group compared to controlled 
(p= 0.031) 
 
LTB4 (isomer 2) production levels were 
inversely related to the n-3 PUFA content of 
maternal erythrocyte membranes (p< 0.05) 
 
Production of IL-6 responses and IL-10 
responses by CBMNC was lower in neonates 
with lower neutrophil LTB4 production 
Fish oil 
supplementation 
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Outcome measures  Results  Conclusions 
Krauss-Etschmann 













on subcohort  
 
n= 45 FO 
n= 49 5-
MTHF 
n= 49 FO + 5-
MHTF 
n= 50 Control 
4 groups: 




















molecules in maternal 
blood at delivery and in 
CB: mRNA expression 
of CCR4, IL-13, IL-4, 
CRTH2, CXCR3, INF-γ, 
IL-1, TGF-β  
 
CB lymphocyte subsets 
Maternal FO supplementation compared to 
control was associated with: 
 
Increased mRNA expression of TGF-β in 
maternal blood at birth (χ 0.85, 95% CI 0.80-
0.89; placebo χ 0.68, 95% CI 0.64-0.72), and in 
CB (χ 0.85, 95% CI 0.81-0.90; placebo χ 0.75, 
95% CI 0.71-0.79) (all p< 0.001) 
 
Decreased mRNA expression of INF-γ (χ 0.54, 
95% CI 0.51-0.57; placebo χ 0.65, 95% CI 
0.61-0.69) and IL-1 (χ 0.69, 95% CI 0.66-0.73; 
placebo χ 0.83, 95% CI 0.79-0.88) in maternal 
blood at birth (all p< 0.001) 
 
Decreased CB mRNA levels of IL-4 (χ 0.54, 
95% CI 0.52-0.57; placebo χ 0.64, 95% CI 
0.61-0.68), IL-13 (χ 0.61, 95% CI 0.58-0.65; 
placebo χ 0.85, 95% CI 0.80-0.89), and CCR-4 
(χ 0.70, 95% CI 0.67-0.73; placebo χ 0.88, 95% 
CI 0.84-0.92) (p< 0.001) 
 
Decreased CB NK (χ 9.0%, 95% CI 7.5-11.0%; 
placebo χ 14.6%, 95% CI 12.3-17.2%, p< 
0.001) and CCR3
+ CD8
+ T-cells (χ 0.2%, 95% 







mRNA levels of 
Th2-related 
molecules in CB 
and decreased 
maternal Th1 
cytokines at birth. 
These effects may 
be mediated by 
TGF-β.   91 
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1. FO: 1.6 
g/day EPA, 1.1 
g/day DHA 





From week 25 
of pregnancy 




Clinical examinations of 
infants: 
 
-Skin prick testing to cows‟ 
milk, egg, and wheat at 6 and 
12 months of age 
 
-IgE associated eczema and 
food allergy at 3, 6, and 12 
months of age 
 
Detection of plasma specific 
IgE to egg/milk/wheat at 3 
and 12 months age 
 
Sensitisation within the 1
st year of life:  
-prevalence of food allergy was lower in the 
n-3 group (2%) compared to the placebo 
group (15%, p<0.05) 
-prevalence of IgE-associated eczema was 
lower in the n-3 group (8%) compared to 
placebo (24%, p<0.05). 
-prevalence of any positive SPT was 15% in 
the n-3 and 32% in the control group(p= 
0.04). 
-the prevalence of positive egg SPT in the n-3 
group at 12 months was 12% compared to 
29% in the placebo group (p= 0.02). 
Logistic regression analysis: 
-Reduced risk of developing any positive 
SPT (OR=0.36, 95% CI 0.14-0.95, p<0.05), a 
positive SPT to egg (OR=0.31, 95% CI 0.11-
0.89, p<0.05), and IgE-associated eczema 
(OR=0.22, 95% CI 0.06-0.81, p<0.05) during 
the first year of life 
-The risk of developing food allergy was 
reduced 10 times in the n-3 group compared 













eczema and food 
allergy during 
the first year of 
life. 
Warstedt et al. 
2009 (182) 
 
Double blind RCT 
 
Linkoping, Sweden 
The same  The same  From week 25 
of pregnancy 
till 1 week 
after birth 
Maternal outcomes only 
 
Whole blood cultures: 
-analysis of PGE2 and LTB4 
-analysis of cytokines and 
chemokines (IFNγ, IL-5, IL-
6, ΤΝF, IL8, IL10, CCL2, 
CCL3) 
 
Analysis of plasma or serum 
phospholipids 
 
Analysis of serum IgE 
antibodies 
Phospholipid fatty acid proportions altered 
after supplementation (1 week after birth): 
-Increase in EPA (by 6.3%) and DHA (by 
2.4%) in the n-3 group (p<0.001) 
-Decrease in ARA (by 1.1%) in the n-3 group 
(p<0.001), whereas it increased in the control 
grp (by 1.6%; p<0.001) 
 
From 25wk gestation till 1wk after delivery: 
-LPS-induced PGE2 secretion decreased in 
64% of the n-3-supplemented mothers and 
increased in 77% of the control group (p= 
0.002). 
-The decreased PGE2 production was more 
pronounced among non atopic (80%) than 
atopic mothers (69%) (not significant) 
 
The LPS induced cytokine and chemokine 








and is associated 
with reduced 
secretion of pro 
inflammatory and 
Th2-promoting 
PGE2, which in 
turn may 
contribute to an 
allergy-
preventing effect.   92 
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followed up at 









olive oil 4 
g/day (72% 
oleic acid, 12% 
LA) 







diagnosis at 16 years old: 
allergic asthma, asthma of 
mixed type, atopic 
dermatitis or allergic 
rhinitis  
 
Data taken from the 
National patient registry in 
Denmark 
In the fish oil compared to the olive oil group: 
-the hazard rate of asthma was reduced by 
63% (95% CI 8%-85%, p= 0.03) 
-the hazard rate of allergic asthma was 
reduced by 87% (95% CI 40%-97%, p= 0.01)  
-the hazard rate of asthma all types, atopic 
dermatitis or allergic rhinitis was reduced by 
57% (95% CI 4%-81%, p= 0.04) 
-the hazard rate of allergic asthma, atopic 
dermatitis or allergic rhinitis was reduced by 
69% (95% CI 16%-89%, p= 0.02) 
 
Stratification by maternal baseline fish intake 
(low, medium, high): 
-no differences between stratification groups 
-almost no differences between fish oil and 
control group within stratification categories, 
although in the low fish intake group the risk 
of asthma (all types), atopic dermatitis or 
allergic rhinitis was decreased by 90% (95% 
CI 13-99%, p=0.04) in the n-3 group 
Increasing n-3 
PUFA intake in 
late pregnancy may 
be an important 
prophylactic 
potential 
in relation to 
offspring asthma in 
adolescence. 














n= 37 FO 











1.5 g/day of n-
3 LC PUFA 
(equivalent to 
4.5 g/day of 
















membranes FA (4 months 
and 2.5 years of age) 
 
Infant plasma IgE levels 
and cytokine production in 
endotoxin-stimulated 
whole-blood cultures (2.5 
years old) 
 
Parental report of allergy 
diagnosis or tendency to 
allergy 
Erythrocyte n-3 PUFA at 4 months were 
higher in infants from the fish oil group 
compared with the olive oil group (p< 0.001) 
but were no longer different at 2.5 years old. 
 
The median production of INF-γ in the fish oil 
group was 4fold higher than that in the control 
group (p= 0.034) 
 
IL-10 production was similar between groups. 
The INF-γ/ IL-10 ratio was 2 fold higher in 
the fish oil group (p= 0.019) and was 
positively correlated with 20:5n-3/ 20:4n-6 in 





increased in vitro 
INF-γ production 
in children 2 years 
after the 
supplementation 
was given, which 
may reflect a faster 
maturation of the 
immune system. 
RCT, randomized control trial; OR, odds ratio; CI, confidence interval; SD, standard deviation; FA, fatty acids; PUFA, polyunsaturated fatty acids; LC, long 
chain; FO, fish oil; 5-MTHF, 5-methyl-tetra-hydrofolic acid; SPT, skin prick testing; DHA, hocosahexaenoic acid; EPA, eicosapentaenoic acid; ARA, 
arachidonic acid; CB, cord blood; CBMNC, cord blood mononuclear cells; NK, natural killer cells; APC, antigen presenting cells; HLA-DR, human leukocyte 
antigen-DR; sCD14, soluble CD14; Eo/BCFU, eosinophil/basophil colony forming units; Ig, immunoglobulin; INF, interferon; IL, interleukin; TNF, tumour 
necrosis factor; TGF-β, transcription growth factor β; χ, geometric mean; vs, versus. 
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1.5.2.2      Randomized controlled trials investigating the effects of fish oil 
supplementation during infancy/childhood on allergic outcomes in 
those infants/ children 
 
Table 1.10 summarizes the randomized controlled trials investigating the effects of fish oil 
supplementation  during  infancy/childhood  on  allergic  outcomes  in  those  infants/children 
(atopy, asthma, eczema, dermatitis, cough). Five studies were identified. Six scientific papers 
have been published from the Childhood Asthma Prevention Study (CAPS), of which one 
describes extensively the study protocol (183). Table 1.10 includes the results at 18 months 
(184;185), at 3 years (186), and at 5 years of age (187;188). Damsgaard et al. (189) also 
studied the impact of LC n-3 PUFA supplementation on allergy risk in infants. Studies done 
by Hodge et al. (190), Nagakura et al. (191), and Vaisman et al. (192) investigated the effect 
of LC n-3 PUFA supplementation in children covering a wide age range. 
Study design 
 
The study carried out by Hodge et al. (190) and the CAPS study took place in Australia (183). 
In the latter, infants were recruited from 6 different hospitals in Sydney. The study done by 
Nagakura et al. (191) took place in Japan in a hospital/clinical setting; the study done by 
Vaisman et al. (192) took place in Israel; and the study conducted by Daamsgaard et al. (193) 
was conducted in Denmark in a community setting. 
 
Infants who participated in the CAPS study (183) were at high risk of developing asthma, 
whereas infants that took part in the Danish study were not (189). Children who participated in 
Vaisman et al. (192) study were healthy but children in the Hodge et al. and Nagakura et al. 
studies were asthmatic (190;191). 
 
All 5 trials were of parallel design, meaning that they compared LC n-3 PUFAs with placebo. 
Three of the studies were double-blinded controlled trials. CAPS was a single blinded study 
and the Danish study (189) was an unmasked randomized trial. Of the 5 trials, 2 compared LC 
n-3 PUFA supplements with placebo (191;192) and the other three compared LCn-3 PUFAs 
with n-6 PUFAs (183;189;190). The CAPS study intervention consisted not only of a diet 
intervention but of a house dust mite (HDM) avoidance intervention as well. It has to be noted 
for  the  CAPS  study  that  there  was  no  blinding  for  the  HDM  modification.  Some  of  the 
volunteers reported „fishy‟ smell of the fish oil supplements, so it might have been that that the   94 
subjects were un-blinded. Also, the CAPS study tried to achieve an intake of n-3 to n-6 fatty 
acids of ratio 1:5 in the intervention group. Parents were asked to add the fish oil supplement 
to milk formulas and after six months of age also to favourite foods and beverages. Parents 
were finally asked to avoid using specific formulas that had added LC n-6 PUFAs and to cook 
with oils and margarines provided (183). 
 
The constituents of the placebos used in the RCTs studies varied and are described in Table 
1.10. Hodge et al. (190) used capsules containing n-6 PUFAs; these were a mix of palm oil, 
olive oil, safflower oil (plus usual dietary fat replaced by sunflower oil); Nagakura et al. (191) 
used capsules containing olive oil; the CAPS study used capsules containing sunola oil and 
dietary modification; Vaisman et al. (192) used capsules containing canola oil as a placebo; 
Daamsgaard et al. (189) used milk or formula without added oils. Thus the different studies 
provided different sources and amounts of n-6 PUFAs to the control group.  
 
The LC n-3 PUFA content of the fish oil capsules used in the different studies and the relative 
proportions of EPA and DHA differed between studies (Table 1.10). It is also worth noting 
that in the study of Nagakura et al. (191) the daily dose of LC n-3 PUFAs varied between 
subjects due to the fact that it was adjusted to the body weight of the children, which was of a 
wide  range.  Also,  the  supplementation  period  varied  between  the  studies,  ranging  from  3 
months (192;193), 6 months (190), 10 months (191), to 5 years (183). The differences in 
supplementation  dosages  and  period  of  supplementation  between  the  studies  may  have 
contributed to the heterogeneity of the effect of fish oils on allergic and atopic disease during 
infancy/childhood seen in the studies.  
 
Finally, as has been said above, infants and children taking part in these five studies were 
supplemented during different periods of life. The CAPS study conducted the intervention 
from onset of formula feeding (or 6 months of age) to 5 years of age (183). The study of 
Damsgaard et al. (189) supplemented infants between months 9 and 12 of life. The other three 
studies of Hodge et al. (190), Nagakura et al. (191), and Vaisman et al. (192) conducted the 
intervention on children of a wide age range (8-12, 4-17, and 8-12 years of age respectively). 
The age differences of the subjects between the studies may also partially explain the different 
effects observed between the studies. 
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Sample size, follow up, compliance 
Referring to sample size, in the CAPS study, it is possible that failure to show a clinical 
benefit resulted from lack of power (188). In the study conducted by Hodge et al. (190), 
authors suggested that significant changes in TNF-α production may have been detected if the 
sample size was larger. Finally, in the study of Damsgaard et al. (189), it was recognized that 
sample size was small and that the rate of completion with blood samples was low.  
Regarding the follow up of the trials, in the CAPS study, 68% of the children remaining in the 
study (excluding those lost to follow-up) were available for assessment and had their blood 
taken at 18 months of age. At 5 years of age, 84% of the children that participated in the 
randomized cohort were available for assessment. In the study of Damsgaard et al. (189), the 
attrition rate was 32% (30 subjects out of 94 dropped out), and the completion rate was 88% 
(and it did not differ significantly between the groups). In the study of Hodge et al. (190) 6 
children out of 45 dropped out at baseline (13% withdrawal). Vaisman et al. (192) did not 
have any dropouts given the fact that the sample size was small. In the study of Nagakura et 
al. (191) only one child out of thirty dropped out.  
In the CAPS study, the moderate compliance rates might be related to the lack of effect of the 
intervention on allergic outcomes at 3 and 5 years of age. In the CAPS study, compliance was 
assessed by counting the number of capsules used. The proportion of parents who reported to 
have remembered to use the study spreads and oils all or most of the time of the study was 
88%, and this proportion was not different between groups (188). However, when the weight 
change of the used capsule containers was measured, the median adherence to oil capsules 
during the period after age 2.5 years was only 56% and was higher in the control versus the 
fish oil group (62% vs. 51%, p= 0.004).  
As far as compliance is a major issue in supplementation studies, Damsgaard  et al. (189) 
asked volunteers to return remaining bottles and report any waste. They reported that mean 
fish oil consumption was 3.4 ml/day (range 0.8-5 ml/day), which was according to the advice 
given to the subjects (1-2 teaspoonfuls/day of the oil supplement into milk or formula). Hodge 
et  al.  (190)  assessed  compliance  by  counting  the  number  of  unused  capsules  by  the 
participants and by food diary records repeated at 3 time points after dietary modification and 
supplementation. Mean number of capsules taken per day was 3 instead of 4 (for both groups), 
and there were no children with an average of less that 2 capsules per day. Moreover, subject   96 
compliance was confirmed by the observed changes in plasma EPA levels over the whole 
period of the trial. Vaisman et al. (192) ensured compliance of the participants by recording 
the empty containers of chocolate spread in both groups on a weekly basis. However, the 
compliance  rate  was  not  reported.  In  the  study  of  Nagakura  et  al.  (191)  compliance  was 
controlled within the hospital setting.  
 
Confounding factors 
Potential confounders in the CAPS study include those related to the family (age of parents, 
socioeconomic status,  ethnicity, parental smoking, number and age of siblings), the home 
environment, lifestyle and diet (intake of potential allergens, foods high in n-3 fatty acids), 
duration  of  breastfeeding,  and  maternal  diet  during  late  pregnancy  and  breastfeeding 
(including fish eating habits, oils/margarines use, organ meat eating habits as well as use of 
vitamin/mineral supplements) (183). The clinical setting (hospital) in the study carried out by 
Nagakura et al. (191), and the fact that subjects stayed in the hospital ward for almost 85% of 
the intervention, was ideal as the environment was highly controlled. However, in this study 
the  two  groups  differed  significantly  in  the  amount  of  medication  used  for  acute  asthma 
attacks during the study. In the Danish study, sex, parity and breastfeeding duration were 
tested as covariates because they are known to modify immune function and development of 
allergies. In the formula groups, parents were asked to use formulas with a ratio of LA to ALA 
of about 8:1 (189). 
Hodge et al. (190) assessed the dietary intake of children using dietary records of 1 week (at 
baseline, 3 months, and 6 months after intervention). It was found that the fish oil group ate 
significantly more fresh fish than the control group (370 ﾱ 148 vs. 109 ﾱ 70 g/month, p= 
0.0045). Oil and margarine use did not differ between the two groups throughout the study. 
However, like with the studies of Nagakura et al. (191) and Vaisman et al. (192), the study of 
Hodge et al. (190) did not control for fish intake or for any other confounding factors in their 
analyses.  
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Outcome measures 
The CAPS study assessed clinical outcomes of allergic diseases in children at three different 
time points (18 months, 3 years and 5 years of age) (188). Primary outcomes were asthma and 
cough  at  3  years  of  age,  and  probable  current  asthma  at  5  years  of  age.  Wheeze  was  a 
secondary  outcome  measure  at  5  years  of  age  (Table  1.10).  Clinical  outcomes  were  also 
measured in the study conducted by Hodge et al. (190) in which lung function, atopy and 
asthma severity were assessed. Asthma was also assessed in the study of Nagakura  et al. 
(191). No clinical allergy outcomes were evaluated in the studies conducted by Vaisman et al. 
and Damsgaard et al. Blood immune markers were determined in the studies conducted by 
Vaisman et al. (192), Damsgaard et al. (189), the CAPS study and in the study of Hodge et al. 
(190).  
Effect of fish oil on outcome measures 
In the CAPS study, primary results at 18 months of age suggested that increasing  LC n-3 
PUFAs in the diet had a beneficial effect on wheezing in high-risk infants (184). The results 
from  the  follow-up  at  3  years  of  age  suggested  fish  oil  supplementation  from  infancy  to 
childhood could modulate the development of allergic sensitization and airway disease at an 
early age, as fish oil supplementation reduced cough, but not wheeze  (186). However, no 
effect was reported on the other end points measured such as eczema, serum IgE or doctor 
diagnosis of asthma. At 5 years of age there were no significant beneficial effects on clinical 
outcomes (lung function, allergy) (188). Almqvist et al. (187) reported that increased intake of 
LC n-3 PUFAs from early life did not affect atopy and asthma at age 5 years, which agrees 
with the results published by Marks et al. (188) about the CAPS study. Almqvist et al (187) 
reported that dietary and plasma LC n-3 PUFAs were significantly higher in the intervention 
group in comparison to the control group at all ages. Also, plasma n-6 PUFA levels were 
lower in the fish oil group. 
It has to be noted that the CAPS study (188) was the first study to examine the effects of 
dietary modification of n-3/n-6 balance during infancy and childhood on the incidence of 
asthma or allergic disease in children. The infants participated in that study had a family 
history of asthma, which put them in higher risk of developing asthma. Possible reasons for 
the lack of beneficial effects of LC n-3 PUFAs on the incidence of any allergic outcome at 5 
years  of  age  may  be  related  to  suboptimal  adherence  to  the  intervention  (50%  and  56%   98 
compliance in the intervention and control group, respectively), as well as to the dose of fish 
oil used, loss to follow-up and lack of power. The investigators estimated that the diet supplied 
30 mg/day EPA and 128 mg/day DHA, an amount 3 times higher than the reference intakes 
for children in Australia and New Zealand (National health and medical research council, 
2006). Higher doses might have resulted in more evident effects and clinically significant 
differences. 
Damsgaard et al. (189) concluded that a relatively high dose of LC n-3 PUFAs from 9 to 12 
months of age did not affect markers of innate immunity or inflammation in healthy infants. 
The tendency for an increased IFN-γ production in the fish oil group (p = 0.08) could be 
related  to  acceleration  of  immune  system  maturation.  The  accompanying  tendency  of  a 
reduced  IL-10  production  could  indicate  a  decrease  in  Th2  responses,  with  possible 
implications  for  the  development  of  allergies  (189),  although  clinical  outcomes  were  not 
assessed. 
In the study of Hodge et al. (190) fish oil supplementation along with the addition of canola 
oil and canola oil margarine to the diet over 6 months increased plasma n-3 fatty acid levels, 
but had no effect on clinical severity of asthma in the children. On the contrary, in the study of 
Nagakura et al. (191), a positive effect of the dietary supplementation with fish oil on asthma 
severity score and lung function in children with bronchial asthma was observed. Vaisman et 
al.  (192)  found  that  long  term  supplementation  of  moderate  amounts  of  LC  n-3  PUFAs 
increased the production of both pro- and anti-inflammatory cytokines which may result in a 
better clinical response, although clinical outcomes were not assessed. However, in this study, 
no baseline data on population characteristics and diet were given. Both of the groups were 
provided with canola oil (which is high in the n-3 PUFA -linolenic acid). Also, the amounts 
of n-3 and n-6 fatty acids (mg/day) coming from the oil added to the chocolate spread were 
not reported for the control group. 
Conclusion 
According to the findings of the CAPS study which was conducted on high risk infants (184), 
fish oil supplementation during infancy and childhood resulted in increased n-3 PUFA status 
and decreased n-6 PUFA status at 18 months, 3 years and 5 years of age. However, this was 
not associated with the expected beneficial effects on atopic outcomes and asthma. At 18 
months of age, fish oil resulted in decreased prevalence of wheeze, and higher plasma n-3   99 
PUFA  levels  were  associated  with  lower  bronchodilator  use,  irrespective  of  the 
supplementation group. At 3 years of age, there was a lower prevalence of cough only in 
atopic children. Finally, at 5 years of age, no significant effects were detected on asthma, 
wheezing, eczema, atopy (SPT positivity) and IgE levels. The CAPS study concluded that 
fatty acid  supplementation in  infants  cannot  be recommended as  an effective measure  for 
primary prevention of asthma. The authors suggested that influential dietary, socioeconomic 
and lifestyle factors should further be explored in order to explain the apparent protective 
effect of oily fish consumption on asthma among children (187).  
The Danish study of fish oil supplementation in low risk infants (189) also showed increased 
LC n-3 PUFA status, and in addition a tendency to increased IFN- production in the fish oil 
group that may be linked to faster immune system maturation. However, no other immune 
parameters were affected.  
The  other  three  studies  were  conducted  in  older  children.  Two  of  the  studies  included 
asthmatic children and showed that fish oil supplementation increased n-3 PUFA status. Also, 
Hodge et al. (190) showed a decrease in TNF-α production in the fish oil group, but clinical 
outcomes of asthma were not affected. On the other hand, Nagakura et al. (191) showed a 
decrease  in  asthma  symptom  scores,  although  the  study  took  place  in  a  controlled 
environment. Finally, the study of Vaisman et al. (192) did not provide a clear effect as fish oil 
supplementation resulted in increased pro- and anti-inflammatory cytokine production. It has 
to be noted that these children were healthy/free of atopic disease. 
In  conclusion,  larger  long-term  randomized  infant  trials  are  needed  to  further  explore  the 
immuno-modulating effects of long-chain n-3 PUFAs and the associated impact on disease 
indicators and manifestations.  
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616 Infants with 
family history of 
asthma (at least 




554 Children of 
616 completed the 
study at 18 
months 
1. HDM reduction, 
placebo supplement 
 
2. No HDM reduction, 
placebo supplement  
 
3. HDM reduction, fish 
oil supplement  
 
4. No HDM reduction, 
fish oil supplement  
 
Fish oil group: 500 
mg/day tuna oil 
capsules (37% n-3 
PUFAs, 6% n-6, 24% 
MUFAs, 28% SFAs, 
5% minor FAs), plus 
canola margarines and 
oil (16% n-6, 40% n-9, 
6% n-3 PUFAs) 
From 6 months 
old or onset of 
bottle-feeding 













and oil (40% n-
6, 20% n-9, 
1.2% n-3) 
 
Results at 18 
months of age 
At 18 months: 




















Plasma n-3 PUFAs were higher in the FO 
compared to the control group (6.7%, 95% 
CI 6.5-7.0, vs 5.0%, 95% CI 4.8-5.2, p< 
0.0001) 
 
Plasma n-6 PUFAs were lower in the FO 
compared to the control group (35% vs 
32.5%, p< 0.0001) 
 
Significant difference in the ratio of n-3 to 
n-6 FAs between the FO and control group 
(1:5 vs 1:7.14, p< 0.0001) 
 
The diet intervention resulted in a 9.8% 
absolute 
reduction (95% CI 1.5-18.1, p = 0.02) in 
the prevalence of any wheeze, and a 7.8% 
absolute reduction (95% CI 0.5-15.1, p= 
0.04) in prevalence of wheeze for more 
than 1 week 
 
No effect of FO on serum IgE, SPT, 
doctors‟ diagnosis of asthma, cytokine 
responses 
 
The HDM intervention did not affect 
outcomes 
Increasing dietary 
n-3 fatty acids 
might have a 
beneficial effect 
on the prevalence 
of wheeze during 
the first 18 months 
of life. 
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Same as above 
 
376 Children of 
616 completed the 
study at 18 
months and had 
blood taken 
Same as above 
 
Same as above 
 
Results at 18 
months of age 
At 18 months: 
Plasma FAs 
(expressed in 















Total serum IgE 
Wheeze ever (p-trend 0.031), doctor visits 
for wheeze (p-trend 0.047), bronchodilator 
use (p-trend <0.001) and nocturnal 
coughing (p-trend 0.032) were 
significantly reduced in children in the 
higher n-3 exposure quintiles 
 
After adjusting for breastfeeding and 
smoking during pregnancy, the highest 
exposure quintiles were only protective for 
bronchodilator use (OR 0.46, 95% CI 
0.30-0.71, p< 0.0001) 
 
Serum IgE was reduced in the highest 
quintile of n-3 exposure but not 
significantly 
There was no difference in diagnosed 
asthma or atopy (SPT) between the 
exposure quintiles 
Although wheeze 
at this age may not 
be a good 
indicator of 
asthma in later 
childhood, it is 
encouraging that 
some symptoms 
have been reduced 
in children with 
high n-3 fatty acid 
concentrations in 
plasma. 












Same as above 
 
526 Children of 
616 completed the 
study at 3 years of 
age  
Same as above  Same as above 
 
Results at 3 
years of age 
At 3 years: 













Total serum IgE 
Plasma n-3 PUFAs were higher in the FO 
compared to the control group (6.3% vs 
4.9%, p< 0.0001) 
 
Plasma n-6 PUFAs were lower in the FO 
compared to the control group (33.3% vs 
35.7%, p< 0.0001) 
 
Significant difference in the ratio of n-3 to 
n-6 FAs between the FO and control group 
(1:5.9 vs 1:7.7, p< 0.0001) 
 
In the active diet group there was a 10.0% 
(95% CI, 3.7-16.4) reduction in the 
prevalence of cough only in atopic 
children (p= 0.003; number needed to 
treat, 10)  
 
In the active allergen avoidance group 
there was a 7.2% (95% CI 10.1-14.3) 
reduction in sensitization to HDM (p= 
0.05; number needed to treat, 14) 
 
No significant differences in wheeze, 
eczema, asthma, and serum IgE were 
found with either intervention 
These results 
suggest that such 
interventions may 





airways disease in 
early childhood. 
This offers the 
prospect of 
reducing allergic 
disease in later 
life.   102 
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Same as above 
 
516 Children of 
616 completed the 
study at 5 years of 
age 
Same as above  Same as above 
 
Results at 5 
years of age 



















Total serum IgE 
Dietary intervention resulted in: 
Significant difference in the ratio of n-3 to 
n-6 fatty acids in plasma between FO and 
control group (1:5.8 vs 1:7.4, p< 0.0001) 
 
The prevalence of asthma, wheezing, 
eczema, atopy (SPT), and IgE levels did 
not differ between the diet groups (p> 0.1) 
 
HDM avoidance intervention had no effect 
on the prevalence of asthma, wheeze or 
atopy at 5 years 
 
The prevalence of eczema was higher in 
the active HDM avoidance group (26% vs 
19%, RR 1.39, CI 1.00-1.93, p= 0.06) 
HDM avoidance 
measures and 
dietary fatty acid 
modification, in 
infancy and early 
childhood to 
prevent the onset 
of asthma and 
allergic disease in 
children at 
increased risk of 
asthma cannot be 
recommended. 
Indeed, the former 
may be 
contraindicated 
because of an 
increased risk of 
eczema. 
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Same as above 
 
516 Children of 
616 completed the 
study at 5 years of 
age 
Same as above  Same as above 
 
Results at 5 
years of age 



















Dietary intake of 
FA: 
At 18 months with 
3-day weighed food 
record 
At 3 years with 
semi-quantitative 
FFQ 
Plasma n-3 FA were higher and plasma n-
6 FAs were lower in the FO group than in 
the control group (p< 0.0001) 
 
Dietary intake of n-3 was higher and that 
of n-6 was lower in the FO compared to 
control group 
 
n-3 and n-6 FAs intake from the diet at 18 
months and 3 years, and from FAs 
supplementation throughout the 5 years 
were not associated to respiratory and 
allergic outcomes at 5 years (p= 0.39-
0.85) 
 
Plasma n-3 or n-6 FA levels were not 
associated with wheeze, eczema or atopy 
at 18months, 3 years, and 5 years (p= 
0.11-0.96) 
 
The overall effect of plasma FA, dietary 
intake and supplements compliance was 
not associated with any respiratory or 




and n-6 restriction 
during early 
childhood in 
children with high 
risk of developing 
asthma did not 
prevent atopy and 
asthma, despite 
the significant 
increase in n-3 
plasma levels. 












n= 13 FO 
n= 20 Control 
 
Infant Formula 
n= 20 FO 
n= 11 Control 
4 Intervention groups: 
 
Cows‟ milk and FO 
Cows‟ milk only 
Infant formula and FO 
Infant formula only  
 
Mean fish oil 
consumption 3.4 
mL/day (571 mg EPA 





month of age 
 





IgE, CRP, sIL-2R 
 
TNF-α, INF-γ, and 




Fecal IgA at 10 
months of age 
FO supplementation: 
Raised erythrocyte n-3 PUFA (p< 0.001) 
 
Increased induced INF-γ production (p= 
0.05) 
 
Tended to reduce stimulated IL-10 
production (p= 0.08)  
 
The FO intervention did not affect any of 
the other analyzed immune variables. 
 
Erythrocyte EPA was negatively 
associated with stimulated IL-10 
production (p= 0.02) 
FO 
supplementation 







the capacity to 
produce INF-γ has 
been proposed as 
a maturation 
marker for the 
immune system in 
early life. 
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children aged 8-12 
years 
 
n= 20 FO 
n= 19 Control 
Intervention: 
4 fish oil capsules (0.18g 
EPA, 0.12g 
DHA/capsule) providing 
1.2 g/day n-3 PUFAs 
Diet: canola oil and 
canola-oil based 




4 capsules (0.45g 
safflower, 0.45g palm, 0.1 
g olive oil/capsule)  
Diet: sunflower oil 
and sunflower-oil based 
margarines and salad 
dressing 
6 months  At baseline, 3, and 6 







lung function and 





(record of expiratory 
flow rate, symptoms, 
medication) 
Plasma phospholipid n-3 FAs were 
significantly higher in the n-3 group at 3 
and 6 months compared to the n-6 group 
(p< 0.001)  
 
In the n-3 group TNF- production 
decreased significantly compared to 
baseline (p= 0.026) but the magnitude of 
change between groups was not significant 
(p= 0.075) 
 
No significant changes in clinical outcome 
measures 
Dietary 
enrichment of n-3 
fatty acids over 6 
months increased 
plasma levels of 




had no effect on 
the clinical 
severity of asthma 
in these children. 









children aged 4-17 
years 
 
n = 15 FO 
n = 14 Control 
Intervention: 300 mg fish oil 
in capsules (84 mg EPA, 36 
mg DHA)  
 
Control: 300 mg olive oil 
capsules 
 
The number of capsules were 
adjusted to body weight: 
daily dosages of EPA and 
DHA were 17.0-26.8 and 
7.3-11.5 mg/Kg body weight, 
respectively. 






inhalation tests (FEV1) 
 
Plasma EPA at 1, 5, 7, 
10 months after 
baseline 
In the fish oil group but not in control : 
 
Asthma symptom scores decreased at 6, 7, 8, 9, 
10 months after administration compared to 
baseline (p< 0.05) 
 
Responsiveness to acetylcholine decreased in 6, 
8, 10 month after administration (p< 0.03) 
 
Plasma EPA levels increased only in fish oil 
group (p< 0.008) 
Dietary 
supplementation 
with fish oil rich in 
EPA and DHA was 
beneficial for 
children with 
bronchial asthma in 
a strictly controlled 
environment in 
terms of inhalant 
allergens and diet. 








children aged 8-12 
years 
 
n = 7 FO 
n = 14 Control 
 
Intervention: 300 mg/day 
n-3 PUFA (180 mg EPA, 
120 mg DHA) + 700 mg 
canola oil 
 
Control: 1 g of canola oil  
 
 
Oils were blended in 
chocolate spread 
3 months  PBMNC cytokine 









The levels of all cytokines were higher in non-
stimulated and stimulated cultures, in n-3 
PUFA-treated subjects compared to controls:  
 
Without stimulation: IL-lβ, TNF-α,IL-6 (p= 
0.003, p= 0.052, p= 0.004, respectively), IL-10 
and IL-1Rα (p= 0.004, p= 0.02, respectively) 
 
With stimulation: IL-β, TNF-α and IL-6 (p= 
0.002, p= 0.011 and p= 0.006, respectively) 
IL-10 and IL-1Rα (p= 0.073 and p= 0.008, 
respectively) 
 
There was no difference in the IL-1b/ IL-1Rα 
ratio between the two groups, with and without 
stimulation (p= 0.76 vs p= 0.20, respectively) 












RCT, randomized control trial; CAPS; Childhood Asthma Prevention Study; OR, odds ratio; CI, confidence interval; FA, fatty acids; PUFA, polyunsaturated fatty acids; 
MUFA, monounsaturated fatty acids; SFA; saturated fatty acids; FO, fish oil; SPT, skin prick testing; HDM; house dust mite; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; ARA, arachidonic acid; sCD14, soluble CD14; CRP, C-reactive protein; Ig, immunoglobulin; IFN, interferon; IL, interleukin; TNF, tumour necrosis 
factor; vs, AHR, airway hyper-responsiveness; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; versus.   105 
 
1.6  Summary, conclusions, aims and hypotheses 
LC n-3 PUFAs from oily fish and fish oils affect inflammation and immune function. They 
act, in part, by opposing the actions of LC n-6 PUFAs. Dietary intake of n-6 PUFAs has 
increased in the previous 40 years or so. Prevalence of atopy and its clinical manifestations 
has also increased over this period. It is suggested that the increase in n-6 PUFA intake is 
causally linked to the increase in atopy, with ARA-derived eicosanoids playing a role. 
Studies of fatty acid composition in atopy provide some support for a predisposing effect 
of n-6 PUFAs and propose a protective effect of LC n-3 PUFAs, but these data are rather 
inconsistent.  Epidemiological  studies  provide  consistent  evidence  that  fish  intake  in 
pregnancy  is  associated  with  reduced  risk  of  atopy  in  infancy  and  childhood.  This  is 
important because atopic sensitisation occurs early in life, perhaps in utero, and so it may 
be  that  very  early  exposures  to  n-6  or  n-3  PUFAs  might  be  critical.  Indeed, 
supplementation studies with fish oil in pregnant women demonstrate some immunological 
effects in cord blood although longer term effects on disease are less clear. One reason for 
discrepancy  between  epidemiological  studies  of  fish  consumption  and  supplementation 
studies with fish oil is that fish provide not only LC n-3 PUFAs, but other nutrients as well, 
and these other nutrients could play a role. It could be speculated that it is the nutrients of 
the oily fish as a whole or the combination of these nutrients with LC n-3 PUFAs that is 
important.  To  test  this  idea  early  intervention  with  oily  fish  is  required,  as  the 
epidemiology only suggests associations and is not proof of a causal effect.  
There have been no intervention trials conducted with oily fish in pregnant women. This 
thesis  describes  such  a  study:  The  Salmon  in  Pregnancy  Study  (SIPS).  SIPS  is  a 
randomised controlled trial of oily fish (farmed salmon) in pregnant women looking at 
fatty acid status, immune functions and atopic outcomes in their offspring. The hypotheses 
being investigated in SIPS are that: „increased consumption of oily fish during pregnancy 
by women at risk of having offspring who will develop atopy will increase their LC n-3 
PUFA status and antioxidant status and that of their developing baby and will ameliorate 
the development of atopic markers and manifestations in the infants‟. The work described 
in this thesis is part of SIPS. The aims of my study are: 
1.  to increase oily fish consumption from a habitually low intake (≤ 2 portions/month) 
to  the  recommended  maximum  level  of  intake  (two  portions/week)  during 
pregnancy,  in  women  whose  offspring  are  at  a  high  risk  of  developing  atopic 
disease;   106 
2.  to investigate the effect of increased maternal oily fish consumption on cord plasma 
and cord blood mononuclear cell (CBMC) LC n-3 PUFA status; 
3.  to investigate the effect of increased maternal oily fish consumption on markers of 
infant immunity at birth (i.e. in cord blood); 
4.  to  investigate  the  effect  of  increased  maternal  oily  fish  consumption  on  atopic 
sensitization and atopic dermatitis in infants at 6 months of age. 
The research hypotheses of my study are that increased consumption of farmed salmon 
during pregnancy by women with high risk of having an atopic offspring will:  
1.  increase maternal LC n-3 PUFA intake; 
2.  increase cord plasma LC n-3 PUFA status; 
3.  increase CBMC LC n-3 PUFA status; 
4.  alter immune markers in cord blood in a way that would indicate decreased atopy 
risk;  
5.  reduce  sensitisation  to  common  allergens  and  reduce  atopic  dermatitis  score  in 
infants at 6 months of age. 
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2  Salmon in pregnancy study (SIPS): Aims & 
hypotheses, study design and characteristics of the 
subjects    108 
 
2.1  Aims and research hypotheses of my study 
In section 1.3 the early life origins of atopic disease were described, including some of the 
evidence that sensitisation occurs in utero. In section 1.4 the effects of polyunsaturated 
fatty acids (PUFAs) on the immune system were summarised; through these effects n-6 
and  n-3  PUFAs  might  differentially  influence  sensitisation  and  the  immunological 
processes  associated  with  atopic  diseases.  Based  on  these  effects  long-chain  (LC)  n-3 
PUFAs might reduce the risks of developing atopic diseases. Oily fish and fish oils are 
good  sources  of  these  fatty  acids.  Epidemiological  studies,  reviewed  in  section  1.5.1, 
suggest a protective effect of fish consumption by pregnant women or by children towards 
atopic diseases, while intervention studies with fish oil supplements in pregnant women, 
reviewed  in  section  1.5.2,  demonstrate  some  immunological  effects  in  cord  blood  but 
longer term effects on disease outcomes are less clear. One reason for discrepancy between 
epidemiological studies of fish consumption and supplementation studies with fish oil is 
that fish provide not only LC n-3 PUFAs, but other nutrients as well, and these other 
nutrients could play a role. It could be speculated that it is the nutrients of the oily fish as a 
whole or the combination of these nutrients with LC n-3 PUFAs that is important. To test 
this idea early intervention with oily fish is required, as the epidemiology only suggests 
associations and is not proof of a causal effect.  
Currently in the UK it is recommended that pregnant women and women of reproductive 
age  should  consume  oily  fish  but  not  more  than  two  portions  weekly,  because  of  the 
presence of contaminants in some fish (23). However, this concern can be reduced by 
consuming farmed fish in which contaminant levels can be controlled and made to be very 
low since the feeds of the fish can be controlled as well as the waters in which they breed 
and grow.  
There have been no intervention trials conducted with oily fish in pregnant women. The 
Salmon in Pregnancy Study (SIPS) described here is the first randomised controlled trial of 
oily fish (farmed salmon) in pregnant women;  the study was single blind (investigator 
blind)  and  the  babies  of  the  women  recruited  were  at  high  risk  of  developing  atopic 
disease. SIPS is registered at www.clinicaltrials.gov website with the official title: „The 
effects of oily fish in pregnancy on markers and manifestations of allergic diseases in 
infants  at  risk  of  atopy‟  (clinical  trials  identifier  number:  NCT00801502) 
(http://www.clinicaltrials.gov/ct2/show/NCT00801502?term=sips&rank=1).   109 
This study sets out to identify the effects of increasing salmon intake in pregnant women. 
The hypotheses being investigated, as stated at  www.clinicaltrials.com are that: „increased 
consumption of oily fish during pregnancy by women at risk of having offspring who will 
develop atopy will increase their LC n-3 PUFA status and antioxidant status and that of 
their  developing  baby  and  will  ameliorate  the  development  of  atopic  markers  and 
manifestations in the infants‟. 
The primary outcome measures of SIPS (as stated at www.clinicaltrials.gov) are LC n-3 
PUFA fatty acid status in maternal and umbilical cord plasma [Time Frame: weeks 20, 34 
and 38 of pregnancy and at birth (in cord)]. 
The secondary outcome measures of SIPS (as stated at www.clinicaltrials.gov) are:  
1.  Antioxidant status in maternal and umbilical cord blood [Time frame: weeks 20, 34 
and 38 of pregnancy and at birth (in cord)];  
2.  Allergic sensitisation of infants [Time frame: 6 months of age];  
The aims of my study are: 
1.  to increase oily fish consumption from a habitually low intake (≤ 2 portions/month) 
to  the  recommended  maximum  level  of  intake  during  pregnancy  (two 
portions/week) in women whose offspring are at a high risk of developing atopic 
disease; 
2.  to investigate the effect of increased maternal oily fish consumption on cord plasma 
and cord blood mononuclear cell (CBMC) LC n-3 PUFA status; 
3.  to investigate the effect of increased maternal oily fish consumption on markers of 
infant immunity at birth (i.e. in cord blood); 
4.  to  investigate  the  effect  of  increased  maternal  oily  fish  consumption  on  atopic 
sensitization and atopic dermatitis in infants at 6 months of age.   110 
 
The research hypotheses of my study are that increased consumption of farmed salmon 
during pregnancy by women with high risk of having an atopic offspring will:  
1.  increase maternal LC n-3 PUFA intake; 
2.  increase cord plasma LC n-3 PUFA status; 
3.  increase CBMC LC n-3 PUFA status 
4.  alter immune markers in cord blood in a way that would indicate decreased 
atopy risk;  
5.  reduce sensitisation to common allergens and reduce atopic dermatitis score in 
infants at 6 months of age. 
The  research  hypotheses  are  presented  (description,  methodology  and  results)  and 
discussed in chapters 3-6.  
 
The core SIPS investigators were: 
Professor Philip C. Calder  Program  coordinator  and  principal 
investigator 
Dr Elizabeth A. Miles         Senior investigator 
Dr Paul S. Noakes           Postdoctoral investigator 
Mrs Norma D. Diaper, MSc        Senior research nurse 
Miss Lefkothea-Stella Kremmyda, MSc    PhD student and nutritionist 
Miss Maria Vlachava (MV), MSc      PhD student and nutritionist   111 
 
It is important to make a clear statement of my involvement. Table 2.1 lists the activities in 
which  I  (MV)  participated  and  the  activities  from  which  results  were  generated  for 
inclusion in this thesis. 
 
Table 2.1: Statement of the activities of MV in the SIPS 
 
Activities performed by MV  Activities generating results in MV thesis 
Recruitment and screening appointment:  
Allergy and lifestyle questionnaires 




20, 34, 38 week maternal appointment:  
Ultrasound scan 
Health and lifestyle questionnaires 
FFQ 
BC measurements 
Urine sample collection 
Blood samples: processing and analysis 
Fish diary during pregnancy: given at 20 week 
appointment (started at 21
st week) and collected 
at 38 week appointment  














Cord blood samples: processing and analysis,  





Within 2 weeks after birth: 
DXA scan: maternal and infant 
Maternal BC 
 
Yes (infant only) 
No 
Maternal BC measured at home for 14 days  No 
3 month visit: 
Maternal FFQ: 
Partial collection of diaries: infant feeding and 
health, post partum maternal fish diary 
Collection of infant stool samples from days: 1, 
7, 14, 28 after birth 
Collection of breast milk samples from days: 1, 








6 month visit: clinical assessment of allergy:  
Infant, maternal, paternal SPT, infant SCORAD 
Paternal blood sample 
Infant anthropometry 
Infant blood sample: processing and analysis 
Infant FFQ  
Collection of diaries: post partum maternal (fish 
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2.2  Study design, power calculation, population studied and data 
collection 
2.2.1  Study design 
SIPS was a randomised, controlled intervention trial with oily fish in pregnant women. A 
group of 123 pregnant women with high risk of giving birth to an atopic infant and with a 
self-reported low habitual  intake of oily  fish were randomly  assigned to consume two 
portions of oily fish (salmon) per week or to continue their habitual diet low in oily fish, 
from week 20 of gestation until the end of their pregnancy.  
Eligibility criteria for inclusion in the study were:  
1.  In the early stages of pregnancy (around 13 weeks). 
2.  Habitual intake of ≤ 2 portions of oily fish per month (excluding tinned tuna). 
3.  Family  history  of  atopy  within  the  last  5  years  (including  asthma,  atopic 
dermatitis (itchy rash/eczema), seasonal rhinitis (hay-fever), perennial rhinitis 
(other allergies)) in any first degree relative (mother, father or sibling of the 
fetus). 
4.  Not consuming fish oil supplements. 
5.  Aged between 18-40 years. 
Exclusion criteria were: 
1  Habitual consumption of oily fish (> 2 portion of oily fish per month excluding 
tinned tuna). 
2  Use of fish oil supplements within the previous 3 months. 
3  Use  of  non-steroidal  anti-inflammatory  drugs  (NSAIDs)  (e.g.  aspirin, 
diclofenac, ibuprofen). 
4  Multiple pregnancy. 
5  Not  willing  for  essential  identifiable  information  being  stored  for  tracking 
purposes. 
6  Participation in another research study. 
7  Known diabetic.  
8  Known to  suffer from auto-immune disease, e.g., multiple sclerosis, thyroid 
disease, systemic lupus erythematosis.   113 
9  Having a learning disability. 
10  Having a terminal illness. 
11  Having a mental health problem. 
Ethical  approval  for  the  study  was  obtained  from  the  Southampton  and  South  West 
Hampshire Research Ethics Committee (07/Q1704/43).  
2.2.2  Power calculation  
 
The  SIPS  study  was  powered  according  to  two  outcomes:  fatty  acid  composition  of 
maternal plasma phospholipids and infant sensitisation to at least one common allergen. 
 
 Fatty acid composition of plasma phospholipids 
 
Based  upon  previous  work,  the  content  of  eicosapentaenoic  acid  (EPA)  in  plasma 
phospholipids in these women was expected to be approx. 1% of fatty acids (196). Two 
salmon meals per week were anticipated to provide a total of approximately 4 g EPA plus 
docosahexaenoic acid (DHA)/week; of this about 2.8 g would be EPA, equivalent to an 
increased intake of 0.4 g EPA/day (background intake was expected to be approx. 0.1 
g/day). This was expected to increase the EPA content of plasma phospholipids by 50% to 
about 1.5% of fatty acids. Using known standard deviations for the EPA content of plasma 
phospholipids  in  adults  in  the  Southampton  area,  a  sample  size  of  50  per  group  was 
anticipated to have a 99% power to detect this difference with P < 0.05 (90% power to 
detect with P < 0.001). This power calculation was performed before the study salmon had 
been produced and analysed. It turned out that the EPA plus DHA content of the salmon 
was  lower  than  anticipated  (equivalent  to  3.46  g/week),  but  this  difference  was  not 
considered to affect the power of the study to identify a significant effect of the salmon 
twice per week on the EPA content of maternal plasma phospholipids. 
 Sensitisation to at least one common allergen  
 
Infants  born  to  women  recruited  into  the  study  were  considered  to  be  at  high  risk  of 
becoming sensitized to allergens. Based upon personal communication with Professor John 
Warner it was anticipated that 45% of infants would be sensitized at 6 months of age. It 
was estimated that infants of women in the oily fish group would be 30% less likely to 
have been sensitized (based upon data from Dunstan et al. (132) using fish oil in at risk 
pregnant women). A sample size of 50 per group would have a 70% power to detect this   114 
difference with P < 0.05. It turned out that a much lower percentage of infants than this 
were sensitised (see Chapter 6). 
 
2.2.3  Subject appointments - data collection and follow-up 
Women taking part in the study were seen at 13, 19-20 (referred to as 20 weeks hereafter), 
32-34  (referred  to  as  34  weeks  hereafter),  and  38  weeks  of  pregnancy.  At  13  weeks 
gestation  women  were  screened  for  eligibility  during  their  routine  ultrasound  scan 
appointment at the Southampton Women‟s Survey Ultrasound Unit (SWS UU) of Princess 
Anne Hospital in Southampton, UK. Prior to their appointment, they had received an initial 
information sheet about the SIPS (Appendix 1), along with their appointment notes sent by 
the SWS UU. Women were initially approached by a researcher of the SIPS team (myself, 
Stella Kremmyda or Norma Diaper) and were asked if they would like to hear more about 
the study and be screened for eligibility. Women who agreed to be screened were asked to 
sign a consent form for initial screening (Appendix 2). Initial screening included a health 
and lifestyle questionnaire administered by the researcher including questions on eligibility 
criteria,  weight  and  height  measurement  (Appendix  3),  and  body  composition 
measurement performed by bioelectrical impedance.  
Women who were eligible for the study were provided with a second information sheet 
(Appendix 4), the study was further explained to them and their intention to take part in the 
study  irrespective  of  randomization  group  was  confirmed.  A  randomization  plan  was 
created through the website http://randomization.com, which randomized each subject (in 
the order that they were found to be eligible) to one of the two groups by using the method 
of randomly permuted blocks (2 blocks: control and salmon). Women who were interested 
in the study but had a preference for either of the two groups were not included. At 15 
weeks of pregnancy women were phoned to remind them about the study, discuss any 
concerns and confirm their next appointment at 19-20 weeks of pregnancy at SWS UU.  
Women attended the 19-20 week appointment in the fasted state. They were asked to sign 
the consent form for participating in SIPS (Appendix 5) and they were randomly assigned 
to one of the two groups, intervention or control. The appointment included an ultrasound 
scan, weight measurement and body composition analysis by bioelectrical impedance, a 
researcher-administered health and lifestyle questionnaire (Appendix 6), blood collection, 
urine collection, and a food frequency questionnaire (FFQ) covering the past three months 
administered  by  an  appropriately  trained  researcher  (myself  or  Stella  Kremmyda; 
Appendix 7). Women were given breakfast after sample collection and before the FFQ was   115 
administered. Women in the intervention group were also provided with a cook book with 
salmon recipes and a fish diary to record their consumption of the study salmon (and any 
other fish they may consume), how it was cooked, and whether there were any leftovers 
from the standard portion (Appendix 8). Women in the control group were provided with a 
general cook book including information on healthy eating during pregnancy, and a fish 
diary (Appendix 9) to record their fish consumption (type, way of cooking, portion size). 
Fish  diaries  were  used  to  measure  compliance  of  the  subjects  in  both  groups  and  to 
estimate nutrient intake from fish consumption.  
The fasting appointments at 32-34 and 38 weeks of pregnancy were identical to the one at 
19-20 weeks of pregnancy, except that at week 38 a stool sample was also collected and 
there was no FFQ administration or body composition measurement (Appendices 10 and 
11).  
The  health  and  lifestyle  questionnaire  was  administered  by  an  appropriately  trained 
member of the SIPS team (myself, Lefkothea-Stella Kremmyda, Norma Diaper) at 13, 20, 
34, and 38 weeks of pregnancy. It included questions on medication, use of nutritional 
supplements/vitamins/minerals in the previous 4 weeks, smoking, alcohol consumption, 
atopic symptoms of the mother, father and sibling(s) (only at 13 weeks), pet ownership, 
visiting households with pets, oily and non-oily fish consumption frequencies (only at 13 
weeks), level of education and occupation (only at 20 weeks), and problems with eating the 
salmon if in the intervention group (at 32-34 and 38 weeks) (Appendices 3, 6, 10, and 11). 
Any problems related to the salmon were reported to the research nurse to ensure that both 
nutritionists remained blind to the treatment group of the subjects. Characteristics of the 
women at study entry were identified from information gathered from the week 13 and 20 
questionnaires. 
Physical activity questions were incorporated in the Health and Lifestyle questionnaire and 
were administered by an appropriately trained member of the SIPS team at 20, 34 and 38 
weeks  of  pregnancy.  They  included  questions  on  frequency  of  performing  physical 
activities of different intensity (vigorous, moderate, gentle exercise), as well as hours spent 
sleeping/lying down, sitting, standing/walking over a typical 24 h day, and walking speed 
at present. The questions reflected average physical activity in the three months prior to the 
time point of the interview. The questions were adopted from the Southampton Women‟s 
Survey (SWS) questionnaire for estimating physical activity, which has been used before 
on women in Southampton (194-196).   116 
Height was measured at 13 weeks gestation using a stadiometer. Subjects were asked to 
remove their shoes and stand straight. The head was placed in the Frankfort Plane, such 
that an imaginary line joining the upper margin of the external auditory meatus and the 
lower border of the orbit of the eye was horizontal. The measurement was taken once and 
to the nearest 0.1 cm. 
Weight and body composition were measured using a MC-180MA Tanita, at 13, 20, 34, 
and 38 weeks gestation. This is a bioelectrical impedance device using multi-frequency 8-
electrodes  to  measure  body  composition.  Electrolytes  within  the  body  are  naturally 
conductive. More electrolytes are contained in muscle and blood, but few in fat. Electricity 
flows more easily through body tissue with more muscle and less fat while, conversely, 
electricity experiences more resistance in body tissue with less muscle and more fat. Using 
this fact, the component ratios of each can be estimated by measuring body impedance. 
Using the 8-electrode method, an electric current is supplied from electrodes at the ends of 
the fingers on both hands and the toes on both feet, and the voltage is measured at the ball 
of  the  thumbs  on  both  hands  and  at  the  heels  of  both  feet.  This  method  enables 
measurement of impedance per segment – in other words for the whole body, right leg, left 
leg, right arm or left arm – by switching the points at which the current is applied and the 
voltage  is  measured.  A  multi-frequency  measurement  is  used  to  separate  between 
intercellular  and  extracellular  water,  and  estimate  total  body  water.  Subjects  were 
measured in the fasting state and having emptied their bladder. They were asked to remove 
their shoes and socks, and wipe their hands and the soles of their feet before making the 
measurements. They were also asked to remove rings, watches and metallic accessories 
when possible, as well as heavy clothing. They were then asked to stand on the electrode 
panel, placing their feet apart so as to avoid inner thighs contact. Similarly, subjects were 
asked to avoid contact between arms and torso. The measurement was performed once 
following the instructions given by the manufacturer. The results of the body composition 
measurements are not included in the present thesis. 
Midwives at the Princess Anne Hospital, Southampton and the rest of birth centres (if a 
subject was planning to deliver in a birth centre different from the Princess Anne Hospital 
or at home) were provided with information about the study and were given laminated 
instructions to remind them to collect cord blood (at room temperature and at 4˚C). They 
were asked to contact the SIPS team once any samples were collected. At birth or very 
soon after occipito-frontal circumference (head circumference) (cm), crown-heel length 
(cm) and weight  (kg) of the baby were measured by the SIPS  research nurse (Norma 
Diaper) (Appendix 19).   117 
The neonate's crown-heel length was measured with a neonatometer (CMS Ltd., London, 
United Kingdom), and length was measured with a portable stadiometer (Leicester height 
measurer; CMS Ltd.). Within 14 days of birth infant body composition was assessed by 
dual-energy  X-ray
  absorptiometry  (DXA)  with  a  Lunar  DPX-L  instrument  (GE  Corp, 
Madison, WI, USA). Fat mass and fat-free mass were derived with a whole-body scan by 
using  pediatric  software.  The  total  X-ray  dose  for  the  whole-body  scans  was  10.5 
microsieverts (pediatric scan mode), equivalent to 1–2 d background radiation (197). The 
infant  body  composition  information  is  included  in  this  chapter  (characteristics  of  the 
infants at birth). 
At 3 months after delivery, a home visit was arranged with all subjects. This appointment 
included  administration  of  the  maternal  FFQ,  partial  collection  of  the  fish  and  infant 
feeding diaries (Appendices 8/9 and 12) which women were asked to complete until 6 
months after birth, collection of breast milk and infant stool samples and provision of the 
information sheet corresponding to the final visit of the study at 6 months of baby age 
(Appendix  13).  The  breast  milk  and  stool  samples  were  stored  in  the  freezers  of  the 
volunteers  and  were  transferred  to  the  IDS  Building,  University  of  Southampton  in  a 
portable cooler on the day of the 3-month visit. The mothers were also asked to measure 
their  body  composition  for  the  first  14  consecutive  days  after  birth  (body  weight  and 
percentage  of  body  fat)  using  Tanita  portable  scales  (UM-014S)  provided  to  them 
(Appendix 15). None of this information is included in the present thesis. 
At 6 months of baby age, a clinical visit was arranged. The mother, father and study infant 
were  invited  to  attend  the  Wellcome  Trust  Clinical  Research  Facility  (WTCRF)  at 
Southampton General Hospital. The main purpose of the visit was the clinical assessment 
of atopic disease of all the family members including the infant. In addition to members of 
the SIPS research team, a paediatric nurse was involved. The duration of this visit was 1.5 
hours. Initially the research nurse gave an overview of the visit to the parents and obtained 
written informed consent from them (Appendix 14). The appointment included skin prick 
testing (SPT) (Appendices 16 & 17) of both parents and infant, measuring infant weight 
and length, assessment of atopic dermatitis using SCORAD and the UK Working Party 
Diagnostic  Criteria  for  Atopic  Dermatitis  adapted  for  use  in  infant  (Appendix  18), 
administering a clinical assessment questionnaire (adapted from the questionnaire used by 
SWS at age 6 months) and assessment of infant diet (using an infant FFQ adapted from the 
FFQ used by SWS at age 6 months) all included in the 6 month questionnaire (Appendix 
20) as well as collection of the rest of the fish diaries covering maternal fish consumption 
from month 3 to month 6 post-natally and a diary recording infant feeding and health. On   118 
completion of clinical examination, the research nurse discussed any significant clinical 
findings  with  the  parents  and  explained  options  available  for  further  clarification  and 
management issues. The infant clinical results and other (diet, anthropometry) information 
are included in Chapter 6. 
Maternal  and  paternal  SPT  were  performed  at  6  months  post  partum  at  the  6  month 
appointment. All the different appointments and assessments during the study described 
above are summarised in Figure 2.1. 
SPT was performed by the research nurse of the study (N.D. Diaper) on the flexor aspect 
of the forearm using a standardized technique and allergen extracts, as well as histamine as 
a positive control and glycerine diluent (Soluprick SQ, ALK Abello) as a negative control. 
A drop of each allergen and the controls was introduced into the epidermis using a lancet, 
without drawing blood. A wheal diameter of ≥ 2 mm greater than the negative control was 
considered positive after the application of the allergen extracts. Table 2.2 presents the 
allergens and controls used. The potency is expressed in „Histamine Equivalent in skin 
Prick testing‟ (HEP) which is related to the allergenic activity of the allergen. This data is 
included in this chapter (baseline characteristics). 
13 w 19-20 w 32-34 w 38 w EDD 3 mo 6 mo































Blood collection (paternal and infant) 





Collection of maternal fish diary
Collection of infant health and feeding diary
Intervention period
DEXA (maternal and infant)
Maternal Body composition 
Breast milk collection (days 1, 5, 14, 28) Infant stool sample collection (days 7, 14, 28, 86)
 
Figure 2.1: Flow chart of the study design and the different assessments conducted at the different 
timepoints.   119 
Table 2.2: Allergens used in maternal and paternal SPT 
 
Type  Strength 
Negative control (glycerine)  Glycerine diluent 
Dermatophagoides pteronyssinus 
(house dust mite (HDM)) 
10 HEP 
Felix domesticus (cat fur; referred to as cat)  10 HEP 
Canis familiaris (dog fur; referred to as dog)  10 HEP 
6 Grass pollen mix 
(Avena/Dactylis/Poa/Festuca/Lolium/Phleum) 
10 HEP 
3 Tree pollen mix 
(Alnus/Betula/Corylus) 
10 HEP 
Aspergillus fumigatus (mould)  1:20 w/v 
Alternaria alternata (mould)  1:20 w/v 
Cladosporium herbarum (mould)  1:20 w/v 
Penicillum notatum (mould)  1:20 w/v 
Positive control (histamine)  10 mg/ml 
2.2.4  The intervention – farmed salmon  
Salmon  for  use  in  the  SIPS  were  reared  at  Skretting  Aquaculture  Research  Centre, 
Stavanger, Norway using high quality feed ingredients in order to be low in contaminants 
(dioxins  and  dioxin-like  polychlorinated  biphenyls  (PCBs),  dichloro  diphenyl 
trichloroethanes (DDTs)) including heavy metals (arsenic, cadmium, mercury, lead). The 
diet contained (g/kg): fish meal (298.6), soya concentrate (141.3), maize gluten (99.5), 
wheat gluten (29.9), wheat (120.1), Southern Hemisphere fish oil (132.1), rapeseed oil 
(132.1), flaxseed oil (33.5), DL-methionine (0.32), L-lysine (0.9), monocalcium phosphate 
(5.64), and vitamin and mineral mix. The dietary ingredients used were selected to be low 
in contaminants. Salmon were farmed until they averaged 4 kg in weight and were then 
killed; a total of 2280 kg (gutted) of salmon were produced. They were then filleted into 
150 g portions and the portions frozen in vacuum sealed bags in Norway, from where they 
were shipped to Southampton and stored at -30˚C (Figure 2.2). The salmon were delivered 
to the intervention group, on a monthly basis, and enough to cover intake of two portions 
(150 g/portion) per week by the pregnant women and their partners was provided. After 




Figure 2.2: Vacuum sealed salmon as delivered to the pregnant women. 
Frozen  portions  of  salmon  were  analysed  by  the  National  Institute  for  Nutrition  and 
Seafood  Research,  Bergen,  Norway.  Thirty  (30)  portions  were  randomly  sampled  for 
analysis.  The  individual  portions  were  pooled  into  3  samples  of  10  portions  each  for 
analysis of nutrient and contaminant content. Table 2.3 presents the fatty acid content of 
the tailored salmon with data expressed as g/100 g of total fatty acids, as g/kg of salmon 
fillet, and as g/per standard 150 g portion of salmon. The sum of EPA plus DHA was 1.73 
g/portion and these two fatty acids provided 10.6% of the total fatty acids in the salmon.  
Table 2.4 presents selected vitamin, mineral, total protein and fat content in the tailored 
salmon expressed as per kg of salmon, as well as per standard 150 g portion of salmon. 
Table 2.5 presents selected contaminant and heavy metal content of the salmon, expressed 
also per standard portion of salmon. As a result of the controlled farming environment and 
the high quality feeds used, the contaminant content of the salmon fillets was low, with 
two  portions  providing  much  less  than  the  provisional  tolerable  weekly  intake  of  all 
contaminants.   121 
Table 2.3: Fatty acid composition of tailored salmon (mean ﾱ standard deviation; n = 3) 
 
FATTY ACID  % OF TOTAL 
FATTY ACIDS 
G/KG FILLET  G/150 G FILLET 
C14:0  2.3 ﾱ 0.1  2.4 ﾱ 0.3  0.36 
C16:0  12.3 ﾱ 0.3  13.2 ﾱ 0.7  1.98 
C18:0  3.3 ﾱ 0.1  3.6 ﾱ 0.2  0.54 
Sum of SFAs  18.6 ﾱ 0.3  20.1 ﾱ 1.2  3.02 
C16:1n-7  2.5 ﾱ 0.1  2.7 ﾱ 0.3  0.41 
C18:1n-9  33.1 ﾱ 0.4  35.7 ﾱ 2.5  5.31 
C18:1n-7  2.7 ﾱ 0.1  2.9 ﾱ 0.2  0.44 
C20:1n-9  2.8 ﾱ 0.1  2.9 ﾱ 0.4  0.44 
Sum of MUFAs  43.3 ﾱ 0.4  46.8 ﾱ 3.8  7.02 
C18:2n-6  11.6 ﾱ 0.2  12.5 ﾱ 1.1  1.88 
C20:2n-6  1.2 ﾱ 0.1  1.3 ﾱ 0.1  0.20 
C20:4n-6  1.3 ﾱ 0.1  1.4 ﾱ 0.1  0.21 
Sum of n-6 PUFAs  14.3 ﾱ 0.1  15.4 ﾱ 1.2  2.31 
C18:3n-3  7.4 ﾱ 0.3  7.9 ﾱ 0.3  1.19 
C18:4n-3  0.6 ﾱ 0.1  0.7 ﾱ 0.1  0.11 
C20:4n-3  1.1 ﾱ 0.1  1.2 ﾱ 0.1  0.18 
C22:5n-3  2.1 ﾱ 0.1  2.3 ﾱ 0.2  0.35 
C20:5n-3 (EPA)  3.5 ﾱ 0.2  3.8 ﾱ 0.4  0.57 
C22:6n-3 (DHA)  7.1 ﾱ0.1  7.7 ﾱ 0.5  1.16 
Sum of EPA + DHA  10.6  11.5  1.73 
Sum of n-3 PUFAs  22.0 ﾱ 0.2  23.7 ﾱ1.5  3.56 
Sum of total PUFAs  36.5 ﾱ 0.2  39.4 ﾱ 2.7  5.91 
Total Fatty Acids  100 ﾱ 0.00  107.9 ﾱ 7.8  16.19 
n-3 PUFA/n-6 PUFA  1.53 ﾱ 0.02   122 
Table 2.4: Vitamin, mineral, total protein and total fat content of tailored salmon 
 (mean ﾱ standard deviation; n = 3) 
 
VITAMINS   ΜG/KG FILLET  ΜG/150 G FILLET 
α-tocopherol   27.3 ﾱ 0.1  4.1 
γ-tocopherol  10.9 ﾱ 1.2  1.6 
Vitamin A (sum of retinols)  0.039 ﾱ 0.006  0.006 
Vitamin D3  0.093 ﾱ 0.001  0.014 
Vitamin K1  < 1    
Vitamin K2  < 1 
Minerals   mg/kg fillet  mg/150 g fillet 
Iodine  0.044 ﾱ 0.008  0.006 
Iron  2.49 ﾱ 0.21  0.373 
Selenium  0.288 ﾱ 0.008  0.043 
Zinc  2.85 ﾱ 0.06  0.428 
  g/kg fillet  g/150 g fillet 
Total protein  203 ﾱ 2  30.5 




Table 2.5: Contaminant and heavy metal content of tailored salmon (mean + standard deviation; n=3) 
 
COMPOUND  PER KG FILLET  PER 150 G FILLET 
Sum of dioxin and dl-PCBs  0.35 ﾱ 0.06 pg WHO TEQ/g  52.5 pg 
Sum of DDTs   3.28 ﾱ 0.4 μg  0.492 μg 
Arsenic  0.34 ﾱ 0.05 mg  0.051 mg 
Cadmium  0.001 ﾱ 0.01 mg  0.15 μg 
Mercury  0.023 ﾱ 0.00 mg  3.45 μg 
Lead   0.001 ﾱ 0.001 mg  0.15 μg 
PCBs, polychlorinated biphenyls; dl, dioxin like; DDTs, dichloro diphenyl trichloroethanes; WHO TEQ, 
World Health Organisation toxic equivalent   123 
Table 2.6 presents the calculated total intake of selected compounds from consumption of 
two  150  g  portions  of  the  tailored  salmon  per  week.  As  can  be  seen  from  the  table, 
consumption of two portions of the salmon per week will result in an intake of 493 mg of 
EPA plus DHA per day, which meets the proposed intake set by the SACN (23), which is 
450 mg/day. The calculated weekly contaminant intake expressed as per kg body weight is 
lower than the provisional tolerable weekly intake (PTWI) established by the Joint Food 
and  Agricultural  Organisation/World  Health  Organisation  Expert  Committee  on  Food 
Additives (198;199). 
Table 2.6: Weekly and daily intake of DHA plus EPA, and weekly intake (crude and per kg of body 
weight) for selected contaminants from consumption of two portions (each 150 g) of tailored salmon 
per week 
 
COMPOUND  PER WEEK
1  PER DAY




EPA+DHA  3.45 g  493 mg   
Sum  of  dioxin 
and dl-PCBs 
105 pg    1.3-1.75 pg WHO TEQ  14 pg WHO TEQ 
Sum of DDTs   0.984 μg  0.012-0.016 μg   
Arsenic  0.102 mg  1.3-1.7 pg  15 μg 
Cadmium  0.3 μg  0.004-0.005 pg  7 μg 
Mercury  6.9 μg  0.09-0.115 pg  5 μg 
Lead   0.3 μg  0.004-0.005 pg  25 μg 
PTWI, provisional tolerable weekly intake; PCBs, polychlorinated biphenyls; dl, dioxin like; DDTs, dichloro 
diphenyl trichloroethanes; WHO TEQ, World Health Organisation toxic equivalent
 
1 Based on consumption of 2 × 150 g tailored salmon fillets per week 
2 Calculations based on a range of 60-80 kg body weight 
   124 
2.3  Progress of the study and subject follow-up 
 
Figure 2.3 shows the recruitment process of the subjects who participated in SIPS in both 
treatment groups. 692 women were sent the initial information sheet about SIPS together 
with the appointment letter for their 13 week gestation ultrasound scan. Out of those, 377 
agreed to and were screened for eligibility for SIPS. The major reason for not agreeing to 
be screened was lack of interest in the study. The recruitment period lasted for 12 months 
(from July 2007 until July 2008). From the 377 women who agreed to be screened, 166 
were eligible to participate to SIPS and the other 211 were ineligible mainly because of 
absence of atopy. Of the 166 eligible, 123 women were finally randomized at 15 weeks (by 
telephone contact) to participate. The other 43 women were either randomized at 15 weeks 
but not enrolled at the first SIPS appointment (20 weeks of gestation) (n=35) or were not 
anymore interested at 15 weeks to participate in the study (n=8). The number of women 
recruited  (n=123)  was  to  assure  that  approximately  100  mother-neonate  pairs  would 
remain in the study at birth on the assumption that about 20% would drop-out. In fact there 
were 107 mother-neonate pairs still in the study at birth (see below). 
 
Figure 2.4 presents the progress of women and their neonates through the study from the 
first appointment (20 weeks gestation; i.e. baseline) until the end of the study at 6 months 
post-partum (clinical assessment of the infants). After signing the SIPS consent form, 62 
and  61  pregnant  women  were  randomly  assigned  to  the  salmon  and  control  groups, 
respectively. Before delivery 9 subjects withdrew from the salmon group and 7 from the 
control group. 14 subjects delivered before their 38 week appointment. Between delivery 
and 6 months 6 more subjects withdrew from the salmon group and 15 more from the 
control group and finally 86 subjects completed the 6 month appointment (n=47 in salmon 
group and n=39 in control group). In total the attrition rate was 30%; in the salmon group 
this was 24% and in the control group 36%. At the 6 month appointment the parents were 
also offered SPT and this was completed by 86 mothers and 76 fathers.  
 




































Figure 2.3: Recruitment of women into SIPS 
 
Screened for eligibility for SIPS [at week 13] (n = 377) 





Sent SIPS information and offered appointment (n = 692) 
Not screened  
for eligibility (n = 315) 
Not interested = 241 
Did not arrive = 22 
Miscarriage = 14 
Poor English = 11 
Moving away = 4  
Twins = 4 
High risk = 4 
> 14 weeks gestation = 2 
On another study = 2 
Vegetarian = 1 
Fish allergy = 1 
Assisted pregnancy = 1 
Emotionally distressed = 2 
< 18 years old = 3 
Using n-3 supplements  = 3 
 
 
Not eligible (n = 211) 
High oily fish intake = 50 (24%) 
High risk pregnancy = 2 (1%) 
Use of NSAIDs = 2 (1%) 
Use of n-3 supplements = 11 (5%) 
No atopy history (< 5 yrs) = 146 
(69%) 
Randomised at week 15 
& enrolled onto SIPS 
 (n = 123) 
Randomised at week 15 
& not enrolled onto SIPS  
(n = 8) 
No longer interested = 1 
Not happy with study group = 3 [2 
Salmon; 1 Control] 
Medical termination = 1 
Started using n-3 supplements = 2 
Increased oily fish intake = 1 
 
 
Not randomised at week 15 
& not enrolled onto SIPS 
(n = 35) 
No longer interested = 32 
Needle phobia = 2 
Wanted antenatal care at another centre = 1 
 


















































Figure 2.4: Progress of enrolled subjects through the study 
 
Enrolled on SIPS at week 34 (n = 111) 
i.e. 123 – 12 withdrawn  
55 Salmon; 56 Control 
Attended week 34 appointment n = 110 
(111 – 1 very premature delivery) 
 
 
Enrolled onto SIPS (n = 123) 
62 Salmon (S); 61 Control (C) 
Withdrew between weeks 34 and 38 
(n =3) n=2 (C), n=1 (S) 
No longer interested n=1 
Personal reasons n=2 
Enrolled on SIPS at week 38 (n = 108) 
i.e. 111 – 3 withdrawn 
54 Salmon; 54 Control 
Attended week 38 appointment (n = 91) 
(108 – 4 Cancelled tired/busy/injured; 13 delivered before appointment) 
 
 
Enrolled on SIPS at delivery (n =107) 
i.e. 123 – 6 missed; 16 withdrawn 
53 Salmon; 54 Control 
Birth samples collected (n =101)[51 salmon; 50 control] 
(107 – 6 missed, 2 team not informed, 4 samples not collected) 
Withdrew between week 38 and 
delivery 
n =1 (S) 
Personal reasons n=1 
 
3 Month visits possible (n = 101)  
(Completed n = 88)  
47 Salmon; 41Control 
Home visits=86; FFQ on the phone =2 
 
Withdrew by 3 months post-partum  
(n = 6) 
n=5 (C), n=1 (S) 
Lost contact n=2 
Personal reasons n=2 
No reason given n=2 
 
(n = 15 – did not have 3 month appointment, 
but not officially withdrawn; unable to make 
contact). 
Withdrew between 3 and 6 
months post-partum 
n = 2 (C) 
Too busy n=2 
 
6 Month visits possible (n = 99)  
(Completed n = 86) 
Infants: 47 Salmon; 39 Control 
 
Maternal SPT n = 86: 38 Control; 48 Salmon 
Paternal SPT n = 76: 32 Control; 44 Salmon 
Withdrew between weeks 20 and 34 
(n =12) n=5 (S), n=7 (C) 
Hard to bleed n=1 
Personal reasons n=5 
Did not like salmon n=4 
No reason given n=1 
No longer interested n=1   127 
2.4   Subject characteristics 
2.4.1  Maternal characteristics at study entry 
 
Table 2.7 describes some characteristics of the pregnant women at study entry (information 
acquired  at  13  and  20  weeks  of  gestation)  according  to  the  group  to  which  they  were 
randomised.  Maternal  age,  weight,  and  height,  number  of  pregnancies  (gravida),  maternal 
smoking, nutritional supplement use, alcohol intake, and education, and keeping pets at home 
did not differ between the two groups, but significantly more women in the salmon group did 
not already have a child (p=0.013). Among those still in the study at 6 months after birth 
(n=86; control group n=39, salmon group n=47), birth order remained significant (p=0.042) 
with more women in the salmon group having their first child (n=31 out of 47) than those in 
the control group (n=17 out of 39). The difference was smaller when comparing the numbers 
of women who now had a second child (n=22 out of 39 for the control group and n=16 out of 
47 for the salmon group). Paternal education was almost significantly different between the 2 
groups at baseline (p=0.055), but this marginal difference disappeared when those remaining 
in the study at 6 months postpartum were considered.  
 
Table 2.8 describes the characteristics of the pregnant women who dropped out of the study at 
any time from the start of the the intervention (week 20 of pregnancy) until the end of the 
follow-up  (6  months  postpartum).  There  are  no  significant  differences  between  the  study 
groups. 
 
Figure 2.5 shows the distribution of the groups in conducting gentle, moderate and strenuous 
physical activity. There was no difference between the two groups in any type of activity.  
 
Table 2.9 shows that the total duration of gestation and blood loss during delivery did not 
differ significantly between the two study groups, although women in the salmon group had an 
average of a 4 day longer pregnancy compared with those in the control group (p=0.094). 
Table 2.10 presents the different modes of birth, with most frequent being the normal vaginal 
delivery. There were no differences in mode of delivery between the two groups.  
 
Table 2.11 shows self reported maternal, paternal and sibling (any type) atopy in the two 
groups. Paternal self reported atopy was different between the two groups with more fathers in   128 
the salmon group reporting atopy (p=0.015). Among those remaining in the study 6 months 
after birth, paternal atopy remained different between the two groups; 25 fathers in the control 
group and 40 in the salmon group self-reported atopy (p=0.042). Maternal and sibling self 
reported atopy were not different between groups when those remaining in the study at 6 
months post-partum were considered.  
   129 






(n=62)  p 
Mean  SD  Mean  SD   
Maternal age (years) (at 13 weeks) 
1  28.4  4.7  29.5  4.3  0.174 
Maternal height (cm) (at 13 weeks) 
1  165.6  6.8  165.4  6.2  0.885 
Maternal weight (kg) (at 13 weeks) 
1  71.4  15.4  67.4  11.9  0.117 
Number of children (at 13 weeks) 
1   
none  26  42.6  38  61.3 
0.013  1  23  37.7  9  14.5 
≥2  12  19.7  15  24.2 
Pregnancies including the current (at 13 weeks) 
2   
1  23  37.7  27  43.5 
0.509 
≥2  38  62.3  35  56.5 
Maternal smoking (at 13 weeks) 
2   
never  30  49.2  33  53.2 
0.460  past  23  37.7  25  40.3 
current  8  13.1  4  6.5 
Maternal alcohol intake (at 13 weeks) 
2   
no  46  78  46  76.7 
0.866 
yes (1-7 units/week)  13  22  14  23.3 
Maternal supplement use (at 20 weeks) 
2   
no  15  24.6  14  22.6 
0.966  containing folic acid  45  73.8  47  75.8 
not containing folic acid  1  1.6  1  1.6 
Maternal education (at 20 weeks) 
2   
school  9  15.5  9  14.5 
0.513  further  24  41.4  20  32.3 
higher  25  43.1  33  53.2 
Paternal education (at 20 weeks) 
2   
school  17  29.8  16  25.8 
0.055  further  25  43.9  17  27.4 
higher  15  26.3  29  46.8 




no  43  70.5  44  71 
0.954 
yes  18  29.5  18  29 
Dog           
no  49  80.3  50  80.6 
0.965 
yes  12  19.7  12  19.4 
Other           
no  42  68.9  49  79 
0.198 
yes  19  31.1  13  21 
1Values are mean (standard deviation (SD)), independent t-test p-values 
2Values are number of subjects (within group percentage (%)), Chi-square test p-values   130 
 
Table 2.8: Baseline characteristics of the SIPS parents who dropped out of the study  






(n=15)  p 
Mean  SD  Mean  SD   
Maternal age (years) (at 13 weeks) 
1  25.6  5.04  28.4  4.28  0.076 
Maternal height (cm) (at 13 weeks) 
1  164.9  7.05  162.8  4.8  0.292 
Maternal weight (kg) (at 13 weeks) 
1  70.8  11.9  65.4  9.9  0.152 
Number of children (at 13 weeks) 
1   
none  13  59.1  5  33.3 
0.107  1  1  4.5  4  26.7 
≥2  8  36.4  6  40 
Pregnancies including the current (at 13 weeks) 
2   
1  9  40.9  3  20 
0.286 
≥2  13  59.1  12  80 
Maternal smoking (at 13 weeks) 
2   
never  8  36.4  3  20 
0.545  past  10  45.5  8  53.3 
current  4  18.2  4  26.7 
Maternal alcohol intake (at 13 weeks) 
2   
no  19  90.5  13  86.7 
0.560 
yes (1-7 units/week)  2  9.5  2  13.3 
Maternal supplement use (at 20 weeks) 
2   
no  10  55.6  4  44.4 
0.858  containing folic acid  5  27.8  3  33.3 
not containing folic acid  3  16.7  2  22.2 
Maternal education (at 20 weeks) 
2   
school  5  22.7  7  46.7 
0.311  further  13  59.1  6  40.0 
higher  4  18.2  2  13.3 
Paternal education (at 20 weeks) 
2   
school  8  36.4  7  46.7 
0.064  further  13  59.1  4  26.7 
higher  1  4.5  4  26.7 




no  18  81.8  12  80 
0.890 
yes  4  18.2  3  20 
Dog           
no  18  81.8  12  80 
0.890 
yes  4  18.2  3  20 
Other           
no  17  77.3  12  80 
0.843 
yes  5  22.7  3  20 
1Values are mean (standard deviation (SD)), independent t-test p-values 
2Values are number of subjects (within group percentage (%)), Chi-square test p-values 





Figure 2.5: Distribution of frequency of conducting: a) gentle (p=0.448), b) moderate (p=0.499), c) strenuous physical activity (p=0.102) according to study group 
Values are percentages of subjects, Chi-square test p-values
c 
b  a   132 
Table 2.9: Characteristics of SIPS mothers at birth according to study group  
 
 
Control group  
(n=61) 
Salmon group  
(n=62)  p 
Mean  SD  Mean  SD 
Duration of gestation (days)   277  9  282  8  0.094 
Blood loss at delivery (mL)  332  193  446  429  0.086 
Values are mean ﾱ standard deviation (SD), independent t-test p-values 
 
 
Table 2.10: Mode of delivery according to study group and overall 
 
Delivery mode  Control group 
(n=54) 
Salmon group 
(n=53)  p  Total 
(n=107) 
Normal Vaginal  35  35 
0.914 
70 
Elective Lower Segment Caesarian Section (LSCS)  2  3  5 
Emergency LSCS  7  5  12 
Instrumental (ventouse/forceps)  10  10  20 
Values are number of subject, Chi-square test p-values 
 
 
Information on self-reported allergy history (different manifestations of atopy) in the two 
groups is presented in Figure 2.6. Maternal and paternal atopy characteristics did not differ 
between  the  two  groups,  but  in  the  salmon  group  there  was  less  self-reported  asthma 
amongst siblings of fetus (p=0.011) compared to the control group.  
 
Table 2.11: Self-reported atopy at 13 weeks screening according to study group 
 
Self-reported atopy 
Control group (n=61)  Salmon group (n=62) 
p 
counts  % within 
group  counts  % within 
group 
Maternal (any)   
yes  38  62.3  43  69.4 
0.409 
no  23  37.7  19  30.6 
Paternal (any)   
yes  37  60.7  50  80.6 
0.015 
no  24  39.3  12  19.4 
Sibling (any)                       (n=36)                                    (n=25) 
yes  17  27.9  10  16.1 
0.610 
no  19  31.1  15  24.2 
Values are number of subjects (within group percentage), Chi-square test p-values 
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Figure 2.6: Distribution of self-reported atopy categories according to study group  
at 13 weeks screening 
* Chi-square test p=0.011 
 
 
Table 2.12 shows that the two groups did not differ according to maternal and paternal 
positive SPT. The breakdown of the positive maternal/paternal SPT results is shown on 
Table 2.13.  
 
Table 2.14 shows how maternal and paternal self-reported atopy (at 13 weeks) is matched 
with SPT (determined at 6 months post-partum). 44.7 % and 52.1 % of the mothers in the 
control and salmon groups who were tested, were confirmed by positive SPT to be atopic 
while for fathers the figures were 59.4% and 68.2%, respectively.   134 
Table 2.12: Any positive maternal or paternal skin prick tests (SPT) according to study group 
 
Positive SPT  Control group  
(n=38) 
Salmon group 
 (n=48)  p 
Maternal (any)  counts  % within group  counts  % within group 
yes  21  55.3  31  70.5 
0.380 
no  17  44.7  17  35.4 
           
Paternal (any)  (n=32)  (n=44)   
yes  20  62.5  31  70.5 
0.466 
no  12  37.5  13  29.5 
Values are number of subjects (within group percentage), Chi-square test p-values 
 
 
Table 2.13: Percentage (%) of subjects sensitized to each allergen assessed by skin prick testing (SPT)  
 
Skin Prick Test Allergen 
Maternal – 
Control group 
(n = 38) 
Maternal – 
Salmon group 
(n = 48) 
Paternal – 
Control group 
(n = 32) 
Paternal – 
Salmon group 
(n = 44) 
Dermatophagoides 
pteronyssinus  36.8  47.9  40.6  56.8 
Felis domesticus (cat)  28.9  35.4  18.8  38.6 
Canis familiaris (dog)  31.6  39.6  34.4  45.4 
6 Grass mix  47.3  54.2  50.0  59.0 
3 Tree mix  15.8  29.2  15.6  36.4 
Alternaria alternata  5.3  12.5  6.25  18.2 
Aspergillus fumigatus  10.5  4.2  0  11.4 
Cladosporium herbarum  0  2.1  3.2  9 
Penicillum notatum  2.6  0  0  0 
 
 
Table 2.14: Maternal and paternal self reported atopy confirmed by skin prick testing (SPT) 
 
  Control group  
(n=38) 
Salmon group  
(n=48)  p 
Maternal  counts  % within group  counts  % within group   
Reported atopy confirmed by +SPT  17  44.7  25  52.1 
0.433 
No reported atopy confirmed by -SPT  12  31.6  8  16.7 
Reported atopy but no +SPT  5  13.2  9  18.8 
No reported atopy but +SPT  4  10.5  6  12.5 
Paternal  (n=32)  (n=44)   
Reported atopy confirmed by +SPT  19  59.4  30  68.2 
0.057 
No reported atopy confirmed by -SPT  9  28.1  3  6.8 
Reported atopy but no +SPT  3  9.4  10  22.7 
No reported atopy but +SPT  1  3.1  1  2.3 
Values are number of subjects (within group percentage of those skin prick tested), Chi-square test p-values   135 
 
2.4.2  Infant characteristics at birth  
 
Table 2.15 shows the infant gender distribution in the two study groups at birth. There 
were more male infants in the control group and more female infants in the salmon group. 
However, this  difference was  not  statistically significant.  Table 2.16 presents  the birth 
characteristics of the infants. Weight at birth, apgar score and head circumference did not 
differ  between  the  two  groups.  Infants  in  the  salmon  group  were  almost  significantly 
longer (measured from crown to heel) (1.5 cm; p=0.057). After adjustment for gestational 
age and gender by univariate analysis (General Linear Model), birth weight did not differ 
between the 2 groups (pgroup=0.527, pgender< 0.001, pgestational  duration< 0.001). Apgar score 
(pgroup=0.557, pgender=0.231, pgestational duration=0.091) and head circumference (pgroup=0.078, 
pgender=0.313, pgestational  duration=0.034) were not different between groups after adjustment 
for gender and length of gestation. Crown heel length was significantly different between 
the two groups after adjustment (pgroup=0.037, pgender=0.042, pgestational duration=0.091), with 
neonates in the salmon group being longer. Table 2.17 shows some body composition 
measurements (bone mineral content, bone mineral density, whole body mass, fat mass, fat 
percentage, and lean mass) of the infants assessed by DXA within days of being born. 
There was no difference in any of these measurements between the two groups even after 
controlling for gender, gestational length and age of the neonates at DXA. 
 
Table 2.15: Distribution of newborn gender according to study group and overall 
 
Gender by group 
Group 
Total  p 
Control  Salmon 
Male  33 (61.1%)  23 (43.4%)  56 (52.3%) 
0.067 
Female  21 (38.9%)  30 (56.6%)  51 (47.7%) 
Values are number (% within group), Chi-square test p-value 
 
 
Table 2.16: Characteristics of infants at birth according to study group 
 
 
Control group  Salmon group 
p  n  Mean  SD  n  Mean   SD 
Weight at birth (g)   54  3425  605  53  3449  525  0.83 
Apgar score 5 min after birth  53  9.1  0.6  51  9.1  0.7  0.9 
Occipito-frontal circumference 
(head circumference) (cm)   32  36.0  4.3  44  34.9  1.5  0.188 
Crown-heel length (cm)   32  49.0  3.9  44  50.5  2.1  0.057 
Values are mean and SD, independent t-test p-values   136 
 
 
Table 2.17: Infant body composition measured by DXA within 14 days of birth 
 
 
Control group (n=33)  Salmon group 
(n=35)  p 
Mean  SD  Mean  SD 
Whole body global bone mineral content (g)  62.2  11.5  63.8  15.6  0.63 
Whole body global bone mineral density (score)  0.20  0.02  0.21  0.03  0.72 
Whole body global fat (g)  479.5  285.3  578.9  374.8  0.22 
Whole body global fat (%)  13.1  6.4  15.7  7.5  0.14 
Whole body global lean (g)  3007.7  338.5  2964.9  391.5  0.63 
Whole body global mass (g)  3487.2  511.8  3543.9  558.1  0.66 
Values are mean and SD, independent t-test p-values   137 
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3.1  Introduction 
 
The  richest  dietary  source  of  the  long  chain  n-3  polyunsaturated  fatty  acids  (LC  n-3 
PUFAs) eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) 
is seafood. Among different types of seafood, oily fish have a higher content of EPA and 
DHA compared to non-oily fish, and these LC n-3 PUFAs are found mainly in the flesh of 
the fish and a smaller amount is accumulated in the liver. Examples of oily fish are salmon, 
sardines, pilchards, kippers, mackerel, herring, trout and fresh tuna. One portion/serving of 
oily  fish  (140  g)  will  provide  between  1.5  g  and  3.5  g  EPA  and  DHA  (24;25).  In 
comparison one portion/serving of white fish will provide about 0.3 g of EPA and DHA 
(1;2). LC n-3 PUFAs are also found in fish oil supplements. 
 
Data from the last National Diet and Nutrition Survey (NDNS) of adults aged 19-64 years 
showed that most people in the UK consume very little fish. Mean consumption of total 
fish was 217 g per week, white fish was 103 g per week and oily fish was 50 g per week 
(23). The latest NDNS (2008/2009), from which the first results were published in 2010, 
showed that women aged 19-64 years consume on average 49 g/week coated and fried 
white fish, 105 g/week other white fish, shellfish and tinned tuna, and 77 g/week oily fish. 
This latest data also showed that over 70% of women aged 19-64 years old do not consume 
any oily  fish, although  30% of  consumers‟ intake is  in  accordance with  the minimum 
recommendation (200). EPA and DHA intakes were not reported in the first report of the 
latest NDNS (2008/2009). The previous NDNS data showed that mean intake of EPA plus 
DHA for adults in the UK was 0.244 g/day from fish and animal sources. So, typical daily 
intakes of EPA plus DHA in adult individuals in UK who do not regularly consume either 
oily fish or fish oil capsules are probably less than 0.25 g per day (23). 
 
Data (27) from the Australian National Nutrition Survey in 1995 showed that the average 
daily intakes of EPA and DHA acids were 0.056 and 0.106 g, respectively, and LC n-3 
PUFA intake (addition of EPA, DPA, and DHA) was 0.189 g, similar to the above data for 
the UK. However, median intakes were considerably lower (0.008 g EPA, 0.015 g DHA, 
and  0.029  g  LC  n-3  PUFAs)  (27).  Thus  50%  of  the  adult  Australian  population  was 
consuming < 0.03 g LC n-3 PUFAs/day. Similar low intakes seem likely in the UK. As 
expected, seafood was the main source of LC n-3 PUFAs in Australia (5), contributing 
71%, while meat and eggs contributed 20% and 6%, respectively. These results indicate 
that the majority of Australians are failing to meet intake recommendations for LC n-3   139 
PUFAs.  This  emphasises  the  need  for  strategies  to  increase  the  availability  and 
consumption of LC n-3 PUFA containing foods. 
 
Recommended intakes for n-3 PUFAs are not uniform. In 2000, Simopoulos recommended 
daily intakes for EPA plus DHA at 0.65 g, with at least 0.222 g for each of EPA and DHA, 
and  2.22  g/d  for  -linolenic  acid  (ALA)  (28).  The  American  Heart  Association 
recommends adults to eat fish (in particular fatty fish) at least two times per week (29). 
The guidelines proposed by the US Food and Nutrition Board (Food and nutrition board 
2005) established adequate intakes  for ALA at  1.6 g/d  and 1.1 g/d  for adult men and 
women, respectively, and that EPA plus DHA could account for up to 10% of the total n-3 
fatty acid intake as a contribution toward the adequate intake for ALA (30). The latest 
report from World Health Organisation and Food Agriculture Organisation (WHO/FAO) in 
2008 on total fat and fatty acids concluded that for adult males and non-pregnant/non-
lactating  adult  females  0.25  g/day  of  EPA  plus  DHA  is  recommended,  and  that,  with 
insufficient evidence to set a specific minimum intake of either EPA or DHA alone, both 
should be consumed (9). For adult pregnant and lactating females, the minimum intake for 
optimal adult health and fetal and infant development is 0.3 g/d EPA+DHA, of which at 
least 0.2 g/d should be DHA (199). 
Current UK recommendations propose that people should eat at least 2 portions of fish, of 
which one should be oily, per week; this recommendation also applies to pregnant women 
(23). This was equated to a daily intake of at least 0.45 g of LC n-3 PUFAs (23). There are 
several  published  recommendations  concerning  the  intake  of  n-3  fatty  acids  during 
pregnancy and lactation:  
  Mele & Miggiano (31) recommended a DHA intake of 100 mg/day (with an extra 
50-60 mg/day in the third trimester) in pregnant women; 
  Makrides & Gibson (32) suggest an intake of LC n-3 PUFAs of 200-400 mg/day in 
pregnant and lactating women;  
  the European Food Safety Authority suggests an intake of 250 mg/day of DHA (33) 
during pregnancy and lactation; 
  the (UK) Scientific Advisory Committee on Nutrition (SACN) recommends 450 
mg/day intake of LC n-3 PUFAs in pregnant and lactating women (23); 
  the latest EFSA report on reference values for fats and fatty acids proposed to set 
an  Adequate  Intake  of  250  mg/day  for  EPA  plus  DHA  for  adults  based  on 
cardiovascular considerations. To this 100 to 200 mg of preformed DHA should be   140 
added  during  pregnancy  and  lactation  to  compensate  for  oxidative  losses  of 
maternal dietary DHA and accumulation of DHA in body fat of the fetus/infant 
(201). 
Despite  these  recommendations,  based  upon  an  assumed  need  for  LC  n-3  PUFAs, 
especially  DHA,  in  pregnancy  and  lactation,  concern  about  contaminants  such  as 
methylmercury, dioxins and dioxin like PCBs in some species of oily fish, has lead to the 
Food  Standards  Agency  (FSA)  to  advise  that  pregnant  women,  women  intending  to 
become  pregnant,  and  girls  under  16  years  old  should  avoid  eating  shark,  marlin  and 
swordfish. The Committee on Toxicology advices that “women of reproductive age and 
girls should aim to consume within the range of one to two portions of oily fish per week, 
based on maintaining consumption of dioxins and dioxin like PCBs below the tolerable 
daily intake (TDI) of 2 pg WHO-TEQ/kg bodyweight per day. Women past reproductive 
age, boys and men should aim to consume within the range of one to four portions of oily 
fish a week, based on maintaining consumption of dioxins and dioxin-like PCBs below the 
guideline value of 8 pg WHO-TEQ/kg bodyweight per day” (23). 
 
The provision of EPA and DHA to the fetus is important for fetal growth and development. 
Preformed LC n-3 PUFAs, particularly DHA, but also EPA, may need to be provided in 
the diets of infants to meet the high requirements of rapidly growing tissues and organs 
(23). The mother is the primary source of these fatty acids for the fetus and breast-fed 
infant. These fatty acids are important for brain and visual development, and may also be 
important for optimal development and functioning of the vascular, cardiac and immune 
systems. Regarding the immune system, there is evidence (see literature review; Section 
1.5) that early fish and LC n-3 PUFA exposure reduces the risk of immune dysfunctions, 
such as allergic disease and asthma in infancy and childhood (202;203). 
 
According to data reviewed by SACN in 2004 (23), there is some evidence that many 
women have a marginal status of LC n-3 PUFAs during pregnancy and lactation. However, 
there is a lack of agreed markers which are suitable for defining LC n-3 PUFA status. The 
markers usually reported relate to concentrations of fatty acids within the circulation. They 
may be expressed as a percentage of total fatty acids or as their absolute concentrations in 
different circulating pools. Concentrations of fatty acids in maternal or umbilical blood 
have been used as measures of LC n-3 PUFAs during pregnancy. These measures have 
been related to maternal dietary intake (35), as well as to pregnancy outcomes such as 
gestation duration and birthweight  (36-39). During pregnancy a woman must meet the 
additional  demands  related  to  the  accretion  of  maternal,  placental,  and  fetal  tissues.   141 
Although, the formation of DHA and EPA appears to be tightly regulated, a marginal state 
for  many  women  during  pregnancy  and  lactation  cannot  be  excluded.  The  additional 
demands for EPA and DHA or other fatty acids during a normal pregnancy have not been 
adequately defined. It was concluded that the extent of dietary dependence on increased 
levels  of  consumption  of  LC  n-3  PUFAs,  or  specifically  DHA,  to  improve  pregnancy 
outcome needs to be demonstrated (23). 
 
Oily fish  are also  good sources  of vitamin D  and antioxidants  such as  vitamin E and 
selenium.  Early  fish  and  vitamin  D  exposure  improves  bone  health  in  infancy  and 
childhood, and there is evidence that vitamin D supplementation in pregnant women may 
reduce the risk of osteoporotic fracture in the offspring (204). Also, more recently, it has 
been suggested that increased dietary exposure to antioxidants in the early stages of fetal 
and infant development influence the risk of childhood asthma and atopic sensitization 
possibly  by  affecting  the  first  interactions  between  the  neonatal  immune  system  and 
allergens (205). Evidence from birth cohort studies has suggested that there are potentially 
beneficial  associations  between  maternal  intake  of  vitamin  D  and  some  antioxidants 
(vitamin E, Se, Zn) during pregnancy and early childhood wheezing/asthma (206-209). On 
the contrary, there is limited data suggesting associations between maternal antioxidant 
intake  and  childhood  atopic  dermatitis  and  allergic  rhinitis.  The  exact  nature  of  these 
associations remain unclear and more interventions in the window or early life are needed 
to be proven (205). A recent publication by Nurmatov et al. has reviewed and analysed 
systematically whether intake of vitamins A, C, D, E, selenium and zinc can modify the 
risk of children to develop allergy (210).  
 
Data from birth cohort studies showed beneficial associations between maternal vitamin E 
intake and childhood asthma/wheeze outcomes (206;209;211). Meta-analysis of the data 
from three cohort studies showed higher maternal vitamin E intake during pregnancy to be 
associated with a significant decrease in the odds of wheezing in children at age two years: 
OR=0.68  (95%CI  0.52-0.88),  p=0.004  (210).  However,  most  cross-sectional  studies 
reported  no  associations  between  intake  or  serum  levels  of  vitamin  E  in  children  and 
sensitization,  atopic  eczema,  current  wheeze,  allergic  rhinoconjunctivitis,  lung  function 
and asthma outcomes (212-214).  
 
A number of studies investigate associations with vitamin D (208;210;215-218). Cohort 
studies reported that higher maternal vitamin D intake during pregnancy may decrease the 
risk  of  wheezing  in  early  childhood  (208;216).
  Two  cohort  studies  reported  on  the   142 
association between
 maternal vitamin D intake and childhood asthma at age five years, 
with  one  study  reporting  no  association  (208)  and  one  reporting  a  beneficial  inverse 
association (217): higher maternal vitamin D intake was associated with reduced odds of 
wheezing (i.e. either recurrent wheezing/wheeze in the previous year: OR=0.56, p<0.001). 
Two other cohort studies reported adverse associations between maternal blood vitamin D 
levels  during  pregnancy  or  high  dose  vitamin  D  supplementation  during  infancy  and 
childhood asthma, atopic dermatitis and/or allergic rhinitis (218). 
 
Many studies have assessed whether there is an association between selenium exposure 
and atopic risk (171;207;214;219;220).
 Three reports, including two birth cohort studies 
related  blood  selenium  in  pregnant  women,  umbilical  cord  and  early  childhood  to 
childhood outcomes (207;219). One cohort study concluded that higher plasma selenium 
during pregnancy (maternal and cord) were associated with a reduced risk of childhood 
wheezing at age 2 years but not at 5 years (207). Another cohort study also found higher 
cord  selenium  to  be  associated  with  a  reduced  risk  of  persistent  childhood  wheeze: 
(OR=0.67  (95%CI  0.45-0.99))  (219).  Case-control  studies  reported  no  associations 
between serum/urine selenium levels or selenium intake and atopic dermatitis or asthma-
related outcomes (220;221). Overall, the body of evidence in relation to selenium was 
unsupportive of an association between childhood asthma and allergy and selenium status 
during pregnancy or childhood.  
 
The body of evidence from studies examining vitamin A in relation to childhood allergy 
risk was weak, but possibly suggestive of an association between reduced vitamin A and 
childhood  asthma,  but  not  between  maternal  vitamin  A  intake  during  pregnancy  and 
childhood wheeze (210).  
 
The evidence from studies examining vitamin C in association with allergy risk in children 
was weak and unsupportive to show possible effectiveness of vitamin C to prevent asthma 
or atopic outcomes (210). The evidence from studies examining zinc in association with 
atopy risk in childhood was also weak but suggestive of the possible effectiveness of zinc 
in relation to the prevention of asthma (210). 
 
Overall, it seems that a higher consumption of oily fish during pregnancy will result in 
better provision of several nutrients (LC n-3 PUFAs, vitamin D, antioxidants such as Se 
and vitamin E) to the fetus and that this likely to be associated with improved health in 
infancy and childhood. There is evidence of the protective effect of these nutrients based on   143 
supplementation and cohort studies (132;178;207-209). However, there are no published 
intervention trials with fish during pregnancy. Since eating fish is advised, but fish are also 
a source of contaminants, aquaculture of fish to have low contaminant levels could be an 
ideal solution to enable oily fish consumption by pregnant women and possibly the intake 
of the recommended amounts of LC n-3 PUFAs. The Salmon in Pregnancy Study (SIPS) is 
the first randomised controlled trial with oily fish in pregnant women. SIPS focuses on 
pregnant women whose offspring have increased risk of developing atopic disease, aiming 
to  identify  whether  there  is  an  effect  on  atopy  outcomes  in  the  offspring.  Also, 
consumption of tailor-made salmon by pregnant women could prevent the depletion of the 
mother‟s EPA and DHA and could improve the fetal/newborn status of EPA and DHA. A 
total of 123 women were randomly assigned to consume either 2 portions of farmed salmon 
per week (from week 20 till delivery) or to continue their habitual diet low in oily fish (less 
or equal to two portions per month) (see Chapter 2). 
 
The aim of this chapter is to describe the diets of the subjects of both groups at baseline 
(frequencies of intake of specific foods and nutrient intakes) and to find out whether and 
how the diet and nutrient intakes changed over the course of pregnancy in the salmon and 
the control groups. Moreover, the compliance of the salmon and the control groups to the 
intervention and their habitual dietary habits, respectively, is assessed. 
 
The  primary  hypotheses  of  the  work  described  in  this  chapter  are  that  the  oily  fish 
intervention will: 
1.  increase oily fish consumption from a habitually low intake (≤ 2 portions/month) 
to  the  recommended  maximum  level  of  intake  (two  portions/week)  during 
pregnancy  in  women  whose  offspring  is  at  a  high  risk  of  developing  atopic 
disease; 
2.  increase maternal LC n-3 PUFA intake during pregnancy, and that this intake will 
be higher in the salmon than in the control group. 
 
The  secondary  hypotheses  of  the  work  described  in  this  chapter  are  that  the  oily  fish 
intervention will: 
1.  change the dietary patterns in the salmon group;   144 
2.  increase the maternal intake of vitamin D and selenium, and that their intakes will 
be higher in the salmon than in the control group.   145 
 
3.2  Materials and methods 
3.2.1  Study design and subjects  
 
Chapter 2 described the study design, the subjects‟ characteristics, and the intervention. In 
summary, the population studied were pregnant women with high risk of having an atopic 
offspring. The study groups were two, of which the control group (n=61) was asked to 
keep their habitual diet unchanged during the remainder of pregnancy (from 20 weeks of 
pregnancy until delivery) and the salmon group (n=62) consumed two portions of farmed 
salmon per week (from 20 weeks of pregnancy until delivery). Each portion of salmon 
provided 1.73 g of EPA plus DHA, 14 μg of vitamin D, and 43 μg of selenium. The 
nutrient analysis of salmon is described in Chapter 2; Table 2.3. Women of both groups 
completed a Food Frequency Questionnaire (FFQ) at weeks 20 and 34 of pregnancy. They 
also  completed  the  FFQ  3  months  after  delivery  (data  not  included  in  this  thesis). 
Moreover, the women were asked to complete fish diaries to record any fish intake during 
intervention (from week 19/20 until delivery). These diaries were also completed by most 
of the women from delivery till 6 months post-partum (data not included in this thesis). 
 
3.2.2  Dietary assessment (fish, whole diet and nutrient intakes) 
3.2.2.1 General Comments: Selection of methodology - connection with 
SWS 
 
In SIPS, diet was assessed retrospectively by FFQ. As for all dietary assessment methods, 
FFQs are subject to error since they depend on individuality and memory. The FFQ has 
some advantages and disadvantages. Compared to the gold standard prospective method of 
weighed records, which are considered to be more accurate for determining nutrient intake, 
FFQs can be applied to a larger number of people and can assess diet for longer periods. 
Weighed records can cover a small period of time (3-7 days) and can be implemented on 
small groups of subjects, as they are labour intensive, and more expensive. Whilst cheaper 
to administer, FFQs also have the advantage that by summarising data over a longer period 
of time they may better describe habitual diet than assessments over a shorter period. In 
this  way,  FFQs  have  become  the  principal  method  for  dietary  assessment  in  large 
population studies. However, there are concerns that the nutrient intake estimates derived 
from FFQs are not very accurate, to the point that disease-nutrient associations may be 
concealed (222).   146 
SIPS  was  based  in  the  Southampton  area  and  had  a  small  sample  size  (n=123).  The 
maternal  FFQ  used  by  SIPS  was  initially  developed  for  a  large  cohort  study,  the 
Southampton Women‟s Survey (SWS) that was also conducted in the Southampton area. 
The  use  of  a  tool  that  had  already  been  implemented  in  the  same  population  seemed 
appropriate. The FFQ included questions on fish consumption and reflected diet over the 
previous  three  months.  In  addition,  so  as  to  assess  compliance  to  the  intervention, 
volunteers  in  both  groups  were  asked  to  complete  a  daily  record  of  fish  consumption 
throughout  pregnancy,  here  termed  the  “fish  diary”.  The  combination  of  the  FFQ 
retrospectively and of the fish diary prospectively, could provide more accurate assessment 
of nutrient intake, information on fish consumption frequencies and dietary patterns. 
 
The  SWS  FFQ  has  been  validated  to  assess  nutrient  intakes  and  dietary  patterns  in 
pregnant  women  in  Southampton  (223).  The  SWS  is  an  on-going  population  study  of 
initially  12,579  non-pregnant  women  aged  20-34  years  in  Southampton.  Women  who 
subsequently became pregnant were followed up; 2,270 women in early and 2,649 in late 
pregnancy  completed dietary information  (224). The SWS children are being followed 
through infancy and childhood to examine how their pre-natal growth interacts with their 
postnatal growth, and how both affect the children‟s risk factors for a range of chronic 
diseases (195). 
3.2.3  Maternal food frequency questionnaire (FFQ) 
The  semi-quantitative  100  item  FFQ  was  administered  by  an  appropriately  trained 
nutritionist (myself or Stella Kremmyda) at 20 and 34 weeks gestation and reflected food 
intake over the past 12 weeks (3 months). The FFQ at 20 weeks reflected dietary intake 
prior to the intervention (i.e. at baseline (from 8
th week till 20
th week of pregnancy), and 
the FFQ at 34 weeks reflected intake during the intervention period (from 22
nd week till 
34
th week). Both nutritionists were blinded to the treatment group of the subjects. 
The FFQ (Appendix 7) reflected intake of a hundred different food items including the 
following  categories:  bread,  cereals,  different  types  of  fruit,  fruit  juices,  types  of 
vegetables, pasta, rice, potatoes, beans/pulses, different types of meat and meat products, 
fish, eggs, diary products, milk, nuts, types of spreading fat and cooking oils, desserts/ 
sweets, savoury snacks, tea/coffee, soft drinks. Amongst those, the FFQ included questions 
of consumption frequency of different types of fish in four categories: „oily fish‟, „non-oily 
fish‟ (including tinned tuna), „fish fingers and fish dishes‟ and „shellfish‟. Also the FFQ 
included questions on composite food dishes, including foods they ate out or cooked at   147 
home.  Moreover,  there  were  questions  about  nutritional  supplement  intake 
(vitamins/minerals/fibre) and alcohol consumption. An additional question was added to 
the FFQ asking about intake of any „functional food products‟ with added n-3 and/or n-6 
fatty acids, probiotics, prebiotics or combinations of those. Subjects were asked to indicate 
the brand, quantity and weekly frequency of any functional food they had consumed on a 
systematic weekly basis in the 12 weeks prior to the FFQ administration. 
3.2.3.1 Consumption frequencies & nutrient intakes 
Subjects were asked to recall their intake during the three months prior to the time point of 
the interview. To help their recall, subjects were given prompt cards with examples of food 
items included in each food category and they were asked to think about composite food 
dishes,  including  foods  they  ate  out  or  cooked  themselves.  Categories  of  consumption 
frequency were also given in a prompt card and were: „more than once a day‟, „once a 
day‟, „3-6 times per week‟, „1-2 times per week‟, „once a fortnight‟, „once a month‟, „once 
every  2-3  months‟,  „never‟.  The  FFQ  administered  at  20  and  34  weeks  was  used  to 
calculate the weekly consumption frequencies for each food group for all subjects. The 8 
categories  of  consumption  frequency  described  above,  correspond  to  a  different 
multiplication factor as described in Table 3.1 below so as to calculate weekly frequencies.   148 
 
Table 3.1: Factors used to calculate frequencies and number of portions eaten per week 
 
Frequency eaten  Multiplication factor 
Never  0 
Once every 2-3 months  0.1 
Once a month  0.25 
Once a fortnight  0.5 
1-2 times per week  1.5 
3-6 times per week  4.5 
Once a day  7 
More than once a day  7 x times per day 
Because of the interest in fish consumption, the frequencies of consumption of the 4 fish 
categories included in the FFQ (questions 68-71 of the FFQ; white fish, fish fingers and 
fish dishes (FFFD), oily fish and shellfish) were calculated.  
Standard  portion  sizes  were  assigned  for  each  food  item  on  the  FFQ  according  to  a 
published list for the UK (225). The nutrient content of a standard portion of each food was 
multiplied by its reported frequency (Table 3.1) so as to calculate weekly nutrient intake. 
To get the daily nutrient intake, weekly nutrient intake was divided by seven. Total intake 
for each nutrient was obtained by summing up the specific nutrient intake from all FFQ 
food items. The macro- and micro-nutrients that had complete values  (12;13;226), and 
could provide a reliable estimate of intake are included in Table 3.2. Selenium values were 
complete, however they were used with caution, as selenium content varies depending on 
soil content (227).    149 










Total n-3 PUFAs 
Total n-6 PUFAs 
EPA, DHA 
A (retinol/carotene), D, E, K 
C 
B1, B2, B3, B6, B12 
Folate 
Ca, Mg P, Zn 
Fe, Se* 
Na, K 
For fish intake (for the 4 fish FFQ categories; Questions  68-71; see Appendix 7) and for 
seven nutrients (EPA, DHA, n-3 PUFA, n-6 PUFA, vitamin D, vitamin E and Se) myself 
and Lefkothea-Stella Kremmyda calculated the intake using the weekly frequencies (using 
the multiplication factors) from the FFQ analysis but different fish recipes from the ones 
that SWS used. The reason for doing so is that the SWS recipes were not as accurate (they 
were rough estimates) for those nutrients. In this way, we developed different recipes for 
each fish category, which gave us different amounts of those nutrients per portion from the 
amounts calculated by SWS. The fish diaries (described below) were  used to identify 
which fish types to include in each of the four fish recipes  that were  developed. We 
defined portion sizes as well for the 4 fish categories, which were slightly different from 
the ones that SWS used. Afterwards the average amounts of thos e nutrients for each fish 
category were calculated. When calculating the nutrients from the oily fish category for the 
salmon group, the nutrient composition information from the study salmon was used 
instead of the oily fish recipe. To make it clear, belo w is the table including the recipes 
used with the corresponding amounts to those seven nutrients (Table 3.3).    150 
Table 3.3: Content of total n-3 PUFAs, total n-6 PUFAs, EPA, DHA, Se, vit D and vit E in fish, shellfish 
and fish dishes per 100 g (12;13) 
 
Composition of fish and fish dishes per portion 
   Total n-3 
PUFAs 
(g) 
Total n-6  
PUFAs 
(g) 




WHITE Fish-150 g portion                      
Cod raw   0.39  0.03  0.12  0.24  42.00  0.00  0.66 
Haddock raw   0.26  0.05  0.08  0.15  40.50  0.00  0.59 
Plaice raw   0.48  0.02  0.24  0.15  55.50  0.00    
Tinned tuna in water, drained   0.26  0.06  0.03  0.21  117.00  5.40  0.83 
Tinned tuna in oil, drained   1.83  4.89  0.09  0.41  135.00  4.50  2.91 
Average amount per 150 g portion  0.64  1.01  0.11  0.23  78.00  1.98  1.25 
                       
OILY Fish-150 g portion                      
STUDY Salmon  3.56  2.31  0.57  1.16  43.00  14.00  4.10 
Average amount per 150 g portion 
CONTROL Salmon  
2.78  0.41  0.83  1.29  37.50  13.80  2.28  Pink/red canned in brine 
Mackerel raw  4.17  0.77  1.07  1.65  45.00  12.30  0.65 
Trout grilled  1.98  0.62  0.33  1.13  31.50  14.40  1.52 
Average amount per 150g portion  2.98  0.60  0.74  1.36  38.00  13.50  1.48 
                       
SHELLFISH-75 g portion                      
Prawns (boiled/frozen raw)  0.08  0.02  0.05  0.03  17.25  0.00    
Mussels boiled  0.51  0.06  0.31  0.12  32.25  0.00  0.79 
Scampi breaded cooked  0.05  0.11  0.00  0.00  12.75  0.00    
Crab boiled  0.83  0.18  0.35  0.34  63.00  0.00    
Average amount per 75 g portion  0.37  0.09  0.18  0.12  31.31  0.00  0.79 
                       
FFFD-100 g portion                      
Fish cakes frozen raw  0.33  0.60  0.05  0.09  NA  0.00  NA 
Fish fingers frozen raw  0.17  1.28  0.04  0.03  21.00  0.00  NA 
Average amount per 100 g portion  0.25  0.94  0.05  0.06  21.00  0.00    
FFFD: fish fingers and fish dishes, NA: data is not available   151 
3.2.3.2 Dietary patterns 
In order to determine possible changes occurring in the diets of the pregnant women in 
relation to the intervention and/or pregnancy, the FFQ items were grouped. The 98 foods 
and non alcoholic beverages listed on the FFQ were combined into 48 food groups on the 
basis of similarity of nutrient composition and comparable useage, as Crozier et al. had 
done before for the SWS FFQ (224). For example, the 4 food categories of white fish, fish 
fingers and fish dishes, oily  fish, and shellfish were  combined into the „total  fish and 
shellfish‟ group. Weekly consumption frequency of these 48 food groups was calculated 
by adding the weekly consumption frequency of each food item. Table 3.4 lists all the food 
groups, and how the separate food items were incorporated in those groups. 
Table 3.4: FFQ food groupings 
 
Food group  Food items included 
Rice and pasta  Rice, pasta 
White bread  White bread 
Wholemeal bread  Wholemeal bread 
Quiche and pizza  Quiche and pizza 
Yorkshire pudding and 
savoury pancakes 
Yorkshire puddings and savoury pancakes 
Breakfast cereals  „Bran‟ breakfast cereal, other breakfast cereals 
Cakes and biscuits  Cakes, buns, pastries, biscuits, other biscuits 
Puddings  Fruit based puddings, milk based puddings, other puddings, ice cream 
Cream  Cream 
Full-fat milk  Full-fat liquid milk 
Reduced-fat milk  Reduced-fat liquid milk 
Yoghurt  Yogurt 
Cheese and cottage cheese  Cheese, cottage cheese 
Eggs and egg dishes  Eggs, omelette 
Full-fat spread  Full-fat spread 
Reduced-fat spread  Reduced-fat spread 
Cooking fats and salad oils  Cooking fats and salad oils 
Red meat  Pork, lamb, beef 
Chicken and turkey  Chicken and turkey 
Liver, liver pate and kidney  Liver and kidney, pate and liver sausage, faggots and black pudding 
Offal Processed meat  Bacon and gammon, meat pies, sausages, ham and canned meats 
Fish and shellfish  White fish, fish fingers and fish dishes, oily fish, shellfish 
Salad vegetables  Salad, coleslaw, tomatoes, green peppers, watercress 
Green vegetables 
Spinach, brussels sprouts and broccoli, cabbage and cauliflower, peas, courgettes, 
marrow and leeks 
Root vegetables  Carrots, parsnips, swedes and turnips 
Other vegetables  Sweetcorn, onions, mushrooms 
Tinned vegetables  Tinned vegetables   152 
Vegetable dishes  Vegetable dishes, vegetarian foods 
Beans and pulses  Beans and pulses 
Chips and roast potatoes  Chips and roast potatoes 
Boiled potatoes  Boiled, mashed and jacket potatoes 
Crisps  Crisps and savoury snacks 
Crackers  Crackers and cheese biscuits, wholemeal crackers 
Citrus fruit and fruit juices  Oranges and orange juice, grapefruit and grapefruit juice 
Other fruit 
Apples and pears, bananas, peaches, plums, cherries and grapes, strawberries and 
raspberries, melon, pineapple, mango and kiwi 
Other fruit juices  Other fruit juices (not squashes) 
Dried fruit  Dried fruit 
Cooked and tinned fruit  Cooked fruit, tinned fruit 
Nuts  Nuts 
Sugar (teaspoons)  Added sugar 
Sweet spreads and jam  Sweet spreads and jam 
Sweets and chocolate  Chocolate, other sweets and confectionery 
Soft drinks 
Blackcurrants and blackcurrant drinks (Ribena), fizzy drinks and squashes, cola 
drinks 
Diet coke  Diet cola drinks 
Tea and coffee  Tea, coffee 
Decaffeinated tea and coffee  Decaffeinated tea (including herbal tea) and decaffeinated coffee 
Hot chocolate drinks  Drinking hot chocolates and milkshakes 
Miscellaneous 
Soups, stock cubes and marmite, mayonnaise and salad cream, pickles, chutney and 
ketchup, added bran to foods 
 
Some additional food groups were created for SIPS. These were also created by adding up 
the consumption frequencies of either individual FFQ items or food groups.  Table 3.5 
shows these extra groups. The categories of fats and oils were formed after combining the 
different types of fats and oils consumed (specific brands and names were recorded on the 
FFQ).   153 
 
Table 3.5: Extra FFQ food groupings created for SIPS 
 
Extra food groups for 
SIPS 
Food items or food groups included 
Total fruit  Citrus fruits and fruit juices + other fruit+ other fruit juices + dried fruit + cooked and 
tinned fruit 
Total vegetables  Salad vegetables + green vegetables + root vegetables + other vegetables  
+beans and pulses + tinned vegetables + vegetable dishes and vegeterian foods 
Total meat  Red meat + processed meat+ offal + chicken and turkey + liver, liver pate and kidney 
Low alcohol (alcohol units)  Low alcohol beer + low alcohol wine 
Normal alcohol  
(alcohol units) 
Normal alcohol beer + wine + spirits 
Total alcohol  
(alcohol units) 
Low alcohol + normal alcohol 
Margarine  Margarines + vegetable oil spreading fats 
Butter  Butter 
Olive spread  Olive oil based spreading fat 
Other vegetable oil  Other vegetable oils consumed (vegetable blend + sunflower + corn + hazelnut + walnut  
+ sesame + hemp seed) 
Olive oil  Olive oils ( all kinds including extra virgin) 
Animal fat  Animal fat (lard, goose fat) 
Salad dressings  Salad dressings 
 




Subjects in both groups (salmon and control) were asked to keep a record of their fish 
consumption (including oily and non-oily fish, shellfish and fish dishes) on a daily basis 
during the study, from week 21 of pregnancy until delivery and postnatally for 6 months. 
All subjects were asked to fill in the quantity, exact name, and cooking method of any fish 
consumed  during  pregnancy.  Women  in  the  salmon  group  were  also  asked  to  record 
exactly the days of every week that they ate study salmon, quantity eaten and method of 
cooking. They also recorded any other seafood that they consumed in addition to the study 
fish. 
 
The fish diary was used as a tool for estimating compliance and evidence of eating two 
portions of salmon per week in the salmon group, as well in the control group for not 
eating more than two portions of oily fish per month. The only difference to the diaries 
provided to the control and the salmon group was that the control group was given a list of 
fish categorised as oily and non-oily so as to be aware and to remain within the limit of the 
low consumption level of oily fish (twice per month) (Appendices 8 and 9). 
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3.2.4.2 Consumption frequencies  
 
The fish diaries were used to identify frequencies of fish intake as well as to aid estimation 
of nutrient intake. Fish diaries were analysed by myself and Lefkothea-Stella Kremmyda. 
Portion sizes were defined for all fish (white and oily) to be 150 g, for shellfish 75 g, for 
fish fingers 4 fish fingers, for fish cakes 2 fish cakes, for fish pie 1/3 portion of haddock, 
1/3 portion of salmon and 1/3 portion of prawns. Similarly to the FFQ, fish were identified 
in 4 categories: „oily‟, „white‟, „fish fingers and fish dishes‟, „shellfish‟. Oily fish included 
the sum of study salmon + fresh tuna + fresh salmon + tinned salmon + sardines + kippers 
+ pilchards + herring + mackerel + sward + trout + anchovies. White fish included the sum 
of tinned tuna + cod + haddock + plaice + sole + whitebait + halibut + scabbard + hake 
+monkfish + pollack + sea bass + marlin. „Fish fingers and fish dishes‟ included the sum of 
fish fingers + fish cakes. Shellfish included the sum of scampi + crab + oyster + shrimp + 
prawn + mussels + scallop + crayfish. Finally, „Total fish‟ included the sum of white fish + 
oily fish + fish fingers and fish dishes + shellfish. 
 
3.2.4.3 Nutrient calculations 
 
Fish diaries were also used to calculate intakes of the seven nutrients of interest (EPA, 
DHA, n-3 PUFAs, n-6 PUFAs, Se, vitamin D and vitamin E). The fish recipes used were 
the same as those used for calculating nutrient intake from the FFQs (Table 3.3). The 
information collected from the fish diaries played a major role in deciding the specific kind 
of  fish  the  nutritionists  (myself  and  Stella  Kremmyda)  chose  to  include  in  the  „fish 
recipes‟. Weekly intake of the seven nutrients of interest was calculated by multiplying the 
weekly fish consumption frequency by the nutrients per portion (Table 3.3), and the daily 
intake  of  those  nutrients  was  deriving  by  dividing  the  weekly  intake  by  seven.  Mean 
weekly consumption frequencies of fish categories and mean daily nutrient intakes were 
calculated for the period 21 to 38 weeks of pregnancy, as from week 39 until birth the 
diary records were poor.   155 
 
3.2.5  Statistical analysis 
 
The statistical package for social sciences (SPSS) version 16 was used for all the statistical 
analysis, and a p value equal or less to 0.05 (p ≤0.05) was considered to be statistically 
significant. Data that were not normally distributed were not log transformed but were 
subjected to anlysis using non-parametric tests.  
3.2.5.1 FFQ 
 
Where data were normally distributed they are described as mean and standard deviation 
(SD)  and  differences  between  treatment  groups  were  determined  using  independent 
samples t-test. Where data were not normally distributed they are described as median and 
interquartile range and differences between treatment groups were determined using the 
Mann-Whitney test. Differences within a group were determined by Wilcoxan ranked signs 
test.  
3.2.5.2 Fish diaries 
 
Data from the fish diaries were not normally distributed, and are described as median and 
interquartile range. Differences between treatment groups were determined using the 
Mann-Whitney test.    156 
 
3.3  Results 
 
3.3.1  Food groups consumption frequencies based on the FFQ 
 
Consumption frequencies of the 48 food groups according to the SWS categorization at 
baseline (20 weeks) and during intervention (34 weeks of pregnancy) are described in 
Table 3.6. Although the subjects were randomly assigned in the two groups, consumption 
frequencies  at  baseline  differed  significantly  between  groups  for  the  following  food 
groups: whole-meal bread, total fish and shellfish, citrus fruit and fruit juices, other fruit 
juices, sweets and chocolate. The salmon group had higher intake for each of these food 
groups apart from sweets and chocolate for which it had a lower intake. Specifically the 
salmon  group  had  a  median  intake  of  total  fish  and  shellfish  of  1.75  times  per  week 
compared to that of the control group that was 0.75 times per week at baseline (p<0.001). 
During intervention the salmon group had a significantly higher consumption frequency of 
total fish and shellfish (2.35 vs. 0.75 times per week, p<0.001) and a significantly lower 
consumption frequency of red meat than the control group (1.75 vs. 2.5 times per week, 
p=0.022).  Consumption  frequencies  of  chips  and  roast  potatoes  and  of  sugar  differed 
between the two groups at 34 weeks of pregnancy (lower in the salmon group).  
 
Table 3.6: Weekly consumption frequency of food groups in the FFQ administered at 20 and 34 weeks 
gestation according to study group 
 
Food group 
20 weeks gestation  34 weeks gestation 
Control group 
(n=61) 
Salmon group  








Rice and pasta  3 (1.9, 3)  3 (1, 3)  0.533  2 (1, 3)  2 (1, 3)  0.729 
White bread  9 (2.3, 14)  3.75 (0.9, 14)  0.096  9 (3, 14)  3 (1, 14)  0.061 
Whole-meal bread  3 (0.3, 9)  4.5 (0.7, 14)  0.048  1.25 (0, 9)  3 (0.2, 14)  0.051 
Quiche and pizza  0.5 (0.25, 1.5)  0.5 (0.25, 1.5)  0.437  0.5 (0.25, 0.5)  0.5 (0.25, 0.5)  0.967 
Savory pancakes (incl. 
Yorkshire pudding)  0.25 (0, 0.5)  0.1 (0.1, 0.25)  0.298  0.1 (0, 0.25)  0.1 (0, 0.25)  0.287 
Breakfast cereals  4.5 (0.5, 7)  4.5 (0.9, 7)  0.212  4.6 (1.5, 7)  7 (1.5, 7)  0.233 
Cakes and biscuits  5.5 (3, 9.8)  4.38 (2, 9.4)  0.331  5.8 (3, 10)  8 (3.5, 11)  0.252 
Puddings  1 (0.5, 2.5)  1.55 (6, 2.3)  0.691  1.7 (0.8, 2.6)  1.5 (0.8, 2.3)  0.634 
Cream  0.25 (0, 0.5)  0.18 (0, 0.5)  0.652  0.25 (0, 0.5)  0.25 (0, 0.5)  0.461 
Full-fat milk (pt/day)  0 (0, 0)  0 (0, 0)  0.706  0 (0, 0)  0 (0, 0)  0.851 
Reduced-fat milk (pt/day)  0.5 (0.09, 0.75)  0.5 (0.15, 0.56)  0.580  0.5 (0.2, 1)  0.5 (0.25, 1)  0.649 
Yogurt  1.5 (0.25, 4.5)  1.5 (0.25, 4.5)  0.758  1.5 (0.5, 4.5)  1.5 (0.25, 4.5)  0.515 
Cheese and cottage cheese  4.5 (1.5, 4.5)  4.5 (1.5, 4.6)  0.222  4.5 (1.5, 4.5)  4.5 (1.5, 4.5)  0.368   157 
 
Eggs and egg dishes  0.5 (0.1, 1.8)  0.5 (0.25, 1.1)  1.000  0.5 (0.2, 1.5)  0.5 (0.2, 1)  0.736 
Full-fat spread  4.5 (0, 7)  1.5 (0, 7.4)  0.712  4.5 (0, 7.4)  4.5 (0.25, 9)  0.701 
Reduced-fat spread  0 (0, 5.3)  1.5 (0, 7)  0.108  0 (0, 7)  0 (0, 7)  0.979 
Cooking fats and salad 
oils  3 (1.5, 4.5)  3.1 (1.5, 6)  0.234  3 (1.5, 5.1)  4.5 (1.5, 6)  0.348 
Red meat  2.5 (1, 3.5)  2.1 (0.95, 3.1)  0.354  2.5 (1.8, 3.5)  1.8 (1, 3)  0.022 
Chicken and turkey  1.5 (0.5, 1.5)  1.5 (1.5, 1.5)  0.498  1.5 (1.5, 1.5)  1.5 (0.5, 1.5)  0.152 
Liver, liver pate, and 
kidney 
0 (0, 0)  0 (0, 0)  0.545  0 (0, 0)  0 (0, 0)  0.394 
Processed meat  2.8 (1.4, 5.3)  2.8 (1.8, 4.8)  0.877  2.4 (1.2, 3.6)  2.5 (1.3, 5.1)  0.501 
Total fish and shellfish  0.75 (0.35, 2)  1.75 (0.75, 2.25)  0.001 
0.75 (0.26, 
1.85)  2.4 (2, 3)  <0.001 
Salad vegetables  4.6 (3, 9.4)  6.9 (3.8, 10.1)  0.072  4.8 (2.7, 7)  5.3 (3.3, 9.6)  0.376 
Green vegetables  3.7 (2.1, 5.6)  3.7 (2.1, 6.1)  0.581  3.7 (1.7, 5.3)  3.8 (2.6, 6)  0.310 
Root vegetables  1.8 (1.5, 4.5)  1.75 (1.5, 4.5)  0.711  1.75 (1.4, 3)  1.75 (1.5, 3)  0.710 
Other vegetables  3.5 (2, 6.5)  4.5 (2.25, 6.7)  0.966  3.3 (2.2, 6.3)  3.3 (2, 6.3)  0.956 
Tinned vegetables  0.25 (0, 1.5)  0.1 (0, 0.5)  0.192  0.2 (0, 1.5)  0 (0, 0.5)  0.189 
Vegetable dishes  0.25 (0, 1.25)  0.25 (0, 0.9)  0.667  0.25 (0, 0.5)  0.25 (0, 0.5)  0.865 
Beans and pulses  1.5 (0.25, 1.5)  1.5 (0.4, 1.5)  0.910  1 (0.25, 1.5)  1.5 (0.5, 1.5)  0.641 
Chips and roast 
potatoes 
3 (1.5, 6)  3 (1, 4.5)  0.314  3 (1.5, 4.5)  1.5 (1, 4.5)  0.021 
Boiled potatoes  9 (4.1, 13.5)  4.5 (4.5, 6.8)  0.090  4.5 (3.6, 13.5)  4.5 (4.5, 13.5)  0.660 
Crisps  4.5 (1.5, 4.5)  1.5 (1.25, 4.5)  0.176  1.5 (1.5, 4.5)  1.5 (0.5, 4.5)  0.158 
Crackers  0.25 (0, 0.5)  0.25 (0, 0.75)  0.274  0.1 (0, 0.5)  0.25 (0, 0.5)  0.692 
Citrus fruit and fruit 
juices  1.5 (1.5, 4.6)  4.5 (1.5, 7)  0.047  4.5 (1.5, 5.2)  4.5 (1.5, 7.1)  0.244 
Other fruit  9.3 (5.4, 16.3)  9 (3.8, 14.4)  0.487  7.6 (3.3, 14)  8.8 (5, 14)  0.346 
Other fruit juices  0.5 (0, 4.5)  1.5 (0.25, 7)  0.018  1.5 (1, 4.5)  1.5 (0.1, 4.5)  0.735 
Dried fruit  0.1 (0, 0.5)  0.25 (0, 0.75)  0.490  0.18 (0, 0.5)  0.1 (0, 0.5)  0.695 
Cooked and tinned fruit  0.2 (0, 0.6)  0.15 (0, 0.5)  0.476  0.25 (0, 0.5)  0.25 (0, 0.5)  0.522 
Nuts  0 (0, 0.25)  0.1 (0, 0.5)  0.060  0.05 (0, 0.5)  0 (0, 0.5)  0.559 
Sugar (tsp/day)  0 (0, 3)  0 (0, 2)  0.886  1 (0, 3)  0 (0, 1)  0.049 
Sweet spreads and jam  0.5 (0.25, 1.5)  1.5 (0.25, 4.5)  0.071  1 (0.25, 1.5)  1.5 (0.25, 1.5)  0.347 
Sweets and chocolate  5 (2, 9)  3 (1.8, 6)  0.037  6 (2.8, 8.6)  4.8 (2, 7)  0.216 
High-energy soft drinks  6 (1.5, 10)  4.5 (0.5, 9.8)  0.354  7.4 (1.6, 14.0)  3 (0.5, 10.5)  0.058 
Diet cola  0.25 (0, 1.5)  0.18 (0, 1.5)  0.464  0 (0, 0.25)  0.1 (0, 0.5)  0.209 
Tea and coffee  11.5 (0.6, 21)  7 (1.5, 15.5)  0.508  8.8 (4.5, 21)  7 (1.5, 15.5)  0.187 
Decaffeinated tea and 
coffee 
0 (0, 4.5)  0 (0, 5.1)  0.864  0 (0, 2.25)  0 (0, 4.5)  0.559 
Hot chocolate drinks  0.5 (0.05, 1.5)  0.25 (0, 1.5)  0.081  0.25 (0, 1.5)  0.5 (0, 1.5)  0.635 
Miscellaneous  5.9 (3.1, 9)  4.8 (3.23, 8.6)  0.792  5 (3.3, 8)  5 (2.5, 8.6)  0.450 
Values are median (interquartile range) number of times per week (apart from milk (pints/day) and sugar 
(teaspoons/day)); Mann Witney test p-values 
Food grouping performed according to principal component analysis (PCA) of the SWS FFQ 
 
 
Table 3.7 compares within group differences in frequency of consumption of food groups 
over time. Chicken intake decreased in the salmon group from 20 to 34 weeks gestation 
(p=0.018) as did intake of non-oily fish (p=0.014).   158 
 
Table 3.7: Within group comparisons of weekly consumption frequency of food groups in the FFQ 
administered at 20 and 34 weeks gestation 
 
Food group 
Control group   Salmon group 
20 weeks   34 weeks   p  20 weeks  34 weeks  p 
Rice and pasta  3 (1.9, 3)  2 (1, 3)  0.097  3 (1, 3)  2 (1, 3)  0.248 
White bread  9 (2.3, 14)  9 (3, 14)  0.337  3.8 (0.9, 14)  3 (1, 14)  0.721 
Whole-meal bread  3 (0.3, 9)  1.25 (0, 9)  0.556  4.5 (0.7, 14)  3 (0.2, 14)  0.861 
Quiche and pizza  0.5 (0.25, 1.5)  0.5 (0.25, 0.5)  0.877  0.5 (0.25, 
1.5) 
0.5 (0.25, 




0.25 (0, 0.5)  0.1 (0, 0.25)  0.092  0.1 (0.1, 
0.25)  0.1 (0, 0.25)  0.817 
Breakfast cereals  4.5 (0.5, 7)  4.6 (1.5, 7)  0.202  4.5 (0.9, 7)  7 (1.5, 7)  0.778 
Cakes and biscuits  5.5 (3, 9.8)  5.8 (3, 10)  0.401  4.4 (2, 9.4)  8 (3.50, 11)  0.006 
Puddings  1 (0.5, 2.5)  1.7 (0.8, 2.6)  0.552  1.6 (6, 2.3)  1.5 (0.75, 
2.3)  0.485 
Cream  0.25 (0, 0.5)  0.25 (0, 0.5)  0.152  0.18 (0, 0.5)  0.25 (0, 0.5)  0.486 
Full-fat milk 
(pt/day) 
0 (0, 0)  0 (0, 0)  0.972  0 (0, 0)  0 (0, 0)  0.646 
Reduced-fat milk 
(pt/day)  0.5 (0.09, 0.75)  0.5 (0.2, 1)  0.048  0.5 (0.15, 
0.6)  0.5 (0.25, 1)  0.044 
Yogurt  1.5 (0.25, 4.5)  1.5 (0.5, 4.5)  0.311  1.5 (0.25, 
4.5) 
1.5 (0.25, 
4.5)  0.223 
Cheese and cottage 
cheese 
4.5 (1.5, 4.5)  4.5 (1.5, 4.5)  0.793  4.5 (1.5, 
4.6) 
4.5 (1.5, 
4.5)  0.003 
Eggs and egg 
dishes  0.5 (0.10, 1.75)  0.5 (0.2, 1.5)  0.071  0.5 (0.25, 
1.1)  0.5 (0.2, 1)  0.456 
Full-fat spread  4.5 (0, 7)  4.5 (0, 7.4)  0.896  1.5 (0, 7.4)  4.5 (0.25, 9)  0.165 
Reduced-fat 
spread  0 (0, 5.25)  0 (0, 7)  0.165  1.5 (0, 7)  0 (0, 7)  0.555 
Cooking fats and 
salad oils 
3 (1.5, 4.5)  3 (1.5, 5.1)  0.708  3.1 (1.5, 6)  4.5 (1.5, 6)  0.404 
Red meat  2.5 (1, 3.5)  2.5 (1.8, 3.5)  0.736  2.1 (0.95, 
3.1)  1.8 (0.95, 3)  0.263 
Chicken and 
turkey  1.5 (0.5, 1.5)  1.5 (1.5, 1.5)  0.718  1.5 (1.5, 
1.5) 
1.5 (0.5, 
1.5)  0.018 
Liver, liver pate, 
and kidney  0 (0, 0)  0 (0, 0)  0.369  0 (0, 0)  0 (0, 0)  0.719 
Processed meat  2.8 (1.4, 5.3)  2.4 (1.2, 3.6)  0.013  2.8 (1.8, 
4.8) 
2.5 (1.25, 
5.1)  0.214 
Total fish and 
shellfish 
0.75 (0.35, 2)  0.75 (0.25, 
1.85)  0.519  1.75 (0.75, 
2.25)  2.35 (2, 3)  <0.001 
Salad vegetables  4.6 (3, 9.4)  4.8 (2.7, 7)  0.743  6.9 (3.8, 
10.1) 
5.3 (3.3, 
9.6)  0.028 
Green vegetables  3.7 (2.1, 5.6)  3.7 (1.7, 5.3)  0.510  3.7 (2.1, 
6.1)  3.8 (2.6, 6)  0.763 
Root vegetables  1.8 (1.5, 4.5)  1.8 (1.4, 3)  0.334  1.8 (1.5, 
4.5)  1.8 (1.5, 3)  0.314 
Other vegetables  3.5 (2, 6.5)  3.3 (2.2, 6.3)  0.337  4.5 (2.3, 
6.7)  3.3 (2, 6.3)  0.271 
Tinned vegetables  0.25 (0, 1.5)  0.18 (0, 1.5)  0.705  0.1 (0, 0.5)  0 (0, 0.5)  0.290 
Vegetable dishes  0.25 (0, 1.25)  0.25 (0, 0.5)  0.293  0.25 (0, 
0.94)  0.25 (0, 0.5)  0.025 
Beans and pulses  1.5 (0.25, 1.5)  1 (0.25, 1.5)  0.494  1.5 (0.44, 
1.5) 
1.5 (0.5, 
1.5)  0.322 
Chips and roast 
potatoes 
3 (1.50, 6)  3 (1.5, 4.5)  0.735  3 (1, 4.5)  1.5 (1, 4.5)  0.273 
Boiled potatoes  9 (4.1, 13.5)  4.5 (3.6, 13.5)  0.111  4.5 (4.5, 
6.8) 
4.5 (4.5, 
13.5)  0.105   159 
 
 
Crisps  4.5 (1.5, 4.5)  1.5 (1.5, 4.5)  0.089  1.5 (1.3, 
4.5) 
1.5 (0.5, 
4.5)  0.232 
Crackers  0.25 (0, 0.5)  0.1 (0, 0.5)  0.239  0.25 (0, 
0.75)  0.25 (0, 0.5)  0.010 
Citrus fruit and 
fruit juices  1.5 (1.5, 4.6)  4.5 (1.5, 5.2)  0.956  4.5 (1.5, 7)  4.5 (1.5, 
7.1)  0.662 
Other fruit  9.3 (5.4, 16.3)  7.6 (3.3, 14)  0.079  9 (3.8, 14.4)  8.8 (5, 14)  0.883 
Other fruit juices  0.5 (0, 4.5)  1.5 (1, 4.5)  0.888  1.5 (0.25, 7)  1.5 (0.1, 
4.5)  0.001 
Dried fruit  0.1 (0, 0.5)  0.2 (0, 0.5)  0.949  0.25 (0, 
0.75)  0.1 (0, 0.5)  0.183 
Cooked and tinned 
fruit 
0.2 (0, 0.55)  0.25 (0, 0.5)  0.086  0.15 (0, 0.5)  0.25 (0, 0.5)  0.064 
Nuts  0 (0, 0.25)  0.05 (0, 0.5)  0.075  0.1 (0, 0.5)  0 (0, 0.5)  0.183 
Sugar (tsp/day)  0 (0, 3)  1 (0, 3)  0.079  0 (0, 2)  0 (0, 1)  0.240 
Sweet spreads and 
jam  0.5 (0.25, 1.5)  1 (0.25, 1.5)  0.178  1.5 (0.25, 
4.5) 
1.5 (0.25, 
1.5)  0.675 
Sweets and 
chocolate 
5 (2, 9)  6 (2.8, 8.6)  0.991  3 (1.8, 6)  4.8 (2, 7)  0.151 
High-energy soft 
drinks  6 (1.5, 10)  7.4 (1.6, 14.0)  0.951  4.5 (0.5, 
9.8)  3 (0.5, 10.5)  0.577 
Diet cola  0.25 (0, 1.5)  0 (0, 0.25)  0.005  0.18 (0, 1.5)  0.1 (0, 0.5)  0.304 
Tea and coffee  11.5 (0.6, 21)  8.8 (4.5, 21)  0.248  7 (1.5, 15.5)  7 (1.5, 15.5)  0.018 
decaffeinated tea 
and coffee 
0 (0, 4.5)  0 (0, 2.25)  0.516  0 (0, 5.13)  0 (0, 4.5)  0.686 
Hot chocolate 
drinks 
0.5 (0.05, 1.5)  0.25 (0, 1.5)  0.936  0.25 (0, 1.5)  0.5 (0, 1.5)  0.317 
Miscellaneous  5.9 (3.1, 9)  5 (3.3, 8)  0.434  4.8 (3.3, 
8.6)  5 (2.5, 8.6)  0.266 
Values are median (interquartile range) number of times per week (apart from milk (pints/day) and sugar 
(teaspoons/day)); Wilcoxon test p-values 
Food grouping performed according to principal component analysis (PCA) of the SWS FFQ 
 
 
Table  3.8  describes  the  between  group  comparisons  for  consumption  frequencies  of 
additional food groups. There were no differences between the groups in consumption 
frequencies of total fruit, total vegetables, total meat and total alcohol at any time point. 
However, as shown in  
Table 3.9, within the salmon group total meat consumption decreased (p=0.048) from 20 to 
34 weeks gestation, and total vegetable consumption showed a strong trend of decrease 
(non-significant)  within  the  salmon  group.  Table  3.9  also  includes  information  on 
consumption  frequencies  of  different  types  of  spreading  fat,  cooking  fat,  and  salad 
dressings.  The  only  significant  difference  between  the  two  groups  was  in  olive  oil 
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Table 3.8: Between group comparisons of weekly consumption frequency of additional food groups in 
the FFQ at 20 and 34 weeks 
 
Food group 
20 weeks gestation  34 weeks gestation 
Control  Salmon  p  Control  Salmon  p 
Total fruit  15.5 (10.2, 23.8)  18.9 (10.9, 
28.2)  0.268  11.8 (8.4, 
24.5) 
18.1 (10.5, 
27.1)  0.096 
Total vegetables  18.6 (14.3, 28.3)  21.2 (15.3, 
27.8)  0.491  16.8 (12.9, 
26.5) 
19.3 (13.7, 
25.5)  0.476 
Total meat  7.4 (5.1, 11.7)  7.3 (5.5, 10.2)  0.638  7.3 (4.4, 
10.6) 
6.5 (4.6, 
9.5)  0.495 





0 (0, 4.5)  0 (0, 7)  0.810  0.13 (0, 4.5)  0 (0, 6)  0.773 
Butter  1.5 (0, 7)  1.5 (0, 7)  0.781  4.5 (0, 7)  2 (0, 7)  0.943 
Olive oil based 
spreading fat 
0 (0, 0)  0 (0, 0.44)  0.191  0 (0, 0)  0 (0, 0)  0.582 
Vegetable oils  0.5 (0, 1.5)  0.38 (0, 1.5)  0.435  0.5 (0, 1.5)  0.25 (0, 1.5)  0.159 
Olive oil  1.5 (0, 3.75)  1.5 (0, 4.5)  0.067  0.13 (0, 3.4)  1.5 (0, 4.5)  0.038 
Animal fat  0 (0, 0)  0 (0, 0)  0.152  0 (0, 0)  0 (0, 0)  0.322 
Salad dressing  0 (0, 0)  0 (0, 0)  0.800  0 (0, 0)  0 (0, 0)  0.538 
Values are median (interquartile range) number of times per week; Mann Witney test p-values 
 
Table 3.9: Within group comparisons of weekly consumption frequency of additional food groups in 
the FFQ at 20 and 34 weeks 
 
Food group 
Control group  Salmon group 
20 weeks  34 weeks  p  20 weeks  34 weeks  p 
Total fruit  15.5 (10.2, 
23.8) 
11.8 (8.4, 
24.5)  0.241  18.9 (10.9, 
28.2) 
18.1 (10.5, 
27.1)  0.080 
Total vegetables  18.6 (14.3, 
28.3) 
16.8 (12.9, 
26.5)  0.201  21.2 (15.3, 
27.8) 
19.3 (13.7, 
25.5)  0.059 
Total meat  7.4 (5.1, 
11.7) 
7.3 (4.4, 
10.6)  0.386  7.3 (5.5, 10.2)  6.5 (4.6, 9.5)  0.048 
Total alcohol  0 (0, 0.33)  0 (0, 0.5)  0.202  0.6 (0, 0.26)  0 (0, 0.25)  0.683 
Margarine/ Vegetable oil 
based spreading fat  0 (0, 4.5)  0.13 (0, 4.5)  0.461  0 (0, 7)  0 (0, 6)  0.611 
Butter  1.5 (0, 7)  4.5 (0, 7)  0.064  1.5 (0, 7)  2 (0, 7)  0.309 
Olive oil based spreading fat  0 (0, 0)  0 (0, 0)  1.000  0 (0, 0.44)  0 (0, 0)  0.700 
Vegetable oils  0.5 (0, 1.5)  0.5 (0, 1.5)  0.422  0.38 (0, 1.5)  0.25 (0, 1.5)  0.194 
Olive oil  1.5 (0, 3.75)  0.13 (0, 3.4)  0.656  1.5 (0, 4.5)  1.5 (0, 4.5)  0.908 
Animal fat  0 (0, 0)  0 (0, 0)  0.180  0 (0, 0)  0 (0, 0)  0.317 
Salad dressing  0 (0, 0)  0 (0, 0)  0.440  0 (0, 0)  0 (0, 0)  0.529 
*Values are median (interquartile range) number of times per week; Wilcoxon test p-values 
 
Due  to  the  fact  that  differences  were  observed  at  baseline  for  total  fish  and  shellfish 
consumption between the two groups, the different fish categories were further analysed 
(Table 3.10, Table 3.11). At week 20 the salmon group was consuming more frequently 
non-oily  fish  (medians  0.5  and  0.25  times  per  week,  for  salmon  and  control  group 
respectively, p=0.005) as well as oily fish (medians 0.25 and 0 times per week, for salmon 
and control group respectively, p<0.001) in comparison to the control group. At week 34 
(during intervention) there were no significant differences in non-oily fish intake between   161 
the two groups, but there was a significant increase in the oily fish intake in the salmon 
group, (medians 1.5 and 0 times per week  for salmon and control  group respectively, 
p<0.001). This is very important because it shows that the women in the salmon group had 
increased their oily fish intake as required by the study protocol. 
 
Table 3.10: Between group comparisons of weekly consumption frequency of meat and fish categories 
in the FFQ 
 
Food group 
20 weeks gestation  34 weeks gestation 
Control group  Salmon group  p  Control group  Salmon group  p 
Non-oily fish  0.25 (0.25, 0.5)  0.5 (0.25, 1.5)  0.005  0.25 (0.08, 1.5)  0.5 (0.25, 1.5)  0.204 
Fish fingers and fish dishes  0.25 (0, 0.5)  0.25 (0, 0.5)  0.597  0.18 (0, 0.5)  0.1 (0, 0.25)  0.866 
Oily fish  0 (0, 0.25)  0.25 (0, 0.5)  <0.00
1 
0 (0, 0.14)  1.5 (1.5, 1.5)  <0.001 
Shellfish  0 (0, 0.1)  0 (0, 0.1)  0.855  0 (0, 0)  0 (0, 0.1)  0.0760 
Pork  0.25 (0, 0.5)  0.17 (0, 0.5)  0.526  0.25 (0.8, 0.5)  0.25 (0.1, 0.5)  0.189 
Chicken  1.5 (0.5, 1.5)  1.5 (1.5, 1.5)  0.498  1.5 (1.5, 1.5)  1.5 (0.5, 1.5)  0.152 
Lamb  0.1 (0, 0.5)  0.17 (0, 0.5)  0.894  0.25 (0, 0.5)  0.1 (0, 0.5)  0.92 
Beef  0.5 (0.1, 1.5)  0.4 (0.25, 1.5)  0.959  0.5 (0.25, 1.5)  0.5 (0.1, 0.50)  0.351 
Minced meat dishes  1.5 (0.25, 1.5)  0.5 (0.43, 1.5)  0.315  1.5 (0.5, 1.5)  0.5 (0.25, 1.5)  0.301 
Sausages  0.5 (0.25, 1.5)  0.5 (0.25, 1.5)  0.463  0.5 (0.21, 0.5)  0.5 (0.25, 0.5)  0.395 
Ham and luncheon meat  1.5 (0.25, 1.5)  1.5 (.43, 1.5)  0.467  0.5 (0.25, 1.5)  1.5 (0.25, 1.5)  0.156 
Values are median (interquartile range) number of times per week; Mann Witney test p-values 
 
Table 3.11: Within group comparisons of weekly consumption frequency of meat and fish categories in 
the FFQ at 20 and 34 weeks of gestation 
 
Food group  Control group  Salmon group 
  20 weeks  34 weeks  p  20 weeks  34 weeks  p 
Non-oily fish  0.25 (0.25, 0.5)  0.25 (0.08, 1.5)  0.736  0.5 (0.25, 1.5)  0.5 (0.25, 1.5)  0.014 
Fish fingers and fish dishes  0.25 (0, 0.5)  0.18 (0, 0.5)  0.766  0.25 (0, 0.5)  0.1 (0, 0.25)  0.132 
Oily fish  0 (0, 0.25)  0 (0, 0.14)  0.025  0.25 (0, 0.5)  1.5 (1.5, 1.5)  <0.001 
Shellfish  0 (0, 0.1)  0 (0, 0)  0.066  0 (0, 0.1)  0 (0, 0.1)  0.841 
Pork  0.25 (0, 0.5)  0.25 (0.8, 0.5)  0.787  0.17 (0, 0.5)  0.25 (0.1, 0.5)  0.167 
Chicken  1.5 (0.5, 1.5)  1.5 (1.5, 1.5)  0.718  1.5 (1.5, 1.5)  1.5 (0.5, 1.5)  0.018 
Lamb  0.1 (0, 0.5)  0.25 (0, 0.5)  0.909  0.17 (0, 0.5)  0.1 (0, 0.5)  0.735 
Beef  0.5 (0.1, 1.5)  0.5 (0.25, 1.5)  0.603  0.4 (0.25, 1.5)  0.5 (0.1, 0.50)  0.756 
Minced meat dishes  1.5 (0.25, 1.5)  1.5 (0.5, 1.5)  0.962  0.5 (0.43, 1.5)  0.5 (0.25, 1.5)  0.670 
Sausages  0.5 (0.25, 1.5)  0.5 (0.21, 0.5)  0.040  0.5 (0.25, 1.5)  0.5 (0.25, 0.5)  0.558 
Ham and luncheon meat  1.5 (0.25, 1.5)  0.5 (0.25, 1.5)  0.064  1.5 (.43, 1.5)  1.5 (0.25, 1.5)  0.723 
Values are median (interquartile range) number of times per week; Wilcoxon test p-values 
 
 
Figure  3.1  and  Figure  3.2  show  the  distribution  of  intake  of  non-oily  and  oily  fish, 
respectively, according to the FFQ frequency categories, for both study groups at baseline 
(20 weeks gestation) and during intervention (34 weeks gestation). In Figure 3.2 all women 
in  the  salmon  group  reported  consuming  oily  fish  1-2  times  per  week,  which  was 
interpreted as 1.5 times per week. 
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Figure 3.1: Distribution of non-oily fish consumption into FFQ categories at a) 20 weeks gestation, b) 




   
Figure 3.2: Distribution of oily fish consumption into FFQ categories at a) 20 weeks gestation, b) 34 
weeks gestation 
 
In order to compare the changes in intake associated with the intervention between the two 
study groups, the changes in consumption frequencies for all food groups were calculated 
(i.e. 34 weeks minus 20 weeks gestation) for the control and the study group and these are 
presented in Table 3.12. The changes in intake of cheese and sugar were significantly 
smaller for the salmon group compared to the control group, whereas the change in fish 
intake was significantly greater in the salmon group than in the control group as expected 
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Because of the baseline differences in fish intake between the groups, changes in fish 
consumption frequencies were calculated (i.e. 34 weeks minus 20 weeks gestation) (Table 
3.13). Based upon the FFQ data and categories, the increase in the oily fish consumption 
observed in the salmon group was 1.21 times per week from 20 to 34 weeks gestation, 
whereas the oily fish consumption in the control group remained almost unchanged (0.04 
times per week less), and this change was different between the groups (p<0.001) (Figure 
3.3). Also the increase in total fish consumption in the salmon group (0.85 portions per 
week)  was  significantly  different  from  the  almost  unchanged  total  fish  consumption 
frequency in the control group (0.05 times per week less) (p<0.001) (Figure 3.4). Changes 
in consumption frequencies of all 48 food groups are described in Table 3.12 Changes in 
consumption frequencies of the different categories of meat were not different between 
control and salmon groups (Table 3.13).  
 
 




Change in consumption : 34-20 weeks gestation 
Control group  Salmon group   p 
Rice and pasta  -0.45 (2.01)  -0.14 (1.64)  0.385 
White bread  -1.16 (9.89)  -0.95 (5.81)  0.895 
Whole-meal bread  -0.18 (3.74)  -0.33 (8.82)  0.905 
Quiche and pizza  -0.02 (0.47)  -0.11 (0.49)  0.329 
Savory pancakes (incl. Yorkshire pudding)  -0.18 (0.98)  -0.01 (0.31)  0.234 
Breakfast cereals  0.43 (3.09)  0.18 (2.97)  0.674 
Cakes and biscuits  -0.53 (6.26)  1.48 (5.70)  0.081 
Puddings  0.06 (2.14)  0.23 (1.80)  0.649 
Cream  -0.05 (0.31)  -0.04 (1.14)  0.905 
Full-fat milk (pt/day)  0.01 (0.23)  -0.05 (0.32)  0.303 
Reduced-fat milk (pt/day)  0.11 (0.52)  0.09 (0.39)  0.877 
Yogurt  -0.34 (2.58)  -0.33 (2.18)  0.983 
Cheese and cottage cheese  0.07 (1.72)  -0.71 (2.40)  0.055 
Eggs and egg dishes  -0.40 (1.29)  0.01 (1.10)  0.075 
Full-fat spread  -0.04 (5.49)  1.23 (6.45)  0.272 
Reduced-fat spread  0.61 (3.19)  -0.60 (5.17)  0.144 
Cooking fats and salad oils  0.18 (2.54)  0.20 (3.04)  0.966 
Red meat  0.11 (2.20)  -0.20 (1.85)  0.424 
Chicken and turkey  0.13 (1.73)  -0.32 (0.96)  0.094 
Liver, liver pate, and kidney  -0.04 (0.26)  -0.01 (0.16)  0.390 
Processed meat  -0.87 (2.68)  -0.30 (2.16)  0.224 
Total fish and shellfish  -0.05 (1.07)  0.85 (0.85)  <0.001 
Salad vegetables  -0.62 (4.46)  -1.15 (3.61)  0.497 
Green vegetables  -0.29 (3.22)  0.17 (3.27)  0.459 
Root vegetables  -0.20 (1.90)  -0.20 (2.03)  0.990 
Other vegetables  -0.28 (2.63)  -0.43 (2.36)  0.757 
Tinned vegetables  0.06 (0.90)  0.35 (1.38)  0.201 
Vegetable dishes  -0.05 (0.89)  -0.26 (0.77)  0.191 
Beans and pulses  -0.14 (1.45)  -0.20 (1.37)  0.811 
Chips and roast potatoes  0.07 (4.21)  -0.68 (3.17)  0.292   164 
Boiled potatoes  -1.38 (6.99)  1.90 (8.16)  0.026 
Crisps  -0.39 (1.97)  -0.30 (2.42)  0.821 
Crackers  -0.01 (1.79)  -0.41 (1.70)  0.239 
Citrus fruit and fruit juices  0.22 (5.64)  -0.22 (7.17)  0.721 
Other fruit  -2.05 (7.20)  -0.12 (6.60)  0.148 
Other fruit juices  -0.02 (3.66)  -1.36 (3.08)  0.041 
Dried fruit  -0.20 (1.93)  -0.23 (1.47)  0.923 
Cooked and tinned fruit  -0.21 (1.14)  0.28 (1.06)  0.024 
Nuts  0.33 (1.41)  -0.12 (1.50)  0.114 
Sugar (tsp/day)  0.43 (1.74)  -0.13 (0.84)  0.037 
Sweet spreads and jam  0.34 (1.78)  0.22 (2.01)  0.749 
Sweets and chocolate  0.32 (5.00)  0.99 (4.02)  0.442 
High-energy soft drinks  1.18 (15.70)  0.10 (12.12)  0.689 
Diet cola  -0.94 (4.36)  0.37 (4.70)  0.135 
Tea and coffee  1.49 (10.69)  1.55 (5.20)  0.970 
Decaffeinated tea and coffee  -0.06 (5.11)  -0.19 (5.90)  0.898 
Hot chocolate drinks  -0.02 (2.23)  0.02 (2.83)  0.927 
Miscellaneous  -0.32 (4.05)  -0.32 (3.29)  0.993 
Values are mean (ﾱstandard deviation)number of times per week; independent samples t-test p values 
 
 
Table 3.13: Changes in fish and meat weekly consumption frequencies - between group comparisons 
 
Food category  Change in consumption: 34-20 weeks gestation 
  Control group  Salmon group  p 
Non-oily fish  0.02 (0.96)  -0.25 (0.7)  0.104 
Fish fingers and fish dishes  0.01 (0.38)  -0.11 (0.43)  0.128 
Oily fish  -0.04 (0.14)  1.21 (0.26)  <0.001 
Shellfish  -0.04 (0.27)  -0.25 (0.7)  0.298 
Total fish  -0.05 (1.07)  0.85 (0.085)  <0.001 
Pork  0.08 (0.91)  0 (0.12)  0.149 
Chicken  0.13 (1.73)  -0.12 (0.46)  0.094 
Lamb  0.08 (0.69)  -0.32 (0.96)  0.320 
Beef  -0.04 (1.38)  -0.03 (0.37)  0.673 
Total red meat  0.11 (2.2)  -0.2 (1.85)  0.424 
Total meat  -0.67 (4.47)  -0.83 (3.24)  0.831 
Values are mean (ﾱstandard deviation)number of times per week; independent samples t-test p values 
 
 
Figure 3.3: Change in oily fish consumption according to study group (times per week) (p<0.001) 
   165 
 
Figure 3.4: Change in total fish consumption according to study group (times per week) (p<0.001) 
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3.3.2  Nutrient intakes based on FFQ 
 
Table 3.14 describes the between group comparisons for total dietary intake of nutrients 
derived from the FFQ at baseline (20 weeks gestation) and during intervention (34 weeks 
gestation). At baseline the only differences noted were the significantly higher intake of 
EPA, DHA, and EPA plus DHA in the salmon group (all p<0.001). During intervention 
intakes  of  EPA,  DHA,  EPA  plus  DHA  were  significantly  higher  in  the  salmon  group 
compared to the control group (all p<0.001). It must be noted that the determination of 
EPA and DHA intakes from the FFQ is not accurate, and these must be considered to be 
crude estimates. Since fish are a major source of LC n-3 PUFAs (none of the subjects 
consumed fish oil supplements), the intake of those nutrients from the fish categories was 
explored as described in Table 3.15, Table 3.16, Table 3.17, Table 3.18, Table 3.19 and 
Table 3.20. At 34 weeks gestation (but not at baseline), the intake of LC n-3 PUFAs was 
higher in the salmon group (p<0.001). Also at 34 weeks there were a number of significant 
differences in intake of specific micronutrients between the two groups. Specifically, the 
salmon group had a higher intake of vitamin B12, selenium, and vitamin D than the control 
group (Table 3.14).  
 
Table 3.14: Between group comparisons of daily intake of selected nutrients from total diet calculated 
from FFQ at 20 weeks and 34 weeks gestation  
 
Nutrient 




group  p  Control 
group 
Salmon 
group  p 
Energy (Kcal)
 1  2231 (ﾱ671)  2169 (ﾱ569)  0.583  2229 (ﾱ543)  2184 (ﾱ533)  0.668 
Energy (KJ)
 1  9393 (ﾱ2822)  9133 (ﾱ2393)  0.582  9388 (ﾱ2289)  9197 (ﾱ2240)  0.661 
Carbohydrates (g)
 1  297 (ﾱ94)  279 (ﾱ79)  0.260  297 (ﾱ82)  280 (ﾱ77)  0.276 
Protein (g)
1  81 (ﾱ24)  80 (ﾱ21)  0.968  80 (ﾱ22)  81 (ﾱ19)  0.948 
Total fat (g)
 1  88 (ﾱ29)  89 (ﾱ26)  0.905  88 (ﾱ24)  90 (ﾱ24)  0.635 
SFA (g)
 1  34 (ﾱ13)  34 (ﾱ12)  0.810  34 (ﾱ10)  35 (ﾱ11)  0.604 
MUFA (g)
 1  31 (ﾱ10)  32 (ﾱ9)  0.573  32 (ﾱ9)  33 (ﾱ8)  0.514 
PUFA (g)
 1  15.5 (ﾱ5.7)  15.5 (ﾱ4.7)  0.994  15.6 (ﾱ4.9)  15.3 (ﾱ4.7)  0.730 
Total n-3 PUFAs (g)
1  1.8 (ﾱ0.6)  1.9 (ﾱ0.5)  0.900  1.9 (ﾱ0.6)  2.5 (ﾱ0.5)  <0.001 
Total n-6 PUFAs (g)
1  13.5 (ﾱ5.1)  13.4 (ﾱ4.3)  0.902  13.6 (ﾱ4.4)  12.9 (ﾱ4.3)  0.445 
Dietary fibre (g) (Englyst 
method)
1 
17.5 (ﾱ5.7)  17.8 (ﾱ5.9)  0.730  16.2 (ﾱ4.8)  17.4 (ﾱ5.4)  0.215 
Sodium (g)
 1  3212 (ﾱ906)  3110 (ﾱ804)  0.508  3057 (ﾱ768)  2989 (ﾱ868)  0.669 
Potassium (g)
 1  3470 (ﾱ1002)  3526 (ﾱ1051)  0.762  3439 (ﾱ926)  3530 (ﾱ895)  0.604 
Calcium (mg)
 2  1135 (ﾱ432)  1167 (ﾱ517)  0.711  1199 (ﾱ429)  1200 (ﾱ404)  0.990   167 
 
Magnesium (mg)
 2  348 (ﾱ105)  355 (ﾱ101)  0.722  342 (ﾱ102)  355 (ﾱ96)  0.475 
Phosphorus mg)
 2  1485 (ﾱ452)  1504 (ﾱ469)  0.816  1514 (ﾱ428)  1534 (ﾱ391)  0.797 
Zinc (mg)
 2  12.8 (ﾱ5.5)  12.8 (ﾱ5.6)  0.942  12 (ﾱ5.4)  12.3 (ﾱ5.4)  0.796 
Retinol (μg)




361 (ﾱ200)  357 (ﾱ190)  0.915  355 (ﾱ168)  327 (ﾱ132)  0.334 
Carotene (μg)
 2  3120 (ﾱ1254)  3230 (ﾱ1432)  0.650  2847 (ﾱ1195)  3008 (ﾱ1216)  0.486 
Thiamin (B1) (mg)
 2  2.49 (ﾱ1.18)  2.43 (ﾱ1.05)  0.789  2.23 (ﾱ1.08)  2.29 (ﾱ1.05)  0.768 
Riboflavin (B2) 
(mg)
2  2.64 (ﾱ1.13)  2.68 (ﾱ1.08)  0.861  2.64 (ﾱ1.13)  2.68 (ﾱ0.96)  0.821 
Niacin (mg)
 2  25.5 (ﾱ10.8)  26.2 (ﾱ9)  0.685  24.8 (ﾱ10.5)  26 (ﾱ10.6)  0.554 
Vitamin B6 (mg)
 2  3.96 (ﾱ2.92)  4.02 (ﾱ2.98)  0.913  3.50 (ﾱ2.72)  3.74 (ﾱ2.73)  0.649 
Vitamin B12 (μg)
 2  5.84 (ﾱ2.44)  5.94 (ﾱ2.46)  0.823  5.91 (ﾱ2.65)  7.15 (ﾱ2.17)  0.009 
Folate (μg)
 2  564.9 (ﾱ591)  556 (ﾱ632)  0.935  399 (ﾱ199)  409 (ﾱ197)  0.784 
Vitamin C (mg)
 2  164 (ﾱ80)  173 (ﾱ82)  0.508  177 (ﾱ160)  179 (ﾱ106)  0.902 
Selenium (μg)
 2  52.4 (ﾱ20.4)  56.4 (ﾱ16.8)  0.244  49.0 (ﾱ17.0)  58.2 (ﾱ16.7)  0.005 
Vitamin E (mg)




25.8)  15.4 (12.1, 24.3)  0.495  20.3 (11.0, 30.9)  15.5 (11.2, 27.2)  0.641 
Vitamin D (μg)
 3  4.1 (2.5, 10.1)  3.6 (2.8, 9.9)  0.590  2.9 (2.0, 12.4)  5.8 (5, 9.5)  <0.001 
EPA (mg)
 3  17.6 (5.1, 36.3)  42.6 (23.8, 66.7)  <0.001  11.9 (3, 34.8)  133.7 (127.7, 
145.9)  <0.001 
DHA (mg)
 3  29.4 (9.1, 65.3)  77.6 (45.6, 
121.9)  <0.001  19.7 (6.2, 67)  269 (260.7, 
298.1)  <0.001 
Total EPA+DHA 
(mg)
 3  46.4 (13.7, 100)  124.6 (69.4, 
184.7)  <0.001  30.1 (9.1, 103)  402.6 (309.0, 
444)  <0.001 
1 Nutrient intake only from diet (supplements did not contribute to the intake of these nutrients). Values are 
mean (ﾱstandard deviation), independent samples t-test p-values 
2 Nutrient for which supplements contributed to intake (diet plus supplement intake). Values are mean 
(ﾱstandard deviation), independent samples t-test p-values 
3 Nutrient for which supplements contributed to intake (diet plus supplement intake). Values are medians 
(interquartile range), Mann Witney test p-values 
Note: EPA and DHA: the FFQ cannot provide reliable data on intake from the whole diet (incomplete values 
for some foods); Selenium: values completed for all foods in the FFQ - however data are limited as the 
content of foods varies widely and depends on soil content of the region. 
 
 
Table 3.15 to Table 3.20 show the daily intake of seven nutrients of interest (EPA, DHA, 
total  n-3  PUFAs,  total  n-6  PUFAs,  selenium,  vitamins  D  and  E)  from  non-oily,  oily 
(including study salmon) and total fish (including oily, non-oily, shellfish and fish dishes), 
compared between and within groups for each fish category, at baseline (20 weeks) and 
during intervention (34 weeks). Table 3.15 and Table 3.16 show the daily intake of these 
seven nutrients from non-oily fish, before and after intervention. At 20 weeks, pregnant 
women in the salmon group had a higher intake of all the seven nutrients from white fish 
(p=0.005) compared to  the pregnant  women in the control  group, revealing a baseline 
difference between the two groups. This was not apparent at 34 weeks (p=0.204). For the 
within groups comparison (Table 3.16), the effect of the intervention is obvious as the 
salmon group showed a significant difference for all the seven nutrients from the white fish 
(for all nutrients p=0.014). There is no such difference within the control group (p=0.736).   168 
 
Table 3.15: Between group comparisons of daily nutrient intakes from non-oily (white) fish according 
to the FFQ 
 
Nutrient 
20 weeks gestation  34 weeks gestation 
Control group  Salmon group  p  Control group  Salmon group  p 
Total n-3 PUFAs 
(mg) 
22.9 (22.9, 45.9)  45.9 (22.9, 137.6) 
0.005 
22.9 (6.9, 137.6)  45.9 (22.9, 137.6) 
0.204 
Total n-6 PUFAs 
(mg) 
36 (36, 72)  72 (36, 216)  36 (10.8, 216)  72 (36, 216) 
EPA (mg)  4 (4, 7.9)  7.9 (4, 23.8)  4 (1.2, 23.8)  7.9 (4, 23.8) 
DHA (mg)  8.3 (8.3, 16.5)  16.5 (8.3, 49.5)  8.3 (2.5, 49.5)  16.5 (8.3, 49.5) 
Selenium (μg)  2.79 (2.79, 5.57)  5.57 (2.79, 16.71)  2.79 (0.84, 16.71)  5.57 (2.79, 16.71) 




0.071 ( 0.021, 
0.424)  0.141 (0.071, 0.424) 






0.267)  0.089 (0.044, 0.267) 
Values are medians (interquartile range), Mann Witney test p-values 
 
Table 3.16: Within group comparisons of daily nutrient intakes from non-oily (white) fish according to 
the FFQ  
 
Nutrient 
Control group (n=55) 
 
Salmon group (n=54) 
 
20 weeks  34 weeks  p  20 weeks  34 weeks  p 
Total n-3 PUFAs 
(mg)  22.9 (22.9, 45.9)  22.9 (6.9, 137.6) 
0.736 
45.9 (22.9, 137.6)  45.9 (22.9, 137.6) 
0.014 
 
Total n-6 PUFAs 
(mg)  36 (36, 72)  36 (10.8, 216)  72 (36, 216)  72 (36, 216) 
EPA (mg)  4 (4, 7.9)  4 (1.2, 23.8)  7.9 (4, 23.8)  7.9 (4, 23.8) 
DHA (mg)  8.3 (8.3, 16.5)  8.3 (2.5, 49.5)  16.5 (8.3, 49.5)  16.5 (8.3, 49.5) 
Selenium (μg)  2.79 (2.79, 5.57)  2.79 (0.84, 
16.71)  5.57 (2.79, 16.71)  5.57 (2.79, 16.71) 
Vitamin D (μg)  0.071 (0.071, 
0.141) 














Values are medians (interquartile range), Wilcoxon test p-values 
 
 
Table 3.17 and Table 3.18 show the daily intake of those seven nutrients from oily fish, 
including  study  salmon,  at  20  and  34  week  of  pregnancy.  At  both  20  and  34  weeks 
pregnant women in the salmon group had a higher intake of all the seven nutrients (all 
p<0.001) in comparison to the control group. For the within groups comparison, the effect 
of the intervention is obvious for the salmon group, as expected, and in the control group 
as well. There is a significant difference within the salmon group for intake of all the seven 
nutrients from oily fish (for all p<0.001), and also within the control group (p=0.025).   169 
 
Table 3.17: Between group comparisons of daily nutrient intakes from oily fish
* according to the FFQ 
 
Nutrient  20 weeks gestation  34 weeks gestation 
  Control group  Salmon group  p  Control group  Salmon group  p 
Total n-3 PUFAs 
(mg) 
0 (0, 106)  106 (0, 213) 
<0.001 
0 (0, 58)  763 (763, 763) 
<0.001 
Total n-6 PUFAs 
(mg) 
0 (0, 21.3)  21.3 (0, 42.5)  0 (0, 11.7)  495 (495, 495) 
EPA (mg)  0 (0, 26.4)  26.4 (0, 52.9)  0 (0, 14.5)  122 (122, 122) 
DHA (mg)  0 (0, 48.4)  48.4 (0, 96.8)  0 (0, 26.6)  249 (249, 249) 
EPA+DHA from 
oily fish (mg)  0 (0, 74.8)  74.8 (0, 149.6)  0 (0, 41.2)  371 (371, 371) 
Selenium (μg)  0 (0, 1.36)  1.36 (0, 2.71)  0 (0, 0.75)  9.21 (9.21, 9.21) 
Vitamin D (μg)  0 (0, 0.482)  0.482 (0, 
0.964)  0 (0, 0.265)  3 (3, 3) 
Vitamin E (mg)  0 (0, 0.053)  0.053 (0, 
0.106)  0 (0, 0.029)  0.879 (0.879, 
0.879) 
*Including study salmon. When consumption was 2 times/week, it was recorded in the FFQ category „1-2 
times/week‟ which was interpreted as „1.5 times/week‟ for nutrient calculations. 
Values are medians (interquartile range), Mann Witney test p-values 
 
Table 3.18: Within group comparisons of daily nutrient intakes from oily fish
* according to the FFQ 
 
Nutrient 
Control group (n=55) 
 
Salmon group (n=54) 
 
20 weeks  34 weeks  p  20 weeks  34 weeks  p 
Total n-3 PUFAs 
(mg)  0 (0, 106.3)  0 (0, 58.4) 
0.025 
106 (0, 213)  763 (763, 763) 
<0.001 
Total n-6 PUFAs 
(mg)  0 (0, 21.3)  0 (0, 11.7)  21.3 (0, 42.5)  495 (495, 495) 
EPA (mg)  0 (0, 26.4)  0 (0, 14.5)  26.4 (0, 52.9)  122 (122, 122) 
DHA (mg)  0 (0, 48.4)  0 (0, 26.6)  48.4 (0, 96.8)  249 (249, 249) 
EPA+DHA from 
oily fish (mg) 
0 (0, 74.8)  0 (0, 41.2)  74.8 (0, 149.6)  371 (371, 371) 
Selenium (μg)  0 (0, 1.36)  0 (0, 0.75)  1.36 (0, 2.71)  9.21 (9.21, 9.21) 
Vitamin D (μg)  0 (0, 0.482)  0 (0, 0.265)  0.482 (0, 0.964)  3 (3, 3) 
Vitamin E (mg)  0 (0, 0.053)  0 (0, 0.029)  0.053 (0, 0.106)  0.879 (0.879, 
0.879) 
*Including study salmon. When consumption was 2 times/week, it was recorded in the FFQ category „1-2 
times/week‟ which was interpreted as „1.5 times/week‟ for nutrient calculations. 
Values are medians (interquartile range), Wilcoxon test p-values 
 
The same pattern occurred for nutrient intake from all (i.e. total) fish (Table 3.19, Table 
3.20). At 20 weeks gestation, pregnant women in the salmon group had a higher intake of 
all these nutrients from total fish, compared to the control (p≤0.001). This result reveals a 
baseline difference between the 2 groups. The intakes of all seven nutrients of interest from 
total  fish,  were  higher  in  the  salmon  group  compared  with  the  control  at  34  weeks 
(p<0.001). Within each group (Table 3.20), the salmon group had a higher intake of all 
seven nutrients during intervention (all p<0.001), whereas the control group‟s daily intake 
of those nutrients did not change significantly  (p>0.2). As it shown in Figure 3.5, the   170 
median  daily  intake  of  LC  n-3  PUFAs  for  the  salmon  group  from  total  fish  during 
intervention at 34 weeks, was 133 mg EPA, 267 mg DHA, and 402 mg EPA plus DHA, 
according to FFQ fish consumption frequencies. 
 
Table 3.19: Between group comparisons of daily nutrient intakes from total fish
* according to the FFQ 
 
Nutrient 
20 weeks gestation  34 weeks gestation 
Control group  Salmon group  p  Control group  Salmon group  p 





















EPA (mg)  17.6 (4.6, 36.3)  42.6 (23.8, 
66.2)  <0.001  11.9 (3, 34.4)  133.3 (127.7, 
145.9) 
DHA (mg)  29.4 (8.9, 65.3)  74.5 (45.6, 
117.7)  <0.001  19.7 (5.1, 63)  267.2 (259, 
298.1) 
EPA+DHA from 















Vitamin D (μg)  0.141 (0.071, 
0.617) 
0.624 (0.374, 













*Total fish including non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. 
Values are medians (interquartile range), Mann Witney test p-values 
 
Table 3.20: Within group comparisons of daily nutrient intake from total fish
* according to the FFQ 
 
Nutrient 
Control group (n=55)  Salmon group (n=54) 
20 weeks  34 weeks  p *  20 weeks  34 weeks  p * 
Total n-3 PUFAs 
(mg) 






Total n-6 PUFAs 
(mg) 
90.8 (47.4, 252.9)  91.5 (18.6, 237.7)  0.582  219.3 (105, 271.6)  600.6 (551, 710) 
EPA (mg)  17.6 (4.6, 36.3)  11.9 (3, 34.4)  0.262  42.6 (23.8, 66.2)  133.3 (127.7, 
145.9) 
DHA (mg)  29.4 (8.9, 65.3)  19.7 (5.1, 63)  0.334  74.5 (45.6, 117.7)  267.2 (259, 298.1) 
EPA+DHA from 
total fish (mg) 
46.4 (13.7, 100)  30.1 (8.1, 96.7)  0.322  118 (69.4, 182.7)  402.6 (386.7, 444) 
Selenium (μg)  5.87 (2.79, 12.83)  5.46 (1.75, 17.42)  0.761  10.71 (6.3, 19.43)  15.54 (12.75, 
25.93) 








*Total fish including non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. 
Values are medians (interquartile range), Wilcoxon test p-values   171 
Because the two groups had a significantly different baseline intake of the seven nutrients 
of interest  from  fish, the change in  daily intake of these nutrients  from  total  fish was 
calculated (Table 3.21). The mean daily intake of EPA plus DHA from total fish increased 
by 269 mg in the salmon group and decreased by 12 mg in the control group (p<0.001). 
Also the change of intakes of EPA, DHA, total n-3 PUFAs, total n-6 PUFAs, selenium, 
vitamin D and vitamin E from total fish were different between groups (all p<0.001 apart 
from selenium p=0.011). 
 
Table 3.21: Changes in daily nutrient intakes from total fish
* according to the FFQ 
 
Nutrient  Change in intake: 34-20 weeks gestation 
  Control group  Salmon group  p 
Total n-3 PUFAs (mg)  -16.5 (120.6)  611.8 (110.6)  <0.001 
Total n-6 PUFAs (mg)  0.2 (145.0)  420.0 (119.8)  <0.001 
EPA (mg)  -4.8 (25.4)  86.5 (26.7)  <0.001 
DHA (mg)  -7.5 (47.7)  182.8 (49.0)  <0.001 
EPA+DHA(mg)  -12.2 (72.8)  269.3 (75.6)  <0.001 
Selenium (μg)  -0.18 (10.92)  4.53 (7.86)  0.011 
Vitamin D (μg)  -0.07 (0.44)  2.37 (0.45)  <0.001 
Vitamin E (mg)  -0.01 (0.19)  0.77 (0.12)  <0.001 
*Total fish including non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. 







Figure 3.5: Daily intake of a) EPA, b) DHA and c) EPA plus DHA from total fish at 20 and 34 weeks 
gestation according to the FFQ 
p≤0.002 between groups (Mann-Whitney test) 
a 
b 
c   173 
 
3.3.3  Consumption frequencies and nutrient intakes based on fish 
diaries  
 
The results presented represent a subset of the data, as not all of the subjects returned 
completed  fish  diaries,  although  the  majority  did  (salmon  group  n=49;  control  group 
n=47). The weekly consumption of study salmon by the salmon group during weeks 21 to 
38 of pregnancy is shown in Figure 3.6.  
 
 
Figure 3.6: Weekly consumption of study salmon by the salmon group throughout pregnancy 
 
 
Figure 3.7 describes the weekly consumption of non oily, oily and total fish in both groups 
during the intervention period. 
 








a   175 
 
Table 3.22 summarises the mean weekly consumption frequency of study salmon and other 
fish categories (similar to the FFQ categorisation) consumed by the two groups during 
intervention (21 to 38 weeks of gestation). According to the fish diaries, the salmon group 
was consuming 1.94 portions of study salmon per week whereas the control group was 
consuming 0 portions of oily fish per week (p<0.001). The salmon group was consuming 
fewer  portions  of  white  fish  than  the  control  group  (0.17  and  0.33  portions  per  week 
respectively, p=0.036). Therefore, total fish consumption was higher in the salmon group 
(2.11 portions  per week) in  comparison  to  the  control  group (0.47 portions  per week) 
(p<0.001).  
 
Figure 3.8 shows the mean weekly consumption of study salmon in the salmon group 
during intervention, which was 1.94 portions per week.  
 
Table 3.22: Between group comparison of mean weekly consumption frequencies of fish categories as 
recorded in the fish diaries (data on 21-38 weeks gestation) 
 
Fish category 
21 to 38 weeks gestation 
Control group (n=47)  Salmon group (n=49)  p 
Study salmon  0 (0, 0)  1.94 (1.83, 2.00)  <0.001 
White fish  0.33 (0.06, 0.56)  0.17 (0.06, 0.33)  0.036 
Oily fish
*  0 (0, 0.07)  1.94 (1.87, 2.00)  <0.001 
Fish fingers and fish dishes  0 (0, 0.11)  0 (0, 0)  0.002 
Shellfish  0 (0, 0)  0 (0, 0)  0.507 
Total fish
**  0.47 (0.17, 0.8)  2.11 (2, 2.35)  <0.001 
*Including study salmon 
**Total fish including non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. 




Figure 3.8: Mean weekly consumption of study salmon by the salmon group during the 21
st-38
th week 
of pregnancy (p<0.001 between groups (Mann Whitney test))   176 
 
Table  3.23,  Table  3.24  and  Table  3.25  show  the  daily  nutrient  intakes  of  the  seven 
nutrients of interest from non-oily, oily and total fish for both groups during intervention, 
based upon the information recorded in the fish diaries. The salmon group had a lower 
intake of those nutrients from white fish in comparison to the control group (p=0.036) 
(Table 3.23). In contrast, the intake of the seven nutrients from oily fish (including study 
salmon) and total fish was higher in the salmon group compared to the control (for both 
oily and total fish p<0.001) (Table 3.24, Table 3.25). From total fish, the daily intake of 
EPA, DHA, and EPA plus DHA was 162 mg, 326 mg, and 490 mg for the salmon group 
and 10 mg, 16 mg, 24 mg for the control group, respectively. 
 
 
Table 3.23: Between group comparisons of mean daily nutrient intake from non-oily (white) fish as 
recorded in the fish diaries 
 
Nutrient 
21 to 38 weeks gestation 
Control group (n=47)  Salmon group (n=49)  p 
EPA (mg)  5.2 (0.9, 8.7)  2.6 (0.9, 5.2) 
0.036 
DHA (mg)  11.0 (1.8, 18.3)  5.5 (1.8, 11) 
Total n-3 PUFAs (mg)  30.6 (5.1, 51)  15.3 (5.1, 30.6) 
Total n-6 PUFAs (mg)  48 (8, 80)  24 (8, 48) 
Selenium (μg)  3.71 (0.62, 6.19)  1.86 (0.62, 3.7) 
Vitamin D (μg)  0.094 (0.016, 0.157)  0.047 (0.016, 0.094) 
Vitamin E (mg)  0.056 (0, 0.01)  0.03 (0.01, 0.059) 





Table 3.24: Between group comparisons of mean daily nutrient intake from oily fish
* as recorded in 
the fish diaries 
 
Nutrient 
21 to 38 weeks gestation 
Control group (n=47)  Salmon group (n=49)  p 
EPA (mg)  0 (0, 7.6)  158 (153, 164) 
<0.001 
 
DHA (mg)  0 (0, 14)  322 (311, 333) 
Total n-3 PUFAs (mg)  0 (0, 30.7)  989 (950, 1017) 
Total n-6 PUFAs (mg)  0 (0, 6.1)  642 (609, 660) 
Selenium (μg)  0 (0, 0.392)  11.9 (11.5, 12.3) 
Vitamin D (μg)  0 (0, 0.14)  3.89 (3.74, 4) 
Vitamin E (mg)  0 (0, 0.015)  1.14 (1.08, 1.17) 
*Oily fish includes study salmon 
Values are median (interquartile range) nutrient unit/day. Mann Whitney test p-values   177 
 
Table 3.25: Between group comparisons of mean daily nutrient intake from total fish
* as recorded in 
the fish diaries 
 
Nutrient 
21 to 38 weeks gestation 
Control group (n=47)  Salmon group (n=49)  p 
EPA (mg)  10 (4.5, 18.3)  162 (156, 167)  <0.001 
DHA (mg)  16.2 (7.6, 37.2)  326 (318, 339)  <0.001 
Total n-3 PUFAs (mg)  43.4 (23.2, 98.8)  996 (974, 1035)  <0.001 
Total n-6 PUFAs (mg)  60.3 (16.4, 106.9)  660 (642, 691)  <0.001 
Total fish EPA+DHA (mg)  24.4 (12.7, 56.7)  491 (475, 506)  <0.001 
Selenium (μg)  4.33 (1.51, 6.96)  13.49 (12.27, 15.73)  <0.001 
Vitamin D (μg)  0.123 (0.047, 0.311)  3.9 (3.8, 4.1)  <0.001 
Vitamin E (mg)  0.069 (0.023, 0.130)  1.16 (1.13, 1.19)  <0.001 
*Total fish includes non-oily fish, oily fish (and study salmon), fish fingers and fish dishes, shellfish. 
Values are median (interquartile range) nutrient unit/day. Mann Whitney test p-values 
 
 
Figure 3.9 and Figure 3.10 describe the daily intake (for each week of pregnancy) and 
mean daily intake (for all pregnancy weeks) respectively of EPA, DHA and EPA plus 
DHA, from non-oily, oily and total fish, in both study groups. 
 
Finally  Figure  3.11  represents  the  compliance  of  the  salmon  group  to  consuming  two 
portions of study salmon weekly. The fish diaries data subset showed that 79.6% of the 
volunteers in the salmon group were having two or more portions of study salmon per 
week  for  81.25%  of  the  weeks  during  intervention.  The  data  used  covers  the  period 
between 21 to 38 weeks of pregnancy. Also 24.5% of the volunteers in the salmon group 
had two or more portions per week of study salmon every week from gestation week 21 to 
38. So, the salmon group complied well with consuming the salmon as requested for the 
intervention (2 portions per week).   178 
 
 
Figure 3.9: Daily intake of a) EPA, b) DHA, c) EPA plus DHA, from total fish during the 21
st-38
th week 









Figure 3.10: Daily intake of a) EPA, b) DHA, c) EPA plus DHA, from total fish during the 21
st-38
th 








Figure 3.11: Compliance of the salmon group to consume ≥ 2 portions of study salmon from gestation 
week 21 to 38 
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3.4  Discussion 
SIPS is an intervention study with oily fish in pregnant women. It is the first such study to 
be conducted. The intervention took women who did not normally eat oily fish up to the 
maximum level of consumption recommended by the UK government (two portions per 
week). According to information available from self-reporting fish diaries, the oily fish 
intervention was successful and compliance was high in both control and salmon groups. 
The  primary  hypotheses  of  the  work  presented  in  this  chapter  were  that  the  oily  fish 
intervention  will:  a)  increase  oily  fish  consumption  from  a  habitually  low  intake  (≤  2 
portions/month) to the recommended maximum level of intake (two portions/week) during 
pregnancy, in women whose offspring is at a high risk of developing atopic disease; and b) 
increase maternal  LC n-3 PUFA intake during pregnancy, and that  this  intake will be 
higher in the salmon than in the control group. According to the results presented these 
hypotheses can be accepted.  
The secondary hypotheses of the study were that the oily fish intervention will: a) change 
the dietary patterns for the salmon group; and b) increase the maternal intake of vitamin D 
and selenium, and that their intakes will be higher in the salmon than in the control group. 
According to the results presented these hypotheses can be accepted. 
Thus, if women who do not normally consume much oily fish, increase their consumption 
to twice per week, in accordance with current UK recommendations, they will increase 
their intake of LC n-3 PUFAs, selenium and vitamin D. 
 
Information gathered from the FFQs indicates that subjects in the salmon group complied 
to  the  intervention  and  at  34  weeks  women  in  that  group  were  all  eating  salmon 
corresponding to the category 1-2 times per week; this is consistent with information from 
the fish diaries that show that the women were eating 1.94 portions of study salmon per 
week during pregnancy (weeks 21 to 38 of gestation) indicating that women in this group 
were eating about 2 portions of salmon per week.  
 
It is of importance to note that the FFQ most likely underestimates the intake of salmon, 
since an intake of 2 portions per week falls into the FFQ category 1-2 times per week, for 
which the multiplication factor for all calculations was 1.5. This is a limitation of the FFQ 
as a dietary assessment method, because it has an ordinal scale of consumption frequency   182 
categories, rather than a scale providing a true measure. So, according to the FFQs at 34 
weeks the salmon group consumed oily fish 1.5 times per week during the 22
nd to 34
th 
week of  gestation, whereas  according to  fish  diaries  the salmon  group  consumed 1.94 
portions per week from week 21 to 38 of gestation. This shows that the fish diaries were 
important not only to assess and demonstrate compliance to the intervention but also as a 
precise measure of consumption  frequency  and subsequently nutrient  intake as  will be 
discussed further later on. The use of the diaries can be considered as a strength of SIPS. 
 
Moreover, the FFQs suggested that the control group was keeping its consumption of oily 
fish at low levels, with the majority eating oily fish „never‟ or „once per month‟. Again this 
is consistent with information from the fish diaries, which show that the control group had 
0 (median) weekly consumption frequency. 
 
From  between  group  comparisons  of  consumption  frequencies  of  FFQ  fish  groups,  at 
baseline (20 weeks gestation), there was a higher consumption of total fish in the salmon 
group (1.75 times/week) in comparison to the control group (0.75 times/week). This is an 
existing baseline difference between the two groups, which cannot be explained. When 
looking at the weekly frequencies of fish consumption according to the four fish categories 
of  the  FFQ,  at  study  entry  the  salmon  group  had  higher  oily  fish  consumption  (0.25 
times/week equal to twice per month vs. 0 times/week) as well as white fish consumption 
(0.5 times/week vs. 0.25 times/week) than the control group. There is no baseline data 
from  the  fish  diaries,  as  the  subjects  started  completing  them  at  the  beginning  of  the 
intervention. In this way, the fish diaries can only offer dietary information during the 
study period, and not prior to it, whereas the FFQs provide dietary data for the 3 months 
prior to the FFQ administration. This is considered as an advantage of the FFQ, reflecting 
the consumption frequency over a long period of time in the past. 
 
Another advantage of the FFQ is that it is validated on the Southampton population for use 
in pregnant women (228) and it includes distinct fish categories. The FFQ method has also 
been  used  in  large  epidemiological  studies  testing  similar  hypotheses  to  SIPS  i.e.  the 
maternal fish intake during pregnancy in relation to infant atopic outcomes (203), a fact 
enhancing the choice of FFQ as the main dietary assessment method in SIPS. 
 
Between groups, during intervention (i.e. at 34 weeks) there was a higher consumption 
frequency of total fish in the salmon group compared to the control (2.35 times/week vs. 
0.75 times/week), as expected, since this period is reflecting the intervention period (22   183 
until 34 weeks of gestation). Breaking down the total fish frequency of consumption into 
the  four  fish  FFQ  categories,  only  oily  fish  consumption  (mainly  study  salmon  in  the 
salmon  group)  was  significantly  increased  in  the  salmon  group  to  1.5  times/week 
compared to the control group of which the weekly consumption frequency remained 0. 
However,  the  fish  diaries  showed  that  the  salmon  group  increased  total  and  oily  fish 
consumption  (agreement  with  FFQ  data)  but  also  the  salmon  group  had  a  lower 
consumption frequency of white fish and fish fingers/fish dishes (FFFD), compared to the 
control group. These latter observations were not revealed from the FFQ data. This could 
mean that because of the categorisation of the consumption frequencies the FFQ is not very 
sensitive in picking up such differences. Overall, from the fish diaries, the salmon group 
was consuming more than 2 portions of oily fish per week and the control group was eating 
less than 1 portion of total fish per week during pregnancy. 
 
The  FFQ  identified  that  white  fish  consumption  decreased  in  the  salmon  group,  most 
probably because the salmon replaced some white fish in the diet. Furthermore, red meat 
consumption decreased in the salmon group, probably identifying its replacement by study 
salmon. The within group comparisons also revealed that in the salmon group, chicken and 
turkey consumption decreased. Thus, salmon appears to be incorporated into the diet by 
partly replacing white fish, red meat, chicken and turkey. 
 
The  average  total  fish  consumption  frequency  and  portion  of  total  fish  consumed  at 
baseline was for the control group 0.75 times/week x 140 g/portion = 105 g/week and per 
day the total fish consumed was 105/7 = 15 g/day. For the salmon group the quantity of 
total fish consumed at baseline was 1.75 times/week x 140 g/portion = 245 g/week and per 
day the quantity of total fish consumed was 245/7 = 35 g/d. The SIPS salmon group total 
fish intake (35 g/day) is very close to the intake reported at the latest NDNS (200) intake of 
total fish (33 g/day), but the control group has a much lower intake (15 g/day), being less 
than half of the average reported in the NDNS (200). This reveals that both groups are 
habitually low consumers of seafood. 
 
Overall, from the changes calculated in fish and meat weekly consumption frequencies, it 
is obvious that the oily fish and total fish consumption frequencies were increased in the 
salmon group (1.21 times/week and 0.85 times/week, respectively), whereas they dropped 
slightly in the control group (0.04 times/week and 0.05 times/week, respectively). 
 
   184 
Regarding nutrient intakes, FFQs might not be the ideal tool to investigate nutrient-disease 
associations  (222).  However,  the  SWS  FFQ  used  by  SIPS  has  been  validated  for 
calculating nutrients compared to a 4 day prospective food diary (222). In accordance with 
the decrease in oily fish consumption frequency in the control group, the intake of the 
seven nutrients of interest obtained from oily fish (EPA, DHA, n-3 PUFAs, n-6 PUFAs, 
Se, vitamin D and vitamin E) decreased in that group at 34 weeks. However, within the 
salmon  group,  intake  of  each  of  these  nutrients,  increased  significantly  (within  group 
comparisons) not only from oily fish but also from non-oily and total fish in comparison to 
the control. Nevertheless, in the same way that there was a baseline (i.e. 20 weeks of 
gestation) difference of consumption frequency in non-oily, oily fish and total fish between 
the two study groups, there was a difference in intake of all seven nutrients from non-oily, 
oily and total fish between groups (intakes were higher in the salmon group). However, 
importantly, the intake of all seven nutrients of interest was increased in the salmon group 
during the intervention, although the consumption of salmon twice per week was recorded 
in the FFQ as consumption 1-2 times per week and was interpreted as 1.5 times per week 
for calculations. 
 
Also, a limitation of this FFQ is that it has not been validated to calculate total diet EPA 
and  DHA  intake.  However  the  main  sources  of  EPA  and  DHA  are  fish  and  fish  oil 
supplements or functional foods. The FFQ indicated that no subject was consuming fish oil 
supplements  during  pregnancy  (this  was  an  exlusion  criterion)  and  only  a  minority  of 
subjects was consuming functional foods that contained fish oils. This consumption did not 
differ significantly between the two groups. The calculations of „total diet‟ (Table 3.14) 
EPA and DHA intake were including the functional foods and between the two groups no 
substantial difference was observed in EPA and DHA intake from „total fish‟ (Table 3.19). 
So, it seems that the intake of EPA and DHA from total fish is a good estimation of EPA 
and DHA from total diet. There are recent reviews of the use of FFQs as a validated tool to 
estimate LC n-3 PUFA and micronutrient intake during pregnancy (229;230).  
 
The increase in intake of key nutrients other than LC n-3 PUFAs in the salmon group 
clearly indicates that salmon delivers more than just EPA and DHA and in this respect 
salmon may be superior to supplementation with fish oil capsules. From the calculation 
offered in Table 3.26, it is clear that the minimum UK recommendation for intake of EPA 
and DHA (450 mg/day) can be met, from two portions of study salmon and that the salmon 
can make a major contribution in the intake of vitamin D (40 % of the recommended 
intake) and Se (20 % of the recommended intake).    185 
 
Table 3.26: Calculated contribution of two portions of study salmon to EPA+DHA, vitamin D and Se 


























(23)  > 450 mg  > 3150 mg  1730 mg  3460 mg  109%  < 200mg 
Vitamin D 
1  10 μg  70 μg  14 μg  28 μg  40%  2.7 μg 
3 
Selenium 
2  60 μg  420 μg  43 μg  86 μg  20%  39 μg 
3 
1 Vitamin D Reference Nutrient Intake (RNI) for pregnant and lactating women (231) 
2 Selenium Reference Nutrient Intake (RNI) for 19-50 year old women (231) 
3 According to NDNS 2008/2009 (200) 
 
 
The fish diaries cover most of the intervention period (21-38 weeks of gestation) and the 
nutrient intake results  obtained from  these can be compared to  the results  of the FFQ 
analysis at 34 weeks (during intervention). The intake of all the 7 nutrients from oily and 
total fish was higher in the salmon group, in agreement with the FFQ data. However, the 
fish diaries show a difference for the intake of the seven nutrients from non-oily fish which 
was not seen using the FFQ. This could be another disadvantage of FFQs; they may not be 
able to detect small differences in nutrient intake. In contrast, the fish diaries provided 
detailed information on the quantities and types of fish consumed. Also, as said before, the 
consumption frequencies were not categorised, but measured in an exact and precise way. 
The volunteers had to complete the diaries on a daily basis, so that the recall bias would be 
much less than for the FFQ. However, the fish diaries are not validated, as the FFQs are, 
and  also  they  are  influenced  by  individual  variability  in  the  way  in  which  they  are 
completed (enthusiasm in filling the diaries, psychological/mood fluctuation because of 
pregnancy,  over/under  estimation  of  portion  sizes).  Furthermore,  the  fish  diaries  were 
returned by a subset of subjects while the FFQs were completed by all subjects. 
 
Dietary patterns can be explored using the FFQ data, but the fish diaries are not useful for 
this because they focus only on seafood. However, the feedback from SIPS was that the 
length  and  time  consuming  administration  of  the  FFQ  was  a  burden  for  the  subjects, 
especially at 34 weeks (the second time), since they had already done it at baseline. An 
alternative option, would be the use of a shorter FFQ, more focused on fish consumption 
and LC n-3 PUFA intake, as Crozier et al. have done to summarise the diets of young 
women in Southampton (232). 
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The increased intake of EPA, DHA, and LC n-3 PUFAs in the salmon group at 34 weeks is 
a very important demonstration of SIPS. According to the FFQ, EPA plus DHA intake 
together reached a median of 402 mg/day from total fish in the salmon group and 30 
mg/day  in  the  control  group,  whereas  the  recommendation  for  adults  is  to  consume  a 
minimum of 450 mg /day from the diet (23). According to the fish diaries, which are more 
accurate in this regard, EPA plus DHA intake reached a median of 490 mg/day from total 
fish in the salmon group and 24 mg/day in the control group. The data from the fish diaries 
indicate that almost all of the women in the salmon group were consuming more than the 
minimum recommended amount of EPA plus DHA (450 mg/day) during the intervention.  
Thus SIPS demonstrates for the first time that consuming two portions of oily fish per 
week enables pregnant women to reach the recommended UK minimum intake of EPA 
plus DHA.  
 
There are also specific recommendations for DHA intake by pregnant women to be 200 
mg/day as suggested by Koletzko et al. in 2007 (233). Data from the fish diaries indicates 
median DHA consumption of about 360 mg/day in the salmon group, and further that 
every woman in that group easily met this recommendation. 
 
The finding that eating two portions of farmed salmon per week allows pregnant women to 
achieve recommended intakes for DHA and for LC n-3 PUFAs and to increase their intake 
of  vitamin  D  and  selenium  may  have  health  implications  and  might  contribute  to  the 
reduction of the atopic risk. Since the constraint of eating 2 portions of oily fish per week 
exists because of the contaminants risk, the solution of eating farmed oily fish twice a 
week, might be ideal both for safe consumption of oily fish and for optimal nutrient intake.  
 
There are no studies in the literature of fish intervention during pregnancy. Therefore the 
findings from SIPS cannot be directly compared with similar existing studies. However, it 
is worth noting that there has been considerable recent interest in assessing the effect of 
increased  fish  intake  on  various  health  outcomes  in  adults  including  blood  lipid 
concentrations  (234),  platelet-monocyte  aggregation  (235),  oxidative  stress,  glucose 
metabolism and insulin sensitivity (236), blood pressure (48), markers of colorectal cancer 
risk (237;238) and markers of inflammation (47;48).  
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3.5  Conclusion 
 
SIPS successfully increased oily fish intake in the salmon group to the target of 2 portions 
of study salmon per week. This was reported both in the FFQs and in the fish diaries 
although there were differences in the reporting of the intakes of the seven nutrients of 
interest  (EPA,  DHA,  total  n-3  PUFAs,  total  n-6  PUFAs,  vitamin  D,  vitamin  E  and 
selenium) between the two methods. According to the FFQ (at 34 weeks gestation) all 
women in the salmon group ate salmon 1-2 times per week while according to the fish 
diaries (between 21-38 weeks gestation) the median intake was 1.94 portions (of study 
salmon) per week. According to the FFQ, median daily intake of EPA plus DHA was 403 
mg for the salmon group and 30 mg for the control group. The fish diary results showed 
higher levels of intake for the salmon group (490 mg/day EPA plus DHA) and similar for 
the control group (24 mg/day EPA plus DHA) compared to the FFQ. In addition, increased 
salmon intake increased total diet intake of selenium, vitamin D and total n-3 PUFAs. 
Increased salmon consumption was compensated by decreased consumption of other types 
of seafood (non-oily fish and fish fingers/fish dishes) and of red meat, chichen, and total 
meat. SIPS demonstrated that eating two portions of salmon per week enables pregnant 
women to achieve existing recommendations for intake of DHA and of LC n-3 PUFAs and 
to increase their intake of other key nutrients like vitamin D and selenium. Thus, if women 
who do not normally consume much oily fish, increase their consumption to twice per 
week, in accordance with current UK recommendations, they will increase their intake of 
LC n-3 PUFAs (meeting current recommendations), selenium and vitamin D.   188   189 
 
4  Salmon in pregnancy study (SIPS): the effects of 
pregnancy and salmon intervention on maternal and 
infant fatty acid status    190 
 
4.1  Introduction  
 
A detailed description of fatty acids (terminology, structure, essential fatty acids, dietary 
sources, fatty acid metabolism, and recommendations on intake of long-chain (LC) n-3 
polyunsaturated fatty acids (PUFAs)) was provided in Section 1.1. This chapter describes 
the effects of pregnancy and of the salmon intervention described in Chapter 2 on maternal 
fatty acid status and the effect of the salmon intervention on neonatal fatty acid status. By 
way of introducing this work, the essential fatty acids and the major role that they play in 
fetal development and later infant health status, maternal LC n-3 PUFA provision to the 
fetus and the factors that determine this transfer, and related aspects are described.  
 
4.1.1  Essential fatty acids 
 
Humans  can  synthesize  saturated  and  monounsaturated  fatty  acids,  but  they  cannot 
synthesize the n-3 and the n-6 families of PUFAs. The parent fatty acids of these families, 
alpha-linolenic acid  (18:3n-3, ALA) and linoleic acid  (18:2n-6,  LA) are essential fatty 
acids  and  must  be  present  in  the  diet.  The  fatty  acids  of  these  families  cannot  be 
interconverted, so both n-3 and n-6 fatty acids are essential. ALA and LA are converted to 
longer chain, more highly unsaturated fatty acids through enzymatic chain elongation and 
desaturation.  ALA  is  converted  to  eicosapentaenoic  acid  (20:5n-3,  EPA),  then  on  to 
docosahexaenoic  acid  (22:6n-3,  DHA),  whereas  LA  is  converted  to  arachidonic  acid 
(20:4n-6, ARA). DHA is a critical component of cell membranes, especially in the brain 
and the retina. ARA is both a membrane component and a precursor to potent signaling 
molecules,  the  prostaglandins,  leukotrienes,  thromboxanes.  The  chain 
elongation/desaturation  enzymes  are  shared  by  both  n-3  and  n-6  fatty  acids  with 
competition  between  substrates  for  these  enzymes  (239).  More  detailed  information  is 
provided in section 1.1.5. 
 
4.1.2  Fetal and infant LC PUFA accumulation and health 
 
The supply of essential fatty acids and LC PUFAs is critical and central to the synthesis of 
structural  lipids  and  hence,  to  normal  development  of  the  fetus  (10;34;240).  Brain 
accumulation of DHA starts in utero, with quantitatively marked deposition in the second 
half of gestation. DHA accumulation in the brain continues after birth, total brain DHA 
deposition reaching about 4 g between two and four years of age (34). DHA is also an   191 
important structural component of retina lipids, comprising as much as 50% of total fatty 
acids  of  rod  and  cone  outer  segments  (241;242).  Unlike  DHA,  other  LC  n-3  PUFAs, 
including EPA, do not accumulate to any appreciable extent in the growing brain and eye. 
However, brain accumulation of the n-6 PUFA ARA also occurs during pre- and post-natal 
development. Elongation and desaturation enzymes for PUFA conversion are present in the 
fetal  liver  early  in  gestation,  but  activity  appears  to  be  low  before  birth  (242;243). 
Therefore, the LC PUFAs that the fetus accumulates in utero are derived predominantly 
from the mother through placental transfer, with the amounts in cord blood influenced by 
the maternal diet (177). Both preterm and term infants are capable of synthesizing DHA 
and ARA (244); conversion rates of LA to ARA and of ALA to EPA and on to DHA are 
influenced  by  hormones,  genetics,  gender,  and  the  amount  of  precursor  fatty  acids 
available in the diet (10;245). Human milk always contains both ARA and DHA (246). In 
the past infant formulae did not contain these fatty acids. Synthesis rates of LC PUFAs 
from their essential precursors are insufficient to maintain stable plasma and red blood cell 
LC  PUFA  levels  in  infants  receiving  unsupplemented  formula,  and  LC  PUFA  levels 
decline in infants fed unsupplemented formula compared to those fed human milk (242).  
 
Animal experiments indicate that a lack of n-3 PUFAs in the diet results in poor visual 
development and in learning and behavioural abnormalities (18). There is also evidence 
that  preterm  infants,  in  whom  this  early  supply  is  interrupted,  have  poorer  visual  and 
cognitive development than term infants, although the provision of breast milk or DHA-
supplemented formulas improves these outcomes (10;34;247). 
 
A recent international consensus statement proposed an average DHA intake of at least 200 
mg/day during both pregnancy and lactation to support infant growth and developmental 
outcomes (233;242) Women of child bearing age can meet the recommended intake of 
DHA by consuming one to two portions of fish per week, including oily fish, which is a 
good source of LC n-3 PUFAs; this was confirmed by the findings presented in Chapter 3. 
Consumption of this amount of fish does not generally exceed the tolerable intake levels of 
environmental contaminants. Other sources of LC n-3 PUFAs include enriched foods and 
dietary  supplements.  Dietary  ALA,  the  precursor  to  DHA,  is  much  less  effective  in 
promoting optimal DHA status than consumption of preformed DHA and is insufficient to 
promote desirable levels of DHA deposition in the fetal brain (233). A number of studies 
have also demonstrated that intake of fish or fish oils during pregnancy results in slightly 
longer  gestation,  marginally  higher  birth  weight,  and  reduced  risk  of  preterm  delivery 
(38;39;248), creating an even higher demand for maternal LC PUFAs (249).    192 
 
LC  n-3  PUFAs  have  also  been  shown  to  influence  immune  function  and  it  is  now 
considered that supply of EPA and DHA to the fetus might be important for appropriate 
immune development (48;131). This has been studied mainly in regard to the potential to 
reduce the risk of developing atopic disease in  infancy and children  (35;132;180;181). 
There is evidence from epidemiological studies that maternal intake of fish or fish oils 
during  pregnancy  is  associated  with  reduced  risk  of  allergy,  asthma  and  atopy  in  the 
offspring (Section 1.5; (203)). 
4.1.2.1 Lipid „pools‟ 
 
Fatty acids are insoluble in aqueous solution and thus need to be bound to other molecules 
for transportation. In plasma, fatty acids are either esterified to form more complex lipids 
such as triacylglycerols (triglycerides, TAGs), phospholipids and cholesteryl esters (CEs), 
or bound non-covalently to albumin in the form of non-esterified fatty acids (NEFAs). 
Fatty acids are bound by an ester bond to either the glycerol backbone of TAGs or the 
fourth ring of cholesterol in CEs (Figure 4.1). In phospholipids, fatty acids can be attached 
to the glycerol backbone by either ester, alkyl or alkenyl bonds. Phospholipids containing 
fatty acids with alkyl or alkenyl bonds are found in only small amounts in plasma, but are 
important components of cell membranes, in particular in erythrocytes, leukocytes, brain 
and liver. Phospholipids can be classified according to the head group attached to the third 
carbon of which most frequent and major in the plasma and cells is phosphatidycholine 
(PC) (choline as  head  group), located  at  the outer leaflet  of cell membranes  and  as  a 
monolayer  enclosing  plasma  lipoproteins  (Figure  4.1).  TAGs,  PC  and  CEs  represent 
transport  pools  of  fatty  acids  typically  carrying  fatty  acids  from  the  gut  or  liver  to 
peripheral tissues and back. PC is major component of cell membranes along with other 
phospholipids. The fatty acid composition of plasma PC is similar to the PC composition 
of cell membranes, and in this way plasma PC could crudely reflect the functional fatty 
acid pool (functionality of cells). The composition of plasma NEFAs in the fasting state 
reflects the storage fatty acid pool, because adipose tissue fatty acids are released after 






Figure 4.1: Schematic structures of: a) cholesteryl esters (CEs), b) triglycerides (TAGs), and c) 
phospholipids 
 
4.1.3  Pregnancy and placental transport of LC-PUFA 
 
During early pregnancy, LC PUFAs may accumulate in maternal fat stores and become 
available for placental transfer during late pregnancy (250), when the fetal growth rate is 
maximal and fetal requirements for LC PUFAs are greatly enhanced. During this late part 
of  gestation,  enhanced  lipolytic  activity  in  maternal  adipose  tissue  contributes  to  the 
development  of  maternal  hyperlipidaemia  (250);  there  is  an  increase  in  plasma  TAG 
concentrations, with smaller rises in phospholipid and cholesterol concentrations  (250). 
Besides  the  increase  in  plasma  very  low  density  lipoprotein  (VLDL),  there  is  a 
proportional enrichment of TAGs in both low density lipoproteins (LDLs) and high density 
lipoproteins  (HDLs)  (250).  These  lipoproteins  transport  LC  PUFAs  in  the  maternal 
circulation. The presence of lipoprotein receptors in the placenta allows their placental 
uptake,  where  they  are  hydrolysed  by  lipoprotein  lipase,  phospholipase  A2,  and 
intracellular lipase (250). The fatty acids that are released can be metabolized and diffuse 
into the fetal circulation. Although present in smaller proportions, maternal plasma NEFAs 
are also a source of LC PUFAs for the fetus, their placental transfer being facilitated by the 
presence of a membrane fatty acid binding protein (250). The demands for cholesterol in 
the  fetus  are  high  as  it  is  one  of  the  main  elements  of  the  cell  membrane  structures. 
Although maternal cholesterol substantially contributes to fetal cholesterol during early 
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pregnancy,  during  late  gestation  fetal  cholesterol  biosynthesis  (rather  than  cholesterol 
transfer from maternal lipoproteins) seems to be the main mechanism for satisfying fetal 
requirements (240;250;251).  
4.1.4  Fetal selectivity and studies relating maternal and neonatal fatty 
acid status with or without maternal dietary intake 
 
The presence of membrane fatty acid binding protein in human placenta results in selective 
transfer of certain fatty acids to the fetus (252). Comparison of the maternal and fetal 
concentrations of two of the most important fatty acids for fetal development (ARA and 
DHA) indicates generally higher concentration of these LC PUFAs in all the major lipid 
classes in fetal blood and tissues (253). Figure 4.2 demonstrates the proportions of ARA 
and DHA in all lipid fractions in maternal circulation, placenta and fetal circulation as well 
as in adipose tissue and brain (253). The selective increase in the concentration of LC 
PUFAs, and of DHA and ARA in particular, in the fetal circulation and tissues has been 
termed biomagnification (253). The time at which this gradient manifests also appears to 
be synchronized with the maximum fetal demand (252;253). 
 
 
Figure 4.2: ARA and DHA as a percentage (%) of total fatty acids in the diet of pregnant mothers, the 
adipose tissue, maternal and cord blood plasma phospholipids, triglycerides, cholesteryl esters and 
non-esterified fatty acids, the placental microvillous and basal membranes and adipose tissue and 
brain at birth (taken from (253)).   195 
 
Berghaus et al. showed that LC PUFAs were preferentially incorporated into PC and CEs 
of both maternal and cord plasma. EPA and DHA were found in higher proportions in cord 
than in maternal blood compared to their precursors (ALA and LA), which may indicate a 
selective placental transport for certain physiologically important LC PUFAs (254).  
 
De Vriese et al. found that the fatty acid profile of cord blood plasma was different from 
that of maternal plasma at delivery. LA and ALA were lower in cord plasma CEs than in 
maternal plasma CEs whereas ARA and DHA were twice as high in umbilical cord plasma 
CEs. Cord plasma PC had a higher content of LC PUFAs than maternal plasma PC at 
delivery. The FA profile of umbilical plasma at birth showed preferential accumulation of 
ARA and DHA in CE and PC lipid fractions, indicating a preferential supply of the fetus 
with LC PUFAs needed for development. Also they showed that maternal plasma PC EPA 
and DHA percentages were positively associated with maternal dietary intake of these fatty 
acids during pregnancy (255;256). 
 
Hornstra and colleagues have conducted several studies in this field and have shown that 
the  total  amounts  of  fatty  acids  in  maternal  plasma  increased  significantly  during 
pregnancy (257-259). The pattern of change was similar for the individual fatty acids and 
fatty acid families. The relative amount (i.e. expressed as a percentage of total fatty acids) 
of LA did not change during pregnancy, whereas the relative amount of ARA decreased. 
However, the cord ARA (%) was significantly higher than maternal ARA (%). Despite 
maternal mobilization of DHA, suggested by a temporary increase in maternal blood DHA 
status until 18 weeks gestation, maternal blood DHA status steadily declined thereafter 
(258). In another study by Hornstra‟s group, women of different countries and origins were 
assessed and it was shown that the reduction in maternal fatty acid status during pregnancy 
was  generalisable,  and  independent  of  differences  in  dietary  habits  and  ethnic  origin 
(258;259). Van Houwelingen et al. found that maternal plasma PC fatty acids expressed as 
a percentage were highly significantly correlated with fetal plasma PC fatty acids (260).  
 
Donahue et al. recently published that mean maternal erythrocyte and cord plasma PUFA 
concentrations were 7.0 % and 5.2% (total n-3 PUFAs), 5.0 % and 4.6% (DHA+EPA), and 
27.9% and 31.4% (total n-6 PUFAs). Mid-pregnancy diet to blood and blood to blood 
correlations were strongest for DHA+EPA (r=0.38 for diet to maternal blood, r = 0.34 for 
diet to cord blood, r=0.36 for maternal blood with cord blood), and less strong for n-6 
PUFAs. 
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A  recent  study  has  related  fatty  acids  in  maternal  plasma  and  erythrocytes  with  cord 
plasma and erythrocytes and breastmilk in India. Kilari et al. found that levels of DHA and 
ARA in both plasma and erythrocytes were higher in cord blood compared to maternal 
blood. Maternal plasma and erythrocyte DHA levels had a positive association with the 
respective levels  in  cord blood.  However, such an association was  not seen for ARA. 
Maternal plasma n-3 and n-6 fatty acids were positively associated with the respective milk 
fatty acids. These results showed that milk LC PUFA status reflects the concentrations of 
maternal LC PUFA in women delivering babies at term. Improving the maternal LC PUFA 
status throughout pregnancy and lactation might improve the milk LC PUFA status and 
benefit the offspring. 
 
Tracer studies in vivo using 
13C-labeled fatty acids administered to the mother immediately 
before caesarean section have also demonstrated selective channeling of individual fatty 
acids to the fetal circulation (253). Larque et al. have shown that 
13C-enrichment of fatty 
acids in the NEFAs of cord plasma tended to be higher than in NEFAs of placenta, with a 
significant difference for the non-esterified DHA. These results suggested that only a part 
of the placental NEFAs participated in fatty acid transfer, and that the placenta showed a 
preferential accretion of DHA relative to the other fatty acids. More recently, Gil-Sanchez 
et al. found a significantly higher ratio of 
13C-DHA concentrations in cord plasma than in 
maternal plasma, which was higher than that for the other studied fatty acids. 
13C-DHA 
was  predominantly  esterified  into  phospholipids  and  TAGs  in  maternal  plasma,  which 
might enhance its placental uptake and transfer. 
 
These studies show the direct relation of maternal and fetal fatty acid status through the 
placenta especially for LC PUFAs such as DHA and ARA. The importance of maternal 
dietary fatty acids in controlling the availability of LC PUFAs to the fetus and newborn has 
also been demonstrated. In fact, since it is considered that the developing fetus depends 
mainly,  or  completely,  on  the  maternal  supply  of  LC  PUFAs,  supplementation  of  the 
maternal  diet  with  fish  oils  or  the  intake  of  oily  fish  (at  least  once  per  week)  during 
pregnancy to increase levels in the fetus and in neonates, has been advised (23;201). A 
higher consumption of oily fish during pregnancy is related with the provision of several 
nutrients (LC n-3 PUFAs, vitamin D, antioxidants such as Se and vitamin E) to the fetus 
and  this  may  be  associated  with  improved  health  in  infancy  and  childhood.  There  is 
evidence  of  the  protective  effect  of  these  nutrients  based  on  intervention  trials 
(132;178;207-209). However, there are no published intervention trials with fish during 
pregnancy.  Since  eating  fish  is  advised,  but  fish  are  also  a  source  of  contaminants,   197 
aquaculture of fish to have low contaminant levels could be an ideal solution to enable oily 
fish  consumption  by  pregnant  women  and  possibly  the  intake  of  the  recommended 
amounts of LC n-3 PUFAs. The Salmon in Pregnancy Study (SIPS) is the first randomised 
controlled trial with oily fish in pregnant women. SIPS focuses on pregnant women whose 
offspring have increased risk of developing atopic disease, aiming to identify whether there 
is an effect on atopy outcomes in the offspring. Also, consumption of tailor-made salmon 
by pregnant women could prevent the depletion of the mother and could improve the status 
of the newborn in  EPA  and DHA. A total  of  123 women were randomly assigned to 
consume either 2 portions of farmed salmon per week (from week 20 till delivery) or to 
continue their habitual diet low in oily fish (less or equal to two portions per month) (see 
Chapter 2). 
 
The aim of this chapter is to describe the effect of the increased maternal oily fish 
consumption on the fatty acid composition of maternal plasma PC, cord plasma lipids 
and cord blood mononuclear cells (CBMCs) with an emphasis on LC n-3 PUFAs. 
 
The hypotheses of the work described in this chapter are that the maternal oily fish 
intervention will: 
1.  result in higher amounts of EPA and DHA in maternal PC and in neonatal 
(cord) plasma lipids; 
2.  result in higher amounts of EPA and DHA in CBMCs.  
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4.2  Materials and methods 
 
4.2.1  Study design and subjects  
 
The study design, the subjects‟ characteristics, and the intervention have been described in 
Chapter 2. In summary, the population studied was pregnant women with high risk of 
having an atopic offspring. The study groups were two, of which the control group (n=61) 
was asked to keep their habitual diet unchanged during the pregnancy study period (from 
20 weeks until delivery) and the salmon group (n=62) which was asked to consume 2 
portions of farmed salmon per week from 20 weeks until delivery. Every portion of salmon 
provided 1.73 g of EPA plus DHA; the weekly intake of LC n-3 PUFAs from the study 
salmon was 3.46 g equivalent to a daily intake of 494 mg/day. The nutrient analysis of 
salmon  is  described  in  Chapter  2,  Table  2.3.  The  consumption  of  the  study  salmon 
provided more EPA plus DHA than the minimum recommended intake in the UK for 
pregnant women (450 mg/day; (26)). Subjects of the salmon and the control groups came 
into the maternity hospital fasted at three time points during pregnancy (20, 34, 38 weeks 
gestation), and fasting blood was taken to enable fatty acid analysis of plasma lipids. At 
birth, umbilical cord blood was collected to enable fatty acid analysis of plasma lipids and 
of CBMCs and the measurement of immune markers (Chapter 5).  
4.2.2  Maternal blood collection 
4.2.2.1 Blood tubes  
Plastic  6  mL  lithium  heparin  (LH)  vacutainer  blood  bottles,  plastic  3.5  mL  Serum 
Separator  Tube  (SST  11)  vacutainer  blood  bottles,  and  plastic  2  mL 
ethylenediaminetetraacetic acid (EDTA) vacutainer blood bottles were obtained from NHS 
stores, Southampton General Hospital. 
4.2.2.2 Procedure 
Maternal blood collection was performed by an adequately trained nurse (Norma Diaper or 
a nurse from the SWS) or member of the SIPS team (Paul Noakes, Liz Miles). At 20, 34, 
and 38 weeks gestation, blood was collected into three LH bottles and stored at room 
temperature (for less than 8 hours) for further analysis, and into one EDTA bottle which 
was also stored at room temperature for haematology testing. At 20 weeks gestation blood   199 
was also collected in a SST bottle and stored at room temperature for routine immunology 
testing. 
4.2.3  Cord Blood collection 
4.2.3.1 Blood Tubes 
 
Plastic  6  mL  lithium  heparin  (LH)  vacutainer  blood  bottles,  plastic  2  mL 
ethylenediaminetetraacetic acid (EDTA) vacutainer blood bottles, alcohol wipes– sterets, 
19  gauge  needles,  sterile  50  ml  tubes  (Elkay  Laboratories)  and  50  ml  syringes  were 
obtained from NHS stores, Southampton General Hospital. 
4.2.3.2 Procedure 
 
Midwifery staff at Princess Anne Hospital assisted with all cord blood collections. Umbilical 
cord blood was only collected from normal full-term (> 37 weeks) deliveries with informed 
consent from the mothers. Cord blood was preferentially collected during the third phase of 
delivery  while  the  placenta  is  still  in  the  uterus,  in  order  to  ensure  a  good  volume  of 
collection. If this was not possible, cord blood was collected after delivery and the placenta 
had been expelled. In either case, the umbilical cord was clamped immediately and cleaned 
with 70% alcohol and/or iodine swab, this minimised maternal blood contamination. Whole 
cord blood was collected using a 16-19G needle on a 50 mL syringe. After umbilical cord 
vein puncture, the cord blood was collected into the 50 mL syringe. The volume collected 
ranged from 10 to 30 ml depending on the condition of the placenta. Cord blood samples were 
collected into 2 LH tubes and 2 EDTA tubes, one of each was kept at room temperature and 
the other in the fridge (4C) for less than 8 hours for further analysis. The EDTA bottle which 
was stored at room temperature was sent for haematology testing. The cord blood samples 
were then either stored at room temperature or in fridge and within the next 8-12 hours blood 
was separated into plasma, mononuclear cells and erythrocytes by gradient centrifugation. 
4.2.4  Preparation of plasma and mononuclear cells from maternal and 
cord blood 
4.2.4.1 Materials 
Histopaque (density 1.077 g/L, containing polysucrose 5.7 g/dL, and sodium diatrizoate 
9.0  g/dL),  L-glutamine  (200  mM),  antibiotics  (penicillin,  streptomycin), 
ethylenediaminetetraacetic acid (EDTA), potassium bicarbonate, and ammonium chloride, 
crystal violet were purchased from Sigma-Aldrich. Phosphate-buffered saline (PBS) tablets 
were purchased from  Oxoid. RPMI medium (without  L-glutamine and  antibiotics) and   200 
heat-inactivated  fetal  bovine  serum  (HI-FBS)  were  purchased  from  PAA  Laboratories. 
Dimethyl  sulphoxide  (DMSO)  and  acetic  acid  were  purchased  from  Fisher  Scientific. 
Saline  (0.9%  sodium  chloride)  was  purchased  from  SUHT  Pharmacy,  Southampton 
General Hospital.  
White  cell  counting  fluid  was  made  as  follows:  100  mL  PBS,  2  mL  acetic  acid, 
approximately 5 g crystal violet. The solution was millipore filtered before use. 
4.2.4.2 Procedures 
Heparinised whole blood was layered onto Histopaque (ratio of blood to Histopaque: 2:1) 
and centrifuged for 15 min at 800 × g (2000 rpm, R = 18 cm) at room temperature. Plasma 
was collected from the top layer and frozen at -80˚C for fatty acid and cytokine analysis 
(Chapter 5), as well as to be used for culturing CBMCs.  
The CBMCs were collected from the interphase and washed once for 10 min at 450 × g 
(1500  rpm,  R  =  18  cm)  with  RPMI  medium  containing  0.75  mmol/L  glutamine  and 
antibiotics (penicillin and streptomycin). After being resuspended in 1 mL RPMI medium, 
the cells  were counted  with  a haemocytometer using white cell counting fluid  (crystal 
violet). After counting total CBMCs, 2 × 10
6 cells were removed and frozen at -80˚C for 
fatty acid analysis. 
The  remaining  CBMCs  were  washed  once  (10  min,  450  ×  g)  with  RPMI  medium 
containing 2% HI-FBS. The CBMCs were resuspended in RPMI medium containing 2% 
HI-FBS and were cryopreserved with  15% DMSO in  HI-FBS (freezing medium). The 
freezing  medium  was  added  to  the  resuspended  CBMCs  drop-wise  on  ice  (ratio  of 
resuspended cells in RPMI medium containing 2% HI-FBS to freezing medium: 1:1). The 
CBMC concentrations were adjusted to 12-20 × 10
6 cells/ml/cryovial
 and were frozen at -
80˚C in a Nalgene Cryo 1˚C freezing container (filled with 250 mL isopropanol). After at 
least 4 hours of freezing, cryovials containing the CBMCs were stored in liquid nitrogen 
for later thawing and culturing (Chapter 5). 
4.2.5  Fatty acid analysis of maternal and cord plasma lipids and cord 
blood mononuclear cells by gas chromatography  
4.2.5.1 Materials 
 
Sodium  chloride  (NaCl),  butyrated  hydroxytoluene  (BHT),  potassium  bicarbonate 
(KHCO3), potassium carbonate (K2CO3), heneicosanoin acid, cholesteryl heptadecanoate, 
tripentadecanoin,  and  menhaden  oil  standard  fatty  acid  methyl  ester  mix  were  all   201 
purchased  by  Sigma.  Dipentadecanoyl  PC  was  purchased  from  Avanti  Polar  Lipids. 
Chloroform,  methanol,  hexane, ethyl  acetate, toluene, glacial acid,  sulphuric acid  were 
purchased  from  Fisher  Scientific.  Aminopropylsilica  solid  phase  extraction  (SPE) 
cartridges  (NH2) were  purchased  from  Varian.  Institute of Human Nutrition (IHN) oil 
standard mix was an in house preparation using Sigma and Nuchek fatty acid standards. 
 
4.2.5.2 Procedure 
For  plasma  samples,  quantitative  analysis  of  fatty  acids  was  performed,  and  a  known 
amount  of  plasma  was  used  for  analysis  (0.5  ml).  Internal  standards  of  known 
concentration and volume were added to plasma samples prior to lipid extraction (Table 
4.1). To the plasma with the added standards was also added 0.9% NaCl so as to reach a 
final volume of 0.8 ml. 




formula of  
standard 
fatty acid 
Systemic name of 














(PC)  15:0  Dipentadecanoyl 
PC  1mg/mL  100 μL  100 μg 
Non-esterified fatty 
acids (NEFAs)  21:0  Heneicosanoic 
acid  0.5 mg/mL  25 μL  12.5 μg 
Cholesteryl esters 
(CEs)  17:0  Cholesteryl 
heptadecanoate  3 mg/mL  50 μL  150 μL 
Tryglecerides (TAGs)  15:0  Tripentadecanoin  1mg/mL  50 μL  50 μg 
 
For the CBMCs that had been stored at -80C for fatty acid analysis (2 x 10
6 cells), the 
whole sample was used after defrosting, and 0.9% NaCl was added so as the samples to 
reach the volume 0.8 ml. These samples were not analysed quantitatively so no internal 
standards were added. 
 
Total  lipid  was  extracted  from  plasma  and  CBMCs  with  chloroform:methanol  (2:1; 
vol/vol) containing butylated hydroxytoluene (BHT) as antioxidant. After adding NaCl (1 
M), the sample was centrifuged and the lower non-aqueous phase collected. The sample 
was dried under nitrogen gas at 40C. Plasma lipid classes (TAGs, PC, CEs, NEFAs) were 
separated for plasma samples but total lipids were analysed for CBMCs. 
Separation of plasma lipid classes was performed  by solid phase extraction (SPE). An 
aminopropylsilica SPE cartridge was placed on the SPE tank. Total lipid extracts were 
dissolved  in  chloroform  and  applied  to  the  column.  The  sample  was  allowed  to  drip   202 
through under gravity and the remaining liquid was collected under vacuum. The column 
was washed twice with chloroform under vacuum. The washes contained TAGs and CEs 
and were dried under nitrogen. PC was eluted by chloroform:methanol (60:40; vol/vol) 
under vacuum until dry. The washes containing PC were dried under nitrogen gas at 40C. 
NEFAs  were  eluted  by  chloroform:methanol:glacial  acetic  acid  (100:2:2;  vol/vol/vol) 
under vacuum until dry. The fractions were dried under nitrogen. A new aminopropylsilica 
SPE cartridge was placed on the SPE tank, and the cartridge was washed four times with 
hexane. The TAG and CE fraction collected initially was dissolved in hexane and applied 
to the column. The sample was allowed to drip through under gravity and the remaining 
liquid was collected under vacuum. The column  was washed twice with hexane under 
vacuum. The washes containing CEs were dried under nitrogen gas at 40C. Then TAGs 
were eluted by hexane: chloroform: ethyl acetate (100:5:5; vol/vol/vol) under vacuum and 
the fraction was dried under nitrogen gas at 40C. 
The lipid classes from plasma and the total lipid extractions from CBMCs were diluted 
with  toluene.  Fatty  acid  methyl  esters  (FAMEs)  were  formed  by  adding  methanol 
containing  2%  (v/v)  sulphuric  acid  and  incubating  at  50˚C  for  2  hours.  Neutralising 
solution  (KHCO3,  K2CO3)  and  hexane  were  added  to  the  sample.  The  sample  was 
centrifuged and the upper phase containing the FAMEs collected and then dried under 
nitrogen. The sample was diluted with hexane and transferred to a gas chromatography 
(GC) vial. The sample was dried under nitrogen. 
The FAMEs were separated and analysed by gas chromatography on a Hewlett-Packard 
(Hewlett-Packard; Avondale, PA, USA) 6890 gas chromatograph fitted with a Hewlett-
Packard (HP 6890 Series GC) system autoinjector. A 30 m BPX-70 SGE capillary column 
was used. Helium was used as the carrier gas. The detector was a flame ionising detector 
(FID) held  at 250C. The hydrogen flame caused combustion of the FAMEs and thus 
generated an ion current proportional to the amount of FAME in the sample. However an 
experimentally determined correction needed to be made for the number of carbons in a 
FAME. The resulting chromatogram contained a series of peaks, each corresponding to a 
FAME.  FAMEs  were  identified  by  comparison  with  standards  (Institute  of  Human 
Nutrition  fatty  acid  methyl  esters  mixture  (IHN)  and  Menhaden  oil  fatty  acid  methyl 
esters) (Figure 4.3; Figure 4.4) run previously. The area under its peak is propotional to the 
mass of the FAME injected onto the column. Figure 4.5 to Figure 4.9 show a typical trace 
of fatty acids in PC, the major plasma phospholipid, NEFAs, CEs, and TAGs of plasma 
and a typical trace of fatty acids in CBMCs .   203 
 
4.2.6  Fatty acid analysis 
 
4.2.6.1 Proportion of FAs 
Each peak is characteristic and unique for each fatty acid and it appears according to the 
order that each of the FAME is detected by the FID on the GC. The time that each FAME 
peak appears on the chromatogram is called retention time, and is characteristic for each 
fatty acid. Typically, FAMEs with shorter chains and fewer double bonds have a shorter 
retention time than FAMEs with longer hydrocarbon chains and more double bonds, and 
thus they appear first on the chromatogram. This is attributed to the physical properties of 
the  FAMEs  according  to  their  structure.  The  identification  of  the  specific  fatty  acids 
happens by comparison of the retention times of FAMEs within the standard mixtures 
(IHN, Menhaden) with those of FAMEs in the sample. After the identification of the fatty 
acid, the area under the peak is calculated and the proportion of each peak area to the sum 
of all peak areas is calculated. This represents the percentage of the fatty acid in the total 
fatty acids in the sample analysed: total lipids (for CBMCs) and lipid class (for plasma; 
PC, NEFAs, CEs, TAGs). 
4.2.6.2 Absolute concentration of FAs 
The addition of internal standards in the plasma sample at the lipid extraction phase, allows 
the determination of the absolute concentrations of each fatty acid in the chromatogram. 
The area under the internal standard peak refers to the known amount of standard fatty acid 
added to the sample. This piece of information along with the known initial amount of 
sample used for analysis, allows for calculations of the absolute concentration of each fatty 
acid in the sample.    204 
  
 
Figure 4.3: Typical GC profile of the Institute of Human Nutrition mixture standard mix  
 
 












Figure 4.6: Typical trace of fatty acids in plasma CEs 














Figure 4.9: Typical trace of fatty acids in plasma TAGs 
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4.2.7  Statistical analysis 
 
Fatty acid data were normally distributed and the statistical tests used to interpret these 
data were parametric. For between group comparisons during pregnancy (20, 34, 38 weeks 
of gestation) and in cord blood, independent samples t-test was used. The General Linear 
Model (GLM) of analysis, 3 repeated measures analysis of variance (ANOVA) was used to 
examine  overtime  changes  during  pregnancy  related  to  the  dietary  intervention. 
Correlations were also made between maternal and cord PC percentages (%) of fatty acids 
and CBMC fatty acid composition. Also correlations between maternal diet and fatty acid 
status  at  birth  were  made  as  well  as  correlations  between  infant  birth  characteristics, 
gestational  length  and  fatty  acid  status  in  cord  blood.  For  all  correlations,  bivariate 
Spearman correlations were used. For all comparisons a p-value equal to or less that 0.05 
(p≤0.05) was considered statistically significant.  
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4.3  Results 
 
4.3.1  Maternal fatty acid status: Fatty acid composition of plasma 
phospholipids (PC) (% only) 
 
PC is the major phospholipid in the circulation, typically contributing about 80% of the 
plasma phospholipid pool (261). PC is a component of all plasma lipoproteins. PC may be 
regarded as a transport pool of fatty acids, playing a role in delivery of fatty acids to cells 
and tissues. The fatty acid composition of plasma PC has a strong similarity to that of cell 
membrane PC (262). Table 4.2 describes the maternal plasma PC fatty acid composition 
expressed as the percentage contribution of each fatty acid (to total PC fatty acids), for the 
two  groups  during  pregnancy  (20,  34,  and  38  weeks  gestation).  Repeated  measures 
ANOVA identified significant effects of time on the percentages of most fatty acids and 
significant effects of group (i.e. salmon vs. control) on the percentages of elaidic acid 
(trans  18:1n-9),  ALA,  EPA,  docosapentaenoic  acid  (DPA;  22:5n-3),  DHA,  total  n-3 
PUFAs, dihomo--linolenic acid (DGLA; 20:3n-6), ARA and total n-6 PUFAs. There were 
also significant time x group interactions for EPA, DHA, total n-3 PUFAs, DGLA, ARA 
and total n-6 PUFAs. These were explored further by between group comparisons at each 
time point. At 20 weeks gestation (baseline), the salmon group had higher percentages 
EPA, DHA, and total n-3 PUFAs and a lower percentage of ARA compared to the control 
group. During the intervention period, at 34 and 38 weeks of pregnancy, the salmon group 
continued to have higher percentages of EPA, DHA, total n-3 PUFAs and also of DPA, 
and a lower percentage of ARA, and additionally of DGLA and total n-6 PUFAs (Table 
4.2). 
 
Figure  4.10  shows the  percentages  of EPA,  DHA, ARA, and DPA in  the PC fraction 
during pregnancy at the 3 timepoints studied (20 weeks, 34 weeks and 38 weeks) and how 
those changed between the groups at each time point, and within the groups throughout 
pregnancy. EPA and DHA decreased in the control group but increased in the salmon 
group during pregnancy. ARA decreased in both groups during pregnancy but less so in 
the control group. DPA slightly increased in the salmon group whereas it decreased in the 
control group. 
 
The changes in percentages EPA, DHA and ARA in plasma PC were different between 
groups (p<0.001 for all). The changes in plasma PC DPA % were different between the   209 
two groups only for the calculated 34-20 week change (Table 4.3). Table 4.4 shows the 
within group comparisons for the calculated changes (34-20 and 38-20 weeks) in the % of 
EPA, DHA, ARA and DPA in maternal plasma PC. It is clear from these comparisons that 
within the control group EPA, DPA, DHA, and ARA decreased during pregnancy. In the 
salmon group EPA and DHA increased, while the decrease in ARA was greater than in the 
control group and the decrease on DPA was smaller.  
 
   
   
Figure 4.10: Maternal plasma a) EPA, b) DHA, c) ARA, d) DPA expressed as percentage of total fatty 
acids during pregnancy in both groups; refer to Table 4.2 for exact values 
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(n=62)  p  Control group 
(n=55) 
Salmon group 
(n=56)  p  Control group 
(n=41) 
Salmon group 
(n=47)  p  p for time  p for group  p for interaction 
(grp*time) 
Mean  SD  Mean  SD    Mean  SD  Mean  SD    Mean  SD  Mean  SD         
EPA (20:5n-3)  0.6  0.3  0.7  0.3  0.028  0.5  0.2  0.9  0.4  <0.001  0.4  0.2  0.9  0.4  <0.001  0.758  <0.001  <0.001 
DHA (22:6n-3)  4.2  0.7  4.7  0.9  0.001  3.9  0.7  5.1  1.1  <0.001  3.7  0.7  5.0  0.9  <0.001  0.003  <0.001  <0.001 
14:00  0.4  0.1  0.4  0.1  0.738  0.4  0.1  0.4  0.1  0.669  0.4  0.1  0.4  0.1  0.598  0.590  0.555  <0.001 
16:00  33.0  1.7  32.8  1.4  0.573  34.1  1.1  34.2  1.7  0.793  34.5  0.9  34.3  0.9  0.390  0.001  0.640  <0.001 
16:1n-7  0.9  0.3  0.8  0.2  0.101  0.9  0.2  0.8  0.2  0.300  0.9  0.2  0.8  0.3  0.555  0.096  0.300  <0.001 
18:00  10.8  0.9  10.7  1.0  0.379  9.8  0.8  9.7  0.8  0.670  9.8  0.9  9.7  0.8  0.552  <0.001  0.728  <0.001 
18:1n-9  11.2  1.5  11.1  1.4  0.738  11.9  1.2  11.7  1.3  0.317  12.1  1.2  11.9  1.2  0.776  <0.001  0.530  <0.001 
18:1n-9Trans  1.5  0.2  1.5  0.2  0.676  1.4  0.2  1.3  0.2  0.005  1.5  0.2  1.4  0.2  0.008  <0.001  0.010  <0.001 
18:2n-6  21.5  2.5  22.1  2.5  0.176  22.2  2.2  22.7  2.3  0.314  22.7  2.4  22.7  2.2  0.904  <0.001  0.666  <0.001 
18:3n-6  0.1  0.1  0.1  0.1  0.899  0.1  0.1  0.1  0.1  0.789  0.1  0.02  0.1  0.02  0.401  0.003  0.790  <0.001 
18:3n-3  0.3  0.1  0.3  0.1  0.137  0.4  0.1  0.4  0.2  0.020  0.4  0.1  0.4  0.2  0.038  <0.001  0.038  <0.001 
20:00  0.1  0.1  0.1  0.03  0.702  0.1  0.1  0.1  0.1  0.411  0.05  0.02  0.06  0.03  0.658  <0.001  0.934  <0.001 
20:1n-9  0.2  0.1  0.2  0.2  0.534  0.2  0.04  0.2  0.1  0.343  0.2  0.03  0.2  0.03  0.517  <0.001  0.688  <0.001 
20:2n-6  0.5  0.2  0.5  0.1  0.965  0.5  0.1  0.5  0.1  0.173  0.4  0.1  0.4  0.1  0.358  <0.001  0.650  <0.001 
20:3n-6  4.4  0.7  4.2  0.8  0.148  4.4  0.7  3.7  0.6  <0.001  4.2  0.6  3.7  0.6  <0.001  <0.001  <0.001  <0.001 
ARA (20:4n-6)  9.7  1.5  9.0  1.8  0.032  8.7  1.3  7.5  1.4  <0.001  8.4  1.2  7.4  1.3  <0.001  <0.001  0.002  <0.001 
DPA (22:5n-3)  0.7  0.2  0.7  0.2  0.189  0.6  0.1  0.7  0.2  <0.001  0.5  0.1  0.6  0.1  0.003  <0.001  0.002  <0.001 
SFAs  44.3  2.0  44.0  1.7  0.344  44.4  0.7  44.4  1.5  0.893  44.7  0.7  44.5  0.7  0.088  0.078  0.431  <0.001 
MUFAs  13.8  1.7  13.6  1.6  0.570  14.4  1.3  14.0  1.5  0.167  14.5  1.3  14.3  1.4  0.457  <0.001  0.273  <0.001 
PUFAs  41.9  2.4  42.4  1.9  0.212  41.3  1.6  41.6  1.8  0.285  40.7  1.5  41.2  1.5  0.141  <0.000  0.153  <0.001 
Total n-3 PUFAs  5.8  0.9  6.5  1.2  <0.001  5.4  0.8  7.1  1.5  <0.001  5.0  0.9  6.9  1.3  <0.001  0.005  <0.001  <0.001 
Total n-6 PUFAs  36.1  2.3  35.9  2.1  0.576  35.8  1.5  34.5  1.7  <0.001  35.7  1.740  34.2  1.9  <0.001  <0.001  <0.001  <0.001 
Values are mean (SD) percentage (%) of total fatty acids in PC; p-values from ANOVA and independent samples t-test 
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Table 4.3: Changes in the percentage of the four fatty acids of interest in maternal plasma PC 






n=56  p 
Mean  SD  Mean   SD    
EPA change 34-20 weeks   -0.16  0.30  0.15  0.45  <0.001 
DHA change 34-20 weeks  -0.17  0.50  0.38  0.93  <0.001 
ARA change 34-20 weeks  -1.09  0.94  -1.54  1.36  0.042 






n=47  p 
  Mean  SD  Mean   SD    
EPA change 38-20 weeks  -0.17  0.16  0.13  0.40  <0.001 
DHA change 38-20 weeks  -0.41  0.49  0.13  0.69  <0.001 
ARA change 38-20 weeks  -1.29  0.82  -1.86  1.08  0.007 
DPA (n-3) change 38-20 weeks  -0.14  0.17  -0.11  0.16  0.318 








Control group  Salmon group 
34-20 weeks  38-20 weeks  p  34-20 weeks  38-20 weeks  p 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
EPA   -0.16  0.30  -0.17  0.16  0.324  0.15  0.45  0.13  0.40  0.614 
DHA   -0.17  0.50  -0.41  0.49  <0.001  0.38  0.93  0.13  0.69  0.054 
ARA   -1.09  0.94  -1.29  0.82  0.014  -1.54  1.36  -1.86  1.08  0.269 
DPA (n-3)   -0.09  0.17  -0.14  0.17  0.004  -0.01  0.18  -0.11  0.16  <0.001 
Values are mean (SD) change in percentage; paired t-test p-values   212 
 
4.3.2  Cord blood fatty acid status 
 
4.3.2.1 Fatty acid composition of lipid classes in cord blood 
 
4.3.2.1.1  Fatty acid composition of plasma phospholipids (PC) 
 
Table 4.5 describes the cord plasma PC fatty acid composition expressed as percentages 
(%) of each fatty acid and also as absolute concentrations (μg/mL plasma). Independent 
samples t-tests were conducted so as to compare the PC fatty acid status of the two groups 
at  birth.  The salmon  group had higher percentages  of EPA,  DPA, DHA, and total  n-3 
PUFAs and lower percentages of ARA and total n-6 PUFAs than the control group. For the 
absolute concentrations of the fatty acids in the cord plasma PC, the same pattern was 
found. However, only EPA and total n-3 PUFAs were significantly higher in the salmon 
group compared to the control group i.e. the higher concentrations of DPA and DHA in the 
salmon group did not reach statistical significance. Fatty acid ratios of interest in the cord 
plasma PC (ARA/EPA, ARA/DHA, ARA/(EPA+DHA), n-6 PUFA/n-3 PUFA) are also 
shown. Each of these ratios was higher in the control group. Total PC fatty acids (μg/mL) 
were not different between the groups. 
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Table 4.5: Cord plasma phospholipid (PC) fatty acid composition according to study group 
 




(n=47)  p 
Fatty acid 





(n=47)  p 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
EPA (20:5n-3)  0.3  0.1  0.6  0.3  <0.001  EPA (20:5n-3)  1.79  0.89  3.50  1.77  <0.001 
DHA (22:6n-3)  6.4  1.3  7.4  1.4  0.001  DHA (22:6n-3)  35.71  12.52  40.60  14.64  0.087 
14:00  0.3  0.1  0.3  0.1  0.593  14:00  1.58  0.55  1.56  0.59  0.895 
16:00  31.1  1.6  31.0  1.5  0.809  16:00  172.77  57.97  172.38  57.86  0.974 
16:1n-7  0.9  0.2  1.0  0.2  0.907  16:1n-7  5.37  2.05  5.51  2.45  0.761 
18:00  14.6  1.4  14.6  1.1  0.862  18:00  80.23  23.37  80.68  26.20  0.930 
18:1n-9  9.0  1.1  8.9  1.1  0.670  18:1n-9  49.59  17.97  49.73  17.93  0.969 
18:1n-9 Trans  2.9  0.3  2.8  0.3  0.066  18:1n-9 Trans  15.91  4.81  15.59  5.74  0.773 
18:2n-6  8.7  2.3  8.9  1.6  0.500  18:2n-6  49.02  27.61  49.59  18.09  0.906 
18:3n-6  0.1  0.03  0.1  0.05  0.251  18:3n-6  0.64  0.27  0.69  0.32  0.467 
18:3n-3  0.1  0.05  0.1  0.04  0.966  18:3n-3  0.84  0.25  0.88  0.27  0.525 
20:00  0.2  0.05  0.2  0.05  0.377  20:00  0.51  0.37  0.49  0.23  0.885 
20:1n-9  0.1  0.05  0.1  0.03  0.291  20:1n-9  0.67  0.32  0.64  0.28  0.616 
20:2n-6  0.4  0.1  0.4  0.1  0.089  20:2n-6  2.03  0.86  2.17  0.74  0.391 
20:3n-6  6.0  1.0  6.3  1.0  0.138  20:3n-6  32.68  9.48  35.07  11.80  0.283 
ARA (20:4n-6)  18.3  2.4  16.6  1.8  <0.001  ARA (20:4n-6)  101.27  31.69  91.17  29.97  0.118 
DPA (22:5n-3)  0.5  0.2  0.6  0.2  0.019  DPA (22:5n-3)  2.92  1.40  3.47  1.73  0.097 
Total SFAs  46.1  1.0  46.1  1.5  0.911  Total SFAs  255.08  79.58  255.12  83.91  0.998 
Total MUFAs  13.0  1.4  12.8  1.3  0.399  Total MUFAs  71.54  24.10  71.48  25.83  0.991 
Total PUFAs  40.9  1.6  41.2  1.9  0.465  Total PUFAs  226.9  69.73  227.15  71.07  0.987 
Total n-3 PUFAs  7.4  1.5  8.8  1.6  <0.001  Total n-3 PUFAs  41.27  14.25  48.45  17.26  0.031 
Total n-6 PUFAs  33.5  1.4  32.4  2.0  0.002  Total n-6 PUFAs  185.63  58.38  178.69  56.58  0.562 
 
          Total fatty acids  553.52  171.32  553.74  178.71  0.995 
          ARA/DHA  2.92  0.57  2.32  0.51  <0.001 
          ARA/EPA  65.51  29.40  31.45  16.88  <0.001 
          ARA/(EPA+DHA)  2.78  0.54  2.13  0.49  <0.001 
          n-6/n-3  4.64  0.91  3.83  0.92  <0.001 
Values are mean (SD) percentage (%) of total fatty acids and absolute concentrations (g/mL) in PC; independent samples t-test p-values 
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4.3.2.1.2 Fatty acid composition of cord plasma non-esterified fatty acids 
(NEFAs) 
 
Table 4.6 describes the cord plasma NEFA fatty acid composition expressed as percentages 
(%) of each fatty acid and as absolute concentrations (μg/mL plasma). Independent samples 
t-tests were conducted so as to compare the plasma NEFA fatty acid status of the two 
groups at birth. The salmon group had higher percentages of 18:1n-9 trans, DPA, DHA, and 
total n-3 PUFAs and a lower percentage of total MUFAs than the control group. Although 
the absolute concentrations of EPA, DPA, DHA, and total n-3 PUFAs tended to be higher 
in the salmon group, and the absolute concentrations of ARA and total n-6 PUFAs tended 
to  be  lower,  the  data  did  not  reach  statistical  significance.  The  ratios  ARA/DHA, 
ARA/(EPA+DHA),  and  n-6  PUFA/n-3  PUFA  were  higher  in  the  control  group.  Total 
NEFA concentration (μg/mL) did not differ significantly between the groups.  
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Table 4.6: Cord plasma NEFA fatty acid composition according to study group 
 











(n=47)  p 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
EPA (20:5n-3)  0.2  0.1  0.2  0.2  0.065  EPA (20:5n-3)  0.26  0.14  0.29  0.24  0.554 
DHA (22:6n-3)  2.5  0.7  3.1  1.1  0.001  DHA (22:6n-3)  3.86  2.36  4.20  3.35  0.573 
14:00  1.5  0.4  1.5  0.6  0.695  14:00  2.41  1.63  2.11  2.15  0.446 
16:00  32.1  2.8  31.1  4.1  0.211  16:00  50.49  29.89  42.31  31.80  0.205 
16:1n-7  3.3  0.9  3.0  0.9  0.076  16:1n-7  5.48  4.17  4.34  4.53  0.211 
18:00  18.8  3.6  19.5  4.8  0.420  18:00  28.39  14.45  25.05  14.3  0.265 
18:1n-9  22.4  3.8  20.9  3.8  0.067  18:1n-9  37.26  28.45  29.67  26.63  0.188 
18:1n-9 Trans  2.3  0.4  2.1  0.5  0.026  18:1n-9 Trans  3.72  2.38  2.72  1.67  0.022 
18:2n-6  10.8  2.3  10.4  2.4  0.425  18:2n-6  17.64  13.06  14.06  11.39  0.163 
18:3n-6  0.5  0.4  0.6  0.5  0.352  18:3n-6  0.61  0.31  0.60  0.42  0.931 
20:00  1.2  0.3  1.3  0.3  0.380  20:00  1.85  1.19  1.58  1.05  0.254 
20:1n-9  0.4  0.3  0.5  0.5  0.172  20:1n-9  0.56  0.33  0.59  0.48  0.701 
20:2n-6  0.2  0.1  0.2  0.1  0.364  20:2n-6  0.30  0.21  0.24  0.21  0.118 
20:3n-6  0.5  0.2  0.7  0.6  0.254  20:3n-6  0.89  0.71  0.93  1.42  0.862 
ARA (20:4n-6)  3.0  1.1  3.2  2.3  0.584  ARA (20:4n-6)  4.76  3.48  4.52  5.67  0.806 
DPA (22:5n-3)  0.3  0.1  0.3  0.1  0.001  DPA (22:5n-3)  0.39  0.23  0.42  0.28  0.686 
Total SFAs  53.6  4.9  53.4  7.2  0.873  Total SFAs   83.14  46.09  71.05  48.04  0.219 
Total MUFAs  28.5  4.3  26.6  4.6  0.042  Total MUFAs   47.01  34.52  37.33  32.27  0.166 
Total PUFAs  17.9  2.8  18.6  4.4  0.349  Total PUFAs  28.72  18.64  25.26  19.07  0.378 
Total n-3 PUFAs  2.9  0.7  3.6  1.2  0.001  Total n-3 PUFAs   4.51  2.65  4.90  3.80  0.572 
Total n-6 PUFAs  15.0  2.6  15.0  3.6  0.982  Total n-6 PUFAs   24.20  16.3  20.36  15.51  0.247 
            Total NEFAs   158.87  97.04  133.63  96.41  0.212 
            ARA/DHA  1.23  0.35  1.03  0.33  0.003 
            ARA/EPA  17.62  8.24  15.59  8.08  0.242 
            ARA/ (EPA+DHA)  1.14  0.32  0.95  0.31  0.003 
            n-6/n-3  5.48  1.61  4.37  1.17  <0.001 
Values are mean (SD) percentage (%) of total fatty acids and absolute concentrations (g/mL) in NEFAs; independent samples t-test p-values   216 
 
4.3.2.1.3 Fatty acid composition of cord plasma cholesteryl esters (CEs) 
 
Table 4.7 describes the cord plasma CE fatty acid composition expressed as percentages 
(%) of each fatty acid and also as absolute concentrations (μg/mL plasma). Independent 
samples t-tests were conducted so as to compare the CE fatty acid status of the two groups 
at  birth.  The  salmon  group  had  a  higher  percentages  of  EPA,  DHA,  ALA,  eicosanoic 
(20:0), and DGLA and lower percentages of tetradecanoic acid (14:0), ARA and DPA than 
the control group. The absolute concentration of EPA in cord plasma CE was higher in the 
salmon group compared to the control group. The higher concentrations of DHA and total 
n-3 PUFAs in the salmon group and the higher concentrations of ARA and total n-6 PUFAs 
in the control group did not reach statistical significance. Each of the ratios calculated 
(ARA/EPA,  ARA/DHA,  ARA/(EPA+DHA),  n-6  PUFA/n-3  PUFA)  was  higher  in  the 
control group. Total CE fatty acids (μg/mL) did not differ between the groups.   
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Table 4.7: Cord plasma cholesteryl ester (CE) fatty acid composition according to study group 
 











(n=46)  p 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
EPA (20:5n-3)  0.4  0.2  0.6  0.2  <0.001  EPA (20:5n-3)  1.92  1.03  2.91  1.53  <0.001 
DHA (22:6n-3)  2.2  0.9  2.3  0.8  <0.001  DHA (22:6n-3)  10.78  6.45  11.49  5.07  0.563 
14:00  0.8  0.2  0.8  0.2  0.050  14:00  4.17  1.83  4.11  1.82  0.880 
16:00  23.2  2.3  22.7  1.8  0.192  16:00  113.08  39.19  114.63  42.48  0.857 
16:1n-7  6.8  1.2  6.9  1.3  0.826  16:1n-7  33.60  14.39  36.81  19.94  0.381 
18:00  2.7  0.6  2.9  0.9  0.138  18:00  13.10  5.37  14.67  7.53  0.255 
18:1n-9  26.2  2.9  26.7  3.3  0.239  18:1n-9  131.12  56.27  138.19  61.84  0.570 
18:1n-9 Trans  3.2  0.5  3.2  0.4  0.958  18:1n-9 Trans  15.75  5.68  16.55  8.07  0.588 
18:2n-6  18.2  5.2  18.6  2.8  0.181  18:2n-6  97.27  80.44  94.12  40.31  0.815 
18:3n-6  0.9  0.2  1.0  0.4  0.279  18:3n-6  4.51  2.09  4.80  2.18  0.514 
18:3n-3  0.3  0.2  0.3  0.3  0.009  18:3n-3  1.34  1.25  1.31  0.59  0.854 
20:00  0.4  0.3  0.5  0.4  0.047  20:00  1.92  1.18  2.08  1.21  0.506 
20:1n-9  0.2  0.1  0.2  0.3  0.188  20:1n-9  1.04  0.58  1.10  0.79  0.679 
20:2n-6  0.2  0.2  0.2  0.2  0.276  20:2n-6  0.84  0.83  0.68  0.78  0.349 
20:3n-6  1.4  0.3  1.5  0.3  0.012  20:3n-6  6.99  2.47  7.42  3.15  0.474 
ARA (20:4n-6)  12.8  2.9  11.4  2.3  0.021  ARA (20:4n-6)  62.52  25.27  57.76  26.11  0.379 
DPA (22:5n-3)  0.3  0.2  0.3  0.2  0.009  DPA (22:5n-3)  1.30  0.98  1.31  0.98  0.967 
Total SFAs  27.1  2.8  26.9  2.2  0.732  Total SFAs   132.26  45.89  135.49  50.45  0.750 
Total MUFAs  36.4  3.9  37.1  4.4  0.415  Total MUFAs   181.52  74.91  192.65  88.96  0.520 
Total PUFAs  36.6  4.9  36.0  4.1  0.577  Total PUFAs  187.47  102.51  181.79  73.22  0.762 
Total n-3 PUFAs  3.1  1.2  3.5  1.0  0.138  Total n-3 PUFAs   15.35  8.37  17.02  6.96  0.305 
Total n-6 PUFAs  33.5  4.9  32.6  4.0  0.351  Total n-6 PUFAs   172.12  97.56  164.77  68.15  0.679 
            Total CE fatty acids   501.26  212.19  509.94  203.13  0.843 
            ARA/DHA  6.41  2.11  5.38  1.72  0.013 
            ARA/EPA  37.17  19.69  22.12  9.96  <0.001 
            ARA/ (EPA+DHA)  5.32  1.69  4.25  1.37  0.001 
            n-6/n-3  11.68  3.99  10.23  2.97  0.054 
Values are mean (SD) percentage (%) of total fatty acids and absolute concentration (g/mL) in CEs; independent samples t-test p-values   218 
4.3.2.1.4 Fatty acid composition of cord plasma triglycerides (TAGs) 
 
Table 4.8 describes the cord plasma TAG fatty acid composition expressed as percentages 
(%) of each fatty acid and also as absolute concentrations (μg/mL plasma). Independent 
samples t-tests were conducted so as to compare the TAG fatty acid status of the two 
groups at birth. The salmon group had higher percentages of ALA, EPA, DPA, DHA, and 
total n-3 PUFAs and lower percentages of LA, ARA and total n-6 fatty acids than the 
control group. For the absolute concentrations of the fatty acids in the cord plasma TAGs, 
the same pattern was found: EPA, DPA, DHA, and total n-3 PUFA concentrations were 
higher in the salmon group compared to the control group, while the concentration of. ARA 
was  higher  the  control  group.  Each  of  the  ratios  (ARA/EPA,  ARA/DHA, 
ARA/(EPA+DHA), n-6 PUFA/n-3 PUFA) was higher in the control group. Total TAG fatty 
acids (μg/mL) did not differ between the groups. 
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Table 4.8: Cord plasma triglyceride (TAG) fatty acid composition according to study group 
 











 (n=47)  p 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
EPA (20:5n-3)  0.3  0.2  0.6  0.3  <0.001  EPA (20:5n-3)  0.50  0.32  0.92  0.59  <0.001 
DHA (22:6n-3)  3.2  1.2  4.7  1.7  <0.001  DHA (22:6n-3)  4.81  2.74  7.79  4.39  <0.001 
14:00  1.7  0.3  1.7  0.4  0.433  14:00  2.86  2.31  3.17  2.28  0.509 
16:00  28.4  1.8  28.5  1.8  0.887  16:00  48.77  38.85  51.74  34.56  0.697 
16:1n-7  6.2  1.1  6.3  1.0  0.751  16:1n-7  10.15  6.42  11.75  8.66  0.316 
18:00  4.2  1.0  4.7  1.5  0.086  18:00  6.77  4.18  8.10  5.11  0.173 
18:1n-9  30.7  3.6  30.0  2.9  0.308  18:1n-9  53.79  51.18  54.21  35.60  0.964 
18:1n-9Trans  3.6  0.9  3.5  0.6  0.439  18:1n-9Trans  5.97  4.07  6.33  4.17  0.680 
18:2n-6  12.5  1.9  12.4  2.2  0.875  18:2n-6  21.61  19.02  22.95  15.73  0.711 
18:3n-6  0.7  0.3  0.6  0.2  0.050  18:3n-6  1.02  0.63  0.97  0.61  0.703 
18:3n-3  0.4  0.2  0.5  0.2  0.015  18:3n-3  0.81  0.98  1.00  0.83  0.313 
20:00  0.1  0.04  0.1  0.1  0.372  20:00  0.13  0.05  0.15  0.08  0.088 
20:1n-9  0.2  0.1  0.2  0.1  0.305  20:1n-9  0.36  0.52  0.31  0.21  0.561 
20:2n-6  0.2  0.1  0.2  0.1  0.725  20:2n-6  0.39  0.30  0.42  0.26  0.512 
20:3n-6  0.9  0.2  0.9  0.2  0.361  20:3n-6  1.39  0.74  1.58  1.09  0.334 
ARA (20:4n-6)  6.2  2.4  4.7  1.7  0.001  ARA (20:4n-6)  9.05  4.77  7.98  4.71  0.275 
DPA (22:5n-3)  0.4  0.2  0.6  0.2  <0.001  DPA (22:5n-3)  0.69  0.54  1.10  0.79  0.004 
Total SFAs  34.4  2.4  34.9  2.4  0.247  Total SFAs  58.52  44.84  63.17  41.43  0.605 
Total MUFAs  40.7  4.2  40.0  3.7  0.360  Total MUFAs  70.28  61.00  72.59  48.25  0.840 
Total PUFAs  24.9  4.6  25.1  4.1  0.849  Total PUFAs  40.25  26.19  44.70  27.36  0.425 
Total n-3 PUFAs  4.4  1.5  6.4  2.1  <0.001  Total n-3 PUFAs  6.80  4.08  10.81  6.35  0.001 
Total n-6 PUFAs  20.5  3.5  18.7  2.8  0.009  Total n-6 PUFAs  33.45  22.97  33.89  21.63  0.924 
            Total TAG fatty acids  169.05  129.89  180.46  115.40  0.656 
            ARA/DHA  2.06  0.79  1.14  0.70  <0.001 
            ARA/EPA  20.38  7.94  9.71  4.92  <0.001 
            ARA/ (EPA+DHA)  1.85  0.69  1.01  0.60  <0.001 
            n-6/n-3  5.12  1.82  3.28  1.40  <0.001 
Values are mean (SD) percentage (%) of total fatty acids and absolute concentration (μg/mL) in TAG; independent samples t-test p-values   220 
Total cord plasma EPA, DHA, ARA, and DPA concentrations 
 
Table  4.9  describes  the  total  cord  plasma  EPA,  DHA,  DPA,  and  ARA  concentrations 
calculated by summing up the concentrations of each of these fatty acids in the four lipid 
fractions (i.e. PC + CE + NEFA + TAG). Independent samples t-test between the groups 
showed that total plasma EPA, DHA, and DPA concentrations in the cord plasma were 
higher in the salmon group. Total plasma ARA concentration was not different between the 
two groups.  Irrespective of the group difference, the concentration of DHA was much 




 Table 4.9: Total cord plasma concentrations (μg/mL) of the 4 fatty acids of interest 
 
Fatty acid 
Control group (n=32)  Salmon group (n=35) 
p 
Mean  SD  Mean  SD 
EPA  4.92  1.77  7.09  2.66  <0.001 
DHA  53.49  17.23  62.24  19.06  0.05 
ARA  165.81  36.69  163.13  40.22  0.78 
DPA (n-3)  5.13  1.83  6.31  2.31  0.02 
Values are mean (SD) absolute concentration (μg/mL); independent samples t-test p-values 
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4.3.2.2 Fatty acid composition of cord blood mononuclear cells (CBMCs) 
 
Table 4.10 describes the fatty acid composition of CBMCs, expressed as percentages (%) of 
each fatty acid, for the two groups. Independent t-tests between the 2 groups were conducted 
and the results showed that some fatty acids tended to follow the same pattern as in the plasma 
lipid fractions (Section 4.3.2.1), but no significant differences between groups were observed. 
EPA, DHA and total n-3 PUFAs tended to be higher in CBMCs in the salmon group, while the 
ratios ARA/DHA and ARA/(EPA+DHA) tended to be higher in the control group. The ratio of 
n-6 PUFA/n-3 PUFA was higher in the control group compared to the salmon group. 
 
Table 4.10: Cord blood mononuclear cell (CBMC) fatty acid composition according to study group 
 
Fatty acid 
Control group (n=40)  Salmon group (n=40) 
p 
Mean  SD  Mean  SD 
EPA (20:5n-3)  0.3  0.3  0.4  0.3  0.339 
DHA (22:6n-3)  3.8  1.4  4.3  0.9  0.110 
ARA (20:4n-6)  17.5  3.9  17.7  3.4  0.843 
14:00  2.2  2.2  2.1  1.7  0.755 
16:00  24.9  2.9  24.7  2.3  0.711 
16:1n-7  1.3  0.9  1.1  0.8  0.517 
18:00  22.1  4.6  21.9  3.7  0.799 
18:1n-9  13.9  2.6  13.5  2.2  0.459 
18:1n-9Trans  2.7  2.6  2.9  2.4  0.695 
18:2n-6  6.0  2.9  5.4  1.6  0.248 
20:00  0.7  0.7  0.6  0.4  0.590 
20:1n-9  0.7  1.4  0.9  1.4  0.507 
20:2n-6  0.4  0.4  0.6  0.4  0.093 
20:3n-6  2.5  1.0  2.9  2.2  0.310 
DPA (22:5n-3)  0.9  0.5  1.0  0.5  0.190 
Total SFAs  49.9  5.5  49.3  4.3  0.550 
Total MUFAs  18.6  4.0  18.5  3.3  0.915 
Total PUFAs  31.5  4.8  32.2  4.2  0.458 
Total n-3 PUFAs  5.1  1.8  5.7  1.3  0.069 
Total n-6 PUFAs  26.4  4.5  26.5  4.2  0.910 
ARA/DHA  5.1  1.9  4.4  1.5  0.071 
ARA/EPA  94.7  78.2  71.3  53.7  0.125 
ARA/(EPA+DHA)  4.7  1.8  4.0  1.4  0.080 
n-6 PUFA/n-3 PUFA  5.8  2.1  4.9  1.4  0.029 
Values are mean (SD) percentage (%) of total fatty acids; independent samples t-test p-value   222 
 
4.3.3  Relationships between fatty acids in different pools  
4.3.3.1 Correlations between LC PUFAs in maternal plasma PC (%), cord 
plasma PC (%) and CBMCs (%) 
 
Figure 4.11 to Figure 4.13 present correlations between maternal plasma PC fatty acids at 38 
weeks gestation, cord plasma PC fatty acids, and CBMC fatty acids. Figure 4.11 shows that 
the percentages of EPA, DPA, DHA, and ARA in maternal plasma PC at 38 weeks gestation 
correlate significantly with the percentages of those fatty acids in cord plasma PC. Figure 4.12 
shows  that  the  percentages  of  EPA,  DPA,  DHA,  and  ARA  in  cord  plasma  PC  correlate 
significantly with the percentages of those fatty acids in CBMCs. Figure 4.13 shows that the 
percentages  of  DPA  and  DHA  in  maternal  plasma  PC  at  38  weeks  gestation  correlate 
significantly with CBMC percentages of those fatty acids; this was not found for EPA or 




   
   
 
Figure 4.11: Correlations between maternal plasma PC fatty acids (%) at 38 weeks gestation and cord 









   
   
 
Figure 4.12: Correlations between cord plasma PC fatty acids (%) and CBMC fatty acids (%): a) EPA, b) 
DHA, c) ARA, d) DPA 
 
a  b 







   
 
Figure 4.13: Correlation between maternal plasma PC fatty acids (%) at 38 weeks gestation and CBMC 
fatty acids (%): a) EPA, b) DHA, c) ARA, d) DPA 
 
a  b 
c  d   226 
4.3.3.2 Correlations between cord fatty acids and birth data and pregnancy 
outcomes  
 
Figure 4.14 shows the highly significant positive correlation between the DHA status in the 
cord blood both in plasma PC (expressed as percentage and absolute concentration) CBMCs 
with the duration of gestation. Gestational duration was not correlated with the maternal PC 
LC PUFAs (% of total fatty acids) at either 34 weeks or 38 weeks of gestation.  
 
 
   
 
 
Figure 4.14: Correlation between gestational duration (days) and a) cord plasma PC DHA %, b) cord 
plasma PC DHa (μg/mL), c) CBMC DHA % 
 
a.  b 
c   227 
Correlations were performed between the cord blood LC PUFAs (EPA, DHA, ARA) and birth 
data (birth weight, head circumference, infant length). Of those the only correlation close to 
significant was the negative correlation between cord blood plasma PC ARA (%) (not in the 
other lipid fractions or CBMCs) and infant length (r=-0.232, p-value=0.061). 
 
4.3.3.3 Correlations between LC PUFA intake during pregnancy (at 34 
weeks gestation) and LC PUFA status in the cord fatty acid status 
 
For both study groups EPA, DHA and ARA intake from the total diet at 34 weeks gestation 
(calculated from the FFQ) were not correlated with maternal plasma PC EPA, DHA or ARA 
percentages (%) at 34 weeks gestation. EPA, DHA and ARA intake from the total diet were 
not correlated with any of the LC PUFAs (%) in cord plasma PC or NEFAs. However, there 
were a number of significant positive correlations between the dietary intakes of EPA, DHA 
and ARA from the total diet and the absolute concentrations of various LC PUFAs in various 
cord plasma lipid fractions. Among these correlations were: 
  Dietary EPA with cord plasma EPA in NEFAs (r=0.335, p=0.002) 
  Dietary EPA with cord plasma TAG EPA (r=0.322, p=0.003) 
  Dietary DHA with cord plasma DHA in NEFAs (r=0.590, p<0.001) 
  Dietary DHA with cord plasma TAG DHA (r=0.251, p=0.023) 
  Dietary ARA with cord plasma ARA in NEFAs (r=0.247, p=0.026) 
 
  Finally, EPA and DHA from the total diet at 34 weeks gestation correlated positively 
with CBMC EPA (r=0.260, p=0.029 for EPA vs. EPA; r=0.267, p=0.024 for DHA vs. 
EPA). 
 
EPA, DHA and ARA intake from the total diet at 34 weeks gestation (calculated from the 
FFQ) were not correlated with maternal plasma PC EPA, DHA or ARA percentages (%) at 34 
weeks gestation. EPA, DHA and ARA intake from the total diet were not correlated with any 
of the LC PUFAs (%) in cord plasma PC or NEFAs for the control group. For the salmon 
group DHA intake from total diet at 34 weeks was significantly correlated with % DHA in 
cord plasma NEFAs (r=0.318, p=0.042). EPA, DHA and ARA intakes from the total diet at 34 
weeks gestation correlated with absolute concentrations (AC) of EPA, DHA and ARA in the 
NEFA  and  TAG  fractions  in  cord  blood  for  salmon  and  control  groups  and  with  the PC 
fraction only for the control group. These correlations were:   228 
For the control group: 
  Dietary EPA and DHA with cord plasma PC EPA (for EPA: r=0.388,p=0.012; for 
DHA: r=0.384, p=0.013) 
  Dietary  EPA,  DHA  and  ARA  with  cord  plasma  NEFA  EPA  (for  EPA:  r=0.487, 
p=0.001; for DHA: r=0.488, p=0.001; for ARA: r=0.439, p=0.004), NEFA DHA (for 
EPA: r=0.649, p<0.001; for DHA: r=0.636, p<0.001; for ARA: r=0.332, p=0.034) and 
NEFA  ARA  (for  EPA:  r=0.712,  p<0.001;  for  DHA:  r=0.696,  p<0.001;  for  ARA: 
r=0.398, p=0.034) 
  Dietary EPA and DHA with cord plasma TAG EPA (for EPA: r=0.353, p=0.024; for 
DHA: r=0.354, p=0.023), TAG DHA (for DHA: r=0.636, p<0.001) and TAG ARA 
(for EPA: r=0.422, p=0.006, for DHA: r=0.404, p=0.009) 
For the salmon group: 
  Dietary  EPA,  DHA  and  ARA  with  cord  plasma  NEFA  EPA  (for  EPA:  r=0.339, 
p=0.003;for DHA: r=0.329, p=0.042), NEFA DHA (for EPA: r=0.621, p<0.001; for 
DHA:  r=0.589,  p<0.001;  for  ARA:  r=0.362,  p=0.02)  and  NEFA  ARA  (for  EPA: 
r=0.563, p<0.001; for DHA: r=0.518, p=0.001) 
  Dietary  EPA,  DHA  and  ARA  with  cord  plasma  TAG  EPA  (for  EPA:  r=0.428, 
p=0.005; for DHA: r=0.402, p=0.009, for ARA:r=0.319, p=0.042), TAG DHA (for 
EPA:  r=0.338,  p=0.031,  for  DHA:  r=0.316,  p=0.044)  and  TAG  ARA  (for  EPA: 
r=0.504, p=0.001, for DHA: r=0.490, p=0.001, for ARA: r=0.411, p=0.008) 
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4.4  Discussion  
4.4.1  Discussion of my findings 
 
SIPS is the first randomised controlled trial with oily fish in pregnant women. In this chapter, 
the effect of the salmon intervention on the fatty acid composition of maternal plasma PC and 
of cord plasma lipids and immune cells is reported. The LC n-3 PUFAs of interest (EPA and 
DHA) have an important role in development and in the health of the fetus and neonate. The 
hypotheses of the work described in this chapter are that the maternal oily fish intervention 
will result in higher amounts of EPA and DHA in maternal PC, and in neonatal (cord) plasma 
lipids, and will result in higher amounts of EPA and DHA in CBMCs. It is very clear that the 
data obtained support the first of these hypotheses (i.e. in the salmon group EPA and DHA in 
maternal plasma PC increased and were higher than in the control group and EPA and DHA 
were higher in cord plasma lipids in the salmon group). However, the data obtained do not 
support the second hypothesis, in that EPA and DHA were not significantly higher in CBMCs 
in the salmon group. Nevertheless higher cord plasma PC DHA was associated with higher 
CBMC  DHA,  suggesting  that  as  supply  of  this  fatty  acid  to  the  fetus  increases  (e.g.  by 
increased oily fish consumption) then there is enhanced incorporation into immune cells.  
The results of the maternal plasma PC fatty acid analysis provide biochemical proof that the 
intervention (i.e. increased salmon consumption) had been successful and that the subjects had 
complied to it. 
 
Regarding the maternal plasma PC fatty acid data, at baseline (20 weeks gestation) the salmon 
group had higher percentages of EPA, DHA and total n-3 PUFAs and a lower percentage of 
ARA compared to the control group. This baseline difference in LC n-3 PUFA status matches 
with the baseline difference in fish consumption reported in chapter 3. Although the subjects 
were  randomly  assigned  to  the  two  groups  at  study  entry,  this  baseline  difference  is  a 
limitation of SIPS study.  
 
The measurements of maternal plasma PC fatty acids represent the effect of fairly short term 
changes in diet; others have reported measurement of fatty acid status in erythrocytes during 
pregnancy, as these reflect longer term diet effects (they have a lifespan of 120 days in blood   230 
circulation) (174). For SIPS, fatty acids in maternal immune cells and erythrocytes have been 
analysed, in order to better capture longer term changes in diet, but these findings are not 
reported in this thesis.  
 
In the control  group, maternal  plasma PC EPA, DPA, DHA, and ARA declined over the 
course of pregnancy. These results suggest that the mother is progressively depleted in these 
fatty  acids  (especially  DHA  and  ARA),  as  they  are  transported  to  the  fetus  to  meet  the 
demands for growth and development. This decline in maternal LC PUFA status over the 
course of pregnancy has been demonstrated previously and the extent of the decline in both 
DHA and ARA seen here is consistent with this earlier work (258;259). This gradual decrease 
is a normal phenomenon of pregnancy, and might reflect the maternal inability to obtain or to 
mobilise adequate amounts of these fatty acids for optimal fetal development The decrease in 
EPA may also be associated with its metabolism to DPA and eventually to DHA which is 
highly demanded in the fetus (58;253). The pregnancy-associated depletion of maternal DHA 
and  ARA  reflects  the  low  dietary  intake  of  these  LC  PUFAs  and  the  possible  maternal 
inadequacy to provide optimal amounts to the fetus.   
 
In contrast to the control group which had a mean daily intake of about 30 mg of EPA plus 
DHA from the total diet, the salmon group, which had a mean daily EPA+DHA intake of over 
400 mg from the total diet, the maternal status of EPA, DPA and DHA (expessed as % of fatty 
acids) did not decline in the salmon group and was higher than in the control group. This is the 
first  time  that  this  effect  of  maternal  salmon  consumption  in  pregnancy  has  been 
demonstrated. A higher LC n-3 PUFA status in maternal blood may mean that the mother can 
supply increased amounts of these important fatty acids to the fetus. This may be important for 
fetal growth and development and also might play a key role in the developmental plasticity of 
the fetal immune system (202). 
 
The  salmon  intervention  enhanced  the  pregnancy  associated  decline  in  ARA  in  maternal 
plasma PC. This may not be a desirable effect as ARA has important roles in fetal growth and 
develolment too (10;243;263).  
 
The higher LC n-3 PUFA status of the women in the salmon group is also important because it 
may indicate better capacity to store these fatty acids for later supply to the neonate through 
breast milk.    231 
 
The  results  of  the  cord  plasma  fatty  acid  analysis  have  been  presented  in  two  ways: 
quantitatively (g/mL plasma) and qualitatively (% of total fatty acids). Percentages reflect the 
level of each fatty acid relative to the rest of the fatty acids in the lipid fraction studied. This 
means that an increase in one fatty acid will be compensated by a decrease in % of at least one 
other fatty acid. It is worth noting that the use of fatty acid percentages is the most common 
way  of  presenting  this  sort  of  data  in  the  literature.  On  the  other  hand  the  absolute 
concentration of a fatty acid is not relative or dependent to the concentration of other fatty 
acids and therefore a change in the concentration of one fatty acid is not necessarily followed 
by a change in the concentration of any other. It must also be realised that a change in the 
absolute concentration of one fatty acid does not mean that there will be a change in the 
percentage of the same fatty acid and vice versa. The inclusion of both expressions in SIPS is 
a  strength  of  the  study  because  the  combination  provides  complete  information  of  the 
differences between the groups. In general greater and more significant effects were observed 
when the percentage data were used.  
 
This is the first study to show that a dietary intervention with fish during pregnancy increases 
LC n-3 PUFA status of the fetus/neonate. Higher cord erythrocyte LC n-3 PUFAs have been 
reported following fish oil supplementation in pregnant women (174). 
 
DHA and ARA in the cord plasma PC were much higher than in the maternal plasma PC (at 
38 weeks). DHA was on average 57% higher and ARA 219% higher in cord plasma PC 
(Figure 4.15). These findings agree with those from previous studies that found that relative 
amounts of ARA and DHA in umbilical cord blood were significantly higher than in maternal 
blood (258;264). This might point to a high neonatal need for ARA and DHA which are the 
most  abundant  n-6  and  n-3  PUFAs  in  neural  and  retinal  tissue,  respectively  (and  also  in 
immune cells). These high proportions could also be attributed to de novo synthesis by the 
fetus, although the capacity of the fetal liver to synthesise such LC PUFAs is limited (265). It 
is more probable that preferential transport through the placenta is favouring the transfer of 
these fatty acids to the fetal circulation, making them available to developing tissues like brain 
and retina (253;266). The study of Berghaus et al. showed that the fetus obtains fatty acids 
from a combination of de novo synthesis, a passive gradient dependent transplacental passage 
of NEFAs and a selective materno-fetal placental transport for certain fatty acids, such as 
physiologically important LC PUFAs (254).   232 
 
The calculation of total concentrations of EPA, DPA, DHA, and ARA across all four plasma 
lipid fractions showed higher concentrations of the three LC n-3 PUFAs in the salmon group 




   
   
Figure 4.15: Mean relative contributions of EPA, DPA, DHA and ARA (% of total fatty acids) to maternal 
plasma PC throughout pregnancy (20, 34, 38 weeks of gestation) and to umbilical cord plasma PC in the 
control group. Data are taken from Table 4.2 and Table 4.5 
 
The positive correlations found between the DHA status in the cord blood [plasma (expressed 
as percentage and absolute concentration) and mononuclear cells] with gestational length is a 
very  important  finding.  This  result  is  supported  by  evidence  in  the  literature  that  relates   233 
maternal  dietary  intake  of  DHA  (and  ARA)  with  gestational  length  and  also  infant 
characteristics at birth (birth weight, head circumference) (39;243;248;263). 
Increased production of PGE2 by decidual macrophages has been shown to regulate labour 
initiation at birth (267).There is evidence that a high intake of long chain (n-3)-fatty acids 
prolongs  gestation  in  humans  by  reducing  uterine  prostaglandin  formation,  possibly  by 
inhibiting formation of prostaglandin F2 alpha and prostaglandin E2 (39;268). 
 Longer  gestational  length  could  be  mediated  by  altered  arachidonic  acid-derived-
prostaglandin  production  in  the  mother,  since  it  was  observed  that  matenal  PBMC  PGE2 
production was lower in pregnant women in the salmon group (unstimulated cells, 34 weeks 
gestation) (p=0.023) (as shown in the thesis of L-S Kremmyda) and PGE2 production tended 
to be lower in CBMC after stimulation with LPS (p=0.056) (Chapter 5).  
4.4.2  Comparison with the findings of other studies 
4.4.2.1 Fatty acid status at birth 
 
Previous studies have shown variations in LC n-3 PUFA status in women during pregnancy 
and in infant blood and this was supported by a review reporting moderate variations in DHA 
and ARA status in cord blood lipids in different populations (269). 
 
Mattoras et al. assessed in a cross-sectional study in Spain the relationship between intake of 
LC  n-3  PUFAs  during  pregnancy  (162  mother–neonate  pairs  from  normal  at-term 
pregnancies) and the levels of these fatty acids in maternal and neonatal plasma lipids and 
erythrocytes (270). The n-3 PUFA intake assessed by interview was significantly correlated 
with n-3 PUFA levels in the plasma of both mothers and neonates. The levels of n-3 PUFAs in 
mothers and neonates were significantly correlated both in plasma fatty acids (expressed both 
as a percentage and as absolute values) and in erythrocyte phospholipids (percentages). In 
conclusion, in a well-nourished population the n-3 PUFA levels of the newborn infants are 
clearly influenced by those of their mothers and the higher the levels in mothers, the higher 
those in the neonates (270). Observations made in this chapter are in accordance with this.  
 
De Vriese et al. described dietary fat intake during pregnancy (by FFQ) and the relationship 
between the intake of PUFAs and the fatty acid composition of maternal and umbilical plasma   234 
PC and CEs at delivery. Maternal and umbilical blood samples were collected at delivery from 
30 healthy pregnant women. Meat and poultry contributed most to the intake of ARA whereas 
fish was the major source of EPA and DHA in the diet. EPA and DHA (%) of maternal plasma 
PC were positively related to the intake of these fatty acids during pregnancy. EPA and the 
sum of n-6 PUFAs (%) in cord plasma PC were positively correlated with the dietary intake of 
these fatty acids (256). In SIPS, EPA and DHA dietary intake measured at 34 weeks gestation, 
was not correlated positively with those fatty acids (%) in cord plasma PC. Dietary EPA intake 
was correlated positively with DHA (r=0.219, p-value=0.048) in cord plasma PC (absolute 
concentrations). 
 
Donahue et al. recently assessed second trimester maternal diet with FFQs (n =1666), mid-
pregnancy maternal erythrocyte PUFA concentrations (n =1550), and umbilical cord plasma 
PUFA concentrations (n =449) in the US (271). Mean maternal intake of total n-3 PUFAs was 
1.17 g/d and of EPA+DHA 0.16 g/d. In SIPS, at 20 weeks gestation mean maternal intake 
assessed by FFQ of total n-3 PUFAs in the control group was 1.8 g/day and in the salmon 
group 1.9 g/day, while EPA+DHA was 0.05 g/day for the control group and 0.125 g/day for 
the salmon group. Compared to the study of Donahue et al. conducted in the US, pregnant 
women in the UK (SIPS control and salmon groups) have similar total n-3 PUFA intake and 
similar EPA plus DHA intake (similar to the SIPS salmon group rather than the control). Mean 
maternal erythrocyte and cord plasma PC PUFA concentrations were 7.0% and 5.2% (total n-
3) and 5.0% and 4.6% (EPA+DHA). In SIPS, at 20 weeks gestation (second trimester) mean 
maternal cord plasma PC PUFA concentrations were 5.8 % in the control group and 6.5 % in 
the salmon group (total n-3 PUFAs) and 4.8% and 5.4% (EPA+DHA) in the control and 
salmon group respectively. Again these values are similar to those reported by Donahue et al. 
(271). Mid-pregnancy diet–blood and blood–blood correlations were strongest for EPA+DHA 
(r = 0.38 for diet with maternal blood, r = 0.34 for diet with cord blood, r = 0.36 for maternal 
blood  with  cord blood).  In SIPS, maternal  diet (EPA plus  DHA) was not  correlated with 
maternal plasma PC fatty acids (expressed as percentages in PC fraction) or cord plasma PC 
EPA or DHA (%), but was positively correlated with CBMC EPA (%) (r=0.265, p-value= 
0.026). This is a strong indication of the dependence of the fetus on the mother and how 
important the window of pregnancy and antenatal nutrition on determining fetal growth and 
child health may be. 
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Zhang et al. recently investigated maternal dietary intake of EPA and DHA (by FFQ) and the 
levels of these fatty acids in plasma PC of pregnant women and their neonates from river/lake, 
coastal and inland regions of China. The median maternal plasma PC levels of DHA and EPA 
were higher in the river/lake and coastal regions compared to the inland region. Neonates in 
the inland group had higher levels of ARA and lower levels of EPA and DHA in their cord 
plasma PC compared to those in the lake/river and coastal regions. In conclusion, there was a 
close association between dietary intake of EPA and DHA and the corresponding levels of 
these  fatty  acids  in  maternal  plasma  PC  and  maternal  plasma  EPA  and  DHA  were  also 
positively  associated  with  the  corresponding  levels  in  cord  plasma  PC  (272).  In  SIPS 
significant correlations were observed between maternal dietary EPA and DHA status and 
those  fatty  acids  in  cord  blood  plasma  in  PC,  NEFAs,  and  TAGs  (expressed  as  absolute 
concentrations and not percentages) as well as with those fatty acids in CBMCs (expressed as 
%). The most interesting is the positive correlations between dietary EPA and DHA (at 34 
weeks gestation) with CBMC EPA (Section 4.3.3.3). 
 
4.4.2.2 Supplementation studies during pregnancy 
 
Although SIPS is the first study to examine oily fish consumption in pregnancy, there are 
several studies of maternal supplementation with fish oil as a strategy to increase EPA plus 
DHA intake. 
 
The  European  trial  by  Kraus-Etschmann  et  al.  showed  that  supplementation  of  pregnant 
women from gestation week 22 until delivery with a fish oil preparation (0.15 g EPA plus 0.5 
g DHA/day) was associated with increased maternal plasma PC EPA (0.18% at 20 weeks to 
0.53% at  30 weeks  gestation) and DHA (5.75% at  20 weeks  to  7.26% at  30 weeks) and 
subsequently greater cord plasma PC DHA compared to the placebo group (9.90% in the 
salmon  group  vs.  8.74%  in  the  control  group)  (177).  SIPS  identified  the  same  pattern  of 
increase of EPA and DHA in maternal and cord plasma PC, although the extent of the increase 
seen was smaller in SIPS. This could be attributed to the fact that the EPA plus DHA weekly 
dose in the supplementation study (0.65 g x 7 = 4.55 g EPA+DHA) was higher compared to 
the dose of EPA plus DHA provided from fish in SIPS in a week (3.46 g EPA+DHA). Also, 
the size of the effect could be due to the fact that supplementation studies provide a constant   236 
amount of selected nutrients on a daily basis in contrast to a food intervention that provides 
specific foods (in this occasion salmon) for certain times in the week. 
 
A RCT, conducted in Australia by Dunstan et al. with LC n-3 PUFA supplementation via fish 
oil (4 g/day that provided 1.1 g/day EPA and 2.2 g/day DHA) in healthy pregnant women 
from 20 weeks gestation to delivery, showed increased maternal erythrocyte PC EPA and 
DHA percentages and significantly decreased ARA percentage compared to baseline. At birth, 
erythrocyte PC EPA and DHA percentages were significantly higher in the salmon group and 
ARA % was significantly lower in the fish oil group compared to the control (174). The size 
of  the  effect  of  this  supplementation  was  large  due  to  the  high  dose  of  EPA  plus  DHA 
provided: Dunstan et al. provided 21.7 g (3.1 g/day x 7 days) EPA+DHA per week from fish 
oil while SIPS provided 3.46 g (1.73 g/portion x 2 portions) EPA+DHA per week from oily 
fish (salmon).  
 
Supplementation  of healthy  Norwegian women with  1.2 g/d  DHA and 0.8 g/d  EPA  from 
gestation week 18 till delivery, led to higher DHA proportion in cord plasma than in the 
control group which received corn oil (247) in accordance to SIPS results. Although this study 
did not assess the maternal plasma DHA status, DHA was increased in breastmilk, showing 
the activation of maternal stores during lactation. 
 
Consistent with the previous study, Velzing-Aarts et al., examining the effect of three low-
dose fish oil supplements, observed an effect on higher neonatal EPA and DHA % of total 
cord plasma fatty acids after supplementation of pregnant women from the second trimester to 
delivery with 0.5-1 g of LC n-3 PUFAs per day (273). 
 
A lower amount of DHA (200 mg/day) was administered to 50 healthy women in the UK from 
gestation  week  15  until  term.  This  increased  DHA  proportions  in  maternal  plasma  and 
erythrocytes but had no effect on cord plasma or erythrocyte fatty acid composition (274). In 
the study of Sanjurno et al., 20 pregnant women received 200 mg/day of DHA during the last 
trimester of pregnancy. DHA was significantly higher and ARA was significantly lower in 
plasma  in  the  study  group  compared  to  the  unsupplemented  control  group.  The  neonates 
showed no differences of LC n-3 and n-6 PUFAs between the two groups. The results showed 
that an oral supplementation with 200 mg/day of DHA during the final stages of pregnancy is   237 
reflected  in  an  increase  in  the  plasma  level  of  this  fatty  acid  in  the  mother,  but  not  the 
offspring (275). 
 
In these latter two supplementation studies the dose of LC n-3 PUFAs used was closer to what 
SIPS delivered as 2 portions of salmon per week (equivalent of 165 mg/day DHA and 82 
mg/day EPA (247 mg/day EPA plus DHA)). Although the “low dose” fish oil supplements did 
not find changes in fetal fatty acid status at birth, SIPS found such an effect of salmon. This 
may mean that the oily fish as a whole food (twice per week) is more effective than a low dose 
supplement on a daily basis. 
 
In another RCT, by van Houwelingen et al., 23 Norwegian women were supplemented with 
2.3 g/day of DHA from week 30 of pregnancy and this high dose supplementation resulted in 
increase both in maternal and subsequent neonatal DHA status (276). 
 
From  the  results  of  the  studies  above  and  of  SIPS  it  seems  that  dosage,  and  duration  of 
supplementation/dietary  intervention  as  well  as  habitual  dietary  fish  consumption  of  the 
subjects could explain the variations in fetal DHA levels. When DHA stores are depleted, 
especially  in  low  consumers  of  oily  fish  or  less  well  nourished  women,  low  dose  DHA 
supplementation may primarily affect the fetal DHA status rather than the maternal, as DHA is 
selectively  transported  to  the  fetus  by  the  placenta  (266;277).  However,  a  higher  dose 
supplementation might be needed so as to satisfy the maternal stores as well. The European 
trial used intermediate amounts of DHA that succeeded in repletion of maternal and fetal DHA 
stores. This was in agreement with the study conducted by Velzing-Aarts et al. (273). On the 
other hand a very high dose supplementation may additionally help to sustain maternal n-3 
PUFA stores during breastfeeding (175) but it is still unclear whether the improved fatty acid 
status of the offspring will have any functional effect on the developing infant such as growth, 
cognitive development or immunomodulatory effects. 
 
Epidemiological studies have shown that neonates with higher levels of plasma phospholipid 
DHA had longer gestational length  and birth weight  (263) and this is  suggested by some 
intervention trials (247;278) but not others (279). In agreement with those epidemiological 
studies, in SIPS there was a strong positive correlation between DHA status in cord blood (in 
plasma and CBMCs) and gestational duration. The salmon group had about 4 days longer   238 
gestation  than  the  control  group,  although  this  difference  was  not  statistically  significant 
(Chapter 2, Table 2.9; p=0.094).  
 
Also a number of studies have demonstrated improved visual and other neurological outcomes 
particularly in preterm infants supplemented with DHA  (10). However, in the latter study 
postnatal rather than antenatal supplementation with DHA was been associated with subtle 
differences  in  neurodevelopment  outcomes.  This  suggests  that  longer  term  and  larger 
intervention studies during the antenatal period are required (with fish oils and oily fish) so as 
to address the potential effects of fetal DHA enrichment on a variety of health issues and 
especially on immune outcomes (202;203).   239 
4.5  Conclusion 
 
Pregnancy  is  associated  with  changes  in  the  blood  lipid  profile  and  in  the  fatty  acid 
components of these lipids. The literature has shown that percentages of EPA and DHA in 
maternal plasma lipids decline during pregnancy. This was also observed in the control group 
in  SIPS,  probably  related  with  preferential  transfer  of  DHA  thought  the  placenta  to  the 
growing fetus. SIPS, being the first randomised controlled trial with fish during pregnancy, 
showed  that  consumption  of  two  portions  of  salmon  per  week  (between  week  20  until 
delivery) prevented the pregnancy associated decrease in percentages of EPA and DHA in the 
phospholipid (PC) fraction, and also resulted in increased levels of these LC n-3 PUFAs in 
maternal PC compared to the control group. Thus the consumption of 2 portions of salmon per 
week that was confirmed by the dietary assessments (FFQs and fish diaries) and provided an 
intake of over 400 mg/day EPA+DHA was proven also biochemically, by the increased status 
of those LC n-3 PUFAs in the mothers. 
 
In the cord blood, significant changes in the status of LC n-3 (EPA and DHA) and n-6 (ARA) 
PUFAs were mostly observed in all lipid fractions when data was expressed as percentages 
rather than absolute amounts. The pattern observed in SIPS was that EPA and DHA status was 
increased significantly whereas the ARA status was decreased significantly in the cord blood 
plasma in the salmon group infants compared to those of the control group. A similar trend 
was found for those same LC PUFAs measured in the immune cells (CBMCs) but here the 
effect of group was not statistically significant. However in the next chapter (immune chapter) 
it is shown that these changes had some impact on the functionality of these cells (eicosanoid 
and cytokine production). 
 
To conclude, the salmon intervention increased EPA and DHA concentrations in maternal 
plasma, and these fatty acids were successfully passed to the fetus in the cord plasma but not 
in the immune cells. The following chapter explores the immunomodulatory effect of this 
improved fatty acid composition in cord blood.   240   241 
 
5  Salmon in pregnancy study (SIPS): The effect of salmon 
intervention on infant immune outcomes in cord blood   242 
 
5.1  Introduction 
 
The maturation of the fetal immune system depends on several maternal influences including 
the maternal immune response (1). Therefore, the focus of early life origins of immunity is on 
factors influencing maternal immune status and the subsequent effect on the immune response 
of the fetus (280). During pregnancy, immunological changes occur in the mother in order to 
suppress cell-mediated responses to fetal and paternal antigens which thus allows the normal 
progression of pregnancy (84). The maternal immune response is skewed during pregnancy 
towards  type  2  helper  T-cell  (Th2)  responses  so  as  not  to  reject  the  fetus,  and  this  Th2-
dominant response is “transferred” to the fetus. Th1 responses normally up-regulate in the 
infant immune system during the first two years of life as a result of antigenic exposure. 
However, different temporal changes have been observed in the infants of atopic mothers, 
which show immature Th1 immunity and altered Th2 responses (82). Although Prescott et al. 
reported  that  newborns  (irrespective  of  their  atopy  heritability)  have  skewed  cord  blood 
mononuclear cell (CBMC) Th2 cytokine responses (interleukin (IL)-4, IL-5, IL-6, IL-9, IL-3) 
to common environmental allergens and a high level of IL-10 production (regulatory cytokine) 
(82;112),  other  studies  have failed to  demonstrate this Th2 bias at  birth and further have 
shown  no  association  between  maternal  allergen  exposure  during  pregnancy  and  CBMC 
responses (281;282). Smillie et al. reported no association between levels of Der p1 in the 
maternal mattress during pregnancy and CBMC proliferative responses after stimulation with 
Der p1 in 225 neonates participating in an allergen avoidance study in Manchester, UK (281). 
Similarly Miller et al. reported no association between measured levels of house dust mite, 
mouse  and  cockroach  allergens  during  pregnancy  and  CBMC  responses,  while  CBMC 
responses  were  observed  in  the  absence  of  allergen  induced  maternal  mononuclear  cell 
responses (282). 
 
Substantial  immune  development  happens  both  in  utero  and  post-natally  (106),  and  it  is 
possible  that  such  development  can  be  influenced  by  nutritional  factors  (58).  However, 
relatively little attention has been devoted to the potential for early life programming of the 
immune system by dietary factors. The food consumed by the mother during pregnancy can 
contribute to the immunologic profile of herself and the offspring (70). During pregnancy, a 
diet enriched in n-6 polyunsaturated fatty acids (PUFAs), which are contained, for example, in 
margarine and vegetable oils, seems to be more likely to be associated with higher risk of   243 
eczema in the child during the first 2 years than n-3 PUFAs, which are contained in fish, at 
least when consumed during the last 4 weeks of pregnancy (77;152). Possible mechanisms 
might be that higher levels of n-3 PUFAs are associated with less neonatal oxidative stress, 
lower  production  of  inflammatory  leukotriene  (LT)  B4  and  inflammatory  cytokines,  and 
enhanced activity of protein kinase c-z (inverse association with allergic diseases) in T cells, 
as shown in human (131) and murine (143) studies. On the other hand, not only the absolute 
content but also the ratio of n-6 to n-3 PUFAs might influence the development of either 
tolerance or sensitization to food allergens: in a rat model a ratio of 9:1 in the mothers‟ diet 
prevented tolerance induction in neonatal rats, which otherwise could be achieved when the 
diet  was  n-3  PUFA  enriched  (283).  Fish  oil  supplementation  during  pregnancy  has  been 
shown to increase the levels of the long-chain (LC) n-3 PUFAs eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) in breast milk up to 6 weeks after delivery in a randomized 
controlled human trial (175). Other human studies showed that fish or fish oil consumption 
decreases atopic dermatitis risk (153) or at least the severity of atopic dermatitis in high risk 
children at 1 year of age (77). A body of mainly epidemiological literature has developed, 
which  associates  temporal  changes  in  the  patterns  of  intake  of  n-6  and  n-3  PUFAs  with 
temporal  changes  in  the  incidence  and  prevalence  of  atopic  sensitisation  or  its  clinical 
manifestations  (allergies,  atopic  dermatitis,  hayfever  and  allergic  asthma),  and  there  is  a 
proposed molecular and cellular mechanism to explain the observed association (112). 
5.1.1  PUFA hypothesis and atopic disease 
 
There have been many reports associating an “abnormal” n-6 and n-3 PUFA exposure or 
composition to the occurrence of atopic diseases. The elongated and desaturated products of 
the essential fatty acids linoleic acid (LA) and -linolenic acid (ALA) regulate inflammatory 
processes. Arachidonic acid (ARA) is a precursor of inflammatoery eicosanoids, and mediates 
chemotactic signals and smooth muscle cell contraction, while EPA, dihomo--linolenic acid 
(DGLA)  and  DHA  are  known  to  be  involved  in  suppressing  inflammatory  pathways.  An 
abnormal PUFA composition has been demonstrated in cord blood (CB) serum, plasma and 
erythrocytes of infants at high risk for atopic diseases compared with CB of infants at no risk 
for atopy (129;130;148). One study reported an altered CB serum PUFA composition to be 
associated with the onset of atopic diseases after a follow-up of 1 year in a cohort of 57 
newborns at risk (148). Another study reported abnormal proportions of n-3 and n-6 PUFAs in 
the serum of allergic mothers; in this study, a higher content of n-3 PUFAs was found in   244 
women whose infants did not develop atopic disease during the first 6 years of life (130;149). 
The predictive value of  PUFA exposure for atopy was  investigated in  a  large  UK cohort 
(Avon longitudinal study of parents and children) of over 1000 newborns (150). By analyzing 
ratios of different n-6 to n-3 PUFAs and their products in erythrocytes the authors could detect 
a  significant  association  of  alteration  in  ratios  to  wheezing  and  eczema  although  these 
associations were no longer significant after adjustment for multiple comparisons. The authors 
concluded that exposure to n-6 and n-3 PUFAs is not a likely predictive factor for an early 
onset of atopic diseases (150).  
A recent review by Sala-Vila et al. summarized studies of fatty acid composition in relation to 
atopy  (287).  Some  studies  report  elevated  LA  in  atopy,  while  some  studies  report  lower 
amounts  of  the  n-6  PUFAs,  including  ARA,  and  of  LC  n-3  PUFAs  in  atopy,  although 
observations on this were not consistent. These data did not support the hypothesis that atopy 
is associated with a high exposure to, and status of, n-6 PUFAs. Intervention studies with n-3 
PUFAs in pregnant women, infants and children suggest some clinical benefits, although how 
long lasting these are remains to be determined. The authors proposed that the observation of 
low ARA (LC n-6 PUFA) status in atopy suggests that fish oil intervention (LC n-3 PUFAs), 
which targets ARA status and metabolism, may not be ideal and that a combination of fish oil 
with some LC n-6 PUFAs could be more efficient (284). Nevertheless, intervention trials with 
larger sample sizes and longer follow up period of the infants are needed so as to draw more 
definite conclusions. 
 
Additionally, in the general introduction (Chapter 1) are explored the other two hypotheses 
associated with atopic disease: „hygiene‟ hypothesis and „antioxidant‟ hypothesis. 
5.1.2  Mediators of atopy in cord blood and in childhood 
 
Miles et al. observed significantly lower numbers of CD25
+ (activated) T cells in the cord 
blood of high risk babies who had developed both allergic symptoms and positive skin prick 
tests by one year of age when compared with the low risk group (285). CD45RO
+ (memory) T 
cells  were  detected  in  both  high  and  low  risk  babies  with  a  trend  for  lower  numbers  of 
memory cells to be detected in high risk infants who later developed allergic symptoms and/or 
positive skin prick tests. The significantly lower numbers of memory T cells in the high risk 
babies suggested a suppression of T cell activation or lack of antigenic priming in this group 
(285). Devereux et al. determined the CD45 isoform of neonatal Th cells that respond to   245 
allergen stimulation  (286).  They  demonstrated that  50% of CBMC proliferative responses 
after stimulation with timothy grass allergen are mediated by T cells expressing CD45RA
high 
and 50% are mediated by T cells expressing the CD45RO
high isoforms. It was concluded that 
timothy grass allergen specific fetal Th cells can be sensitised in utero, but that this priming 
does not occur in all individuals even if their CBMCs are able to respond to the allergen (286). 
This evidence questions the reliability of CBMC responses to allergen sensitisation in utero 
and  the  complexity  of  the  relation  between  antenatal  allergen  exposure  and  in  utero 
sensitisation. 
 
Allam et al. have reviewed the role of soluble mediators of atopy in the serum or plasma of the 
patients in the pathophysiology of atopic diseases (287). A characteristic feature of atopy is a 
Th2-dominated  immune  response;  Th2  related  cytokines  like  IL-4,  IL-5  and  IL-13  are 
involved in the induction of IgE synthesis (84;288). Th2 related cytokines have also been 
analysed in CB. A recent publication reported that detectable levels of IL-4 and IFN-γ in CB 
of newborns were associated with a lower risk of developing allergic asthma and sensitization 
to some inhalant allergens after the follow-up period to 6 years (289). 
Hinz  et  al.  within  the  LINA  (Lifestyle  and  environmental  factors  and  their  Influence  on 
Newborns Allergy risk) mother-child study determined the frequency and function of Treg 
cells, cytokine production and the total IgE concentration in pregnant women in the 34
th week 
of  gestation  and  in  corresponding  CB  at  birth.  Because  CB  IgE  has  been  shown  to  be 
predictive for allergic diseases in early childhood, these results indicated that reduced maternal 
Treg cell numbers and increased Th2 cytokine production during pregnancy might influence 
the allergy risk of the child (290). Balossini et al. found that in newborns of allergic fathers 
IL-10  levels  tended  to  be  lower  and  transforming  growth  factor  (TGF)-β1  levels  were 
significantly lower than in newborns of non-allergic parents (291). Schaub et al. investigated 
Treg cells in CB in the context of maternal atopy. In offspring of atopic mothers, Treg cell 
numbers, expression, and function were impaired at birth. Th17 cells  correlated with Th2 
cells, independently of maternal atopy (292). Smith et al. found that children with egg allergy 
(at 12 months) had evidence of reduced neonatal CD4
+CD25
+CD127
low Treg cell function. 
This study confirmed the presence and activity of Treg cells in CB and provided preliminary 
evidence of differences in neonates who progress to allergic disease in the first year of life 
(293).   246 
5.1.2.1 Cytokine production in cord blood mononuclear cells  
 
Lappalainen et al. found that there is maturation of cytokine production from birth to the first 
year of age. Stimulated cytokine responses were higher in mothers' than in children's blood 
samples; children of food sensitised mothers had elevated cord blood IL-10 responses and a 
decreased  IFN-γ/IL-5  ratio.  The  results  suggested  that  both  adaptive  and  innate  immune 
responses increased from birth to 1 year of age, although they are weak when compared to the 
adult response (294). Warner et al. found reduced IFN-γ secretion in neonates that had a high 
risk of atopy (295), and this reduced IFN-γ secretion was significantly associated with future 
atopic  dematitis  (81).  Liao  et  al.  observed  decreased  production  of  IFN-  and  increased 
production of IL-6 by CBMCs from newborns with a high risk of allergy. CD4
+ T cells in the 
presence of monocytes and isolated monocytes from the high-risk group produced a much 
greater amount of IL-6, either spontaneously or after stimulation, than did those of the low-
risk group; CD4
+ T cells from the low-risk group produced a significantly greater amount of 
IFN-γ than did those from the high-risk group; cord blood basophils stimulated with PHA 
could produce a significant amount of IL-4; there was an inverse correlation between the 
production of IFN- and cord blood IgE level and the number of natural killer (NK) cells was 
significantly  lower  in  high-risk  group  than  the  low-risk  group.  In  conclusion  this  data 
suggested increased production of IL-6 and decreased production of IFN-γ by CBMCs appear 
to be the characteristic of newborns with high risk of allergy (296). 
 
Many studies have focused on the relevance of Th2 cytokine production in neonates for the 
development of atopic disorders in early infancy with sometimes conflicting results. In this 
context, the predictive value of the Th2 cytokine IL-13 as an early marker for atopy has been 
investigated.  Williams  et  al.  showed  that  babies  at  risk  of  atopic  disease  in  infancy 
demonstrate  defective  IL-13  production  at  birth  (297).  This  might  represent  an  inherent 
immaturity in the development of T cell-cytokine responses in babies at genetic risk for atopy 
or  could  be  a  consequence  of  downregulation  of  responses  by  other  factors.  Normal 
pregnancy,  irrespective  of  atopic  status,  is  associated  with  the  production  of  appreciable 
quantities of IL-13 initially by the placenta and subsequently by the fetus (297). Another study 
reported an association between newborns producing elevated IL-13 levels and increased risk 
of developing atopic symptoms (298). Boyle et al. found that infants at high risk of allergic 
disease had a reduced percentage of CD14
+ monocytes and reduced CD14 mean fluorescence 
intensity on mononuclear cells. They also had a decreased dendritic cell (DC) percentage in   247 
mononuclear cells cultured with ovalbumin (OVA) or lipopolysacharide (LPS) as compared 
with infants at intermediate or low risk of allergic disease. No relationship was seen between 
risk  of  allergic  disease  and  toll-like  receptor  (TLR)  2  or  TLR4  expression,  or  FoxP3 
expression in cultured cells. In conclusion, infants with a biparental history of allergic disease 
had altered markers of innate immunity at birth, with reduced expression of membrane bound 
CD14 and consequently reduced in vitro development of DCs.  Further work is needed to 
understand the role that these alterations  play in the pathogenesis of allergic disease, and 
whether interventions to up-regulate fetal CD14 expression can prevent allergic disease (299). 
 
IL-10 and IL-5 responses at birth predict risk for respiratory infections in children with atopic 
family history. Zhang et al. measured cord blood T-cell capacity to produce IL-10 and IL-5, 
and  related  these  to  subsequent  infection  history  (300).  IL-10  and  IL-5  were  associated, 
respectively, with resistance or susceptibility to infections. The greatest contrasting effects of 
these two cytokines were seen when they were considered in combination by generating IL-
10/IL-5 response ratios for each subject. The low IL-10/high IL-5 T-cell response phenotype 
was strongly associated with susceptibility to all grades of acute respiratory infection, relative 
to the more resistant high IL-10/low IL-5 phenotype. In conclusion, excessive production of 
IL-5 by T cells at birth was associated with increased risk for subsequent severe respiratory 
infections, and this risk was attenuated by concomitant IL-10 production (300). 
 
Innate immune responses early in life are critical for the development of allergic illnesses. The 
underlying mechanisms remain unknown, but include T-cell responses either along Th1/Th2 
pathways or via Treg and Th17 cells. Schaub et al. investigated the impairment of T helper 
and  Treg  cell  responses  at  birth  (292).  The  aim  of  this  study  was  to  investigate  T-cell 
responses to innate and adaptive stimuli at birth and to compare these findings with adult 
immune responses. Proliferation and cytokine responses to innate stimuli were less mature at 
birth than in adulthood. Treg and Th17 cells were less expressed in cord than in adult blood. 
Mitogen-induced suppression of Treg cells on T-effector cell function was less efficient in 
cord than in adult blood. At both ages, Th17 cells were correlated with Th1/Th2 cells, but not 
with  IL-10  secretion  following  innate-stimulation.  So,  innate  immune  responses  were 
immature at birth. Furthermore, the functions of Treg and Th17 cells were impaired. Th17 
cells in association with Th1/Th2 cells may be involved in early immunomodulation. Potent 
innate immune stimulation early in life can potentially contribute to protection from allergic 
diseases (292).   248 
5.1.2.2  Cord blood IgE production 
 
Atopic disorders are closely linked to elevated serum IgE levels in early life. Taking positive 
atopy family history into consideration, the percentage of elevated CB IgE concentrations 
increased with the number of close family members suffering from atopic diseases  (287). 
Karmaus et al. found that IgE is reduced with increasing birth order. The findings suggested 
that cord IgE is reduced in pregnancies with higher order, indicating that the sibling effect 
upon atopy may have its origin in utero (301). Liu et al. (302) suggested that maternal, but not 
paternal,  total  IgE  level  correlated  with  elevated  infant  IgE  levels  and  infant  atopy.  This 
provided a high specificity (83%) and a sensitivity of 34% for prediction of infant atopy. Thus, 
maternal factors, placental factors, or both have an impact on perinatal allergic sensitization. 
Kaan et al. suggested that cord blood IgE is a significant risk factor for the development of 
urticaria  due  to  food  allergy  at  12  months  of  age.  As  urticaria  due  to  food  allergy  is  a 
prodrome for anaphylaxis, measurement of IgE in cord blood may be indicated in infants at 
high risk for developing allergic diseases so that preventive measures can be applied (303). 
 
Ferguson et al. recently found that maternal atopy and birth in winter months were risk factors 
associated with detectable CB  IgE. CB IgE was found to be significantly associated with 
allergic sensitization and recurrent wheeze at 7 yrs but not with other outcomes. CB IgE may 
be a useful measure for identifying children at high risk of atopic diseases for the purpose of 
primary prevention (304). Pesonen et al. found after 20 years follow up of 200 newborns that 
the combination of elevated cord serum IgE and positive family history of allergy was strongly 
associated  with  subsequent  atopic  manifestations.  Nevertheless,  it  showed  a  reduced 
sensitivity as compared to cord serum IgE or family history of allergy. They concluded that an 
elevated cord serum IgE level predicts subsequent atopy up to age 20 years (305). 
5.1.3  Summary and hypotheses 
 
In summary, there is evidence (as discussed in the previous sections) that atopic disease is 
initiated  in  utero  and that  risk can be identified in  cord blood  by T-cell  phenotyping, by 
measuring cytokine production (from Th1, Th2, T-reg cells), and IgE production by B cells or 
IgE concentrations. Early exposure to LC n-3 PUFAs may influence early immune responses, 
in a manner that decreases the likelihood of atopic sensitization. There is evidence to support 
this  from  epidemiologic observations  (section  1.5.1) and  from  a small  number of fish oil 
supplementation studies (section 1.5.2). Oily fish is a good source of LC n-3 PUFAs, but there   249 
are no published intervention trials with fish during pregnancy. Since eating fish is advised, 
but fish are also a source of contaminants, aquaculture of fish to have low contaminant levels, 
while maintaining their LC n-3 PUFA content, could be an ideal solution to enable oily fish 
consumption  by  pregnant  women  and  possibly  promote  the  intake  of  the  recommended 
amounts of LC n-3 PUFAs. The Salmon in Pregnancy Study (SIPS) is the first randomised 
controlled trial with oily fish in pregnant women. SIPS focuses on pregnant women whose 
offspring have increased risk of developing atopic disease, aiming to identify whether there is 
an effect on atopy outcomes in the offspring. A total of 123 women were randomly assigned to 
consume either 2 portions of farmed salmon per week (from week 20 until delivery) or to 
continue their habitual diet low in oily fish (less or equal to two portions per month). 
 
The aim of the work described in this chapter is to investigate the effect of the increased 
maternal oily fish consumption on markers of infant immunity at birth (cord plasma and 
CBMC responses) which may potentially influence the development of atopy risk at 6 
months of age (Chapter 6). 
 
The  hypotheses  of  the  work  described  in  this  chapter  are  that  the  maternal  oily  fish 
intervention will: 
1.  alter neonatal immune cell phenotypes; 
2.  decrease PGE2 production by cultured CBMCs; 
3.  alter  neonatal  innate  and  adaptive  immune  T-cell  responses  (increased  Th1, 
decreased Th2, T reg) measured as cytokine expression in plasma and by cultured 
CBMCs;  
4.  decrease cord plasma IgE concentration.    250 
 
 
5.2  Materials and methods 
 
5.2.1  Study design and subjects  
 
Chapter 2 describes the study design, the subjects‟ characteristics, and the intervention. In 
summary, the population studied were pregnant women with high risk of having an atopic 
offspring. The study groups were two, of which the control group (n=61) was asked to keep 
their habitual diet unchanged during the study period (from 20 weeks until delivery) and the 
salmon group (n=62) which was asked to consume 2 portions of farmed salmon per week 
(from 20 weeks until delivery). Every portion of salmon provided 1.73 g of EPA plus DHA; 
the weekly intake of LC n-3 PUFAs was 3.46 g and the daily intake was 494 mg/day. The 
nutrient analysis of salmon is described in Chapter 2; Table 2.3 The consumption of the study 
salmon provided more EPA plus DHA than the recommended minimum intake in the UK for 
pregnant women (450 mg/day; (26)). Subjects in the salmon and the control groups came into 
the  maternity  hospital  fasted  at  three  time  points  during  pregnancy  (20,  34,  38  weeks 
gestation), and fasting blood was taken. At birth, umbilical cord blood was collected to enable 
fatty acid analysis of plasma and CBMCs (see Chapter 4) and measurement of infant immune 
markers related to possible manifestations of atopic disease. This chapter describes the cord 
blood immune outcomes.  
5.2.2  Laboratory materials and methods 
5.2.2.1 Cord blood collection 
5.2.2.1.1 Blood Tubes 
 
Plastic 6 mL lithium heparin (LH) vacutainer blood bottles, plastic 2 mL 
ethylenediaminetetraacetic acid (EDTA) vacutainer blood bottles, alcohol wipes – sterets, 19 
gauge needles, 50 ml tubes – sterile (Elkay Laboratories) and 50 ml syringes were obtained 
from NHS stores, Southampton General Hospital. 
5.2.2.1.2 Procedure 
 
Midwifery staff at Princess Anne Hospital assisted with all cord blood collections. Umbilical cord 
blood was only collected from normal full-term (> 37 weeks) deliveries with informed consent   251 
from the mothers. Cord blood was preferentially collected during the third phase of delivery 
while the placenta is still in the uterus, in order to ensure a good volume of collection. If this was 
not possible, cord blood was collected after delivery and the placenta had been expelled. In either 
instance, the umbilical  cord was  clamped immediately and cleaned  with  70% alcohol and/or 
iodine swab, this minimised maternal blood contamination. Whole cord blood was collected using 
a 16-19G needle on a 50 mL syringe. After umbilical cord vein puncture, the cord blood was 
collected into the 50 mL syringe. The volume collected ranged from 10 to 30 ml depending on the 
condition of the placenta. Cord blood samples were collected into 2 LH tubes and 2 EDTA tubes, 
one of each was kept at room temperature and the other in the fridge (4C) for less than 8 hours 
for  further  analysis.  The  EDTA  bottle  which  was  stored  at  room  temperature  was  sent  for 
haematology testing. The cord blood samples were then either stored at room temperature or in 
fridge and within the next 8-12 hours blood was separated into plasma, CBMCs and erythrocytes 
by gradient centrifugation. 
 
5.2.2.2 Analysis of total cord blood leukocytes 
 
The cord blood kept in the EDTA tube at room temperature was sent to Chemical Pathology, 
SUHT  for  the  assessment  of  total  leukocytes,  neutrophils,  lymphocytes,  monocytes, 
eosinophils  and  basophils.  The  analysis  was  performed  using  a  Sysmex  XE-2100  flow 
cytometer for haematology analysis. 
 
5.2.2.3 Analysis of cord blood immune cell subsets 
5.2.2.3.1 Materials 
Mouse anti-human fluorochrome-conjugated antibodies were purchased from Serotec. Mouse 
RPE-labelled anti-human CD127 was purchased from IOTest-Beckman Coulter. FACS lysing 
solution, cell wash, and cell fix were purchased from BD Biosciences. 
5.2.2.3.2 Procedure 
Flow cytometry was used to measure the presence of markers on the surface of leukocytes. 
Heparinised  whole  blood  (100  μL)  was  incubated  with  fluorochrome-labelled  monoclonal 
antibodies (Table 5.1) for 30 min at 4˚C in the dark to identify different cell subsets. After this 
incubation, erythrocytes were lysed for 10 min using 2 mL 10% FACS lysing solution in   252 
deionised  distilled  water.  After  centrifugation  (7  min,  200  ×  g),  lysed  erythrocytes  were 
discarded and leukocytes were washed with 2 mL cell wash (7 min, 200 × g), and then fixed 
with 200 μL 10% cell fix solution in deionised distilled water. Fixed leukocytes were analysed 
by flow cytometry (FACSCalibur, Becton Dickinson, Oxford, UK) equipped with a 488 nm 
argon blue laser. Lymphocytes were identified by their forward scatter (FSC) and side scatter 
(SSC) properties. FSC and SSC were set to a linear scale and collection of 10,000 events was 
required for all analyses, apart from  the determination of Treg cells  where approximately 
100,000 events were collected. CaliBRITE 3 beads (Becton, Dickinson) were employed for 
instrument  calibration  and  the  same  voltage  settings  were  used  for  each  sample.  In  all 
experiments, gates were set so that isotype control staining consistently yielded < 1% positive 
cells.  Data  were  analysed  using  CELLQuest  software  (Becton,  Dickinson).  Figure  5.1  to 
Figure 5.10 how typical profiles for each stain set. These profiles were used to identify the 
proportion  of  a  smaller  cell  population  within  a  major  cell  group  of  the  leukocytes  (i.e. 
lymphocytes and monocytes). These profiles can also give information on mean fluorescence 
intensity (MFI), a parameter that indicates the level of expression of the marker protein on the 
cell surface (how dense a marker is expressed on the surface of the cells). MFI was determined 
for the expression of CD127 on T-regulatory cells (Figure 5.11). 
Table 5.1: Labelled monoclonal antibodies (“stains”) used to identify different cord blood cell subsets 
 
Stain  Cell type identified  Phenotype of cell type 
identified 
Volume of 
stain used (µl) 
None  Control (No stain)  -   
Anti-CD3-FITC/anti-CD4-RPE  T helper/inducer cells  CD3
+CD4
+  10 
Anti-CD3-FITC/anti-CD8-RPE  T cytotoxic/suppressor 
cells  CD3
+CD8
+  10 
Anti-CD3-FITC/anti-CD16-RPE  NK cells  CD3
-CD16
+  10 
Anti-CD3-FITC/anti-CD19-RPE  B-cells  CD3
-CD19
+  10 
Anti-CD14-FITC + anti-CD282-RPE  TLR2 bearing monocytes  CD14
+TLR2
+  10+10 
Anti-CD4-FITC + anti-CD25-RPE-
Cy5 + anti-CD127-RPE  T regulatory cells  CD4
+CD25
+CD127
low  10+5+20 
Anti-CD4-FITC + anti-CD25-RPE-
Cy5 + IgG1-RPE  T regulatory cells control  -  10+5+10 
IgG1-FITC + IgG1-RPE + IgG1-
RPE-Cy5  Triple isotype control  -  10+10+10 




Figure 5.1: Typical dot plot of leukocyte populations from human blood. A gate has been drawn around 
the lymphocyte population  
 
 
Figure 5.2: Typical profile of the control (no stain) for the gated lymphocytes from Figure 5.1 
Control, (lower left 
quadrant): 100% of the 
gated population, 
27.33% of the total 
leukocyte population.   254 
 
 








Figure 5.5: Typical profile of natural killer (NK) cells (CD3-/CD16+) for the gated lymphocytes from 
Figure 5.1 
Cytotoxic T lymphocytes 
(upper right quadrant): 
12.77% of the gated 
population, 3.61% of the 
total leukocyte population. 
T helper lymphocytes 
(upper right quadrant): 
41.16% of the gated 
population, 10.92% of the 
total leukocyte population. 
NK cells (upper left 
quadrant): 15.12% of the 
gated population, 4.46% of 
the total leukocyte 
population.   255 
 
 
Figure 5.6: Typical profile of B lymphocytes (CD3-/CD19+) for the gated lymphocytes from Figure 5.1 
 
Figure 5.7: Typical dot plot of leukocyte populations from human blood. A gate (R6) has been drawn 
around the monocyte population 
 
Figure 5.8: Typical profile of TLR2 bearing monocytes (CD14+/TLR2+) for the gated monocytes (R4) 
from Figure 5.7 
B lymphocytes (upper left 
quadrant): 11.45 % of the 
gated population, 3.22% of 
the total leukocyte 
population. 
TLR2 bearing monocytes 
(upper left quadrant): 
1.06% of the gated 
population, 0.08% of the 
total leukocyte population. 




Figure 5.9: Gate R3 drawn around the CD4+ lymphocytes included in the gate of Figure 5.1. 
   
Figure 5.10: Typical profile of T regulatory cells (CD4+/CD25+/CD127 
low) included in gate R5, from the 
gated lymphocytes (R3) from Figure 5.9. 
 
Figure 5.11: Typical mean fluorescence intensity (MFI) gated (M1) on the T-regulatory cells 
CD4+/CD25+/CD127 
low 
T regulatory cells at 
gate R5 (lower right 
quadrant)   257 
 
5.2.2.4 Preparation of CBMCs and plasma 
5.2.2.4.1  Materials 
Histopaque (density 1.077 g/L, containing polysucrose 5.7 g/dL, and sodium diatrizoate 9.0 
g/dL),  L-glutamine  (200  mM),  antibiotics  (penicillin,  streptomycin),  EDTA,  potassium 
bicarbonate,  ammonium  chloride,  and  crystal  violet  were  purchased  from  Sigma-Aldrich. 
Phosphate-buffered saline (PBS) tablets were purchased from Oxoid. RPMI medium (without 
L-glutamine and antibiotics) and heat-inactivated fetal bovine serum (HI-FBS) were purchased 
from PAA Laboratories. Dimethyl sulphoxide (DMSO) and acetic acid were purchased from 
Fisher  Scientific.  Saline  (0.9%  sodium  chloride)  was  purchased  from  SUHT  Pharmacy, 
Southampton General Hospital.  
White cell counting fluid was made as follows: 100 mL PBS, 2 mL acetic acid, approximately 
5 g crystal violet. The solution was millipore filtered before use. 
5.2.2.4.2 Procedures 
Heparinised whole blood was layered onto Histopaque (ratio of blood to Histopaque: 2:1) and 
centrifuged for 15 min at 800 × g (2000 rpm, R = 18 cm) at room temperature. Plasma was 
collected  from  the  top  layer  and  frozen  at  -80˚C  for  future  culturing  of  CBMCs  and  for 
determination of total IgE.  
The CBMCs were collected from the interphase and washed once for 10 min at 450 × g (1500 
rpm,  R  =  18  cm)  with  RPMI  medium  containing  0.75  mmol/L  glutamine  and  antibiotics 
(penicillin and streptomycin). After being resuspended in 1 mL RPMI medium, the cells were 
counted with a haemocytometer using white cell counting fluid (crystal violet). After counting 
total CBMCs, 2 × 10
6 cells were removed and frozen at -80˚C for fatty acid analysis (see 
chapter 4). 
The remaining CBMCs were washed once (10 min, 450 × g) with RPMI medium containing 
2% HI-FBS. The CBMCs were resuspended in RPMI medium containing 2% HI-FBS and 
were cryopreserved with 15% DMSO in HI-FBS (freezing medium). The freezing medium 
was added to the resuspended CBMCs drop-wise on ice (ratio of resuspended cells in RPMI 
medium  containing  2%  HI-FBS  to  freezing  medium:  1:1).  CBMC  concentrations  were 
adjusted to 12-20 × 10
6 cells/ml/cryovial
 and were frozen at -80˚C in a Nalgene Cryo 1˚C   258 
freezing  container  (filled  with  250  mL  isopropanol).  After  at  least  4  hours  of  freezing, 
cryovials containing the CBMCs were stored in liquid nitrogen for later thawing and culturing.  
5.2.2.5 Measurement of cord plasma IgE concentration 
 
Cord blood plasma was sent to the Chemical Pathology, SUHT for analysis of total IgE. The 
analysis was done on Phadia ImmunoCAP 250 and the lowest detection of total IgE was 0.00 
kU/L. The test is designed as a sandwich immunoassay. ImmunoCAP provides high sensitivity 




Anti-IgE, covalently coupled to ImmunoCAP, reacts with the total IgE in the infants‟ cord 
plasma sample. After washing, enzyme-labelled antibodies against IgE are added to form a 
complex. After incubation, unbound enzyme-labelled anti-IgE is washed away and the bound 
complex  is  then  incubated  with  a  developing  agent.  After  stopping  the  reaction,  the 
fluorescence of the eluate is measured. The response is then transformed into a concentration 
through a calibration curve. The fluorescence is directly proportional to the concentration of 
IgE in the plasma sample. 
 
5.2.2.6 Measurement of cord plasma interleukin 13 (IL-13) concentration  
5.2.2.6.1 Principle 
 
The human IL-13 ELISA is an enzyme-linked immunosorbent assay for quantitative detection 
of human IL-13. An anti-human IL-13 coating antibody is adsorbed onto microwells. Human 
IL-13 present in the plasma sample or standard binds to antibodies adsorbed to the microwells. 
A conjugate mixture (biotin-conjugated anti-human IL-13 antibody and Streptavidin-HRP) is 
added  and  binds  to  human  IL-13  captured  by  the  first  antibody.  Following  incubation, 
unbound  biotin-conjugated  anti-human  IL-13  antibody  and  Streptavidin-HRP  is  removed 
during a wash step, and substrate solution reactive with HRP is added to the wells. A coloured 
product is formed in proportion to the amount of human IL-13 present in the plasma sample or 
standard. The reaction is terminated by addition of acid and absorbance is measured at 450 
nm. A standard curve is prepared from 7 human IL-13 standard dilutions and human IL-13 




The human IL-13 platinum ELISA kit purchased from by eBiosciece included: a microwell 
plate  (96  wells)  coated  with  monoclonal  antibody  to  human  IL-13,  biotin-conjugate  anti-
human  IL-13  monoclonal  antibody,  streptavidin-HRP,  human  IL-13  standard  lyophilized, 




Serial dilutions of a human IL-13 standard were prepared and then pipetted (100 μl) into wells 
of the ELISA plate. Sample (50 l) was added to the other wells and 50 μl of assay buffer 
added  to  these  wells.  Conjugated  mixture  (50  μl)  was  added  to  all  wells.  The  plate  was 
covered with an adhesive film and incubated at room temperature for 2 hours, on a microplate 
shaker  set  at  100  rpm.  Then  the  microwell  strips  were  washed  3  times.  Then  100  μl  of 
substrate solution was added to all wells. The microwell strips were then incubated at room 
temperature (18° to 25°C) for about 10 min avoiding direct exposure to intense light. After a 
period of time (judged by the colour change that occurred in the well containing the highest 
concentration of standard) stop solution (100 μl) was added into each well. Plates were read 
within  one  hour  on  a  microplate  reader  (Thermo  Labsystems)  set  at  450  nm.  IL-13 
concentration of each sample was calculated from the standard curve. The limit of detection 
was 0.7 pg/ml. 




L-glutamine  (200mL),  antibiotics  (penicillin,  streptomycin),  trypan  blue  and 
phytohaemaglutinin  (PHA;  HA16)  were  purchased  from  Sigma-Aldrich.  RPMI  medium 
without L-glutamine and antibiotics was purchased from PAA laboratories. Ultra pure LPS 
(Escherichia  coli  K12  strain),  bacterial  peptidoglycan  (Staphylococcus  aureus)  and 
polyinosine-polycytidylic  acid  (poly  (I:C))  were  purchased  from  InvivoGen.  LoTox 
Dermatophagoides  pteronyssinus  allergen  1  (Der  p  1)  was  purchased  from  Indoor   260 
Biotechnologies. Low endotoxin ovalbumin (Ova) was purchased from Profos AG (Germany). 
Salmon  paralbumin  (Sal  s1)  was  kindly  provided  by  John  Doe  (University  of  Bergem 
Norway). 
5.2.2.7.2 Procedures 
Cryopreserved  CBMCs  were  thawed  rapidly  in  the  waterbath  at  37C  and  immediately 
resuspended dropwise with 15 mL ice cold RPMI (containing 0.75 mmol/L glutamine and 
antibiotics). After centrifugation, cells were resuspended in 1 mL RPMI, 10 μL of which were 
stained with trypan blue and counted using a haematocytometer. Cell viability was assessed 
(approximately 80%) and live cells were counted. After counting, cells were resuspended in 
PRMI plus 10% (v/v) autologous plasma (used as culture medium) to correct the concentration 
for culturing. 
All cultures were plated in duplicate in 96-well, round bottom plates (2 x 10
6 cells/ml) in 200 
L of RPMI plus autologous plasma and incubated at 37C in a 5% CO2 atmosphere for the 
times  indicated  below.  The  stimuli  used  were:  Der  p1,  Ova,  Sal  s1,  PHA,  TLR-2  ligand 
(peptidoglycan  (PGN)),  TLR  3  ligand  (synthetic  double  stranded  RNA  Poly  I:C),  TLR-4 
ligand  (LPS).  Control  wells  were  left  unstimulated.  Table  5.2  describes  the  exact 
concentration, amount and volume of each stimulus used in the cultures. Stock concentrations 
of stimulants were stored at -20C and the same stimulant stocks were used throughout the 
study. The incubation period for cultures with TLR ligands was 24 h, whereas for the rest 
(allergens and mitogen) it was 48 h. After incubation, the plates were centrifuged and the 
supernatants collected and frozen at -20C for later analysis of cytokines and PGE2.  
Table 5.2: Stimuli used for culturing of cord peripheral blood mononuclear cells 
Stimulant  Type 
Final 
concentration 
Volume/well  Amount/well  Culture time 
Der p 1  Allergen  10 μg/mL  10 μL  200 ng  48 h 
Sal s 1  Allergen  200 μg/mL  10 μL  2000 ng  48 h 
Ova  Allergen  15 μg/mL  10 μL  150 ng  48 h 
PHA  Mitogen  7.5 μg/mL  10 μL  75 ng  48 h 
PGN  TLR-2 ligand  10 μg/mL  10 μL  100 ng  24 h 
Poly I:C  TLR-3 ligand  100 μg/mL  10 μL  1000 ng  24 h 
LPS  TLR-4 ligand  10 ng/mL  10 μL  0.1 ng  24 h   261 
 
5.2.2.8 Measurement of cytokine concentrations in cord blood mononuclear 




The cytometric bead array (CBA) employs a series of particles with discrete fluorescence 
intensities to simultaneously detect multiple soluble analytes. The CBA is combined with flow 
cytometry  to  create  a  multiplexed  assay.  Six  bead  populations  with  distinct  fluorescence 
intensities are coated with capture antibodies specific for Th1 and Th2 cytokines. The six bead 
populations are mixed together to form the CBA that is resolved in the FL3 channel of a 
fluorescence-activated  cell  sorter  (flow  cytometer).  The  CBA  capture  bead  mixture  is  in 
suspension to allow for the detection of multiple analytes in a small volume of sample. The 
cytokine  capture  beads  are  mixed  with  the  PE-conjugated  detection  antibodies  and  then 
incubated  with  recombinant  standards  or  test  samples  to  form  sandwich  complexes. 




The human Th1/Th2 CBA kit purchased from BDBiosciences included human IL-2, IL-4, IL-
5 and IL-10, tumour necrosis factor-α (TNF-α) and IFN-γ capture beads, human Th1/Th2 PE 
detection reagent, lyophilised human Th1/Th2 cytokine standards (all contained in one vial), 
cytometer set up beads, PE positive control detector, FITC positive control detector, wash 
buffer, and assay diluent. 
 
5.2.2.8.3 Procedure 
The BD CBA protocol was followed. The Th1/Th2 cytokine standard containing all 6 human 
Th1/Th2 cytokines was diluted in assay diluent and was allowed to equilibrate for 15 minutes. 
A  serial  dilution  of  the  top  standard  was  performed  using  assay  diluent  to  achieve  final 
concentrations of 5000 (top standard), 2500 (1:2), 1250 (1:4), 625 (1:8), 312.5 (1:16), 156, 
(1:32), 80 (1:64), 40 (1:128), and 20 (1:256) pg/ml for each cytokine in the standard.   262 
All culture beads were pooled together into a „mixed capture beads‟ tube before analysis prior 
to very good vortexing of each of the beads. For each test conducted (standard, control and 
samples) 4.5 μL of each capture bead was used. Each assay tube was added with: 25  μL 
„mixed capture beads‟, 25 μL human PE detection reagent, 25 μL standard dilutions to the 
standard assay tubes, 25 μL assay diluent to the negative control assay tube, and 25 μL CBMC 
culture supernatant to the test assay tubes. The human Th1/Th2 cytokine detection reagent that 
was  used  included  PE-conjugated  anti-human  IL-2,  IL-4,  IL-5,  IL-10,  TNF-α  and  IFN-γ 
antibodies.  
The tubes were incubated for 3 h at room temperature. After incubation, 1 mL of wash buffer 
was added to each tube and the tubes centrifuged (200 ×  g, 5 min). After discarding the 
supernatant, the bead pellet was resuspended with 300 μL of wash buffer. The samples were 
analysed  by  flow  cytometry  using  a  FACSCalibur  (Becton  Dickinson,  Oxford,  UK).  The 
number of events counted was set at 1800 of gated events (i.e 300 events per capture bead). 
The cytometer and instrument settings setup were performed according to the instructions of 
the BD CBA protocol. Compensation for special fluorochrome overlap was performed. The 
BD  CellQuest  software  was  used  for  data  acquisition  and  formatting.  The  results  were 
generated in graphical and tabular format using the Becton Dickinson CBA analysis software. 
The limits of detection for IL-2, IL-4, IL-5, IL-10, TNF-α, IFN-γ were 2.6, 2.6, 2.4, 2.8, 2.8, 
7.1 pg/ml respectively. Values below level of detection (LOD) were set at ½ LOD for all 
cytokines. Figure 5.12 shows a typical acquisition template example with the six distinct bead 
populations in the negative control standard and Figure 5.13 that of a culture supernatant from 
CBMCs stimulated with PHA.  
The CBMC cytokine responses reported in the results (Section 5.3.3) are presented in two 
ways, firstly, as the unstimulated control responses and the responses to various stimuli. There 
were some differences in the background (i.e. unstimulated) cytokine responses between the 
salmon and control groups that make interpretation of the raw results difficult. For this reason, 
the second way for the results to be presented is by difference in cytokine production over the 
corresponding unstimulated secretion (e.g. CBMC IL-10 production after PHA stimulation 
minus CBMC IL-10 production without stimulant (control)) so as to give the stimulus-specific 
response.   263 
 




Figure 5.13: Cytometric bead array acquisition template for culture supernatant from PHA stimulated 
CBMC (48 hours)   265 
5.2.2.9 Measurement of prostaglandin E2 concentration in mononuclear cell 
culture supernatant by enzyme-linked immunosorbent assay 
5.2.2.9.1 Principle 
The  enzyme-linked  immunosorbent  assay  (ELISA)  is  based  on  the  forward  sequential 
competitive binding in which prostaglandin E2 (PGE2) present in a sample competes with 
horseradish peroxidase (HRP)-labelled PGE2 for a limited number of binding sites on a mouse 
monoclonal antibody which is bound to goat anti-mouse polyclonal antibodies covering the 
bottom of the ELISA plate. PGE2 in the sample is allowed to bind with the mouse antibody in 
the first incubation. During the second incubation, HRP-labelled PGE2 binds to the remaining 
antibodies sites. Following a wash to remove unbound materials, a substrate solution is added 
to the wells to determine the bound enzyme activity. The colour is inversely proportional to 
the concentration of PGE2 in the sample. 
5.2.2.9.2 Materials 
PGE2 ELISA kit purchased from R&D Systems included: goat anti-mouse 96-well microplate, 
HRP-PGE2 conjugate, PGE2 standard, primary antibody (monoclonal antibody to PGE2), a 
calibrator diluent, wash buffer, colour reagent A and B, stop solution. 
5.2.2.9.3 Procedure 
The procedure followed was according to the manufacturer‟s protocol. Culture supernatants 
were diluted (1:3, 1:10 or 1:100) prior to the ELISA so that PGE2 could be detected within the 
limits of the assay. All reagents, working standards, and buffers were prepared according to 
the protocol. The lyophilized PGE2 standard was reconstituted with 1 mL distilled water to 
produce a stock of 25,000 pg/ml. This was left for 15 min to stabilize. A serial dilution of the 
stock standard was performed using calibrator diluent to achieve final concentrations of: 2500, 
1250, 625, 313, 156, 78, 39 pg/ml. Calibrator diluent was used as negative control (0 pg/mL). 
200 μL of calibration diluent was added to the non specific binding (NSB) wells. 150 μL of 
calibration diluent was added to the negative control well. 150  μL of standard, control or 
sample was added to the remaining wells and 50 μL of the primary antibody solution was 
added to each well, turning their colour to blue apart from the NSB wells. The plate was then 
covered and incubated for 1 hour at room temperature on horizontal orbital microplate shaker. 
Without washing the plate, after incubation 50 μL of HRP-PGE2 conjugate was added to each   266 
well. All wells turned a violet colour apart from the NSB. The plate was incubated for another 
2 hours at room temperature on the shaker. The plates were then aspired, washed, and blot 
dried 4 times with wash buffer 200 μL of substrate solution (colour reagents A and B mixed 
15 minutes prior to use) was added to each well. The plate was incubated for 30 minutes at 
room temperature in the dark. Finally, 100 μL stop solution was added to all wells. The optical 
density was measured immediately with a microplate reader (Thermo Labsystems) set at 450 
nm. Wavelength correction was set at 450 nm. The NSB optical density was subtracted from 
that  of  the  standards,  controls  and  samples.  A  standard  curve  was  created  for  the  optical 
density and PGE2 standard concentration. PGE2 concentration of each sample was calculated 
from  the  standard  curve.  The  concentration  was  multiplied  by  the  dilution  factor  of  the 
samples. 
5.2.3  Statistical analysis 
 
For  the  cord  blood  immune  cell  phenotypes  independent  samples  t-tests  were  used  for 
comparisons  between  groups  since  the  data  were  normally  distributed.  IgE  data  and  the 
cytokine and PGE2 data from cultured CBMCs were not normally distrubuted. These data 
were not log transformed prior to analysis, but instead 2 independent samples Mann-Whitney 
tests were used for comparisons between groups. The level of statistical significance was for 
all tests at p-value ≤0.005.   267 
5.3  Results 
5.3.1  Cord blood leukocytes 
 
Table 5.3 describes the umbilical cord blood leukocyte counts (cells x 10
3/μL whole blood) at 
birth in the salmon and the control groups. The salmon group had higher counts of neutrophils, 
lymphocytes and total leukocytes compared to the control group.  
 
5.3.2  Cord mononuclear cell phenotypes 
 
Table 5.4 describes the CBMC phenotypes at birth in the salmon and control groups; data are 
expressed as percentages of total lymphocytes or or CD4
+ lymphocytes (for Treg cells) except 
for TLR-2
+ monocytes which are expressed as percentage of total monocytes. There were no 
differences in the percentages of any of the cell subsets between the two groups. 
 
Table 5.5 describes the CBMC phenotypes at birth in the two groups expressed as percentages 
of total leukocytes. Again, there were no differences between the two groups.  
 
Table 5.6 describes the CBMC subset numbers (cells x 10
3/mL whole blood) in both groups. 
These were calculated using the information from the leukocyte percentages of the cell subsets 
(Table 5.5) and total leukocyte counts (Table 5.3). The numbers of helper T-cells, cytotoxic T-
cells and Treg cells were higher in the salmon group compared to the control group. 
 
Figure 5.14 shows the mean fluorescent intensity (MFI) of CD127 on Treg cells in cord blood. 
MFI tended be higher in the salmon group compared to the control group, but the difference 
was not significant. 
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Table 5.3: Cord blood leucocyte counts (cells x 10
3/μL whole blood) at birth according to study group 
Values are mean (SD), independent sample t-test p-values 
 
 
Table 5.4: Cord blood mononuclear cell phenotypes at birth (percentage of the gated cell population) 
according to study group 
 






 (n=35)  p 
Mean  SD  Mean  SD 
Neutrophils  6.940  2.072  8.277  2.640  0.026 
Lymphocytes  4.430  1.503  5.860  2.770  0.011 
Monocytes  1.167  0.511  1.454  0.762  0.075 
Eosinophils  0.393  0.224  0.449  0.262  0.363 
Basophils  0.103  0.100  0.229  0.511  0.165 




Salmon group  
(n=29)  p 
Mean  SD  Mean  SD 
Helper T-cells (CD3
+CD4
+) (% Lymphocytes)  39.7  9.5  40.8  12.1  0.701 
Cytotoxic T-cells (CD3
+CD8
+) (% Lymphocytes)  13.1  5.9  14.9  7.4  0.302 
NK cells (CD3
-CD16
+) (% Lymphocytes)  11.8  6.7  12.4  7.4  0.740 
B-cells (CD3
-CD19










+ lymphocytes)  54.2  15.1  56.9  16.4  0.516   269 
 
Table 5.5: Cord blood cell phenotypes (percentage of the total leukocytes) according to study group 
 
Values are mean (SD) percentage of the total leukocyte population, independent sample t-test p-values 
 
 
Table 5.6: Cord blood mononuclear cell subset numbers (cells x10
3/μL whole blood) at birth according to 
study group 
Values are mean (SD) number of cells x 103/μL whole blood, independent sample t-test p-values 
 
 
Figure 5.14: Geometric mean fluorescence intensity (MFI) of CD127 receptor on T regulatory cells at birth 
according to study group 
independent samples t-test, p= 0.310. 
Cell subsets 
Control group (n=26)  Salmon group (n=29) 
p 


























(% Leukocytes)  1.1  0.5  1.2  0.7  0.642 
Cell type 
Control group (n=20)  Salmon group (n=25) 
p 
Mean  SD  Mean  SD 
Helper T-cells (CD3
+CD4
+)  1.847  0.752  2.369  0.956  0.042 
Cytotoxic T-cells (CD3
+CD8
+)  0.586  0.248  0.820  0.448  0.028 
NK cells (CD3
-CD16
+)  0.496  0.385  0.734  0.510  0.075 
B-cells (CD3
-CD19








low)  0.134  0.064  0.218  0.168  0.030   270 
 
5.3.3  Production of cytokines by cord blood mononuclear cells cultured 
with various stimulants 
 
Table 5.7 to Table 5.9 describe the concentrations of five cytokines (Treg (IL-10), Th1 (IFN-γ, 
TNF-α, IL-2), Th2 (IL-4, IL-5)) in the culture medium of CBMCs stimulated with allergens 
(Der p 1, ovalbumin, salmon paralbumin), a mitogen (PHA), and TLR (-2, -3, -4) ligands. 
 
Table 5.7 presents the concentrations of IL-2, -4, -5 after stimulation of cultures of CBMCs 
with PHA. The concentrations of these cytokines were also measured after stimulation with 
the  TLR  ligands  and  with  the  allergens  but  the  concentrations  were  below  the  limits  of 
detection. In this table are also included the ratios of IFN-γ/IL-4 and IFN-γ/IL-10 representing 
the  ratios  of  Th1/Th2  cytokine  responses  and  Th1/Treg  cell  responses.  CBMCs  from  the 
salmon group produced lower concentrations of all four cytokines and this was significant for 
IL-2, -4 and -5 compared to those from the control group. IFN-γ concentration and the ratios 
IFN-γ/IL-4 and IFN-γ/IL-10 did not differ between the two groups. 
 
Table 5.8 presents the concentration of IL-10 after stimulation of cultures of CBMCs with 
various  stimulants  for  24  and  48  hours.  The  concentrations  produced  in  response  to  all 
stimulants  were  above  detection  level.  CBMCs  from  the  salmon  group  produced  a  lower 
concentration of IL-10 in all conditions tested; this was significant for unstimulated cells at 48 
hr, in response to LPS at 24 hr and in response to PHA at 48 hr.  
 
Table 5.9 presents the concentration of TNF- after stimulation of cultures of CBMCs with 
various  stimulants  for  24  and  48  hours.  The  concentrations  produced  in  response  to  all 
stimulants  were  above  detection  level.  CBMCs  from  the  salmon  group  produced  a  lower 
concentration of TNF- in all conditions tested; this was significant for unstimulated cells at 
48 hr and in response to PHA at 48 hr.  
 
Table 5.10 to Table 5.12 describe the concentrations of five cytokines (Treg (IL-10), Th1 
(IFN-γ, TNF-α, IL-2), Th2 (IL-4, IL-5)) in the culture medium of CBMCs stimulated with 
allergens (Der p 1, ovalbumin, salmon paralbumin), a mitogen (PHA), and TLR (-2, -3, -4) 
ligands after subtracting the corresponding background (i.e. unstimulated) secretion.    271 
Table 5.10 presents the concentrations of IL-2, -4, -5 after stimulation of CBMCs with PHA 
minus the concentrations seen for unstimulated cultures incubated for 48 hours. In this table 
are also included the ratios of IFN-γ/IL-4 and IFN-γ/IL-10 representing the ratios of Th1/Th2 
cytokine responses and Th1/Treg cell responses. CBMCs from the salmon group produced 
significantly lower concentrations of IL-2, -4, -5 after correcting for background secretion.  
 
Table 5.11 presents the concentration of IL-10 after stimulation of cultures of CBMCs with 
various stimulants for 24 or 48 hours minus the concentrations seen for unstimulated cultures. 
Some of these values are negative  as  the  control  responses  were higher than the specific 
stimulus responses. CBMCs from the salmon group produced a lower concentration of IL-10 
in response to LPS at 24 hr after correcting for background secretion.  
 
Table 5.12 presents the concentration of TNF- after stimulation of cultures of CBMCs with 
various stimulants for 24 or 48 hours minus the concentrations seen for unstimulated cultures. 
Again, some of these values are negative as the control responses were higher than the specific 
stimulus responses. There were no differences between the two groups.  
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Table 5.7: Interleukin -2,-4,-5, and Interferon-γ concentrations (pg/mL) and ratios of IFN-γ/IL-4 and IFN-













th perc  75
th perc  25
th perc  75
th perc 
IL-2  196.4  86.9  509.9  69.5  28.8  185.3  0.012 
IL-4  6.9  2.4  14.1  1.3  1.3  7.2  0.019 
IL-5  12.3  3.9  34.1  4.9  1.2  20.5  0.032 
IFN-γ  121.2  34.4  286.4  86.6  24.5  178.2  0.218 
IFN-γ/IL-4  17.6  8.7  42.9  18.8  7.6  63.6  0.743 
IFN-γ/IL-10  1.2  0.6  2.5  2.0  0.7  2.5  0.492 
Values are median (interquartile range (IR)), Mann-Whitney test p-values 
 
Table 5.8: Interleukin-10 concentration (pg/mL) in the medium of cultured CBMCs collected at birth and 











25th perc  75th perc  25th perc  75th perc 
None 
1  41.9  10.5  67.2  13.5  4.7  67.9  0.143 
PGN 
1  166.7  36.1  309.6  68.0  32.9  177.5  0.081 
Poly 1:C 
1  26.1  8.2  52.8  11.6  6.9  51.4  0.284 
LPS 
1  143.5  53.7  281.2  71.1  33.4  159.5  0.043 
None 
2  49.1  13.1  83.5  14.9  6.1  75.0  0.051 
Der p 1 
2  41.8  12.1  63.6  17.2  5.4  60.9  0.192 
OVA 
2  46.5  14.8  84.2  16.7  7.9  75.6  0.086 
Sal s1 
2  62.2  30.2  87.3  26.9  13.8  77.4  0.070 
PHA 
2  106.9  56.3  166.3  43.3  18.4  132.1  0.022 
Values are median (interquartile range (IR)), Mann-Whitney test p-values 
The limit of detection was 2.8pg/ml. When the value was below the LOD was set at LOD/2=1.4 pg/ml 
124 hour culture, 
248 hour culture 
 
 
Table 5.9: Tumor necrosis factor-α concentration (pg/mL) in the medium of cultured CBMCs collected at 






p    IR    IR 
Median  25th perc  75th perc  Median  25th perc  75th perc 
None 
1  78.6  22.9  150.7  47.1  15.4  140.7  0.338 
PGN 
1  591.3  255.8  1850.2  486.4  185.5  931.1  0.484 
Poly 1:C 
1  64.3  21.1  138.1  38.6  9.3  87.2  0.338 
LPS 
1  247.2  124.6  448.5  190.8  126.9  500.1  0.331 
None 
2  47.5  28.9  93.4  22.2  4.3  61.6  0.032 
Der p 1 
2  39.4  11.4  79.2  21.3  8.7  44.9  0.152 
OVA 
2  35.8  18.8  92.1  22.5  9.5  54.3  0.186 
Sal s1 
2  54.6  26.4  97.3  33.1  19.7  53.4  0.066 
PHA 
2  224.9  62.5  429.5  67.0  26.6  129.4  0.01 
Values are median (interquartile range (IR)), Mann-Whitney test p-values 
The limit of detection was 2.8 pg/ml. When the value was below the LOD was set at LOD/2=1.4 pg/mL 
124 hour culture, 
248 hour culture   273 
 
Table 5.10: Interleukin -2,-4,-5, and Interferon-γ concentrations (pg/mL) and ratios of IFN-γ/IL-4 and 
IFN-γ/IL-10 in the medium of cultured CBMCs collected at birth and stimulated with a mitogen (PHA) for 












th perc  75
th perc  25
th perc  75
th perc 
IL-2  195.1  85.6  505.3  68.2  27.5  184.0  0.012 
IL-4  5.6  1.1  12.3  0.0  0.0  5.9  0.019 
IL-5  11.1  2.5  32.3  3.7  0.0  19.3  0.031 
IFN-γ  109.2  30.8  232.4  83.0  20.7  174.6  0.243 
IFN-γ/IL-4  19.2  3.7  55.8  14.6  8.0  40.8  0.754 
IFN-γ/IL-10  2.4  1.1  8.3  2.7  0.7  5.6  0.767 
Values are median (interquartile range (IR)), Mann-Whitney test p-values 
 
 
Table 5.11: Interleukin-10 concentration (pg/mL) in the medium of cultured CBMCs collected at birth and 
stimulated with various TLR ligands, allergens and mitogens for 24 or 48 hours after subtraction of the 











25th perc  75th perc  25th perc  75th perc 
PGN 
1  110.5  20.6  257.4  54.7  22.3  93.4  0.071 
Poly 1:C 
1  -2.1  -18.3  6.8  0.5  -10.5  4.3  0.578 
LPS 
1  99.5  32.1  211.7  56.4  14.5  84.4  0.036 
Der p 1 
2  -7.4  -17.0  0.0  -0.5  -13.5  1.2  0.247 
OVA 
2  0.0  -7.5  8.5  0.0  -1.8  6.0  0.872 
Sal s1 
2  5.3  -5.0  20.0  3.8  0.1  11.4  0.879 
PHA 
2  37.3  8.7  105.9  22.5  3.5  50.7  0.150 
Values are median (interquartile range (IR)), Mann-Whitney test p-values 
The limit of detection was 2.8pg/ml. When the value was below the LOD was set at LOD/2=1.4 pg/ml 
124 hour culture, 
248 hour culture 
 
 
Table 5.12: Tumor necrosis factor-α concentration (pg/mL) in the medium of cultured CBMCs collected at 
birth and stimulated with various TLR ligands, allergens and mitogens for 24 or 48 hours after subtraction 






p    IR    IR 
Median  25th perc  75th perc  Median  25th perc  75th perc 
PGN 
1  460.2  180.1  1505.7  432.1  154.1  896.9  0.553 
Poly 1:C 
1  -10.9  -43.3  9.1  -3.6  -41.6  3.7  0.735 
LPS 
1  136.2  33.5  323.1  125.7  45.1  315.4  0.877 
Der p 1 
2  -16.6  -26.5  2.8  -4.2  -19.2  0.0  0.404 
OVA 
2  -12.3  -30.4  1.4  -1.5  -12.9  1.7  0.174 
Sal s1 
2  -9.4  -33.3  16.2  0.1  -119.6  9.5  0.543 
PHA 
2  49.8  8.1  327.2  25.2  9.7  103.8  0.338 
Values are median (interquartile range (IR)), Mann-Whitney test p-values 
The limit of detection was 2.8 pg/ml. When the value was below the LOD was set at LOD/2=1.4 pg/mL 
124 hour culture, 
248 hour culture 
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5.3.4  Production of prostaglandin E2 by cord blood mononuclear cells 
cultured with various stimulants 
 
Table 5.13 presents the concentration of PGE2 after stimulation of cultures of CBMCs with 
LPS for 24 hr or PHA for 48 hr. Although CBMCs from the salmon group produced a lower 
concentration of PGE2 in all conditions tested, this did not reach significance, although the 
trend towards a difference was strong in response to LPS (p=0.056). Figure 5.15 depicts the 
PGE2 production in response to LPS. When PGE2 (unstimulated and stimulated CBMCs with 
LPS and PHA) was  correlated  against  EPA,  ARA and ARA/EPA  content in  CBMCs,  no 
significant associations were identified. 
 
Table 5.13: Prostaglandin E2 concentration (pg/mL) in the medium of cultured CBMCs collected at birth 






(n=29)   
 
  IR    IR   
Median  25th perc  75th perc  Median  25th perc  75th perc  p 
None 
1  2539  799  4191  1971  559  4456  0.563 
LPS 
1  4463  1577  6773  2518  419  5951  0.056 
PHA 
2  3874  1829  8456  2365  322  6068  0.129 
Values are median (interquartile range (IR)), Mann-Whitney test p-values 
1 24 hour culture, 
2 48 hour culture 
 
 
Figure 5.15: PGE2 production (pg/mL) from CBMCs after stimulation with lipopolysaccharide (LPS; 
TLR-4 ligand) according to study group 
Mann-Whitney test p-value 0.056 
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5.3.5  Cord blood plasma IgE concentration 
 
Figure 5.16 shows the concentration of IgE in umbilical cord blood plasma at birth. There was 
no difference between groups.  
 
 
Figure 5.16: Concentration (IU/mL) of total IgE measured in cord blood plasma according to study group 
Values are medians and interquartile range (IR), p-value=0.616 (Mann-Whitney test) 
 
 
5.3.6  Cord blood plasma IL-13 concentration 
 
IL-13 was not detected in most samples; IL-13 was detectable in three samples in the control 
group and two in the salmon group (7% of samples in total), the concentration in these five 
samples ranged from 0.2 to 156.7 pg/mL.  
Control group n=34 
median=0.16 kU/mL   IR (0.09-0.52) 
 
Salmon group n=37 
median=0.15 kU/mL   IR (0.06-0.44)   276 
5.4  Discussion 
 
In Chapter 4 it was shown that increased intake of salmon during pregnancy results in 
higher total n-3 PUFA status in cord plasma and in a tendency to higher total n-3 PUFA in 
CBMCs. Because of the importance of LC n-3 PUFAs in regulating aspects of the immune 
and inflammatory responses (48), salmon intake could influence the development of infant 
immune system and predisposition of the infant to atopy. Consequently, the hypotheses of 
the work described in this chapter are that the maternal oily fish intervention will: 
1.  alter neonatal immune cell phenotypes; 
2.  decrease PGE2 production by cultured CBMCs; 
3.  alter  neonatal  innate  and  adaptive  immune  T-cell  responses  (increased  Th1, 
decreased  Th2,  Treg)  measured  as  cytokine  expression  in  plasma  and  by 
cultured CBMCs;  
4.  decrease cord plasma IgE concentration.  
 
The results obtained indicate that maternal salmon intake during pregnancy results in some 
differences  in  cord  blood  immune  cell  phenotypes  at  birth  (more  leukocytes,  neutrophils, 
lymphocytes,  helper  T-cells,  cytotoxic  T-cells  and  Treg  cells),  a  generalised  decrease  in 
production of cytokines in response to a T cell mitogen, TLR agonists and allergens, that 
became  significant  for  several  cytokines  in  response  to  the  mitogen  PHA  and  the  TLR-4 
ligand LPS, and a tendency to lower PGE2 production in response to LPS. The cord plasma 
concentration of IgE was not affected by the salmon intervention. IL-13 was not detected in 
most cord plasmas and no other cytokines were measured in those samples. Thus, there is 
evidence to support two of the hypotheses (altered immune cell phenotypes and altered T cell 
responses)  and  to  support  in  part  a  third  (decreased  PGE2  production)  while  there  is  no 
evidence in support of the fourth (decreased IgE concentration). 
 
These findings will be discussed in relation to the findings of studies using LC n-3 PUFAs 
from  fish  oils  as  an  exposure  in  pregnancy  (observational  or  intervention  studies)  and 
measuring  immunological  parameters  in  the  cord  blood  of  the  infants  compared  to  the 
controls. There are two such studies: the first was conducted in Australia by Dunstan et al. 
(35;131;132;136;173;176)  and  the  second  in  Germany  by  Krauss-Etschmann  et  al.  (178). 
Dunstan et al. examined the effect of maternal fish oil supplementation providing 3.7 g LC n-3   277 
PUFAs/day  on  immune  outcomes  in  cord  blood  (IgE  concentration,  IL-13  concentration, 
cytokine  production  by  CBMCs  stimulated  with  various  agents  including  a  mitogen  and 
several allergens) of neonates at risk of developing atopic disease. They also examined the 
effect of the supplementation on clinical development of atopic disease at 12 months of infant 
age  (35;132;173;176).  Krauss-Etschmann  et  al.  examined  the  effect  of  supplementing 
pregnant women with 0.5 g/day DHA plus 0.15 g/day EPA, or 400 μg/day of methyl-tetra-
hydrofolic acid, or both or placebo on modulation of allergy-related parameters in the cord 
blood (178). 
5.4.1  Whole blood immune cell subsets at birth (cord blood) and the 
effect of increased salmon consumption 
 
The immune cell subset analysis in combination with the immune cell numbers obtained from 
the  SUHT  Pathology  Laboratory  analysis  showed  that  the  numbers  of  T  helper  cells 
(CD3
+CD4
+),  cytotoxic  T  cells  (CD3
+CD8
+)  and  Treg  cells  (CD4
+CD25
+CD127
low)  were 
higher in the salmon group compared to the control group. The percentages of these cells in 
the lymphocyte and total leukocyte populations did not differ between the two groups, but the 
numbers of lymphocytes and total leukocytes (and also neutrophils) were higher in the salmon 
group.  Dunstan  et  al.  (35)  observed  no  significant  difference  in  the  frequency  of  various 
lymphocyte subsets (% and absolute concentration) between the fish oil supplemented and the 
control group; they reported total T cells, T helper cells, cytotoxic T cells, NK cells and B 
cells. The current results for NK cells and B cells are in agreement with these earlier findings, 
as  are  the  current  findings  for  percentages  of  the  T  cell  subsets.  Kraus-Etschmann  et  al. 
observed that the number of NK cells (CD16
+) was significantly decreased in the fish oil 
group compared with the placebo group, as were CCR3
+CD8
+ T cells (178).  
 
It should be clarified that the method used to identify the Treg cells in SIPS was not optimal; 
one antibody stain (to the FOXP3 transcription factor), which according to the literature (306) 
would definitely determine CD4
+CD25
+CD127
low cells as Treg cells was not used. The reason 
for this omission is that the flow cytometer used for the SIPS analysis could only detect three 
antibody stains at the same time, and the use of a fourth stain was not possible. 
 
One limitation  of SIPS  is  that the cord blood  immune cell subsets  were characterised by 
extracellular  surface  markers  and  not  intracellular  markers  which  describe  the  functional 
properties of these cells. However, the production of Th1 and Th2 cytokines by unstimulated   278 
and  stimulated  CBMCs  was  investigated  as  a  measure  to  obtain  information  about  the 
functional phenotype of these cells (discussed in the next section). 
5.4.2  Infant innate and adaptive immune responses at birth from CBMCs 
cytokine production and cord plasma IL-13 concentration 
 
SIPS used different stimulants in order to explore different aspects of the immune response 
including both innate and adaptive immunity. The allergens and one mitogen (PHA) were used 
to investigate adaptive immune responses, whereas innate immune responses were tested with 
stimulation of the CBMCs  by TLR ligands  (to  TLR-2, TLR-3  and TLR-4). The adaptive 
immune responses are so-called because these are specific immune responses of the T cells to 
antigens, which for the purpose of SIPS were allergens. The T cells that respond are already 
sensitised to these allergens and have immunologic memory of this event, so that when are 
cultured ex vivo they will respond to the allergen. However, because the number of the T cells 
responding to specific allergens is relatively small, the culture time required for the expression 
of  this  response  is  long  (48  hours).  Nevertheless  the  cytokine-inducing  capacity  of  all 
allergens tested was limited, especially in comparison with that of PHA or LPS, which do not 
act in an antigen-specific way. Thus it seems likely that the number of allergen sensitised cells 
in  the  CBMC  samples  studied  here  was  low.  Another  stimulus  which  activates  adaptive 
immune responses is the T-cell mitogen PHA. PHA activates T-cells non-specifically via the 
CD3 receptor present on their surface, so that all T-cells respond to the mitogen in a non-
specific way and thus can be used as a positive control. There were strong cytokine responses 
to PHA.  
 
Innate immune responses were investigated stimulating via TLR-2, -3, and -4 with specific 
ligands. TLR ligands stimulate mainly monocytes which express the different TLRs on their 
surface. TLR stimulation is non-antigen specific and TLRs being responsible to recognise 
generalised features of „invaders‟ termed pathogen associated molecular patterns (PAMPs). 
The response to TLR ligands is quite rapid compared with T cell responses, because of the 
non-specific nature of the interaction with the responder cells.  
 
In general cytokine responses were lower from CBMCs in the salmon group, although not 
always significantly so and after correcting for the unstimulated concentrations, the statistical 
significance for CBMC IL-10 and TNF-α responses after mitogen stimulation (PHA) was lost. 
Controlling for maternal smoking did not affect the findings (data not shown).    279 
  
The only cytokine measured in plasma, IL-13, was detectable in less than 10% of the samples. 
 
Dunstan et al. measured cytokines in the cord plasma (IL-4, -5, -6, -10, -12, -13, TNF-α, IFN-
γ) and also production by CBMCs (IL-5, -10, -13 and IFN-γ) after stimulating with 3 allergens 
(HDM, OVA and cat hair extract (CAT)) or PHA. All cytokines were measured with ELISAs. 
In the cord plasma IL-13, but not the other cytokines measured, was lower in the fish oil group 
compared  to  the  placebo  reflecting  the  decrease  in  Th2  cytokines  after  the  fish  oil 
supplementation (35;132). Dunstan et al. could detect IL-13 in 64% of plasma samples in the 
control group and in 45% of plasma samples in the fish oil group with an assay with a limit of 
detection of 3 pg/ml. In the current study IL-13 was not detected in the majority (93%) of the 
samples, yet the limit of detection was 0.7 pg/ml.  
 
In the study of Dunstan et al., IL-10 responses of CBMCs stimulated with HDM or CAT were 
significantly lower in the fish oil group. In fact, responses to OVA and CAT for all cytokines 
tended  to  be  lower  in  the  fish  oil  group  but,  apart  from  IL-10,  the  difference  was  not 
significant.  Responses  to  PHA  did  not  differ  between  the  two  groups  for  any  cytokine 
(35;132). However, it is worthy noting that the cytokine responses of CBMCs to allergens 
(HDM, OVA and CAT) and mitogen (PHA) observed by Dunstan et al. were not entirely 
consistent  with  the  clinical  features  of  the  infants  assessed  at  one  year  of  age  (atopic 
dermatitis,  recurrent  wheeze,  asthma,  food  allergy)  (132).  However,  the  observation  of 
generally lower cytokine responses seen in SIPS agrees with the findings of Dunstan et al., 
although these are some differences in the detail. For example, in SIPS all cytokine responses 
to PHA (apart from IFN-γ) were lower in the fish oil group. Dunstan et al. measured innate 
immunity in the cord blood mononuclear cells and found no differences in the proportions of 
lymphocytes  or  monocytes  expressing  HLA-DR  either  with  or  without  stimulation  with 
rhIFN-γ or in the level of expression (136).  
 
Kraus-Etschmann et al. measured cytokine expression patterns in the cord blood by real time 
RT-PCR looking at the mRNA levels of Th2 associated molecules CCR4, IL-13 and IL-4, Th1 
related molecules IL-1 and IFN-γ, and Treg related molecule TGF-β. Fish oil supplementation 
decreased mRNA levels of the Th2 related molecules compared with placebo, whereas levels 
of  mRNA  for  Th1  cytokines  remained  unaffected.  TGF-β  mRNA  expression,  which  has 
shown to be involved in tolerance towards allergens, was significantly higher in the fish oil   280 
group (178). So this European study agrees with the Australian study in that the Th2 related 
molecules (chemokines and cytokines) are reduced with fish oil. In general the current results 
from SIPS are in agreement with this: production of the Th2 cytokines (IL-4 and IL-5) was 
lower in the fish oil group while production of the prototypical Th1 cytokine IFN-γ although 
lower in the fish oil group was not significantly different between groups. Thus it appears that 
fish oil decreases the Th2 type response with less of an impact on the Th1 type response. 
Indeed, although there was no significant effect on the IFN-γ to IL-4 ratio (Th1/Th2) this 
tended to be higher in the salmon group.  
 
5.4.3  IgE concentration in cord plasma 
 
Total IgE concentration was low in the cord blood plasma in both groups with no difference 
between them. The IgE assay used was of high sensitivity (0 kU/L) and that is why IgE was 
detectable in all samples examined. In contrast, Dunstan et al. could detect IgE in only in 5% 
of cord plasma; the lowest level of detection of the assay they used was 0.35 kU/L.  
5.4.4  PGE2 production from cord mononuclear cells 
 
Eicosanoid mediators are involved in modulating the intensity and duration of inflammatory 
responses.  Through  actions  on  dendritic  cells  (DCs),  T  cell  differentiation  and  Ig  class 
switching in B cells, some eicosanoids such as PGE2 are believed to play a role in promoting 
sensitization  to  allergens  (48;182).  Indeed,  allergic  inflammation  in  animal  models  is 
associated with increased PG and LT production. PGE2 is a vasodilator, increases vascular 
permeability, inhibits the production of Th1 cytokines and primes naıve T cells to produce IL-
4 and IL-5 (Th2 cytokines). PGE2 also promotes Ig class switching in uncommitted B cells 
towards the production of IgE (284).  
 
PGE2 production from unstimulated and PHA-stimulated CBMCs did not differ between the 
two study groups, but PGE2 production from LPS-stimulated CBMCs tended to be lower in 
the salmon group compared to the control group (p-value=0.056). Krauss-Etschmann et al. did 
not report PGE2 production in infant immune cells at birth. Neither did Dunstan et al. although 
Prescott and Dunstan (176) showed that fish oil supplementation during pregnancy resulted in 
lower  LTB4  production  and  higher  LTB5  production  by  cord  blood  neutrophils.  Cord 
neutrophil  LTB4  production  was  inversely  related  to  LC  n-3  PUFA  status.  It  could  be   281 
speculated  that  increased  provision  of  EPA  and  DHA  from  the  mother  to  the  fetus  and 
subsequent decreased incorporation of ARA into CB immune cells and lower production of 
ARA lipid mediators (PGE2, LTB4) as well as increased production of the less potent EPA and 
DHA lipid mediators (PGE3, LTB5) from the neonatal immune cells might occur. This could 
possibly  affect  the  offsprings‟  T-cell  and  B-cell  function  and  predisposition  to  a  less 
inflammatory environment in early life so that there is less risk of developing atopic disease in 
infancy and later in life. Atopy outcomes at age 6 months in the infants studied here will be 
reported in the next chapter (Chapter 6).   282 
5.5  Conclusion 
 
The neonatal immune data shows that eating two portions of salmon during pregnancy results 
in:    
  some  differences  in  cord  blood  immune  cell  phenotypes  at  birth  (more 
leukocytes, neutrophils, lymphocytes, helper T-cells, cytotoxic T-cells and T 
regulatory cells); 
  a  generalised  decrease  in  production  of  cytokines  in  response  to  a  T  cell 
mitogen (PHA), TLR agonists and allergens, that became significant for several 
cytokines in response to the mitogen PHA (IL-2, IL-4, IL-5, IL-10, and TNF-α) 
and the TLR-4 ligand LPS (IL-10, TNF-α); 
  a tendency to lower PGE2 production in response to LPS; 
but does not affect IgE concentration in cord plasma. IL-13 was not detected in most cord 
plasmas and no other cytokines were measured in those samples. Thus, there is evidence to 
support two of the hypotheses (altered immune cell phenotypes and altered T cell responses) 
and to  support in  part a third (decreased PGE2 production) while there is  no evidence in 
support of the fourth (decreased IgE concentration). This is the first study demonstrating that 
increased salmon intake in pregnancy can affect fetal/neonatal immune responses. Some of the 
effects seen are similar to those reported from fish oil supplementation studies in pregnant 
women. Some of the immune outcomes affected relate to future risk of infant atopy and so it 
appears  that  salmon  intake  in  pregnancy  has  the  potential  to  reduce  atopy  risk.  The  next 
chapter will examine this possibility.    283 
 
6  Salmon in pregnancy study (SIPS): Atopy outcomes at 6 
months of infant age, infant feeding patterns, 
anthropometry and health  284 
 
6.1  Introduction 
 
Breast milk is normally the single source of nutrients for the infant during the period of rapid 
growth and development in the first moths of life. Besides providing the principal source of 
energy, breast milk fatty acids possess functional properties. Long chain (LC) n-3 and n-6 
polyunsaturated  fatty  acids  (PUFAs)  (i.e.  docosahexaenoic  acid  (DHA;  22:6n-3)  and 
arachidonic acid (ARA; 20:4n-6)) are essential for the development of infants‟ cognitive and 
visual functions (10;242) and have immunomodulatory properties (97;307;308).  
 
Fish, especially oily fish, is a rich source of LC n-3 PUFAs. An inverse association between 
fish  consumption  and  childhood  symptoms  of  atopy  has  been  observed  in  cross-sectional 
studies  (163;309).  Frequent  maternal  consumption  of  fish  during  pregnancy  has  been 
associated  with  reduced  risk  of  infant  eczema,  asthma  and  rhinitis  (151;153;155).  Such 
observations are supported by observations that dietary LC n-3 PUFAs reduce the production 
of  pro-inflammatory  and  pro-allergic  eicosanoid  mediators,  including  prostaglandins  and 
leukotrienes, and thus may reduce the risk of atopic disease (48). Early infancy is believed to 
be  the  key  time  for  the  programming  of  the  immune  system  (202).  Thus,  the  fatty  acid 
composition of the diet in early infancy (or of the mother‟s diet during pregnancy) may have a 
causal influence on risk of developing atopy. This may relate to fatty acid composition of the 
infants immune cells and their capacity to produce fatty-acid derived mediators that influence 
sensitization and allergic responses. A number of studies have examined the fatty acid (FA) 
profile in  breast  milk  as  a risk factor  for subsequent  atopic disease  (172;310-313). These 
studies have shown mixed results, but have generally found that a higher content of LC n-3 
PUFAs in breast milk is associated with lowered risk of atopic diseases. In contrast, Stoney et 
al. reported from the Melbourne Atopy Cohort Study, that LC n-3 PUFAs in colostrum were 
unexpectedly associated with increased risk of allergic sensitization at 6 and 24 months (314). 
Using further data from the same prospective birth cohort, Lowe et al. found that high levels 
of docosapentaenoic acid (DPA; 22:5n-3) in both colostrum and expressed breast milk were 
associated with an increased risk of infantile atopic eczema, and higher concentrations of n-6 
PUFAs in colostrum were associated with increased risk of childhood rhinitis at 7 years of 
age. There were no associations observed between the FA profile and risk of childhood asthma 
(315). A review by Sala-Vila et al. (284) looked at the PUFA concentrations in breast milk 
from atopic women. They found that the studies reporting PUFA concentration in breast milk   285 
of atopic women are contradictory and with inconsistent effects when examining -linolenic 
acid (18:3n-3; ALA) and DHA (284). In SIPS the breast milk fatty acid composition was 
analysed but the results are not included in this thesis. Breast milk samples were collected at 
days 1, 5, 14 and 28 after birth and the fatty acid analysis has shown that LC n-3 PUFA status 
(both EPA and DHA) at all timepoints was higher in the salmon group compared to the control 
group (unpublished data: Heidi Urwin & Parveen Yaqoob). Thus, SIPS infants in the salmon 
group who were breast fed would have received a better supply of LC n-3 PUFAs than those 
in the control gtroup. 
 
The LC PUFA composition of term formula milks has been regulated by EU law for many 
years. At present, about half of term infant formulas on the UK market are fortified with LC 
PUFAs and numbers are increasing (316). However, FA intake and FA biomarkers of infants 
under these conditions need to be investigated. Schwartz et al. investigated plasma LC PUFAs 
in fully milk fed infants that continued consuming breast milk beyond 4 months and those that 
consumed formula (either fortified with or without LC n-3 PUFAs) beyond 4 months. The 
main findings were that infants consuming LC PUFA-supplemented formula achieved similar 
relative plasma levels of LC n-3 PUFAs to breastfed infants, and that those infants consuming 
non-supplemented formula had lower levels of these important fatty acids (317). 
 
The issue of introduction of solids in relation to allergy development has been widely explored 
but the conclusions that can be drawn at present are not definite. Kneepkens et al. support that 
breastfeeding for 4-6 months and the postponement of supplementary feeding (solids) until 4 
months of age are the main measures considered effective for allergy prevention. Although 
meta-analyses  suggest  that  hypoallergenic  formula  after  weaning  from  breastfeeding  is 
protective against the development of allergic disease, the evidence is limited and weak (308). 
Anderson  et  al.  reviewed  from  currently-available  research  that  introducing  solids  at  4-6 
months may result in the lowest allergy risk (318). However, Fiocchi et al. concluded that with 
assessed risk of allergy, the optimal age for the introduction of selected supplemental foods 
should be 6 months, dairy products 12 months, hens‟ egg 24 months, and peanut, tree nuts, 
fish,  and  seafood  at  least  36  months.  For  all  infants,  complementary  feeding  could  be 
introduced from the sixth month, and egg, peanut, tree nuts, fish, and seafood introduction 
require caution (319). A 2008 report from American Academy of Pediatrics concluded that 
although solid foods should not be introduced before 4 to 6 months of age, there was no 
current  convincing  evidence  that  delaying  their  introduction  beyond  this  period  had  a   286 
significant protective effect on the development of atopic disease regardless of whether infants 
were fed cows‟ milk protein formula or human milk. This report did not consider that there is 
stron evidence for delaying the introduction of foods that are considered to be highly allergic, 
such as fish, eggs, and foods containing peanut protein (320). 
 
6.1.1  Clinical outcomes of atopic disease 
 
The  prevalence  of  allergic  diseases  in  childhood  (atopic  dermatitis,  asthma,  and  allergic 
rhinitis and conjunctivitis) has increased considerably in developed countries in the last three 
or four decades (70), and accordingly there is increasing need for allergy testing. Population-
based studies have reported a cumulative prevalence of allergic diseases in childhood around 
25-30%, of atopic dermatitis (AD) around 15-20%, and of asthma between 7-10% (321). In 
infancy the main symptoms of possible allergic nature are AD, gastrointestinal symptoms, and 
recurrent wheezing, whereas bronchial asthma and allergic rhinitis and conjunctivitis are the 
main problems later in childhood. Adverse reactions to foods, mainly cows‟ milk protein and 
hens‟ egg are most common in the first years of life, whereas allergy to inhalant allergens 
mostly occurs later. Correspondingly, specific immunoglobulin (Ig) E antibodies against milk 
and egg are most frequent during the first 2–3 years of life, whereas IgE against inhalant 
allergens is predominant later in childhood. Interestingly, IgE antibodies to allergens (hens‟ 
egg white, cows‟ milk) in infants predict sensitization to inhalant allergens and allergy before 
7–10 years of life. Low levels of specific IgE to several allergens - food allergens as well as 
inhalant allergens - are a normal phenomenon, especially in early childhood and may have no 
clinical significance (321). Infants with early development of IgE sensitization to cows‟ milk 
or hens‟ egg proteins or early sensitization to inhalant allergens have an increased risk for later 
development of allergic diseases. Early identification of children with food allergy and AD 
may provide opportunities to prevent the development of asthma (322). In early infancy food 
allergy  with  manifestations  from  skin,  the  gastrointestinal  or  the  respiratory  tract  is  more 
common than inhalant allergy. Children with food allergy almost always show symptoms from 
two or more organ systems concomitantly, but in some cases, e.g. AD, the children may only 
show one severe persisting symptom. Cows‟ milk allergy is the most common food allergy in 
young  children  followed  by  allergy  to  hens‟  egg,  cereals,  and  nuts.  A  few  children  are 
sensitized to indoor inhalant allergens already during the first 1-2 year of life, and in case of 
persisting asthma symptoms, allergy testing for relevant indoor allergens such as houst dust 
mite and cat hair may be useful.   287 
 
The  potential  role  of  n-6  and  n-3  PUFAs  in  modulating  risk  of  atopic  disease  has  been 
described  previously  (202;203).  There  is  quite  good  evidence  from  observational  and 
intervention trials that early exposure to LC n-3 PUFAs induces immune effects that may be 
associated with reduced atopic sensitisation and with a reduction in allergic manifestations. 
However, data available from existing studies, which are of many different types, are not 
entirely consistent and so it is not possible to draw a firm conclusion at this stage.  
 
There are no published intervention trials with fish during pregnancy. Since eating fish is 
advised,  but  fish  area  also  a  source  of  contaminants,  aquaculture  of  fish  to  have  low 
contaminant levels could be an ideal solution to enable oily fish consumption by pregnant 
women and in order to achieve the recommended intake of LC n-3 PUFAs. The Salmon in 
Pregnancy Study  (SIPS) is  the first  randomised controlled trial with  oily fish in  pregnant 
women. SIPS focuses on pregnant women whose offspring have increased risk of developing 
atopic  disease,  aiming  to  identify  whether  there  is  an  effect  on  atopy  outcomes  in  the 
offspring. A total of 123 women were randomly assigned to consume either 2 portions of 
farmed salmon per week (from week 20 until delivery) or to continue their habitual diet low in 
oily fish (less or equal to two portions per month). 
 
The aims of the work described in this chapter are to describe the feeding patterns of the 
infants  born  to  the  SIPS  mothers  at  6  months  of  age,  to  identify  whether  oily  fish 
consumption  in  pregnancy  affects  the  introduction  of  particular  foods  like  fish  to  the 
infants (up to age 6 months), and to investigate the effect of the increased maternal oily fish 
consumption on atopy risk at 6 months of age. 
 
The  hypotheses  of  the  work  described  in  this  chapter  are  that  the  maternal  oily  fish 
intervention will: 
1.  reduce sensitization to common allergens in infants at 6 months of age (determined 
by SPT) 
2.  reduce AD score in infants at 6 months of age (determined by clinical assessment-
scoring for atopic dermatitis (SCORAD)) 
3.  decrease plasma IgE concentration in infants at 6 months of age.   288 
 
6.2  Materials and methods 
6.2.1  Study design and subjects 
 
Chapter 2 describes the study design, the subjects‟ characteristics, and the intervention. In 
summary, the population studied were pregnant women with high risk of having an atopic 
offspring. The study groups were two, of which the control group (n=61) was asked to keep 
their habitual diet unchanged during the study period (from 20 weeks until delivery) and the 
salmon group (n=62) which was asked to consume 2 portions of farmed salmon per week 
(from 20 weeks until delivery). Every portion of salmon provided 1.73 g of EPA plus DHA; 
the weekly intake of LC n-3 PUFAs was 3.46 g and the daily intake was 494 mg/day. The 
nutrient analysis of salmon is described in Chapter 2; Table 2.3. The consumption of the study 
salmon provided more EPA plus DHA than the recommended minimum intake in the UK for 
pregnant women (450 mg/day;  (26)). The total number of infants at birth was 107; 53 in 
salmon group and 54 in the control group and 101 cord blood samples were collected (n=51 
salmon group, n=50 control group). At 6 months of infant age 86 infants were followed up at a 
family  visit  (mother,  father  and  sibling)  at  the  Welcome  Trust  Clinical  Research  Facility 
(WTCRF) of Southampton  General  Hospital  (SGH). An infant  health  and food  frequency 
questionnaire (FFQ) was completed that also included clinical assessment of atopic disease by 
scoring AD (SCORAD) and skin prick testing (SPT) was performed. The FFQ referred to the 
7 days prior to the 6 month visit. An infant blood sample was collected for IgE measurement 
(total and specific).The parents (mother and father) were also assessed for atopy by SPT and 
these results are included in the description of the subjects at baseline (Chapter 2). 
6.2.2  Infant follow-up (6 month) questionnaire 
 
The aim of the follow-up questionnaire was to collect personal details and information on 
general health and feeding of the baby at 6 months of age. The questionnaire included a visit 
checklist for the appointment, the baby‟s personal details, questions on general health, history 
of immunisation and atopy, feeding history over the 6 months prior to the visit, FFQ referring 
to infant food consumption over the 7 days preceding the visit, and results of the infant clinical 
examination (SCORAD) and SPT (Appendix 20). 
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6.2.3  Infant dietary assessment 
6.2.3.1 Infant feeding and infant health diary 
 
At 38 weeks of pregnancy SIPS mothers were provided with an infant feeding and health diary 
to keep from birth until 6 months of infant age (Appendix 12). They were asked to record on a 
daily basis in three separate columns: 1. the type of feeding they used (breast or formula) as 
well as the brands and types of the formula milks or other milks used; 2. the introduction of 
solids and relevant details of weaning (timing/specific food item/quantity); 3. any health issues 
the baby had including sicknesses such as colds, coughs, vomiting, diarrhoea, wheezes, rashes, 
any  medication  taken/prescribed  as  well  as  a  record  of  the  completed  vaccinations.  The 
purpose of keeping this diary was to help the mothers for reference and to remember details of 
the feeding and health of the infant during the administration of the 6 month infant health and 
FFQ (follow-up questionnaire) at the 6 month visit. These diaries were not analysed as  a 
separate piece of data. The use of these diaries is an advantage of SIPS since a 6 month period 
is a long time to remember accurately and precisely details for example of all the formula 
milks that the baby had, and the duration of consumption of each of them or how many times 
the baby had a cold/cough or runny nose in the past 6 months. Of course the completeness and 
accuracy of the diary depended on individuality - a factor that could not be controlled for - 
personal motivation and interest.  
 
6.2.3.2 6 month questionnaire: Infant feeding history and FFQ 
 
The aim of the FFQ at 6 months of age (section 1-3 of the infant FFQ; Appendix 20) was to 
collect detailed information about the baby‟s breast milk and formula feeding, as well as the 
introduction  of  other  food  items  and  supplement  usage.  The  infant  feeding  questionnaire 
(feeding history) reflected questions about feeding patterns (breastfeeding/formula feeding) 
over the first 6 months of life including types of formulas used during this period. The infant 
FFQ was administered by an appropriately trained nutritionist (myself, L-S Kremmyda) during 
a structured interview lasting around 30 minutes with the infant‟s carer supplying the relevant 
information. The FFQ was developed to assess the diets of infants aged 6 months, and was the 
FFQ was used for dietary assessment in the infant population as part of the SWS (323). It 
includes meat, fish, vegetables, fruit, cereals and snack foods divided into 16 food groups and 
6  types  of  non-milk  drinks.  Human  milk,  baby  formulas  and  other  milk  intakes,  and 
introduction of solids (timing/kind of solid), were recorded in separate sections.    290 
 
The daily non-human milk intake in the previous week was estimated from the average total 
volume of bottle feeds consumed per day; for human milk, the usual feed length and number 
of feeds per day were recorded. The frequency of consumption and the amount of each food in 
the 34 item-FFQ consumed over the last week preceding the 6 month visit were recorded. 
Foods not listed in the FFQ but consumed in the last week, were recorded in an open section. 
Also in case there was consumption of fish recorded in the FFQ, a further question was asked 
about type/types of fish consumed in the past week, and the portion size on each occasion was 
recorded. 
 
 Subjects were asked to recall their infants‟ intake during one week prior to the time point of 
the interview. To help them with remembering, subjects were prompted to keep a detailed 
record of that last week of their infants‟ food intake (types of food and quantities) in the infant 
feeding  diary.  Another  help  to  recall  quantities  consumed  and  portion  sizes  was  the 
presentation and reference to household measures (spoons/cups in different sizes) during the 
administration of the questionnaire as well as the use of prompt cards with the food items. The 
main purpose of the portion size measures was to ensure consistent responses. The question 
„number of times in the past week‟ referred to the frequency of consumption and „average 
amount on each occasion‟ was the question asked about the portion size. 
 
This questionnaire has been validated for use on 6 month old infants in Southampton (324). 
The energy and nutrient intakes obtained from the FFQ were compared with those obtained 
from a 4-day weighted diary. The authors concluded that although there were differences in 
absolute energy and nutrient intakes between methods, the correlation coefficients indicated 
reasonable agreement in the ranking of intakes. Thus the 6 month FFQ is a useful tool for 
estimating  energy  and  nutrient  intakes  in  infants  about  6  months  old  especially  in  the 
Southampton area (324). So the use of this FFQ could be considered as an advantage of the 
SIPS study. Previous studies have mainly used estimated or weighed records to assess diet at 
around 6 months of age (325;326). However such methods are expensive to process in larger 
groups  of  subjects.  FFQs  have  been  used  for  older  age  groups  to  assess  diet  in  large 
populations but few researchers have examined this tool in infants. One Finnish study (327) 
reported food and milk patterns by using semi-quantitative FFQs. 
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The nutrient of focus in SIPS was LC n-3 PUFAs. Gale et al. estimated the DHA exposure of 
infants up to 6 months of age from the feeding history, using average milk volumes for each 
month of feeding together with the DHA content of the formula milk fed (obtained from the 
manufacturers). For breast milk they used an estimated value for the UK (9.56 mg per 100 g) 
(328). In SIPS DHA intake could be estimated in a similar way but it was decided not to do 
this because it would be a rough estimate and this was not the primary outcome of the study. 
Nevertheless, DHA was assessed by the FFQ reflecting the intake from the total diet plus 
supplements.  Moreover,  from  the  feeding  history  information  on  consumption  of  formula 
milks  fortified  or  not  with  LC  n-3  PUFAs  (EPA  and  DHA)  and  n-6  PUFAs  (ARA)  was 
obtained. Also information on the nutritional content of all the formula milks consumed was 
obtained from the manufacturers so as the calculate PUFA intakes from the total diet to be as 
accurate as possible.  
 
The SWS nutrition team declared the following nutrients to be complete to calculate daily 
intakes:  protein,  fat,  carbohydrates,  energy  values  (KJ/Kcal),  fibre,  sodium,  potassium, 
magnesium,  calcium,  phosphorus,  iron,  copper,  zinc,  retinol,  vitamins  D,  E,  thiamin, 
riboflavin, niacin, vitamins B6, B12, C, and folate. 
 
6.2.4  Infant anthropometry at 6 months of age 
 
Infant length (cm) and weight (kg) were measured (Appendix 20). 
 
6.2.5  Infant clinical assessment at 6 months of age 
 
6.2.5.1 Skin prick testing (SPT) 
 
SPT was performed by introducing a small amount of allergen (droplet), approximately 0.1μl 
of extract, into the epidermis using a lancet without drawing blood. The immediate wheal and 
flare  reaction  is  a  consequence  of  allergen-specific  IgE  molecules  being  cross-linked  by 
allergen. This results in signalling via Fc receptors on mast cells which leads to degranulation 
and release of histamine, proteases, proteoglycans, prostaglandin D2 (PGD2), leukotriene C4 
(LTC4) and platelet-activating factor. Histamine is considered to be the major mediator in the 
allergic wheal reaction, which is caused by extravasation of serum from capillaries in the skin. 
Pruritis  and  a  larger  erythematous  flare  accompany  the  wheal.  SPT  is  a  reliable  test  to   292 
determine sensitivity and subsequent confirmation of allergy in susceptible individuals, even 
in infants at 6 months of age. All SPTs were conducted by a trained research nurse (Norma 
Diaper). The SPT was performed using allergen extracts from house dust mite, tree, grass 
pollen, cows‟ milk, hens‟ egg, cat, dog, salmon as well as histamine (positive control) and 
glycerin  (negative  control)  (Appendices  16  &  17).  Table  6.1  presents  the  allergens  and 
controls used. The potency is expressed in „Histamine Equivalent in skin Prick testing‟ (HEP) 
which  is  related  to  the  allergic  activity  of  the  allergen.  All  allergens  apart  from  salmon 
(purchased from Merck) including the positive control and negative control were purchased 
from Soluprick SQ, ALK Abello. Figure 6.1 shows the application of the SPT, while Figure 
6.2 shows the skin area approximately 15-20 minutes after application, demonstrating positive 
responses to some allergens. A wheal diameter of ≥ 2 mm greater than the negative control 
was considered to be positive in the current study.  
 
Table 6.1: Allergens used in the infant SPT 
 
Type  Strength 
Negative control (glycerine)  Glycerine diluent 
Dermatophagoides pteronyssinus 
(House Dust Mite (HDM)) 
10 HEP 
Felix domesticus (cat)  10 HEP 
Canis familiaris (dog)  10 HEP 
6 Grass pollen mix 
(Avena/Dactylis/Poa/Festuca/Lolium/Phleum) 
10 HEP 
3 Tree pollen mix 
(Alnus/Betula/Corylus) 
10 HEP 
Cows‟ milk raw (Bos spp)  1:20 w/v 
Whole hens‟ egg (Gallus spp)  1:100 w/v 
Salmon  5000 NPU/mL 
Positive control (histamine)  10 mg/ml 




Figure 6.1: SPT application at forearm; Figure 6.2: SPT responses to some allergens  
 
6.2.5.2  Score of atopic dermatitis (SCORAD) 
 
The  presence  and  severity  of  AD  can  be  quantified  by  using  an  international  clinical 
measuring tool, SCORAD. SCORAD has been previously validated in other studies (329;330). 
SCORAD was assessed with evaluation of the extent, intensity and subjective criteria. Total 
SCORAD is calculated from the proportion of involved surface area segment by segment. 
Calculations  were  made  using  the  body  map  form  (Appendix  18  and  20  (section  9)). 
SCORAD was assessed by a trained research nurse (Norma Diaper). 
 
On completion of clinical examination any significant clinical findings were discussed with 
the parents as well as with the clinical supervisor. If further action was required after the 
assessment, this was advised.  
 
6.2.6  Infant immunological assessment at 6 months 
6.2.6.1 Plasma total and specific IgE concentrations 
 
A specialised paediatric nurse collected a small amount (1-2 mL) of infant blood from a hand 
or  foot  vein  into  a  plain  tube  (clot  and  gel).  This  blood  was  analysed  by  the  Chemical 
Pathology Laboratory of SUHT for total IgE and for specific IgE to cows‟ milk, hens‟ egg and 
salmon. The analysis was done on Phadia ImmunoCAP 250 and the lowest detection of the 
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total IgE was 5.00 kU/L and of the specific IgE 0.35 kU/L. The test is designed as a sandwich 
immunoassay which provides high sensitivity and very low concentrations of IgE antibodies 
can be detected. 
 
6.2.6.1.1 Total IgE 
 
Anti-IgE, covalently coupled to ImmunoCAP, reacts with the total IgE in the infant‟s cord 
plasma sample. After washing, enzyme-labelled antibodies against IgE were added to form a 
complex.  After  incubation,  unbound  enzyme-labelled  anti-IgE  was  washed  away  and  the 
bound complex was then incubated with a developing agent. After stopping the reaction, the 
fluorescence  of  the  eluate  was  measured.  The  response  was  then  transformed  into  a 
concentration through the calibration curve.  
6.2.6.1.2 Specific IgE 
 
The allergen of interest, covalently coupled to the ImmunoCAP, reacts with the specific IgE in 
the infant‟s plasma sample. The rest of the assay procedure is as described for total IgE. 
 
6.2.7  Statistical analysis 
 
Between group comparisons for data that were not normally distributed data were performed 
using the Mann-Whitney test, as a non-parametric 2 independent samples test, and the data are 
described  using  medians  and  interquartile  ranges  (infant  feeding  at  6  months: 
breastfeeding/formula feeding/exclusive breastfeeding duration). Between group comparisons 
for normally distributed data were performed using the independent samples t-test and the data 
are  described  using  the  means  and  standard  deviations  (SD)  (IgE  concentration,  SPT  and 
SCORAD data, feeding with formula milks, food and nutrient intakes, infant anthropometry). 
Categorical data were compared between groups by Pearson χ
2 (Chi-square) test (dichotomised 
clinical data, food categories and reported allergic associated infections at 6 months). A p-
value of < 0.05 was considered statistically significant for all tests. The statistical package for 
Social Sciences (SPSS version 18) was used for all statistical tests.    295 
 
6.3  Results 
 
6.3.1  Infant diet at 6 months 
6.3.1.1 Feeding history 
 
Table 6.2 presents the feeding practises of the infants up to 6 months of age. The duration of 
breastfeeding did not differ between the 2 groups and was (median) 146 days for the control 
group  and  145  days  for  the  salmon  group.  Infants  in  the  control  group  were  exclusively 
breastfed for more days than the salmon group (median 44 vs. 27), but the difference was not 
significant. Infants in the salmon group received formula milks for (median) 152 days and the 
control for 124 days. This difference was not significant. 
 
Table 6.2: Feeding practices of the infants up to 6 months of age according to study group 









Breastfeeding duration (days)  146 (15, 180)  145 (14, 180)  0.981  146 (15, 180) 
Formula feeding duration (days)  124 (14, 169)  152 (54, 170)  0.152  136 (46, 169) 
Exclusive breastfeeding (days)  44 (10, 163)  27 (9, 125)  0.233  43 (10, 133) 
Values are median (interquartile range) days in the last 6months, Mann-Whitney p-values 
 
Table 6.3 shows the numbers and percentages of infants that were breastfed, fed with formula 
milks or still breastfeeding at 6 months. It is impressive that 43% of the infants in both groups 
(n=86) were still breastfeeding at 6 months of age (Table 6.3). 
 




Yes             No 
Salmon group 
(n=47) 










(10.6%)  0.954 
Still breastfeeding at 6 
months 
16 (41%)  23 (59%)  21 
(44.7%) 
26 
(55.3%)  0.828 
Formula fed  30 (77%)  9 (23%)  42 
(89.4%) 
5 
 (10.6%)  0.149 
Values are number of infants (within group percentage); Chi-square test p-values   296 
 
Table  6.4  shows  the  mean  duration  of  consumption  of  formula  milks  containing  LC  n-3 
PUFAs (EPA and DHA) and milks without such fortification in each group. There was no 
significant difference observed between the two groups in the duration of consumption of 
either milk category. Infants had consumed more days of formula milks with added EPA and 
DHA (85.5 days) than non-fortified formulas (26.5 days). 
 
Table 6.4: Consumption frequency of formula milks either enriched or not with LC n-3 PUFAs according 
to study group 
Values are mean (SD) days in last 6 months, independent t-test p-values 
Formula milks  Control group 
(n=39) 
Salmon group 
(n=47)  p  Total 
(n=86) 
Feeding with LC n-3 PUFA 
fortified formula milks 
(days in the last 6 months) 
71 (67)  97 (69)  0.082  86 (69) 
Feeding with non fortified 
formula milks 
(days in the last 6 months) 
33 (63)  21 (43)  0.311  27 (53)   297 
 
6.3.1.2 Food intake at 6 months of age 
 
Table  6.5  describes  the  mean  weekly  consumption  frequency  of  breastmilk  and  the  food 
groups as recorded in the FFQ. There were no differences between the two groups apart from 
consumption  of  vegetable  jars  that  were  more  frequently  consumed  by  the  salmon  group 
compared to the control (2.9 vs. 0.9 times per week). 
Table 6.5: Consumption of breast milk or various foods according to the FFQ (referring to the past 7 days) 








n  Times/week  n  Times/week 
Mean  SD  Mean  SD 
Breast milk  39  3.05  3.52  47  3.04  3.47  0.991 
Baby rice  38  1.74  2.62  47  2.47  3.76  0.295 
Cereals  38  3.53  3.56  47  2.94  3.25  0.432 
Rusks  38  1.21  2.17  47  0.81  1.62  0.347 
Porridge jar  24  0.08  0.41  28  0.14  0.59  0.671 
Meat jar  24  1.17  1.58  28  1.68  2.09  0.320 
Vegetable jar  24  0.92  1.10  28  2.89  2.57  0.001 
Milk dessert jar  24  1.00  2.19  28  0.71  1.36  0.585 
Fruit dessert jar  24  0.58  1.02  28  1.21  1.66  0.101 
Pure fruit jar  24  2.08  2.64  29  2.03  2.90  0.949 
Potato  35  2.17  2.57  44  1.68  2.65  0.410 
Rice  35  0.31  1.23  44  0.07  0.25  0.252 
Pasta  35  0.54  1.20  44  0.30  0.88  0.310 
Meat  35  1.43  3.01  44  0.86  2.43  0.371 
Fish  35  0.09  0.28  43  0.26  1.09  0.332 
Beans  35  0.26  0.82  44  0.09  0.29  0.258 
Other vegetables  35  4.80  4.30  44  5.55  5.41  0.497 
Yogurt  35  2.26  3.22  44  2.14  3.08  0.866 
Cooked fruit frequency  35  2.57  2.92  44  2.80  4.15  0.780 
Bananas  35  1.54  2.06  44  1.32  2.02  0.629 
Other fruit  35  0.74  1.34  44  1.50  3.71  0.215 
Bread  35  0.09  0.51  44  0.25  0.75  0.251 
Biscuits  35  0.49  1.44  44  0.14  0.63  0.189 
Juice  26  0.92  2.10  35  0.66  2.61  0.661 
Water  28  5.82  4.51  36  6.25  5.24  0.726 
Values are mean (SD) consumption (times/week), independent t-test p-values 
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Table 6.6 shows the number and proportion of infants in each treatment group that had any 
breast milk, expressed breast milk, formula or cows‟ milk, any jars, home made food and any 
other drink apart from breast milk in the last 7 days as recorded in the FFQ at 6 months. There 
were no statistical significant differences in the number of infants that consumed any of those 
food categories between the two groups. 
 
Table 6.6: Number of infants that consumed breast milk, expressed breast milk, formula milk, jars, home 
made food, or other drinks as recorded in the 6 month FFQ referring to the past 7 days 
 
Values are number (within group percentage); Chi-square test p-values 
 
Table 6.7 presents the mean intake (g/day) of breast milk, expressed breast milk, formula milk 
and fish as recorded in the FFQ which referred to the 7 days prior to the 6 month visit, and 
also shows the infant age (in days) when solid foods were introduced into the diet. Moreover 
this table presents the duration of intake of infant supplements (in days) in the last 6 months. 
Only 2 infants in the control group and 3 in the salmon group were taking supplements at 
between 3 and 6 months of infant age. The between group comparisons showed no differences 
in  the  two  groups,  although  fish  intake  (g/day)  tended  to  be  higher  in  the  salmon  group 
compared to the control (50 vs. 15 g/day). 
Categories of food 
Control group 
(n=39) 
Yes             No 
Salmon group 
(n=47) 
Yes              No 
p 







(55.3%)  0.919 







(87.2%)  0.632 







(17%)  0.783 







(38.3%)  0.361 







(23.4%)  0.535 







(31.9%)  0.519   299 






(n=47)  p 
n  Mean  SD  n  Mean  SD   
Infant age when solids introduced (days)  39  132  40  47  147  62  0.181 
Infant supplement intake (days in the last 6 mo)  2  5.5  6.4  3  15  15  0.381 
Fish intake (g/week)  3  15.4  14.4  3  50.0  17.3  0.058 
Intake of breast milk (g/week)  17  4210  1943  21  4834  2034  0.342 
Intake of expressed breast milk (g/week)  5  430  369  5  92  82  0.111 
Intake of formula milk (g/week)  6  4904  808  7  4960  1570  0.936 
Values are mean (SD), independent t-test p-values 
 
 
Table  6.8  shows  in  detail  which  solid  foods  were  primarily  introduced  to  the  infants  as 
recorded to the FFQ at 6 months. Most (n=56) infants were firstly introduced to baby rice as a 
solid food and less to vegetables, cooked fruit and baby cereals.  
 
Table 6.8: Solid food introduction according to study group 
 
 









No solid yet introduced  2  1  3 
First solid food eaten 
 
Baby rice  25  31  56 
Baby cereal  2  2  4 
Vegetables  3  5  8 
Yogurt  2  0  2 
Cooked fruit  2  3  5 
Banana  1  1  2 
Other fresh fruit  0  1  1 
Rusks  1  1  2 
Dried vegetables  0  1  1 
Vegetable jar  1  1  2 
Values are number 
 
Table 6.9 shows the daily intake of selected macro- and micro-nutrients reflecting the 7 days 
prior to the administration of the FFQ at 6 months. As discussed in the methods, some nutrient 
intakes are estimations as the databases providing the relevant values were incomplete or the   300 
manufacturers  of  the  infant  products  did  not  provide  such  nutritional  information.  SFA, 
MUFA, PUFA, n-3 PUFA and n-6 PUFA intakes shown should be treated with caution as the 
SWS have declared these nutrients as incomplete. The between group comparisons showed no 
difference in the intake of any of the macro- or micro-nutrients with the exception of vitamin 
E which was significantly higher in the salmon compared to the control group.   301 






(n=47)  p 
Mean  SD/IR  Mean  SD/IR 
Energy (Kcal)
 1  685  173  720  154  0.330 
Energy (KJ)
 1  2872  730  3016  645  0.336 
Energy/kg body weight  364  96  394  90  0.144 
Protein
1  17.2  7.5  16.8  4.7  0.791 
Total fat
1  32.1  7.5  33.9  7.6  0.279 
Carbohydrate (g)
1  84.1  26.7  89.4  23.2  0.337 
SFAs (g)
1  14.0  4.0  14.7  3.4  0.393 
MUFAs (g)
1  11.2  4.2  12.6  3.3  0.095 
PUFAs (g)
1  4.5  1.9  5.0  1.2  0.123 
Total n-3 PUFAs (g)
1  0.24  0.28  0.27  0.31  0.612 
Total n-6 PUFAs (g)
1  1.26  1.43  1.53  1.62  0.421 
Fibre (g)
1  
(Englyst method)  4.1  3.9  4.4  3.4  0.753 
Sodium (g)
1   210  109  204  71  0.760 
Potassium (g)
1  840  361  865  261  0.716 
Calcium (mg)
 1  499  242  491  169  0.869 
Magnesium (mg)
 1  67.4  38.2  69.0  28.4  0.835 
Phosphorus (mg)
 1  340  211  324  129  0.666 
Iron (mg)
 2  4.8  1.3, 6.9  4.6  2.1, 6.5  0.886 
Zinc (mg) 
1  4.5  1.9  4.6  1.3  0.835 
Selenium (μg)
 1,3  11.3  3.7  11.7  2.6  0.573 
Retinol equivalents (μg)
 1  578  317  571  147  0.902 
Vitamin D (μg)
 2  7.6  1.0, 11.1  7.6  2.5, 11.0  0.907 
Vitamin E (mg)
 2  5.5  3.3, 7.6  7.0  4.8, 8.4  0.050 
Thiamin B1 (mg)
 1  0.63  0.45  0.61  0.30  0.856 
Riboflavin B2 (mg)
 1  0.84  0.48  0.83  0.36  0.917 
Niacin (mg)
 1  5.1  3.2  4.8  2.1  0.604 
Vitamin B6 (mg)
 1  0.53  0.36  0.56  0.56  0.778 
Vitamin B12 (mg)
 1  1.3  1.0  1.3  0.8  0.995 
Folate (μg)
 1  105  53  115  45  0.319 
Vitamin C (mg)
 1  73.7  35.4  77.6  26.5  0.574 
EPA (mg)
 2  0.0  0.0, 0.01  0.0  0.0, 0.004  0.239 
DHA (mg)
 2  0.003  0.0, 0.05  0.017  0.0, 0.047  0.332 
Total EPA plus DHA (mg)
 2  0.004  0.0, 0.057  0.021  0.0, 0.056  0.302 
1 Values are mean (SD), independent t-test p-values  
2 Values are medians (interquartile range), Mann-Whitney test p-values 
3 Values completed for all foods in the FFQ - however data are limited as the content of food varies widely and 
depends on soil content of the region   302 
6.3.2  Anthropometry, allergy and health status of the infants as reported 
in the 6 month questionnaire 
 
Table  6.10  shows  the  height  and  weight  of  the  infants  at  age  6  months;  there  were  no 
differences between groups. Table 6.11 shows height and weight distribution of the infants at 
six months by sex. 
Table 6.10: Height and weight at 6 months of age according to study group 
 
Values are mean (SD), independent t-test p-values 
 




Values are mean (SD) 
 
Table 6.12 presents the atopy-associated events such as wheezing, pneumonia, chest infection, 
itchy skin, and dry skin, as reported by the parents. Also information on having pets at home, 
which could be associated with the protection or sensitization to atopy, is provided. 
  Control group 
(n=39) 
Salmon group 
(n=47)  p  Total 
(n=86) 
Height (cm)  66.9 (2.4)  67.3 (2.5)  0.438  67.13 (0.26) 
Weight (kg)  7.95 (0.97)  7.72 (0.91)  0.282  7.82 (0.10) 
 




Male (n=21)  Female (n=18)  Male (n=19)  Female (n=28) 
Height (cm)  67.4 (2.6)  66.4 (2.2)  68.3 (2.4)  66.7 (2.3) 
Weight (kg)  8.03 (0.99)  7.85 (0.96)  8.15 (0.92)  7.43 (0.79)   303 





Yes               No 
Salmon group 
(n=47) 
Yes              No 
p 
Wheezing  8  31  11  36  0.314 
Pneumonia/bronchiolitis  1  38  1  46  0.894 
Chest infection/bronchitis  2  36  1  46  0.332 
Itchy skin  8  31  10  36  0.539 
Dry skin  4  27  10  32  0.166 
Cat at home  14  25  10  37  0.153 
Dog at home  8  31  7  40  0.574 
Values are number, Chi-square test p-values 
 
Some questions in the 6 month follow up questionnaire referred to the mothers: 3/39 mothers 
in the control group and 1/47 in the salmon group smoked during the first 6 months of their 
infants‟ life. Moreover 13/39 mothers in the control group and 15/47 in the salmon group were 
taking supplements during the 3 months prior to the 6 month visit. The main supplements 
being  used  were:  multivitamins,  special  multivitamin  supplements  for  breastfeeding  or 
pregnancy (with or without n-3 fatty acids), cod liver oil, vitamin C, iron, calcium and vitamin 
D. 
 
6.3.3  Infant clinical outcomes at 6 months 
 
Table 6.13 shows the presence and severity of AD and the frequencies of positive AD scores 
and  the  mean  values  of  the  AD  scores  for  infants  in  both  groups.  Relatively  few  infants 
(19/86;  22.1%)  manifested  AD  and  severity  of  AD  (SCORAD)  in  those  infants  with  the 
disease was not different between groups although it tended to be higher in the control group 
(mean severity score = 10) compared to the salmon group (mean severity score = 7.4) (Table 
6.13). Controlling for birth order, paternal atopy and maternal smoking, did not  influence 
these findings.   304 
 
Table 6.13: Atopic dermatitis at 6 months of age according to study group 
 
Infant clinical outcomes at 6 months: 
SCORAD 
Control group  
(n=38) 
Salmon group  
(n=48)  p 
Positive to SCORAD 
1  7/38 (18.4%)  12/48 (25%)  0.465 
SCORAD 
2  1.84 (5.30)  1.85 (3.65)  0.990 
AD severity score 
2  10.00 (8.851)  7.42 (3.450)  0.483 
1 Values are number (within group %), Chi-square test p-values 
2 Values are mean (SD), independent t-test p-values 
 
 
Positive SPTs were defined as reaction to cows‟ milk and egg allergens. Table 6.14 presents 
the SPT positivity in the two groups and also the mean SPT responses to all allergens. Mean 
SPT responses to allergens were very low, reflecting that many infants were not sensitised (see 
below) and so did not show a response.  
 
Very few infants responded positively to most of the allergens used (Table 6.15). Those that 
did respond were sensitized to cat hair, dog hair, hens‟ egg or cows‟ milk protein. There was 
no difference in pattern between control and salmon groups. No infants in the salmon group 
were sensitized to salmon. After examining whether SPT ≥ 2 mm between the 2 groups could 
be affected by birth order, paternal atopy and maternal smoking, birth order (p=0.032) and 
maternal smoking (p=0.007) proved to be confounding factors. 
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Table 6.14: Frequencies of any positive SPT, positive SPT to milk and egg sensitization and mean SPT 
responses to allergens according to study group 
 
  Control group  
(n=38) 
Salmon group  
(n=48)  p 
Any SPT ≥ 2mm 
1  5/38 (13.1%)  6/48 (12.5%)  0.927 
Any SPT ≥ 3mm 
1  1/38 (2.6%)  2/48 (4.2%)  0.686 
SPT to cows‟ milk ≥ 2mm 
1  2/38 (5.3%)  2/48 (4.2%)  0.810 
SPT to hens‟ egg ≥ 2mm 
1  4/38 (10.5%)  3/48 (6.3%)  0.471 
SPT to negative control (mm) 
2  0.00 (0.00)  0.00 (0.00)  - 
SPT to HDM (mm) 
2  0.00 (0.00)  0.00 (0.00)  - 
SPT to cat (mm) 
2  0.05 (0.32)  0.06 (0.32)  0.888 
SPT to dog (mm) 
2  0.00 (0.00)  0.08 (0.40)  0.159 
SPT to grass pollen (mm) 
2  0.00 (0.00)  0.02 (0.14)  0.322 
SPT to tree (mm) 
2  0.00 (0.00)  0.02 (0.14)  0.322 
SPT to milk (mm) 
2  0.11 (0.45)  0.08 (0.40)  0.816 
SPT to egg (mm) 
2  0.34 (1.15)  0.19 (0.76)  0.477 
SPT to salmon (mm) 
2  0.00 (0.00)  0.00 (0.00)  - 
SPT to histamine (positive control) (mm) 
2  3.61 (1.05)  4.10 (1.12)  0.037 
1 Values are number (within group %), Chi-square test p-values 




Table 6.15: Positive skin prick tests in infants at age 6 months according to study group 
 
Allergen  Control group  Salmon group 
Dermatophagoides pteronyssinus  
(House dust mite (HDM))  0  0 
Felis domesticus (cat)  1  1 
Canis familiaris (dog)  0  2 
6 Grass mix pollen  0  0 
3 Tree mix pollen  0  0 
Salmon  0  0 
Hens‟ egg  4  3 
Cows‟ milk, raw  2  2 
Values are frequency i.e. number 
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Table 6.16 describes total and specific IgE measured in the infant blood at 6 months of age 
and also the frequencies of the infants that had detectable specific IgE to hens‟ egg or cows‟ 
milk in the two study groups. Total IgE was not different between groups. Concentrations of 
specific IgE were low and at the limit of detection. Salmon-specific IgE was not different 
between groups. Controlling total IgE for birth order, paternal atopy and maternal smoking as 
potential effect modifiers did not change the findings. 
 
Table 6.16: Total and specific IgE in infant serum at age 6 months according to study group 
 
Infant clinical outcomes at 6 months: IgE  Control group   Salmon group   p 
IgE to egg albumin detected  
(dichotomized) 
1  2/27 (7.40%)  2/32 (6.30%)  0.860 
IgE to egg yolk detected 
(dichotomized) 
1  2/27 (7.4%)  0/32 (0%)  0.112 
IgE to cows‟ milk detected  
(dichotomized) 
1  2/27 (7.40%)  0/32 (0%)  0.117 
Total Ige (kU/L) 
2  7.98 (5.83)  8.59 (7.01)  0.701 
IgE to egg albumin (kU/L) 
2  0.52 (0.62)  0.37 (0.11)  0.231 
IgE to egg yolk (kU/L) 
2  0.37 (0.09)  0.35 (0.00)  0.161 
IgE to cows‟ milk (kU/L) 
2  0.36 (0.04)  0.35 (0.00)  0.162 
IgE to salmon (kU/L) 
2  0.35 (0.00)  0.35 (0.00)  0.387 
1 Values are number (within group %), Chi-square test p-values 
2 Values are mean (SD), independent t-test p-values 
 
Table 6.17 shows the occurrence of the possible combinations between parental and infant 
SPT positivity/negativity. There were no differences between groups. 
 
Table 6.17: Combination of maternal/paternal SPT with infant SPT according to study group 
 
  Control group 
(n=38) 
Salmon group 
 (n=48)  p 
Both maternal and paternal positive SPT 
and infant positive SPT  1 (2.6%)  2 (4.2%) 
0.928 
Maternal or paternal positive SPT 
and infant positive SPT  2 (5.3%)  3 (6.2%) 
No maternal/paternal positive SPT 
and infant positive SPT  1 (2.6%)  0 (0.0%) 
Either maternal/paternal positive SPT 
and infant negative SPT  17 (44.7%)  28 (58.3%) 
Maternal/paternal negative SPT 
and infant negative SPT  3 (7.9%)  1 (2.1%) 
Both maternal and paternal positive SPT 
and infant negative SPT  9 (23.7%)  13 (27.1%) 
Both maternal and paternal negative SPT 
and infant negative SPT  5 (13.2%)  1 (2.1%) 
Values are number (within group %), Chi-square test p-value, Positive SPT is defined as ≥ 2mm wheal diameter   307 
6.4  Discussion 
 
This chapter describes the feeding patterns of the babies born to the SIPS mothers at 6 
months of age, the concentrations of total and specific IgE in the blood of those infants, the 
results  of  skin  prick  testing  for  sensitisation  to  several  different  allergens,  and  the 
assessment of AD in those infants all at age six months. There was no effect of maternal 
salmon consumption on plasma IgE, SPT positivity, and occurrence of AD or its severity. 
The  hypotheses  of  the  work  described  in  this  chapter  are  that  the  maternal  oily  fish 
intervention will reduce sensitization to common allergens in infants at 6 months of age 
(determined  by  SPT),  reduce  AD  score  in  infants  at  6  months  of  age  (determined  by 
SCORAD) and decrease plasma IgE concentration in infants at 6 months of age. The work 
described here does not provide support for any of these hypotheses. The lack of effect on 
IgE and on clinical outcome at 6 months is despite the differences in immune outcomes in 
umbilical cord blod observed between control and salmon groups (Chapter 5). 
6.4.1  Clinical outcomes 
 
The  results  obtained  in  this  chapter  indicate  that  the  intervention  that  increased  oily  fish 
consumption  from  a  habitually  low  intake  (≤  2  portions/month)  to  the  recommended 
maximum  level  of  intake  (two  portions/week)  during  pregnancy,  was  not  successful  in 
reducing sensitization to common allergens, AD or IgE concentration. These findings will be 
discussed  in  comparison  to  observational  and  supplementation  studies  conducted  during 
pregnancy (and lactation) in relation to LC n-3 PUFA exposure. 
 
SIPS was powered according to an assumed sensitization to at least one common allergen in 
45% of the infants participating in the control arm at 6 months of age, based upon the high risk 
nature of the pregnancies. In fact only about 13% of the infants in the control group were 
sensitized and so the study was underpowered to detect a difference in sensitization.  
 
A higher than anticipated number of the SIPS infants were still breastfeeding and had not been 
introduced to a large amounts of solids. Breastfeeding and avoidance of solids are protective 
against sensitization (318;319) which might explain the low rate of sensitization seen. It will 
be prudent to re-examine sensitization and the other outcomes at a later age (24, 30 or 36 
months). In fact a 30 month follow-up of the infants is about to begin.    308 
 
As indicated above, SPT positive responses to any allergen were very low in both groups; 5 
subjects in the control and 6 in the salmon group had any positive SPT response. Most of these 
infants were sensitized to hens‟ egg (4 in the control and 3 in the salmon group) or cows‟ milk 
(2 in each group), very few to cat (1 in each study group) or dog (2 in the salmon group) and 
none to the grass and tree pollens, or to salmon. The fact that no infant was sensitized to 
salmon antigen in the salmon group suggests that the increased maternal and fetal exposure to 
fish did not sensitize the infant immune system at least up to 6 months of life. 
 
When combining the results of the maternal and paternal SPT responses with the infant SPT 
responses to the same allergens it was interestingly found that when the mother or the father or 
both parents had any positive SPT response, only 8/86 (3 in control and 5 in salmon group) 
infants  had  corresponding  positive  responses  to  any  allergen  whereas  67/86  infants  had 
corresponding negative SPT responses to any allergen (26 in control and 41 in salmon group). 
Out of 7 infants who were SPT positive for egg protein, 6 had detectable anti-egg IgE. Also 
when combining the infant clinical results of IgE and SPT for egg and cows‟ milk, IgE was 
detected and SPT was positive to egg at the same time for 4/86 infants (2/38 in the control and 
2/48 in the salmon group). For 3 infants (2 in the control group and 1 in the salmon group) the 
SPT to egg was positive but the specific IgE was below the detection level. Likewise, out of 4 
infants who were SPT positive for cows‟ milk protein, 2 had detectable anti-cows‟ milk IgE. 
2/38 infants in the control group and none in the salmon group were both positive for SPT and 
IgE to  cows‟  milk  protein.  For 2 offspring in  the salmon  group the SPT  was  positive in 
response  to  cows‟  milk  but  no  IgE  was  detected.  It  is  interesting  that  the  same  pattern 
happened in response to both allergens: more positive responses were detected by SPT which 
were not confirmed by the IgE measurement.  
 
6.4.2  Comparison to other studies investigating the effect of maternal LC 
n-3 PUFA intake 
6.4.2.1 Observational studies 
 
All five studies investigating the effect of maternal fish intake during pregnancy on atopic or 
allergic outcomes in infants/children of those pregnancies concluded protective associations 
(151-155). The study conducted by Salam et al. did not look at SPT or IgE to allergens but   309 
reported asthma related outcomes (155). Romieu et al. found an increase in maternal fish 
intake during pregnancy from once per week to 2.5 times per week was associated with lower 
risk of eczema at age 1 year (OR 0.73; 95% CI 0.55–0.98; p=0.036), positive SPT for HDM at 
6 years (OR 0.68; 95% CI 0.46–1.01; p= 0.058), and atopic wheeze at age 6 years (OR 0.55; 
95% CI 0.31–0.96; p=0.034). Weekly maternal fish intake during pregnancy was inversely 
associated with eczema at 1 year (p=0.050), positive SPT for HDM at 6 years (p=0.048), 
atopic  wheeze  at  6  years  (p=0.028)  (151).  Calvani  et  al.  observed  stronger  and  more 
significant beneficial effects of increased oily fish intake during pregnancy for children (mean 
age 5 years) of non-allergic mothers compared to those of allergic mothers for food (milk and 
egg) sensitizations (p for trend=0.002) but not for inhalant sensitizations. It is not clear why 
these  findings  were  different  (154).  Willers  et  al.  examined  atopic  eczema  in  children 
followed up to 5 years of age in a large cohort. Maternal total fish intake ≥ 1/week vs. never 
was associated with decreased risk of doctor diagnosed eczema (OR 0.57; 95% CI 0.35– 0.92; 
p-trend 0.008), current treated eczema (OR 0.58; 95% CI 0.32–1.06; p-trend 0.028), and ever 
having eczema (OR 0.68; 95% CI 0.43–1.10; p-trend 0.05) (153). Sausenthaler et al. reported 
eczema sensitization and IgE in infants followed up to 2 years in a large prospective cohort 
study.  High  maternal  fish  intake  vs.  low  was  associated  with  decreased  doctor-diagnosed 
eczema risk in children at 2 years (OR 0.75; 95% CI 0.57–0.98; p<0.05) (152). 
 
The large cohort studies conducted by Sausenthaler et al. and Willers et al. concluded similar 
associations:  high  (≥  1  time/week)  vs.  low  maternal  fish  intake  during  pregnancy  was 
associated  with  decreased  doctor-diagnosed  eczema.  The  greater  decrease  in  the  study  of 
Willers et al. compared to the study of Sausenthaler et al. (43% vs. 25%, respectively) could 
be related to the fact that the study of Willers et al. followed-up children for a longer period, 
allowing for manifestations of atopic disease to be revealed at the stage of clinical assessment. 
 
Across these five studies, the extent of lowering atopic risk effect of maternal fish intake was 
highly variable. Fish intake resulted in a decrease in infant or childhood atopy which ranged 
between 25% and 95%. However, most decreases in atopic risk ranged between 40% and 
80%. 
 
There is one study, by Hoppu et al. (156) that investigated maternal fish consumption during 
lactation  (one month after birth  rather pregnancy) on AD development on the infant  at  4 
timepoints. The primary objective of the study was to examine the effect of breast milk fatty   310 
acid  composition  on  atopic  dermatitis  during  the  first  year  of  life.  Although  a  higher 
percentage of EPA in breast milk was related to lower risk of AD, fish consumption frequency 
during lactation was not associated with breast milk EPA content. This may be attributed to 
the fact that breast milk fatty acid composition is determined more by fatty acids accumulated 
in maternal adipose tissue during pregnancy rather than dietary intake of fatty acids during 
lactation (157;158;331). The authors stated that maternal fish intake during pregnancy would 
have been more appropriate to investigate in relation to breast milk composition. 
 
All  these  studies  were  powered  enough  to  show  such  large  effects  on  atopic  outcomes 
compared to SIPS that had no effect on atopic outcomes probably because of the size of the 
study at 6 months in relation to the low level of sensitisation. Also the infants in all these 
observational design studies were followed up later in infancy and childhood (follow up from 
1-5 years of age) compared to SIPS (follow-up only to 6 months) so that the infant immune 
system would mature and develop detectable responses to allergens. 
 
6.4.2.2 Experimental studies 
 
Studies of maternal fish oil supplementation during pregnancy reported effects on umbilical 
cord  blood  immune  markers  (blood  cytokine  mRNA  (178),  plasma  cytokines  (35),  LTB4 
production from neutrophils (176), cytokine production by mononuclear cells (132) and an 
altered  cord  blood  haemopoietic  progenitor  phenotype  (173)).  These  immunologic  effects 
might  be  expected  to  impact  on  allergic  sensitization  and  on  the  development  of  atopic 
disease. Dunstan et al. (132) reported beneficial effects on atopic outcomes in one year old 
infants as a result of maternal fish oil supplementation during pregnancy (less severe atopic 
dermatitis (OR 0.09) only when the SCORAD index was modified to >25, and lower risk of 
positive SPT to egg (OR 0.34)) in the infants in the fish oil group. However, the link between 
the CBMC cytokine responses measured at birth in the two groups and the development of the 
clinical features (AD, asthma and food allergy) at one year of age was not consistent with the 
assumed predisposing immunology of AD (132). This study provided women with the large 
dose of 3.1 g/day EPA plus DHA compared to 0.495 g/day EPA plus DHA that the women 
were taking from study salmon in SIPS The study of Kraus-Etschmann did not report any 
clinical assessments of the infants (178). Olsen et al. (180) identified that, compared with the 
olive  oil  control,  fish  oil  supplementation  in  late  pregnancy  is  associated  with  a  marked   311 
reduction in atopic manifestations in the offspring at age 16 years, suggesting a long-term 
effect of any immunologic changes that occurred in pregnancy and early life of those children. 
After 16 years, there was a lower prevalence of asthma (all types), AD or allergic rhinitis (by 
57%) and of allergic asthma, AD or allergic rhinitis (by 69%) in the fish oil group compared to 
the olive oil control group. However in the Olsen et al. study there was also a no intervention 
group and there were no differencs in outcome between that group and the fish oil group. 
 
A study of fish oil supplementation during both pregnancy and lactation (week 25 of gestation 
to 3-4 months lactation) with atopic outcomes in the offspring at 6 months and 1 year of age, 
showed expected effects on n-3 PUFA status and these were associated with differences in 
PGE2  production  by  stimulated  maternal  blood  (182).  The  latter  might  be  expected  to 
influence Th2 polarisation. Indeed, infants from mothers in the fish oil group had a reduced 
risk of developing allergic sensitisation to egg, IgE-associated eczema and food allergy during 
the first year of life (181). In detail, the prevalence of any positive SPT and of a positive SPT 
to egg in the infants at 1 year of age was significantly lower in the fish oil group compared to 
the  placebo  group.  Eczema  in  the  presence  of  detectable  IgE  antibodies  or  positive  SPT 
towards egg, milk, or wheat and food allergy (reaction to egg or milk) during the first 12 
months of life were significantly lower in the fish oil group. In a regression analysis, after 
controlling for confounding factors, it was found that the risk of developing any positive SPT, 
a positive SPT to egg, or IgE-associated eczema was three to four times less in the fish oil 
group compared to the placebo. The risk of developing food allergy was reduced ten times in 
the fish oil group in comparison to the control. These significant effects were seen in the 
offspring of non-allergic mothers but not of allergic mothers. This study provided women with 
2.7 g/day EPA plus DHA, which is a high supplementation dose when compared with SIPS in 
which the dietary intake of EPA plus DHA per day was 0.495 g, according to the current 
recommendations (two portions of study salmon per week). 
 
A study of maternal fish oil supplementation during lactation (179) was the only one of these 
studies  investigating  immune  outcomes  in  the  offspring  beyond  birth.  Infants  of  lactating 
mothers who received fish oil supplements had a higher n-3 PUFA status at 4 months of age 
and interferon-γ production at 2.5 years of age was higher in the fish oil group, an observation 
that may reflect faster maturation of the immune system. This study was not powered to assess 
clinical outcomes such as atopic sensitization, and no differences in atopic outcomes or in 
plasma IgE were observed between the groups. No significant association was found between   312 
in  vitro  cytokine  production  and  plasma  IgE  levels  and  there  was  also  no  significant 
association between plasma IgE and eczema, wheezing, or food allergy, although both trends 
tended to be positive. 
 
Each  of  the  intervention  trials  described  above  were  conducted  with  fish  oil  supplements 
rather that fish and the dose of LC n-3 PUFAs was much higher compared to the provision of 
EPA and DHA from 2 portions of salmon. Also fish oil supplements were provided on a daily 
basis rather than twice per week. Furthermore, the clinical outcomes in these supplementation 
studies were not assessed before the infant age of one year. These differences in the design of 
the trials besides sample size might explain why SIPS showed no effect on the atopic clinical 
outcomes.  
 
6.4.3  Diet and other characteristics at 6 months 
 
The purpose of this chapter regarding the diet and other characteristics of the offspring at 6 
months  of  age  is  to  describe  the  infants  in  the  two  groups  (anthropometry,  health  status, 
reported allergies), their feeding patterns in the first 6 months of age (milk consumption, type 
of  milk  consumed,  introduction  of  solids)  and  their  nutrient  intakes  at  6  months  by  FFQ 
assessment. Because all these activities depend on the carer/s, the intervention itself and the 
grouping in the treatment  groups might  have affected the dietary  choices  of the 6 month 
population. 
 
At 6 months 90% of the infants in each group had been breastfed; 77% and 89% in the control 
and salmon groups respectively were formula fed, whereas 41% (control group) and 45 % 
(salmon group) were still breastfeeding at 6 months. This shows that the mothers involved in 
SIPS had a healthy lifestyle, feeding the newborns with breastmilk according to the latest 
recommendation (6 months of breastfeeding) for optimum health (332). Data from the latest 
infant feeding survey in the UK has shown that 25% of  all mothers in the UK were still 
breastfeeding at 6 months postnatally (333). The proportion in SIPS is higher than this. 
 
In terms of feeding duration, breastfeeding duration was 146/180 days (almost 5 months) on 
average in both groups, formula feeding was 124 days in the control and 152 days in the   313 
salmon group and exclusive breastfeeding duration was higher in the control group compared 
to the salmon group (44 vs. 27 days), but the difference was not significant.  
 
Regarding  feeding  patterns  and  the  focus  of  the  study  on  LC  n-3  PUFAs,  the  days  of 
consumption of milks fortified with or without EPA plus DHA were recorded. Both groups 
consumed fortified formula milks for most days rather than unfortified, whereas the salmon 
group consumed supplemented milks for more days compared to the control group (97 vs. 71 
days). It may be that being in the salmon group prompted the mothers to be more conscious 
about ensuring a good LC n-3 PUFA intake in their infants.  
 
There were very similar patterns between the two groups regarding consumption frequencies 
of breast milk and other food groups to the 7 days prior to completing the FFQ. The only 
exception was the frequency of consumption of vegetable jars. Regarding quantities consumed 
in the past 7 days the salmon group consumed more breast milk and less expressed breast milk 
(the difference was not significant). Infants in the salmon group tended to have a higher intake 
of fish in the last week compared to control group (50 g/week vs. 15 g/week). Again, some 
mothers in the salmon group may have been influenced by the intervention and knowing the 
potential benefits of fish on reducing allergic risk, fed their infants with larger quantities of 
fish than the mothers in the control group. 
 
The macro- and micro-nutrient intakes for the total diet were similar in the two groups. The 
intake of energy/kg of body weight was 364 kJ/kg and 394 kJ/ kg in the control and the 
salmon  groups,  respectively.  Comparison  of  those  values  to  the  dietary  reference  values 
(DRV) (231) for formula fed infants in the UK (400 kJ/kg/day) at 6 months showed that the 
energy intake derived from the FFQ data is close to the DRV values especially for the salmon 
group.  
 
Length and weight by gender in the control and salmon groups were compared with the DRV 
tables for length and height for boys and girls at 6 months. According to the DRV the average 
height for boys and girls is 67.9 cm and 66.3 cm respectively and the average weight is 8 kg 
and 7.4 kg, respectively. The average values from SIPS are very similar for both groups. 
Overall, mean weight and length in both groups, approximated the 50th percentiles on more 
recent standardized growth charts (334) showing normal growth and development for these 
infants.   314 
 
The ability of the 6 month FFQ to rank intakes of energy and nutrients accurately is enhanced 
by the detail and quality of the information collected and by its short period of recall (1 week) 
which allows capture of the diet without much recall bias. Furthermore the FFQ records both 
the  amount  consumed  and  the  frequency  of  consumption  of  all  foods  and  drinks  and 
information on brands and types of baby foods and milks used. In addition myself and L-S 
Kremmyda in collaboration with the SWS nutrition team found the exact nutritional content of 
the baby foods/milks missing from the SWS database. 
 
A limitation of this study is that the population that was interested to take part had a high 
standard  healthy  living  profile  which  was  reflected  not  only  in  the  compliance  to  eating 
salmon but in the high rate of breastfeeding in both treatment groups. It must be noted that an 
algorithm was used to estimate human milk intake which relates length of suckling to intake 
(324;335). According to the validation of this FFQ that was also used in the 6 month infant 
population of the SWS study, the FFQ tended to produce higher values for actual intakes of 
energy and nutrients (apart from sodium) when compared with the method of 4-day weighed 
diaries, which is a result of gradual change in infant diet over time (324). Nevertheless, the 
FFQ was a useful tool to assess energy and intakes in this relatively large group of infants. 
Overall, the 6 month follow up questionnaire gave very detailed information on the feeding 
and dietary patterns of the infants of both groups at 6 months of age as well as information on 
their growth and development.   315 
6.5  Conclusion 
 
This chapter described the feeding patterns of the babies born to the SIPS mothers at 6 months 
of age, the concentrations of total and specific IgE in the blood of those infants, the results of 
skin prick testing for sensitisation to several different allergens, and the assessment of AD in 
those infants all at age six months. There was no effect of maternal salmon consumption on 
plasma IgE, SPT positivity, and occurrence of AD or its severity. The work described here 
does not provide support for any of the hypotheses being tested. However despite the absence 
of effect on clinical outcomes of atopy at 6 months, the immune system of the newborn had 
shown differences at birth between the two groups (Chapter 5). Thus, the absence of effect 
might be attributed to the fact that 6 months was quite early for SIPS babies to show signs of 
sensitization. The future follow-up of these infants at 30 months might reveal the development 
of detectable responses to allergens. Other than that, all SIPS babies, in both study groups 
have normal and healthy growth. 
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7  Final Discussion   318 
 
7.1  Overview and summary of the main findings of the study 
 
Epidemiological data has shown that in the last 30-40 years the incidence of childhood atopic 
disease has dramatically increased especially in Western environments  (68;72;74;336;337). 
This has happened in parallel with a decrease in infectious diseases which has led to the 
development of the hygiene hypothesis (72;88;111). Numerous environmental factors play an 
important role in determining the risk of atopic disease; these factors include diet, smoking 
and pollutants (338-341). One of the major dietary changes that has happened in the last 3-4 
decades is the decreased intake of LC n-3 PUFAs (EPA and DHA) and a related increased 
intake of n-6 PUFAs (80). It is believed that this dietary change may have a causal role in 
increasing risk of atopic disease. Also, the decreased intake of vitamin D and of antioxidants 
such as selenium (200;342) may also play a causal role. It has been shown that exposure to LC 
n-3 PUFAs, vitamin D, vitamin E and selenium modifies fetal/neonatal immune responses 
(202;203;207-209;337). 
 
Currently, in the UK it is recommended that pregnant women and women or reproductive age 
should consume two portions of fish per week, of each at least one should be oily in order to 
achieve  a  minimum  intake  of  450  mg/day  of  EPA  plus  DHA  (23).  There  is  quite  strong 
evidence from epidemiological studies of lowered risk of infant/childhood atopy with high fish 
consumption during pregnancy. The evidence from the experimental studies with fish oils is 
not  so  strong,  but  there  is  some  evidence  supporting  a  protective  effect  towards  the 
development of atopic disease in the infant (203). However, there are no intervention studies 
with fish during pregnancy. So, it remained to explore the effect of early intervention with fish 
(i.e.  in  pregnancy)  on  atopy-related  outcomes  in  the  infants  of  those  pregnancies.  The 
difference between fish and fish oil supplements, is that fish as a whole food is source not only 
of LC n-3 PUFAs but also source of micronutrients as vitamin D and selenium. 
 
The Salmon in Pregnancy Study (SIPS) described here is the first randomised controlled trial 
of oily fish (farmed salmon) in pregnant women; the study was single-blind (investigator) and 
the  babies  of  the  women  recruited  were  at  high  risk  of  developing  atopic  disease.  SIPS 
specifically  focuses  on  pregnant  women  whose  offspring  are  at  risk  of  developing  atopic   319 
disease, with one aim being to identify whether there is an effect on atopy outcomes in the 
offspring. The overall general hypotheses being investigated, are that: „increased consumption 
of oily fish during pregnancy by women at risk of having offspring who will develop atopy 
will increase their LC n-3 PUFA status and antioxidant status and that of their developing 
baby and will ameliorate the development of atopic markers and manifestations in the infants‟. 
The present thesis focuses on specific aspects of the SIPS.  
The aims of my study are: 
1.  to  increase  oily  fish  consumption  from  a  habitually  low  intake  (≤  2 
portions/month)  to  the  recommended  maximum  level  of  intake  (two 
portions/week) during pregnancy, in women whose offspring are at a high risk 
of developing atopic disease; 
2.  to investigate the effect of increased maternal oily fish consumption on cord 
plasma and cord blood mononuclear cell (CBMC) LC n-3 PUFA status; 
3.  to investigate the effect of increased maternal oily fish consumption on markers 
of infant immunity at birth (i.e. in cord blood); 
4.  to investigate the effect of increased maternal oily fish consumption on atopic 
sensitization and atopic dermatitis in infants at 6 months of age. 
The research hypotheses of my study are that increased consumption of farmed salmon during 
pregnancy by women with high risk of having an atopic offspring will:  
1.  increase maternal LC n-3 PUFA intake; 
2.  increase cord plasma LC n-3 PUFA status; 
3.  increase CBMC LC n-3 PUFA status; 
4.  alter immune markers in cord blood in a way that would indicate decreased 
atopy risk;  
5.  reduce sensitisation to common allergens and reduce atopic dermatitis score in 
infants at 6 months of age. 
The data obtained allowed the first three hypotheses to be accepted, the fourth to be partially 
accepted as there was some impact of the salmon intervention on the infant immunity whereas 
the fifth cannot be accepted as there was no reduction in allergic sensitization at 6 months of 
infant age.   320 
 
The  main  findings  of  the  present  thesis  will  be  summarized  below  and  further  discussed 
according to the literature. In this context, the strengths and limitation of this study will be 
highlighted, final conclusions will be drawn and suggestions/plans for future work will be 
suggested. 
 
A total of 123 women were randomly assigned to consume either 2 portions of farmed salmon 
per week (from week 20 until delivery) or to continue their habitual diet low in oily fish (less 
or equal to two portions per month) from week 20 until the end of their pregnancy. Briefly, 62 
and  61  pregnant  women  were  randomly  assigned  to  the  salmon  and  control  groups, 
respectively. At birth, 107 subjects (n=53 in salmon and n=54 in control group) were enrolled 
in the study. After delivery, at 6 months 86 subjects completed the 6 month appointment 
(n=47 in salmon group and n=39 in control group). In total the drop out rate was 30%. At the 6 
month appointment the parents were also assessed for atopy by skin prick test (SPT) and this 
was completed by 86 mothers and 76 fathers in total. The baseline characteristics of SIPS 
parents and babies are described in detail in Chapter 2. 
 
Main findings of the maternal dietary and nutrient analysis during pregnancy 
 
SIPS successfully increased oily fish intake in the salmon group to the target of 2 portions of 
study salmon per week. This was reported both in the FFQs and in the fish diaries although 
there were differences in the reporting of the intakes of the seven nutrients of interest (EPA, 
DHA, total n-3 PUFAs, total n-6 PUFAs, vitamin D, vitamin E and selenium) between the two 
methods. According to the FFQ (at 34 weeks gestation) all volunteers in the salmon group 
reported intake of 1-2 times per week of salmon and according to the fish diaries (between 21-
38 weeks gestation) the median intake was 1.94 portions of study salmon per week. Also it 
was shown that 79.6% of the volunteers in the salmon group ate 2 or more portions of study 
salmon per week for the 81.3% of intervention period. The control group had a very low 
intake of oily and total fish which was significantly lower than in the salmon group. This 
demonstrates the compliance to the intervention in both arms of the study. 
 
According to the FFQ, median daily intake of EPA plus DHA was 402.6 mg for the salmon 
group and 30 mg for the control group (p<0.001). The fish diary results showed higher intakes 
for the salmon group (490 mg/day EPA plus DHA) and similar intakes for the control group   321 
(24 mg/day EPA plus DHA) compared to the FFQ calculations. The calculated intake of LC n-
3 PUFAs in the salmon group exceeds the recommendation for minimum intake of EPA+DHA 
during pregnancy (109% of 450 mg/day) and the latest WHO/FAO recommendation (2008) 
for minimum DHA intake of 200 mg/day during pregnancy and lactation (199). 
 
In addition, increased salmon intake increased total dietary intake of selenium (58.2 μg/d vs. 
49 μg/d) and vitamin D (5.75 μg/d vs. 2.9 μg/d) in the salmon group compared to the control 
group. Increased salmon consumption was compensated by decreased consumption of other 
types of seafood (non-oily fish and fish fingers/fish dishes) and of red meat, chicken, and total 
meat. 
 
Main findings from the maternal & infant fatty acid status 
 
Fatty acids in the blood stream (plasma and cells) provide the link between the dietary intake 
and the bioavailability of the LC n-3 PUFAs in the mother and subsequent supply to the fetal 
circulation. The data obtained from the fatty acid analysis of maternal blood during pregnancy 
(20, 34, 38 weeks gestation) and infant blood at birth (cord blood) allowed the hypothesis that 
the maternal oily fish intervention will result in higher amounts of EPA and DHA in maternal 
PC and in neonatal (cord) plasma lipids to be supported. However, the hypothesis that high 
oily fish consumption will result in higher amounts of EPA and DHA in CBMCs was not 
proven.  
 
The literature has shown that percentages of EPA and DHA in maternal plasma lipids decline 
during pregnancy (257-259). This was confirmed in the control group in SIPS, and is probably 
related with preferential transfer of DHA through the placenta to the growing fetus (253). 
SIPS,  being  the  first  randomised  controlled  trial  with  fish  during  pregnancy,  showed  that 
consumption of two portions of salmon per week (between week 20 till delivery) prevented 
the pregnancy-associated decrease in the percentages of EPA and DHA in the phospholipid 
(PC) fraction, and actually resulted in increased levels of these LC n-3 PUFAs in maternal PC 
compared to the control group. Thus, the consumption of 2 portions of salmon per week, as 
confirmed by two dietary assessment tools (FFQs and fish diaries) and which resulted in an 
intake of more than the recommended amount of EPA+DHA, was also proven biochemically 
by the increased status of those LC n-3 PUFAs in maternal plasma. The higher EPA and DHA   322 
status  in  maternal  plasma PC may indicate  a  better ability  to  supply  the fetus  with  these 
structurally and functionally important fatty acids.  
 
In the cord plasma, significant changes in the status of LC n-3 (EPA and DHA) and n-6 
(ARA)  PUFAs  were  observed  in  almost  all  lipid  fractions  when  data  were  expressed  as 
percentages rather than absolute amounts. The pattern observed was that EPA and DHA status 
increased significantly, whereas ARA status decreased significantly in cord blood plasma in 
the salmon group neonates compared to those of the control group. A similar trend was found 
in these LC PUFAs in immune cells (CBMCs) but the differences between groups did not 
reach significance. However, in the immune chapter (Chapter 5) some differences in functions 
of  CBMCs  between  the  two  groups  were  seen  (e.g.  eicosanoid  and  cytokine  production) 
suggesting that the observed differences in fatty acid composition of CBMCs were sufficient 
to lead to, or at least mark, changes in cell function. 
 
Main findings from the infant immune system at birth 
 
It  was  hypothesized that the increased intake of EPA  plus  DHA during pregnancy  which 
resulted in higher total n-3 PUFA status in cord blood and in a tendency to a higher n-3 PUFA 
in immune cells (CBMCs), would have immunomodulatory effects in the developing infant 
immune system and predisposition to atopy in a protective way.  
 
The results obtained indicate that maternal salmon consumption during pregnancy results in 
some differences in cord blood immune cell phenotypes at birth (more leukocytes, neutrophils, 
lymphocytes, helper T-cells, cytotoxic T-cells and T-regulatory cells), a generalised decrease 
in production of cytokines in response to a T cell mitogen (PHA), TLR agonists and allergens, 
that became significant for several cytokines in response to the mitogen PHA (IL-2, IL-4, IL-
5, IL-10, and TNF-α) and the TLR-4 ligand LPS (IL-10, TNF-α), and a tendency to lower 
PGE2 production in response to LPS. The cord plasma concentration of IgE was not affected 
by  the  salmon  intervention.  IL-13  was  not  detected  in  most  cord  plasmas  and  no  other 
cytokines were measured in those samples. 
 
Thus, there is evidence to support two of the hypotheses (altered immune cell phenotypes and 
altered T cell responses) and to support in part a third (decreased PGE2 production) while 
there is no evidence in support of the fourth (decreased IgE concentration).   323 
 
Main findings from the clinical assessment of atopy at 6 months 
 
It  was  considered  that  the  maternal  oily  fish  intervention  would  reduce  sensitization  to 
common allergens in infants at 6 months of age (determined by SPT), reduce eczema score in 
infants at 6 months of age (determined by SCORAD) and decrease plasma IgE concentration 
in infants at 6 months of age. The results obtained did not provide support for any of these 
hypotheses and thus they cannot be supported from this study. The lack of effect on IgE and 
on clinical outcome at 6 months is despite the immune differences observed between control 
and salmon groups in cord blood (Chapter 5). 
 
The data collected on infant feeding patterns showed that the babies were not different in the 
two study groups in this regard. 41% of the infants in the control group and 45 % of the infants 
in the salmon group were still being breastfed at age 6 months whereas 34% of the women in 
England and Wales still breastfeed at 6 months post-partum (343). Breastfeeding duration was 
almost 5 months on average in both groups. The salmon group consumed milks fortified with 
n-3 PUFAs for a longer duration compared to the control group (97 vs. 71 days), but the 
difference was not significant. Infants in the salmon group tended to have a higher intake of 
fish in the last week (prior to the 6 month clinic visit) compared to control group (50 g/week 
vs. 15 g/week). Most likely, mothers in the salmon group were influenced by the intervention 
and knowing the potential benefits of fish and n-3 PUFAs on reducing allergic risk, fed their 
infants with larger quantities of fish than the mothers in the control group and also used n-3 
PUFA fortified milks to a greater extent. 
 
There were no gender and anthropometric (weight, length) differences between the babies in 
the two groups, and the nutrient intakes (including kJ/kg body weight) from the total diet did 
not  differ  either.  Overall,  the  growth  and  development  measurements  of  the  SIPS  infants 
compared  to  UK  growth  charts  (231;334)  showed  that  the  SIPS  babies  are  developing 
normally. 
 
To sum up, SIPS is the first randomised control trial to show that if pregnant women who do 
not habitually eat oily fish, consume two portions of oily fish (salmon) per week, from week 
20 of gestation to delivery, they will:   324 
  Increase their intake of LC n-3 PUFAs (achieving recommended intake), vitamin D 
and selenium 
  Increase  their  status  (maternal  blood  plasma  phospholipid  percentages)  of  LC  n-3 
PUFAs 
  Increase their neonates (cord blood plasma) status of LC n-3 PUFAs 
  Modify neonatal immune responses (CBMCs). 
The increased maternal and neonatal LC n-3 PUFA status did not result in changes in the 
clinical outcomes of atopy at 6 months of baby age.  
 
7.2  General comments, strengths & limitations of SIPS study  
 
The  SIPS  intervention  was  conducted  between  mid-pregnancy  to  delivery.  This  period  of 
intervention  was  chosen  based  on  previous  supplementation  studies  with  fish  oils  which 
focused on similar periods of gestation, indicating that this is a critical window for early life 
intervention  (132;177;180;181).  Furthermore,  the  demand  for  LC  n-3  PUFAs  increases 
dramatically the last trimester of pregnancy (250;253).  
 
  Maternal diet 
 
The FFQ most likely underestimates the intake of salmon, since an intake of 2 portions per 
week falls into the FFQ category 1-2 times per week, for which the multiplication factor for all 
calculations was 1.5. This is a limitation of the FFQ as a dietary assessment method, because it 
has an ordinal scale of consumption frequency categories (1-2 times/week), rather than a scale 
providing a true measure. The fish diaries were important not only to prove compliance to the 
intervention but also as a precise measure of fish consumption frequency (this showed that the 
women were eating 1.94 portions of salmon per week) and subsequently nutrient intake. The 
use of the diaries can be considered as a strength of SIPS. The FFQs provide dietary data for 
the 3 months prior to the FFQ administration. This is considered to be an advantage of the 
FFQ, reflecting the consumption frequency over a long period of time. Another advantage of 
the FFQ is that it is validated on the Southampton population for use in pregnant women (228) 
and  it  includes  distinct  fish  categories.  The  FFQ  method  has  also  been  used  in  large 
epidemiological studies testing similar hypotheses to SIPS i.e. maternal fish intake during   325 
pregnancy in relation to infant atopic outcomes (203), a fact enhancing the choice of FFQ as 
the main dietary assessment method in SIPS. 
 
FFQs might not be the ideal tool to investigate nutrient-disease associations (222). However, 
the SWS FFQ used by SIPS has been validated for calculating nutrient intakes compared to a 4 
day prospective food diary (222). A limitation of this FFQ is that has not been validated to 
calculate total diet EPA and DHA. However the main sources of EPA and DHA are fish and 
fish oil supplements or functional foods. The FFQ indicated that no subject was consuming 
fish oil supplements during pregnancy and a minority of subjects was consuming functional 
foods that contained fish oils. This consumption did not differ significantly between the two 
groups. The calculations of „total diet‟ EPA and DHA intake included fish oils in functional 
foods and between the two groups no substantial difference was observed in EPA and DHA 
intake from „total fish‟. So, it seems that the intake of EPA and DHA from total fish is a good 
estimation of EPA and DHA from total diet. Recent studies have reviewed the use of FFQs as 
a  validated  tool  to  estimate  LC  n-3  PUFA  and  micronutrient  intakes  during  pregnancy 
(344;345). However one disadvantage of FFQs is that they may not be able to detect small 
differences in nutrient intake compared to the fish diaries as the consumption frequencies were 
not categorised, but measured in an exact and precise way rather than to an ordinal scale. 
However, the fish diaries have two limitations: they are not validated, as the FFQs are, and 
also are influenced by individual variability in the way in which they are completed by the 
subjects. The FFQ was a very useful tool but at the same time it was long and time consuming 
to complete. In this way, an alternative shorter and more specific FFQ on LC n-3 PUFAs 
could be more practical to use and maybe the drop-out rate of reduced. 
 
The increase in intake of key nutrients other than LC n-3 PUFAs in the salmon group clearly 
indicates that salmon delivers more than just EPA and DHA and in this respect salmon may be 
superior to supplementation with fish oil capsules. From the 2 portions of study salmon, the 
requirements in EPA and DHA can be met (109% of minimum recommended intake), and the 
fish can make a major contribution in the daily intake of vitamin D (40% of the recommended 
intake)  and  Se  (20%  of  the  recommended  intake)  amongst  other  nutrients.  This  could  be 
considered as an additional strength of the study compared to similar design supplementation 
trials. 
 
  Maternal and infant fatty acid status   326 
 
The results of the maternal plasma PC fatty acid analysis provide biochemical proof that the 
intervention (i.e. increased salmon consumption) had been successful and that the subjects had 
complied  to  it.  Regarding  the  maternal  plasma  PC  fatty  acid  data,  at  baseline  (20  weeks 
gestation) the salmon group had higher percentages of EPA, DHA and total n-3 PUFAs and a 
lower percentage of ARA compared to the control group. This baseline difference in LC n-3 
PUFA status matches with the baseline difference in fish and LC n-3 PUFA consumption 
reported in chapter 3. Although the subjects were randomly assigned to the two groups at 
study entry, this  baseline difference is  a limitation  of SIPS study. However, this  baseline 
difference validates the SWS FFQ as a dietary assessment method of n-3 PUFA intakes, and 
this is a novel validation for this FFQ. 
 
The  results  from  plasma  fatty  acid  analysis  were  presented  in  this  thesis;  red  blood  cells 
(RBCs) better to capture longer term characteristics of the diet. Analysis of RBCs from SIPS 
have been performed (group of Angel Gil, University of Granada, Spain) and these show an 
increase in EPA and DHA in the salmon group. The findings on maternal fatty acids in plasma 
PC suggest that the mother is progressively depleted in these fatty acids (especially DHA and 
ARA), as they are transported to the fetus to meet the demands for growth and development. 
This decline in maternal LC PUFA status over the course of pregnancy has been demonstrated 
before and the extent of the decline in both DHA and ARA seen here is consistent with this 
earlier work (258;259). 
 
In contrast to the control group, which had a mean daily intake of about 30 mg of EPA plus 
DHA from the total diet, the salmon group had a mean daily EPA+DHA intake of over 400 
mg from the total diet. In accordance with this difference in dietary intake, the maternal status 
of EPA, DPA and DHA (expressed as % of fatty acids) in the salmon group was higher than in 
the control group. This is the first time that this effect of maternal salmon consumption in 
pregnancy has been demonstrated. A higher LC n-3 PUFA status in maternal blood may mean 
that the mother can supply increased amounts of these important fatty acids to the fetus. This 
may be important for fetal growth and development and also might play a key role in the 
development of the fetal immune system (202). 
 
The  salmon  intervention  enhanced  the  pregnancy  associated  decline  in  ARA  in  maternal 
plasma  PC.  This  effect  is  consistent  with  other  observations  where  LC  n-3  PUFAs  are   327 
incoporated into lipids at the expejse of ARA. This may not be a desirable effect as ARA too 
has important roles in fetal growth and develolment (10;243;263).  
 
The  inclusion  of  both  expressions  of  fatty  acid  results  (percentages  and  absolute 
concentrations)  in  the  current  thesis  is  a  strength  of  the  study  because  the  combination 
provides complete information of the differences between the groups. In general, greater and 
more significant effects were observed when the percentage data were used.  
 
This is the first study to show that a dietary intervention with fish during pregnancy increases 
LC n-3 PUFA status of the fetus/neonate. Higher cord RBC LC n-3 PUFAs has been reported 
following fish oil supplementation in pregnant women (174). In the current study DHA and 
ARA in the cord plasma PC were much higher than in the maternal plasma PC (at 38 weeks). 
DHA was on average 57% higher and ARA 219% higher in cord plasma PC. These findings 
agree with those from previous studies that found that relative amounts of ARA and DHA in 
umbilical cord blood were significantly higher than in maternal blood (258;264). This might 
point to a high neonatal need for ARA and DHA which are the most abundant n-6 and n-3 
PUFA in neural and retinal tissue, respectively (and also in immune cells). 
 
Unfortunately, salmon intervention did not have a significant effect on the LC n-3 PUFA 
composition of the cord blood immune cells (CBMCs). No previous supplementation study 
has  measured  the  fatty  acid  status  of  the  immune  cells  in  the  cord  blood.  Another  novel 
finding of SIPS is the positive correlations between the DHA status in the cord blood (plasma 
(expressed either as percentage and absolute concentration) and mononuclear cells) with the 
gestational length. This result is supported by evidence in the literature that relates maternal 
dietary intake of DHA (and ARA) with gestational length and infant characteristics at birth 
(birth  weight,  head  circumference)  (39;243;248;263),  indicating  the  importance  of  DHA 
supply to the fetus to support in utero brain growth.  
 
  Infant immunity 
 
Immune cell subset analysis in combination with the measurement of immune cell numbers 
showed that the numbers of T helper (CD3
+CD4
+) cells, cytotoxic T (CD3
+CD8




low) cells were higher in the salmon group compared to the 
control  group.  The  percentages  of  these  cells  in  the  lymphocyte  and  total  leukocyte   328 
populations did not differ between the two groups, but the numbers of lymphocytes and total 
leukocytes  (and  also  neutrophils)  were  higher  in  the  salmon  group.  Dunstan  et  al.  (35) 
observed no significant difference in the frequency of various lymphocyte subsets (% and 
absolute  concentration)  between  the  fish  oil  supplemented  and  the  control  group.  It  is 
noteworthy that the method used to identify the T regulatory cells in SIPS was not optimal; 
one antibody stain (to the FOXP3 transcription factor), which according to the literature (306) 
would definitely determine CD4
+CD25
+CD127
low  cells  as  T regulatory  was  not  used. The 
reason for this omission is that the flow cytometer used for the SIPS analysis could only detect 
three antibody stains at the same time, and the use of a fourth stain was not possible. One 
limitation  of  SIPS  is  that  the  cord  blood  immune  cell  subsets  were  characterised  by 
extracellular  surface  markers  and  not  intracellular  markers  which  describe  the  functional 
properties of these cells. However, the production of Th1 and Th2 cytokines by unstimulated 
and  stimulated  CBMCs  was  investigated  as  a  measure  to  obtain  information  about  the 
functional phenotype of these cells.  
 
A  strength  of  the  current  study  is  the  use  of  different  (ex  vivo)  stimulants  in  order  to 
investigate  different  aspects  of  the  immune  system  including  both  innate  and  adaptive 
immunity, using allergens, a mitogen and TLR ligands. Also an advantage was the method of 
cytokine determination by using a flow cytometry based assay, termed cytometric bead array, 
which measures at the same time a range of cytokines characteristic of different responses: 
Th1 (IL-2, TNF-α, IFN-γ), Th2 (IL-4, IL-5), and T regulatory (IL-10). In general, cytokine 
responses were lower from CBMCs in the salmon group compared to the control, although not 
always significantly. The only cytokine measured in plasma, IL-13, was detectable in less than 
10% of the samples. Dunstan et al. could detect IL-13 in 64% of plasma samples in the control 
group and in 45% of plasma samples in the fish oil group (35). The observation of generally 
lower cytokine responses seen in SIPS agrees with the findings of Dunstan et al., although 
these are some differences  in  the detail (132). Kraus-Etschmann  et  al. measured cytokine 
expression patterns in the cord blood by real time RT-PCR method looking at the mRNA 
levels of Th2 associated molecules CCR4, IL-13 and IL-4, Th1 related molecules IL-1 and 
IFN-γ, and T regulatory related molecule TGF-β. Fish oil supplementation decreased mRNA 
levels of the Th2 related molecules compared with placebo, whereas levels of mRNA for Th1 
cytokines remained unaffected. TGF-β mRNA expression, which has shown to be involved in 
tolerance towards allergens (346), was significantly higher in the fish oil group (178). So this 
European  study  agrees  with  the  Australian  study  in  that  the  Th2  related  molecules   329 
(chemokines and cytokines) are reduced with fish oil. In general the current results from SIPS 
are in agreement with this: production of the Th2 cytokines (IL-4 and IL-5) was lower in the 
fish oil group while production of the prototypical Th1 cytokine IFN-γ although lower in the 
fish oil group was not significantly different between groups. Thus it appears that fish oil 
decreases the Th2 type response with less of an impact on the Th1 type response. Indeed, 
although there was no significant effect on the IFN-γ to IL-4 ratio (Th1/Th2) this tended to be 
higher in the salmon group.  
 
PGE2 production from unstimulated and PHA-stimulated CBMCs did not differ between the 
two study groups, but PGE2 production from LPS-stimulated CBMCs tended to be lower in 
the salmon group compared to the control group (p-value=0.056). Krauss-Etschmann et al. did 
not report PGE2 production in infant immune cells at birth. Neither did Dunstan et al. although 
Prescott and Dunstan (176) showed that fish oil supplementation during pregnancy resulted in 
lower LTB4 production and higher LTB5 production by cord blood neutrophils. It could be 
speculated  that  increased  provision  of  EPA  and  DHA  from  the  mother  to  the  fetus  and 
subsequent decreased incorporation of ARA into CB immune cells and lower production of 
ARA lipid mediators (PGE2, LTB4) as well as increased production of the less potent EPA and 
DHA lipid mediators (PGE3, LTB5) from the neonatal immune cells might occur. This could 
possibly  affect  the  offsprings‟  T-cell  and  B-cell  function  and  predisposition  to  a  less 
inflammatory environment in early life so that there is less risk of developing atopic disease in 
infancy and later in life. 
 
  Clinical atopy outcomes 
 
A limitation of the current study is the initial reliance on reported atopy by the parents (at 
study entry, 13 weeks gestation) to determine high risk pregnant women of having an atopic 
offspring. This was based on self-reported clinical signs of atopy in the past 5 years (prior to 
the screening of eligibility to take part in SIPS; 13 weeks of gestation) from the mother, the 
father or sibling. Maternal and paternal atopy was also examined using SPT, but only after the 
end of the intervention, when this action had been approved by the local ethics committee. The 
SPT results showed that the majority of subjects who reported atopy also had positive SPT to 
at least one allergen, despite the fact that at the end of the study it was not possible to examine 
all subjects, as some of them had already dropped out or they declined to participate in this   330 
aspect of the study. It would be better if the examination of the SPT happened at study entry, 
so as to be included as an eligibility criterion. 
 
SIPS was powered according to an assumed sensitization to at least one common allergen in 
45% of the infants participating in the control arm at 6 months of age, based upon the high risk 
nature of the pregnancies. In this event only 13% of the infants in the control group were 
sensitized (i.e. had a positive SPT) and so the study was underpowered to detect a difference 
in sensitization. Furthermore, a higher than anticipated number of the SIPS infants were still 
breastfeeding and had not been introduced to a large amount of solids. Breastfeeding and 
avoidance of solids are protective against sensitization (318;319) which might explain the low 
rate of sensitization seen. It will be prudent to re-examine sensitization and the other outcomes 
at a later age (24, 30 or 36 months). 
 
When combining the results of the maternal and paternal SPT responses with the offsping SPT 
responses to the same allergens it was interestingly found that when the mother or the father or 
both parents had any positive SPT response, only 8/86 (3 in control and 5 in salmon group) 
infants  had  corresponding  positive  responses  to  any  allergen  whereas  67/86  infants  had 
corresponding negative SPT responses to any allergen (26 in control and 41 in salmon group). 
Out  of  7  infants  who  were  SPT  positive  for  egg  protein,  6  had  detectable  anti-egg  IgE. 
Likewise, out of 4 infants who were SPT positive for cows‟ milk protein, 2 had detectable 
anti-cows‟  milk  IgE.  It  is  interesting  that  the  same  pattern  happened  in  response  to  both 
allergens: more positive responses were detected by SPT which were not confirmed by the IgE 
measurement.  
 
Epidemiological studies (151-153;156) were sufficiently powered to show associations with 
atopic outcomes compared to SIPS. Also the infants  studied in observational studies were 
followed up later in infancy and childhood (follow up from 1-5 years of age) compared to 
SIPS  (follow-up  only  to  6  months)  so  that  the  infant  immune  system  would  mature  and 
develop detectable responses to allergic antigens.  
 
Supplementation trials (35;132;173;176;178;180-182) were conducted in pregnancy with fish 
oil supplements rather that fish and the dose of LC n-3 PUFAs was much higher compared to 
the provision of EPA and DHA from 2 portions of salmon. Also fish oil supplements were 
provided on a daily basis rather than twice per week. Furthermore, the clinical outcomes in   331 
these supplementation  studies  were not  assessed before the infant  age  of one  year. These 
differences of the design of the trials besides the power issue might explain why SIPS showed 
no effect on the atopic clinical outcomes at 6 months of infant age.  
 
One general limitation of the results presented within this thesis is that statistical analyses 
were not corrected for multiple comparisons. Thus some of the findings, particularly those 
with weak significance would likely disappear following such correction. However, quite a 
number of highly significant effects were observed, especially in relation to LC n-3 PUFA 
intake and status and these will likely remain significant after correction for multiple testing.   
7.3  Conclusions 
 
SIPS is the first randomized controlled trial that succeeded to increase the intake of oily fish 
during pregnancy from low (≤ portions per month) to the recommended intake (2 portions per 
week). Subsequent to the increased intake of oily fish, significantly increased the intake of LC 
n-3 PUFAs, vitamin D and selenium in the salmon group compared to the control group. The 
salmon intervention not only prevented the pregnancy associated decrease in percentages of 
EPA and DHA in the PC fraction, but also resulted in increased levels of these LC n-3 PUFAs 
in maternal PC compared to the control group. In cord blood plasma, EPA and DHA status 
was increased significantly whereas the ARA status was decreased significantly in the salmon 
group infants compared to those of the control group. A similar trend was found in those LC 
PUFAs measured in  the immune cells  (CBMCs) but  the differences  were  not  statistically 
significant. Nevertheless higher cord plasma PC EPA and DHA were associated with higher 
CBMC EPA and DHA, suggesting that as supply of these fatty acids to the fetus increases (by 
increased oily fish consumption) then there is enhanced incorporation into immune cells. In 
this way the maternal salmon intake during pregnancy resulted in some differences in cord 
blood immune cell phenotypes at birth (more leukocytes, neutrophils, lymphocytes, helper T-
cells,  cytotoxic  T-cells  and  T-regulatory  cells),  a  generalised  decrease  in  production  of 
cytokines in response to a T cell mitogen, TLR agonists and allergens, that became significant 
for  several  cytokines  in  response  to  the  mitogen  PHA  and  the  TLR-4  ligand  LPS,  and  a 
tendency to lower PGE2 production in response to LPS. The cord plasma concentration of IgE 
was not affected by the salmon intervention and IL-13 was not detected in most cord plasmas. 
At the 6 months  post-partum  clinical  assessment,  there was  no effect  of maternal  salmon 
consumption on plasma IgE, SPT positivity, and occurrence of atopic dermatitis or its severity.   332 
However despite the absence of effect on clinical outcomes of atopy at 6 months, the immune 
system of the newborn had shown differences at birth between the two groups. In this way, the 
absence of effect might be attributed to the fact that 6 months was quite early (immune system 
immaturation) for SIPS babies to show signs of sensitization. The future follow-up of these 
infants at 30 months might reveal the development of detectable responses to allergic antigens. 
Other than that, at 6 months, all SIPS babies, in both study groups were growing in a normal 
and healthy way. 
 
7.4  Future work 
 
The SIPS design and results presented in this thesis add valuable knowledge to the existing 
literature in the exciting field of maternal nutrition (in this case LC n-3 PUFAs in oily fish) in 
early life and how this may affect health and disease (atopy) development later in life (infancy 
and  childhood).  Findings  from  the  maternal  fatty  acid  status  and  changes  in  the  immune 
system in both groups during pregnancy have been reported by Lefkothea-Stella Kremmyda in 
her thesis. Future follow up of this cohort would be appropriate since the clinical outcomes of 
atopy at 6 months did not show any effects of the salmon intervention. Clinical manifestations 
of atopy might be more pronounced later on in life (early and/or later childhood) and signs of 
the  development  of  atopic  disease  might  be  more  evident  between  the  two  groups.  The 
principal investigator of SIPS, Professor Philip Calder, has already received approval from the 
ethics committee responsible to follow up the SIPS infants at 30 months of age (starting in 
July  2010)  so  as  to  assess  clinical  signs  of  atopy.  This  timepoint  would  also  be  a  great 
opportunity to explore the effect of the maternal LC n-3 PUFA intake on neurodevelopment 
and visual development of the children, since there are few intervention studies with oily fish 
in  this  field  and  also  taking  into  consideration  that  such  a  study  (with  fish  and  not 
supplements) is quite laborious and expensive. As for most RCTs, SIPS was fairly small in 
size (n=123 mothers at study entry and n=86 infants at 6 months) and this fact limited the 
ability to detect differences in atopic outcomes between the two groups. Ideally, the same 
study design with bigger sample size (for example n=150 infants at 6 months) would be more 
appropriate to identify more clear responses of the infant immune system at birth and to assess 
clinical signs of atopy and probable differences between the two groups at 6 months or 1 year 
of age. Furthermore it would be novel to have multiple sites of intervention (different cities or 
countries), so as to explore regional and ethnic variability and other factors but this would 
require  even  more  resources  and  funding  than  available  to  SIPS.  Also  it  would  be  more   333 
appropriate to assess maternal/paternal/sibling atopy by SPT at study entry rather than the end 
of the intervention, so as have better selection criterion for study entry; self reported atopy 
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We  would  like  to  invite  you  to  participate  in  a 
research study about a mother’s nutrition and her 
baby’s  development  of  allergies  and  growth. 
Before  you  agree  to  participate  it  is  important 
for you to understand why the research is being 
done and what it will involve. Please take time to 
read  the  following  information  carefully  and 
discuss it with others if you wish. Ask us if there 
is anything that is not clear or if you would like 
more information. Take time to decide whether or 
not you wish to take part. 
 
1 What is the purpose of this study? 
The purpose is to study how a mother’s nutrition 
may  influence  their  baby’s  development  in  the 
womb  and  the  likelihood  of  allergies  in  later 
childhood. We wish to select a group of pregnant 
women  who  would  be  suitable  to  help  us  in 
research into the possible protective effects of 
eating  oily  fish  (salmon)  in  pregnancy  on 
development of allergies in babies. 
 
2 Why have I been chosen? 
We are looking for women aged from 18-40 years 
who are in the early stages of pregnancy (about 
14 weeks or less) who may be able to assist us in 
our research.  
 
3 Do I have to take part? 
You are under no obligation to take part. If you 
take  part  you  are  still  free  to  withdraw  at  any 
time and without giving a reason. If you wish to 
withdraw  you  can  request  that  your  data  and 
samples be destroyed. A decision to withdraw at 
any time, or a decision not to take part, will not 
affect the standard of care you receive. If you 
are interested  in having  more information  about 
the  study  please  complete  the  ‘interested  in 
study’ form (found at reception) and give it to the 
receptionist  at  your  13  week  ultrasound  scan 
appointment. Alternatively you can contact us on 
the telephone numbers or email address shown in 
this leaflet. A member of the research team will 
then discuss the study with you and answer any 
questions you may have. If you are satisfied with 
the explanation and would like to help us with our 
research we will ask you to sign a consent form. 
We will give you a copy of the consent form and 
this information leaflet to keep. 
 
4 What will happen to me if I take part? 
If you are happy to take part in this first stage 
of  the  study  we  wish  to  gather  3  pieces  of 
information about you.  
Firstly,  we  would  like  you  to  complete  a  few 
questions  about  your  health  and  any  allergies 
which you or your family may have. 
 
Secondly, we would like to assess the growth and 
development of your baby in pregnancy. This will 
mean  that  during  your  routine  ultrasound  scans 
(13 & 20 weeks) a few extra measurements will be 
made of the baby’s size and of the size and blood 
flow in some of its organs, including the heart and 
liver.  
 
Thirdly, we would like to gather some information 
on how your body adapts to the pregnancy. To do 
this  we  would  like  to  measure  your  height,  your 
weight and your body composition (i.e. amount of 
muscle  and  fat).  We  use  specialised  weighing 
scales, which measure your weight and use a tiny 
electrical  current  to  assess  your  body 
composition. This is a harmless procedure and has   2 
been  used  to  assess  the  body  composition  of 
pregnant mothers in previous studies. 
When we have gathered this information we would 
like to use it to select mothers who are suitable 
to  help  with  assessing  the  possible  benefits  of 
eating salmon in pregnancy. If you were suitable 
for  this,  we  would  provide  more  details  for  you 
and invite you to take part. Once again you would 
be under no obligation to take part, and a decision 
to withdraw at any time, or a decision not to take 
part, would not affect the standard of care you 
receive. 
5 What is an ultrasound scan? 
Ultrasound uses sound waves to produce pictures 
of your body and baby.  Ultrasound has been used 
for many years to help us know if the baby is 
developing normally and growing properly. 
  
6 What do I need to do for the scan? 
A moderately full bladder is needed to allow us to 
obtain good views of your pregnancy.  Please drink 
a pint of water, squash or 3 cups of tea / coffee 
about an hour before your scan appointment.  Do 
not empty your bladder until after your scan. This 
is  a  medical  examination  and  an  important 
antenatal screening test. For your comfort, health 
and  safety  please  ensure  only  one  adult 
accompanies you for your scan. We would advise 
you not to bring young children as this can cause 
delays  and  distraction  to  the  medical  team. 
However if it is unavoidable we ask that any young 
children you wish to bring with you are supervised 
in  the  waiting  area  by  another  adult  while  the 
scan is in progress. 
7  What  are  the  possible  benefits  of  taking 
part? 
By participating in this study you may be able to 
help other children in the future from developing 
allergies.  Suitable  mothers  will  be  offered  the 
additional scan and will be given scan pictures of 
their baby in the womb. 
 
8 What are the possible disadvantages and risks of taking 
part? 
None,  other  than  the  giving  up  of  your  time  to 
help  us  with  our  research.    This  will  include  an 
extra ultrasound scan appointment at the Princess 
Anne  Hospital  which  will  take  no  longer  than  1 
hour and some extra measurements and questions 
asked  at  your  routine  NHS  13  and  20  week 
ultrasound  appointments  which  will  take 
approximately 1 hour. 
9 What will happen if anything goes wrong? 
If  you  have  a  concern  about  any  aspect  of  the 
study  you  should  speak  to  the  researchers  who 
will  do  their  best  to  answer  your  questions 
(telephone  023  8079  6925).  If  you  remain 
unhappy and wish to complain formally you should 
contact  the  Wellcome  Trust  Clinical  Research 
Facility in the first instance (telephone 023 8079 
4989). Any complaint about the way that you have 
been dealt with during the study or any possible 
harm you might suffer will be addressed. In the 
unlikely  event  that  you  are  harmed  due  to 
someone’s negligence, then you may have grounds 
for a legal action for compensation but you may 
have to pay your legal costs.  
 
 
10 Will  my  taking  part in this  study be kept 
confidential? 
All  information  which  is  collected  about  you 
during  the  course  of  the  research  will  be  kept 
strictly confidential.  
 
11 What will happen to the study results? 
The results from this first part of the study will 
be  used  to  identify  pregnant  women  suitable  to 
help  us  with  assessing  the  possible  benefits  of 
eating  salmon  in  pregnancy.  The  results  may  be 
submitted for publication in medical literature. If 
you  wish  to  see  copies  of  any  reports  and 
publications,  please  contact  the  researchers 
listed and they will be happy to supply these for 
you.  
 
12 Who is funding the study? 
This study is funded by the European Commission 
(website: http://ec.europa.eu/index_en.htm). 
 
13 Who has reviewed the study? 
The  Southampton  and  South  West  Hampshire 
Local Research Ethics Committees. 
14 Contact for further information 
If you have any questions then please contact the 
SIPS  Project  Team  on  Tel:  023  8079  6925  or 
023  8079  5252  or  07864  831283.  There  is  an 
answer  phone  available  and  all  calls  will  be 
returned.  Alternatively  email  us  on 
sips@soton.ac.uk 
Thank you for taking the time to read this   3
2  Volunteer initial consent form  
 
Thank you for reading the information about our research project. If 
you would like to take part, please read and sign this form. 
 
Title of study: The effects of oily fish in pregnancy on signs of allergic 
diseases in infants at high risk of developing allergies 
Local ethical committee submission number……………………….. 
Chief Investigator: Professor Philip Calder, Tel: 023 8079 5250 
Contact details for research team: Dr Liz Miles, Tel: 023 8079 6925 or 023 
80 79 5252 
 
PLEASE INITIAL THE BOXES IF YOU AGREE WITH EACH SECTION: 
 
1.  I am not taking part in any other study (i.e. Southampton Women’s Survey). 
 
2.  I have read the initial information sheet dated 8/05/07 (version 2) for the above study 
and have been given a copy to keep. I have had the opportunity to ask questions, 
understand why the research is being done and any possible risks which have been 
explained to me. 
 
3.  I understand that my participation in this study is voluntary and that I am free to 
decline entry into the study, and that during the study I am free to withdraw at any 
time without giving a reason and that withdrawal will not affect any future medical care. 
 
4.  Data to be collected. I agree to have my weight, body composition and height measured 
for research in this project (delete as appropriate).  
 
5.  I agree to have additional measurements made of the growth and development of 
my baby and allow a sample of my afterbirth (placenta) to be collected. 
 
6.  Information to be collected. I agree to complete a short questionnaire on my health and 
I give permission for someone from the research team to look at my medical notes to 
get information pertinent to the study. I understand that the information will be kept 
confidential. 
 
7.  I agree to take part in the above study 
 
 
_____________________      ___________  ______________________ 
Name of Patient      Date      Signature 
 
_____________________      ___________  _______________________ 
Name of Person taking consent  Date      Signature 
 
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes. 
Version 2, 08 May 2007  Ethics Number: 07/Q1704/43   4
3  Initial questionnaire (<14 weeks gestation) 
 
Volunteer Number    P 
 
Date informed consent given 
 
Initial visit check list (please tick when sample/data collected): 
 
a  Ultrasound scan 
 
b  Body composition 
 
c  Initial questionnaire 
 










Telephone – home/work 
 









   5
 
  Personal Details 
 






Date of last menstrual period 
 




Community midwife & clinic 
 
Health visitor & clinic 
 






  Eligible for SIPS? 
 
 
  Yes  No 
Atopy (1
o relative of baby affected by atopy)     
Habitual oily fish intake ≤ 2 portions per month?     
Aged 18-40 year?     
Not consuming fish oil supplements?     
Yes to all above question = eligible for SIPS     
   6
 
















(Note – individuals with indwelling medical devices must not have 
bioelectrical impedance measurements taken 
 
4. Do you have any indwelling electrical devices (i.e. pacemakers)? 
 







Ask volunteer to empty bladder. Take measurements and attach print off 
securely to this page. 
 
IF INELIGIBLE FOR SIPS – END QUESTIONNAIRE HERE 
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5. Medication/supplements/vitamins (taken in the last 4 weeks) 
Therapy  Dose route and regimen  Date started/stopped 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
6. Number of pregnancies (including this pregnancy) 
 
7. Number of children 
 
8. History of smoking Never / Past smoker / current smoker 
 




9. Current alcohol intake in drinks per week (1 beer or 1 glass of wine or 1 
shot of spirits). 
 
Drink per week   
0   
1-7   
8-14   
 
   8
  Family History of Atopy (within the last 5 years) 
10. Have any of the following persons had asthma? 
Mother  Father  Any sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
 
 
               
 







11. Have any of the following persons had hayfever? 
Mother  Father  Any sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
 
 
               
 







12. Have any of the following persons had an itchy rash persisting (even 
sporadically) over 6 months? 
Mother  Father  Any sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
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13. Have any of the following persons had wheezing when breathing? 
Mother  Father  Any sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
 
 
               
 







14. Have any of the following persons had itchy stuffy nose or swollen, 
itchy eyes when not with a cold? 
Mother  Father  Any sibling 
Yes  No  Not sure  Yes  No  Not sure  Yes  No  Not sure 
 
 
               
 






15. Do you have pets in the home? 
  Yes  No  Details 
Cat       
Dog       
Other       
 
16. Do you regularly visit a home where there are pets? 
  Yes  No  Details 
Cat       
Dog       
Other       
   10
 
  Habitual intake of fish 






18. Which types of fish do you eat (i.e. cod, mackerel, sole, kipper, 





19. How often do you eat each of these (i.e. number of time per week or 











Thank you for giving us this information 
 





Date………………………………………………….   11




Salmon in Pregnancy Study (SIPS): 
The effects of oily fish in pregnancy on signs of allergic diseases in 
infants at high risk of developing allergies 
   
 
Ethics Number: 07/Q1704/43  
 
Co-ordinator: Dr Liz Miles 
  
Chief Investigator: Prof Philip Calder 
 
Telephone: 023 8079 5250 or 023 8079 6925  
or 023 8079 5252 
(Mobile - 07864 831283) 
Email sips@soton.ac.uk  
 
Version 4, 7
th May 2008 
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We would like to invite you to participate in research studying whether eating salmon in pregnancy can prevent allergy 
in children. Before you agree to participate it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and discuss it with others if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not 
you wish to take part. 
1 What is the purpose of this study? 
The reason for the large increase in allergies in the last 30 years is not understood. One suggestion is that changes in 
the fats we eat are making us more susceptible to allergies. People in the UK with a typical ‘modern’ diet eat very little 
oily fish. We are interested in studying possible benefits of eating oily fish in pregnancy on development of allergies in 
children. We know that babies who later get allergies show some slight changes in their immune response at birth. 
These changes do not allow us to accurately predict which babies will get allergies, but do tell us that a tendency to do 
so may partly originate before the baby is born. Therefore we wish to study the effect of eating oily fish during 
pregnancy on signs of allergy in the baby. We will start our study in 2007 and it will finish in 2010. 
2 Why have I been chosen? 
We are looking for women aged 18-40 who are in the early stages of pregnancy and who have allergies themselves or 
whose partner, or any other children, suffer from allergies (i.e. hayfever, eczema, asthma or food allergies). This 
increases your baby’s risk of developing allergies him/herself. We wish to investigate the effect of eating oily fish 
(salmon) in pregnancy and need a group of mothers who are happy to eat 2 portions of salmon per week but who usually 
do not eat oily fish more than twice per month. We will provide this salmon for you and your partner. However, we need 
to compare mothers who have eaten salmon with a group of mothers who have not (i.e. mothers who carry on eating 
their normal diet). Thus we will allocate those happy to join our study into the salmon or no salmon group randomly (i.e. 
by chance). Current government guidelines advise that we should all eat more oily fish but that pregnant women should 
not eat more than 2 oily fish meals per week [www.eatwell.gov.uk/healthydiet/nutritionessentials/fishandshellfish/]. 
Our salmon group women will be eating the amount of oily fish recommended by the government but the no salmon 
group, who will continue with their normal diet, will be eating less oily fish than is currently recommended. We are 
hoping that 100 women will agree to take part. 
3 Do I have to take part? 
You are under no obligation to take part. If you take part you are still free to withdraw at any time and without giving 
a reason. If you wish to withdraw you can request that your data and samples be destroyed. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care you receive. If you decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form. 
4 What will happen to me if I take part? 
You and (ideally) your partner will be invited to attend the Southampton Women’s Survey Unit at the Princess Anne 
Hospital at about 20 weeks of pregnancy to meet a member of the research team. The research study will be explained 
fully and you will be given the opportunity to ask questions.  
We will ask both of you some questions about your health, lifestyle and allergies. We will take some blood (30 ml, about 
2  tablespoonfuls  from  you  and  ask  you  to  provide  a  urine  sample.  We  will  measure  your  weight  and  your  body 
composition (i.e. amount of muscle and fat). We use specialised weighing scales which measure your weight and by 
sending  a  very  small  electrical  current  through  your  body  can  assess  your  body  composition.  This  is  a  harmless 
procedure and has been used to assess the body composition of pregnant mothers in previous studies. 
The sonographer will perform an ultrasound scan (this will replace your normal 20 week NHS ultrasound scan) and give 
you pictures of your baby from the scan to keep. On this morning we will ask you not to eat or drink (except water) 
before your appointment and we will give you breakfast at the appointment. We will complete a questionnaire with you 
about your normal diet. This appointment will take approximately 1 hour. At this time we will allocate you to either the 
group of mothers asked to eat salmon or to the no salmon group. If you are in the salmon eating group we will supply 
you (and your partner) with frozen salmon portions sufficient for you to have 2 portions per week. We will give you one 
month’s supply every month from when you join the study until your baby is born. We will ask mothers in the no-salmon 
group not to eat more than 2 portions of oily fish (salmon, tuna, pilchards, sardines) per month whilst on this study 
(tinned tuna is OK).  
We would like to see you for 2 more appointments during your pregnancy (weeks 34 and 38). On each visit we will ask 
you some questions about your health, take a blood sample, measure body composition and ask you to provide a urine   13
sample. We will provide breakfast and also offer you an ultrasound scan of your baby at 34 weeks. These appointments 
will take approximately 1-1½ hours.  
At  week  38  we  would like  you to collect  a small  stool sample for  us.  This is  to  compare  with the  development of 
‘friendly bacteria’ in your baby’s bowel. We are interested in this because it has been suggested that some ‘friendly 
bacteria’ normally found in babies bowels may be protective against the development of allergies. 
At the birth of your baby we will collect a blood sample from the umbilical cord. This is a harmless procedure and does 
not involve the newborn baby at all and is carried out by the midwife present at the birth or a researcher. We will also 
collect a sample of umbilical cord and of placenta (which are normally disposed of). A research nurse will measure the 
size of your baby whilst you are in hospital 
If you decide to breast feed your baby we would like you to provide us with a sample (5 ml, about 1 teaspoonful) of 
your breast milk on the first day of breast feeding and then days 5, 14 and 28 after your baby is born (if you are still 
breastfeeding your baby at this time).  
We would like you to measure your body composition at home daily for the first 2 weeks after your baby is born with 
specialised weighing scales which we will provide. This will take less than 5 minutes each day.  
We would like to measure your body composition as before and your bone mineral density by DEXA scan within 2 weeks 
of you giving birth. The appointment will last, at most, 45 minutes. During this time we will measure your height and 
weight and perform a bone density scan. 
The bone density scan does not work if you are wearing any metal objects like buckles, zips or rings, so we do ask you 
to wear tracksuit bottoms and a T-shirt, if possible. The bone density scan involves lying on a table and a small scanning 
arm will pass over, about two feet in the air; it does not touch you. The dose of x-rays is equivalent to about three 
day’s natural background x-rays (or a day trip to Cornwall). The scan will not cause any pain or harm.  
We would like to follow your baby for his/her first 6 months of life. You will receive a separate information sheet 
about this and you will have the opportunity to discuss this further and to ask any questions that you might have 
before deciding if you wish to help with this research.  
At the follow up appointment (or at a mutually convenient time) we would like to perform some skin prick testing on you 
and  your  partner.  This is  to  confirm  the allergies  you  told  us  about  when  we  first  met  you.  Skin  prick  testing is 
performed by placing a drop of clear solution on the arm and pricking the skin through the solution. From your partner 
we would like to take a blood sample (10mls, about 2 teaspoonfuls). 
All blood and breast milk samples donated for this research study will be frozen and stored for analyses related to the 
development of allergy. 
5 What are the possible benefits of taking part? 
By participating in this study you may be able to help other children in the future from developing allergies. 
6 What are the possible disadvantages and risks of taking part? 
Taking blood can occasionally cause some discomfort and bruising. Skin prick testing can cause some local itching which 
may last for about 15-30 minutes and can be relieved by using some calamine lotion. You will be giving up your time to 
help us with research including a longer appointment at your routine 20 week NHS ultrasound scan appointment and 2 
extra appointments at the Princess Anne Hospital at 34 and 38 weeks of pregnancy (approximately 1-1½ hours). In 
addition, we would like you to record your consumption of fish, provide breast milk samples (on 4 days over the first 
month), collect your baby’s stools (on 4 days over the first three months), measure your own body composition at home 
by standing on a specialised weighing scale (daily for the first two weeks after you give birth – each weighing will take 
no more than 5 minutes), and if possible allow your bone density to be measured within two weeks of giving birth (this 
will require a visit to the Princess Anne Hospital for a 45 minute appointment). 
7 What will happen if anything goes wrong? 
If you have a concern about any aspect of the study you should speak to the researchers who will do their best to 
answer your questions (telephone 023 8079 6925). If you remain unhappy and wish to complain formally you should 
contact the Wellcome Trust Clinical Research Facility in the first instance (telephone 023 8079 4989). Any complaint 
about the way that you have been dealt with during the study or any possible harm you might suffer will be addressed.  
In the unlikely event that you are harmed due to someone’s negligence, then you may have grounds for a legal action 
for compensation but you may have to pay your legal costs.  
8 Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly confidential. We 
will inform your GP that we have approached you and will notify them of your participation.   14
9 What will happen to the study results? 
The  results  will  be  submitted  for  publication  in  medical  literature.  If  you  wish  to  see  copies  of  any  reports  and 
publications, please contact the researchers listed and they will be happy to supply these for you. Once the study is 
complete,  an  open  meeting  will  be  arranged  so  that  participants  may  discuss  outcomes  and  get  a  summary  of  the 
results. 
10 Will I be reimbursed? 
We will reimburse you your travel expenses and parking fee at each appointment. 
11 Who is funding the study? 
This study is funded by the European Commission (website: http://ec.europa.eu/index_en.htm). 
12 Who has reviewed the study? 
The Southampton and South West Hampshire Local Research Ethics Committees. 
13 Contact for further information 
If you have any questions then please contact the SIPS Project Research Team on the numbers/email given on the 
front of this leaflet. 
Thank you for taking the time to read this   15
5  Consent form for pregnant women 
 
Thank you for reading the information about our research project. If you would like to 
take part, please read and sign this form. 
Title of study: The effects of oily fish in pregnancy on signs of allergic diseases in 
infants at high risk of developing allergies 
Study ID Number………………………………………………………………………….. 
Chief Investigator: Professor Philip Calder, Tel: 023 8079 5250 
Contact details for research team: Dr Liz Miles, Tel: 023 8079 6925 or 023 8079 5252 
PLEASE INITIAL THE BOXES IF YOU AGREE WITH EACH SECTION: 
 
8.  I have read the information sheet dated 15/05/07 (version 2) for the above study and 
have been given a copy to keep. I have had the opportunity to ask questions, understand 
why the research is being done and any possible risks which have been explained to me. 
 
9.  I understand that my participation in this study is voluntary and that I am free to 
decline entry into the study, and that during the study I am free to withdraw at any 
time without giving a reason and that withdrawal will not affect any future medical care. 
 
10.  Samples to be collected. I agree to give a sample of my blood, urine, umbilical cord 
blood, umbilical cord, placenta, stool and breast milk (if applicable) for research in this 
project (delete as appropriate). I agree to be skin prick tested. I understand how the 
samples will be collected and how these procedures will be performed and that they will 
be used for the purposes if this investigation and will then be disposed of. I understand 
that my name will not be linked to these samples. 
 
11.  I agree to have my body composition measured by bioelectrical impedence and 
bone mineral density measured by DEXA scan.   
         
12.  Information to be collected. I give permission for someone from the research team to 
look at my medical notes to get information pertinent to the study. I understand that 
the information will be kept confidential. 
 
13.  I understand that my Doctor will be informed of my participation in the study. 
 
7.   I agree to take part in the above study 
 
 
_________________ _              ___________           ___________________ 
Name of Patient      Date      Signature 
 
 
_________________ _              ___________           ___________________ 
Name of Person taking consent  Date      Signature 
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes. 
Version 3, 12
th October 2007    Ethics Number: 07/Q1704/43   16





Date informed consent given 
 
19 week visit check list (please tick when sample/data collected): 
 
a  Urine sample 
 
b  Blood sample 
 
c  Food frequency questionnaire 
 
d  Ultrasound scan 
 
e  Body composition 
 










Telephone – home/work 
 











   17
 
  Personal Details 
 








Community midwife & clinic 
 
Health visitor & clinic 
 
Doctor & surgery 
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4. Medication/supplements/vitamins (taken in the last 4 weeks) 
Therapy  Dose route and regimen  Date started/stopped 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
5. Number of pregnancies (including this pregnancy) 
 
6. Number of children 
 
7. History of smoking Never / Past smoker / current smoker 
 






8. Current alcohol intake in drinks per week (1 beer or 1 glass of wine or 1 




Drink per week   
0   
1-7   
8-14   
>14   
   19
  Activity and Exercise 
 
Can I firstly ask you about your activity and exercise patterns over the last three months? As 
before, we would like you to divide up a “typical” day into three types of activity. These are: 
    (1) sleeping or lying,    (2) sitting,  (3) standing or walking. 
 
 
10.1  Over a typical 24 hour day how many hours have you generally 
spent sleeping or lying with your feet up?                  
      
     hrs            mins    
   
(ask time usually go to bed & wake up, including any at work!) 
 
  This would indicate xx hours sitting or on your feet. 
 
10.2  Of those hours how many on a typical day have you spent sitting  
down?  (e.g. includes sitting at work, mealtimes,  driving, reading, 
watching TV)                                                                                      
                             
    hrs              mins 
                                                                                               
10.3  This would mean that you have spent about xx hours a day on your 
feet.  Does this sound about right? 
                                                                                                                                      
                     
            hrs                 mins 
 
10.4  Out of these xx hours spent on your feet, about how much of the 
time were you actively on the move (rather than standing fairly still)? 
 
    1.  Very little  10% 
    2.  Some   30% 
    3.  About half  50% 
    4.  Most    70% 
    5.  Almost all  90% 
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10.5  During the past three months, how often have you done the 
following kinds of exercise or activities? 
 
a)   strenuous exercise which made your heart beat rapidly AND left 
you breathless e.g. jogging, vigorous swimming or cycling, aerobics. 
           
                FFQ categories 1-7               >x1              
             
and on average about how long did each period of activity last?    
       
 
            hrs                mins 
 
b)  moderate exercise which left you exhausted but not breathless, 
e.g. brisk walking, dancing, easy swimming or cycling, badminton, 
sailing. 
 
     FFQ categories 1-7                   >x1 
 
 
and on average  about how long did each period of activity last?  
 
                  
    hrs                      mins         
 
c) gentle exercise  which left you tired but not exhausted, e.g. walking, 
heavy housework (including washing windows and polishing), gardening, 
DIY, golf. 
 
  FFQ categories 1-7                     >x1 
 
 
and on average  about how long did each period of activity last?  
 
         hrs     mins 
   
     
     
     
     
       21
10.6  Which of the following best describes your walking speed at 
present? 
    1.  Very slow 
    2.  Stroll at an easy pace 
    3.  Normal speed 
    4.  Fairly brisk 
    5.  Fast 
 
Family Social History 
 
18. Mothers’ occupation 
 
19. Fathers’ occupation 
 
 
20. Mothers highest level of education 
   
School   
Further   
Higher   
 
21. Fathers highest level of education 
   
School   
Further   
Higher   
 
   22
Bioelectrical impedance 
(Note – individuals with indwelling medical devices must not have 
bioelectrical impedance measurements taken 
 
22. Do you have any indwelling electrical devices (i.e. pacemakers)? 
 








Ask volunteer to empty bladder. Take measurements and attach print off 














Thank you for giving us this information 
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7  SIPS Food Frequency Questionnaire for Women (to 
be completed at 19-20 weeks, 32-34 weeks of 




Volunteer Number        
Name 







Version 1, 1 September 2006           Ethics Number: 07/Q1704/43 
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2:   DIETARY QUESTIONS 
2.1  Now I am going to ask you about the foods you have eaten over the past 3 months. To do this I have a list of foods and I would like you to tell me how often 
you have eaten each food.  As before the list may include foods you never ate or you may find foods which you eat a lot are missing.  These can be added on at the 
end. (Define the 3 month period) 
 
 
  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 











































When you ate bread/toast/sandwiches, how many slices/rolls did you eat at 
a typical meal? 
                                                                                                     . 
Rolls (count as 2 slices) 




















                                     
 
 
How many slices/rolls did you eat at a typical meal? 
                                                                                                     . 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 













































































When you ate these how many potatoes did you  
eat at a typical meal? 
                                                                                                          . 























When you ate these how many potatoes did you 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 









































Soft drinks not including diet drinks 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 

































































































Spreading fat (1) 



















Spreading fat (2) 



















Spreading fat (3) 



















Frying fat  or oil (1) 



















Frying fat or oil (2) 















    
 
98 
Frying fat or oil (3) 
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  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 



















once a day 
 
99 
Other vegetable oil (1) 



















Other vegetable oil (2) 


















 2.2  Are there food or drinks which you have eaten or drunk once a week or more which are not on the list? Include breakfast bars such as Nutrigrain and 
Kellogg’s 
                                  0.No/1. Yes 
  If Yes 
Name of food/drink 
 



























       
 
F 
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Now I would like to ask in more detail about some specific foods 
 
2.3:  Which types of milk have you used regularly in drinks and added to breakfast cereals 
over the last 3 months? 
    0.  None 
    1.  Whole pasteurised 
    2.  Semi-skimmed pasteurised 
    3.  Skimmed pasteurised 
    4.  Whole UHT 
  5.  Semi-skimmed UHT 
    6.  Skimmed UHT 
    7.  Other 
 
            Milk 1                    Other (specify)___________________________________   
 
  
                        Milk 2                    Other (specify)___________________________________   
                      
                          
            Milk 3                    Other (specify)___________________________________   
  
 
2.4  On average over the last 3 months how much 
 *     of each milk have you consumed per day?                      
  
    Milk 1                                                           .                   pints                                    
     
  
      Milk 2                            .         pints 
  
  
       Milk 3                      .         pints   
           
2.5  Have you added sugar to breakfast cereals, tea & coffee,    
     puddings etc.?         
    0. No go to 2.7   
    1. Yes                       
                                                              
2.6  Approximately how many teaspoons of sugar have you                                  
     added each day?                                
                                                        
 
2.7   When you eat meat, how much of the fat have you           
      usually cut off (including chicken skin)?               
                 1. all       100%                                            
        2. most      60%                                            
        3. some     30%                                            
        4. none        0%                                            
          9. not applicable                  
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2.8  Just thinking about the past week how many servings did you eat of: 
Vegetables and vegetable-containing dishes (excluding potatoes)?   
fruit and pure fruit juices?   
  meat and fish and their dishes?   
 
3:  FOOD SUPPLEMENTS & DIETARY CHANGES 
 
3.1  During the past three months have you taken any pills, tonics or tablets to supplement 
your diet?  (e.g. vitamins, minerals, iron tablets, folic acid, fish oils etc.)  
  0. No     1. Yes                     
           If yes, please state which:  











Did you start taking this: 
1: Less than 1 month ago 
2: 1-2 months ago 
3: More than 2 months ago  
 
       
 
       
 
       
 
       
 
       
 
 
5:  ALCOHOL CONSUMPTION 
 
I’d like to ask you a few questions about your drinking and smoking habits. 
    
5.1  Do you ever drink alcohol? 
  0. No go to section 6 
  1. Yes 
 
5.2  During the past three months: 
 
  a) How often have you drunk                                      
        Shandy or Low Alcohol Beer/Lager/Cider?   FFQ 1-7         >x1 
    (don't include alcohol free lager etc)  
                                                                
  b) When you drank these how many pints did you  
    normally have?                                                                               . 
     (if range given code mid-point)                     
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5.3  a) How often have you drunk                                         
    Beer/Stout/Lager/Cider/Alcopops?               FFQ 1-7           >x1  
                                                                                                     
  b) When you drank these how many pints did you  
    normally have?                                                                               . 
     (if range given code mid-point)               
 
 5.4  a) How often have you drunk                                     
        Low alcohol wine?                                FFQ 1-7            >x1     
                                                         
  b) When you drank this how many glasses did you  
    normally have?                                                                               . 
    (if range given code mid-point)                                                                               
 
5.5  a) How often have you drunk                               
        Wine/Sherry/Martini/Cinzano?               FFQ 1-7             > x1  
                                                                
  b) When you drank these how many glasses did you  
    normally have?                                                                                 . 
    (if range given code mid-point)                                                                                              
                     
5.5  a)  How often have you drunk                               
        Spirits/Liqueurs?                      FFQ 1-7              > x1 
 
    b) When you drank these how many measures did you  
    normally have?                                                                                 . 
    (if range given code mid-point)                                                                                              
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DIETARY QUESTIONS ON FOOD ITEMS FORTIFIED WITH ESSENTIAL FATTY ACIDS, PROBIOTICS, PREBIOTICS 
 
We are particularly interested in your consumption of food items with added omega-3, omega-6, probiotics or prebiotics.  I have a list of food items 
that have these things added to help you remember the specific products you may consume. Are there foods or drinks with added omega-3, omega-6, 
probiotics or prebiotics that you have eaten or drunk once a week or more?  
 
                                  0.No/1. Yes   
If Yes 
Name of food/drink  Code  Portion  Number of days per week  More than 
once a day 
     
1  2  3  4  5  6  7 
 
     
1  2  3  4  5  6  7 
 
     
1  2  3  4  5  6  7 
 
     
1  2  3  4  5  6  7 
 
     
1  2  3  4  5  6  7 
 
     
1  2  3  4  5  6  7 
 
     
1  2  3  4  5  6  7 
   40




Volunteer Name   
Please tick the days on which you eat your salmon. This should be twice per week. Could you 
also include any other fish you eat (which type and how it is cooked). Thank you. SIPS 
research team (tel: 02380 796925 or 02380 795252). 
Month 5 / date started…………………….  Fish eaten 
Week 21 – day 1   
Week 21 – day 2   
Week 21 – day 3   
Week 21 – day 4   
Week 21 – day 5   
Week 21 – day 6   
Week 21 – day 7   
Week 22 – day 1   
Week 22 – day 2   
Week 22 – day 3   
Week 22 – day 4   
Week 22 – day 5   
Week 22 – day 6   
Week 22 – day 7   
Week 23 – day 1   
Week 23 – day 2   
Week 23 – day 3   
Week 23 – day 4   
Week 23 – day 5   
Week 23 – day 6   
Week 23 – day 7   
Week 24 – day 1   
Week 24 – day 2   
Week 24 – day 3   
Week 24 – day 4   
Week 24 – day 5   
Week 24 – day 6   
Week 24 – day 7     41
9  SIPS Fish consumption diary during pregnancy (control group) 
 
Please tick the days on which you eat fish and write what type of fish it is and how it 
is  cooked,  i.e.,  baked  cod  in  crumbs;  smoked  haddock,  poached;  fresh  tuna,  fried; 
tinned tuna; fresh trout, grilled. 
During  your  pregnancy,  while  you  are  on  the  study  (i.e.  from  the  20
th  week  until 
delivery) please could you avoid eating more than 1 portion of oily fish per month. We 
have listed some examples of oily fish below. You can eat as much non-oily fish as you 
usually like to. We have listed some examples of non-oily fish below. Thank you. SIPS 
research team (tel: 023 8079 6925 or 023 8079 5252). 
Oily Fish  Non-oily/white fish 
Please eat no more than once per month  Eat as much as usual 
















Cod    
Tinned tuna                       
Haddock                   
Plaice                       
Coley                                           











     Marlin         
    Sea bream                    
    Lemon sole  
    Halibut 
    Shark 
    Pollack 
    Monk fish 
   Cat fish                  
    Red snapper 
    Seabass    
    Dover sole 
    Crab 
 




Volunteer Name   
Please tick the days on which you eat fish and write which type and how it is cooked. Thank 
you. SIPS research team (tel: 023 8079 6925 or 023 8079 5252). 
Month 5 / date started…………………….  Fish eaten 
Week 21 – day 1   
Week 21 – day 2   
Week 21 – day 3   
Week 21 – day 4   
Week 21 – day 5   
Week 21 – day 6   
Week 21 – day 7   
Week 22 – day 1   
Week 22 – day 2   
Week 22 – day 3   
Week 22 – day 4   
Week 22 – day 5   
Week 22 – day 6   
Week 22 – day 7   
Week 23 – day 1   
Week 23 – day 2   
Week 23 – day 3   
Week 23 – day 4   
Week 23 – day 5   
Week 23 – day 6   
Week 23 – day 7   
Week 24 – day 1   
Week 24 – day 2   
Week 24 – day 3   
Week 24 – day 4   
Week 24 – day 5   
Week 24 – day 6   
Week 24 – day 7   
   43
 








34 week visit check list (please tick when sample/data collected): 
 
a  Urine sample 
 
b  Blood sample 
 
c  Food frequency questionnaire 
 
d  Ultrasound scan 
 
e  Body composition 
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4. Medication/supplements/vitamins (taken in the last 4 weeks) 
Therapy  Dose route and regimen  Date started/stopped 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
5. Do you currently smoke? Yes / No 
 






6. How many alcoholic beverages per week do you drink at the moment (1 beer 








Drink per week   
0   
1-7   
8-14   
>14   
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  Activity and Exercise 
Can I firstly ask you about your activity and exercise patterns over the last three months? As before, we 
would like you to divide up a “typical” day into three types of activity. These are: 
    (1) sleeping or lying,    (2) sitting,  (3) standing or walking. 
 
 
10.1  Over a typical 24 hour day how many hours have you generally spent 
sleeping or lying with your feet up?                  
      
     hrs            mins    
   
(ask time usually go to bed & wake up, including any at work!) 
 
  This would indicate xx hours sitting or on your feet. 
 
10.2  Of those hours how many on a typical day have you spent sitting  
down?  (e.g. includes sitting at work, mealtimes,  driving, reading, watching 
TV)                                                                                           
                       
    hrs              mins 
                                                                                               
10.3  This would mean that you have spent about xx hours a day on your feet.  
Does this sound about right? 
                                                                                                                                      
                                  
hrs                 mins 
 
10.4  Out of these xx hours spent on your feet, about how much of the time 
were you actively on the move (rather than standing fairly still)? 
 
    1.  Very little  10% 
    2.  Some   30% 
    3.  About half  50% 
    4.  Most    70% 
    5.  Almost all  90% 
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10.5  During the past three months, how often have you done the following 
kinds of exercise or activities? 
 
a)   strenuous exercise which made your heart beat rapidly AND left you 
breathless e.g. jogging, vigorous swimming or cycling, aerobics. 
           
                FFQ categories 1-7               >x1              
             
and on average about how long did each period of activity last?      
     
 
            hrs                mins 
 
b)  moderate exercise which left you exhausted but not breathless, e.g. 
brisk walking, dancing, easy swimming or cycling, badminton, sailing. 
 
     FFQ categories 1-7                   >x1 
 
 
and on average  about how long did each period of activity last?  
 
                  
    hrs                      mins         
 
c)  gentle exercise  which left you tired but not exhausted, e.g. walking, 
heavy housework (including washing windows and polishing), gardening, 
DIY, golf. 
 
  FFQ categories 1-7                     >x1 
 
 
and on average  about how long did each period of activity last?  
 
         hrs     mins 
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10.6  Which of the following best describes your walking speed at present? 
    1.  Very slow 
    2.  Stroll at an easy pace 
    3.  Normal speed 
    4.  Fairly brisk 
    5.  Fast 
 
 






(Note – individuals with indwelling medical devices must not have bioelectrical 
impedance measurements taken 
 
9. Do you have any indwelling electrical devices (i.e. pacemakers)? 
 







Ask volunteer to empty bladder. Take measurements and attach print off 
securely to this page. 
 
 
Thank you for giving us this information 
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38 week visit check list (please tick when sample/data collected): 
 
a  Urine sample 
 
b  Blood sample 
 
c  Stool sample 
 
 
  General Health 
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 4. Medication/supplements/vitamins (taken in the last 4 weeks) 
Therapy  Dose route and regimen  Date started/stopped 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
5. Do you currently smoke? Yes / No 
 






6. How many alcoholic beverages per week do you drink at the moment (1 beer 








Drink per week   
0   
1-7   
8-14   
>14   
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  Activity and Exercise 
Can I firstly ask you about your activity and exercise patterns over the last three months? As before, we would 
like you to divide up a “typical” day into three types of activity. These are: 
    (1) sleeping or lying,    (2) sitting, (3) standing or walking. 
 
 
10.1  Over a typical 24 hour day how many hours have you generally spent 
sleeping or lying with your feet up?                  
      
     hrs            mins    
   
(ask time usually go to bed & wake up, including any at work!) 
 
  This would indicate xx hours sitting or on your feet. 
 
10.2  Of those hours how many on a typical day have you spent sitting  
down?  (e.g. includes sitting at work, mealtimes,  driving, reading, watching 
TV)                                                                                           
                       
    hrs              mins 
                                                                                               
10.3  This would mean that you have spent about xx hours a day on your feet.  
Does this sound about right? 
                                                                                                                                      
                                  
hrs                 mins 
 
10.4  Out of these xx hours spent on your feet, about how much of the time 
were you actively on the move (rather than standing fairly still)? 
 
    1.  Very little  10% 
    2.  Some   30% 
    3.  About half  50% 
    4.  Most    70% 
    5.  Almost all  90% 
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10.5  During the past three months, how often have you done the following 
kinds of exercise or activities? 
 
a)   strenuous exercise which made your heart beat rapidly AND left you 
breathless e.g. jogging, vigorous swimming or cycling, aerobics. 
           
                FFQ categories 1-7               >x1              
             
and on average about how long did each period of activity last?      
     
 
            hrs                mins 
 
b)  moderate exercise which left you exhausted but not breathless, e.g. 
brisk walking, dancing, easy swimming or cycling, badminton, sailing. 
 
     FFQ categories 1-7                   >x1 
 
 
and on average  about how long did each period of activity last?  
 
                  
    hrs                      mins         
 
d)  gentle exercise  which left you tired but not exhausted, e.g. walking, 
heavy housework (including washing windows and polishing), gardening, 
DIY, golf. 
 
  FFQ categories 1-7                     >x1 
 
 
and on average  about how long did each period of activity last?  
 
         hrs     mins 
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10.6  Which of the following best describes your walking speed at present? 
    1.  Very slow 
    2.  Stroll at an easy pace 
    3.  Normal speed 
    4.  Fairly brisk 
    5.  Fast 
 
 









Thank you for giving us this information 
 






   53
12  Baby feeding and health diary 
Please keep this daily record of your baby’s feeds and any illness he or she may 
have for the first 6 months after birth. If you need to write more than you can 
fit on the form please write it on the reverse of the page. If you have any 
questions about this form please call us on 023 8079 6925 or 023 8079 5252 
1 Feeding 
Please mark (B) for breastfeeding and (F) for formula feeding or (B&F) for 
both. If your baby is having formula milk please note which brand (i.e. Cow & 
Gate, Farley, Milupa, SMA) and the type (i.e. Premium, First, Aptamil First, 
Gold). If you have not changed anything from the day before just tick the day 
to tell us that it is the same as above. 
2 Weaning 
Please write on the diary any foods and approximate quantities (i.e. 1 teaspoon, 
3 teaspoons) that your baby has when he/she starts to eat some more solid 
food. This will probably be at around 6 months of age (check with your midwife, 
health visitor or doctor for advice). 
3 Health 
Please write on the diary any illnesses that your baby may have during the first 
6 months. This includes sicknesses such as colds, coughs, vomiting, diarrhoea, 
wheezes, rashes etc. Please also note any medicines your baby has and 
immunizations that he/she has. 
Example 
Baby Name……Arthur Salmon 
Date  1 Feed – Breast or Formula (& type)  2 Weaning foods  3 Health 
1  B     
2  B     
3  B     
4  B    Cold 
5  B    Cold 
6  B & F (SMA Gold)    Cold, vomited 
7  ￿    Cold 
8  ￿     
9  ￿     
10  ￿       54




Date  1 Feed – Breast or Formula (& type)  2 Weaning foods  3 Health 
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
15       
16       
17       
18       
19       
20       
21       
22       
23       
24       
25       
26       
27       
28       
29       
30       
31         55
13 Information Sheet for infant visit at 6 months 
 
We would like to invite you and your baby to participate in the next stage of a research study about the development of 
allergy in children. Before you agree to participate it is important for you to understand why the research is being done 
and what it will involve. Please take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or 
not you wish your baby to take part. 
1 What is the purpose of this study? 
The reason for the large increase in the numbers of people with allergies in the last 30 years is not understood. One 
suggestion is that changes in the fats we eat are making us more susceptible to allergies. Notably, people in the UK with 
a typical ‘modern’ diet eat very little oily fish. We (at the Division of Developmental Origins of Health and Disease) are 
interested in studying possible benefits of eating oily fish in pregnancy on development of allergies in children. We know 
that babies who later get allergies show some slight changes in their immune response at birth. These changes do not 
allow us to accurately predict which babies will get allergies, but do tell us that the mechanisms for developing allergies 
probably start before the baby is born. Therefore we wish to investigate the effect of increasing the amount of oily 
fish eaten by women during pregnancy on signs of allergy in the newborn babies. We will start our study in 2007 and it 
will finish in 2010. 
2 Why have I been chosen? 
We are very grateful for your participation in the first stage of this study (from 20 weeks of your pregnancy until the 
birth of your baby) and we would like to collect some information about your baby during the first 6 months of his/her 
life. 
3 Do I have to take part? 
You are under no obligation to take part. If you take part you are still free to withdraw at any time and without giving a 
reason. If you wish to withdraw, you can request that your baby’s data and samples be destroyed. A decision to withdraw 
at any time, or a decision not to take part, will not affect the standard of care you or your baby receives. If you decide 
to take part you will be given this information sheet to keep and will be asked to sign a consent form. 
4 What will happen to me if I take part? 
We wish to follow the progress of your baby in the first 6 months of his/her life. We would like you to fill out a brief diary 
for the first 6 months of your baby’s feeding habits and any illnesses your baby has. 
We would like you to collect a small sample of your baby’s stool on days 1 (or 2), 5, 14, 28 and at the end of his/her first and 
second months. This is to look at the development of ‘friendly bacteria’ in your baby’s bowel. We are interested in this 
because it has been suggested that some ‘friendly bacteria’ normally found in babies bowels may be protective against the 
development of allergies. 
We would like to see you and your baby for two appointments in this time, the first when your baby is less than 2 weeks of 
age and the second when he/she is 6 months old. At both of these appointments we will explain all the checks which we wish 
to perform and ask you to give written consent if you are happy with the explanation. 
We want to assess your baby’s growth with a bone density test (DEXA scan) when your baby is less than 2 weeks old. 
You will be invited to bring your baby to Burley Ward at the Princess Anne Hospital. The appointment will last, at most, 
45 minutes. During this time we will measure your child’s height and weight, arm size and perform a bone density scan 
for your child. Please bring your baby wearing easily removable clothing if possible as we undress them and wrap them in 
a blanket for the scan.  
Later, at 6 months of age, we would like to see your baby for a clinical check at the Wellcome Trust Clinical Research 
Facility at Southampton General Hospital. At this appointment we wish to assess your baby for any symptoms of allergy 
and perform skin tests to some common allergens. This will involve placing 8 - 10 drops of clear solutions on the back or 
forearm and pricking the skin through the solutions.  These are placed in an area about one-third of the area of this 
information sheet. If your baby is sensitised to one of the substances used, there will be a small reaction on the skin 
around the area of application. We would like to take a small sample of blood (3-5mls, no more than 1 teaspoonful). We 
will use lignocaine cream that will numb the area before taking the sample. It will be taken by a Paediatric trained 
Doctor or nurse. We will collect the diaries which you have completed (from the first stage of the study) on your baby’s 
feeding and health in the first 6 months. This appointment will take approximately 1 hour. 
5 What are the possible benefits of taking part? 
Your baby will have an assessment of bone density. We will of course provide any medical advice necessary if the bone 
mineral density values are found to be low. 
By participating in this study you may be able to help other children in the future from developing allergies. 
6 What are the possible disadvantages and risks of taking part? 
The bone density scan will not cause any pain or harm. It involves your child lying on a table and a small scanning arm will pass 
over, about two feet in the air; it does not touch your child. The dose of x-rays is equivalent to about three day’s natural 
background x-rays (or a day trip to Cornwall).    56
Skin prick testing will cause itching due to the reaction to the positive control (histamine); this is similar to a “nettle 
rash”. The itching may last between 15 – 30 minutes and calamine lotion will be offered to relieve this. Taking blood can 
sometimes cause the baby to cry as we will ask you to hold your baby firmly and some bruising may occur. 
7 What will happen if anything goes wrong? 
If you have a concern about any aspect of the study you should speak to the researchers who will do their best to 
answer your questions (telephone 023 8079 6925). If you remain unhappy and wish to complain formally you should 
contact the Wellcome Trust Clinical Research Facility in the first instance (telephone 023 8079 4989). Any complaint 
about the way that you have been dealt with during the study or any possible harm you might suffer will be addressed.  
  In the unlikely event that you are harmed due to someone’s negligence, then you may have grounds for a legal 
action for compensation but you may have to pay your legal costs.  
8 Will my taking part in this study be kept confidential? 
All information which is collected about you and your baby during the course of the research will be kept strictly 
confidential. We will inform your GP that we have approached you and will notify them of your participation. 
9 What will happen to the study results? 
The  results  will  be  submitted  for  publication  in  medical  literature.  If  you  wish  to  see  copies  of  any  reports  and 
publications, please contact the researchers listed and they will be happy to supply these for you. Once the study is 
complete, an open meeting will be arranged so that participants may discuss outcomes and get a summary of the results. 
10 Will I be reimbursed? 
We will reimburse you your travel expenses and parking fee at each appointment. 
11 Who is funding the study? 
This study is funded by the European Commission (website: http://ec.europa.eu/index_en.htm). 
12 Who has reviewed the study? 
The Southampton and South West Hampshire Local Research Ethics Committees. 
13. Contact for further information 
If you have any questions then please contact the SIPS Project Research Team, Tel: 023 8079 6925 or 023 8079 5252. 
There is an answer phone available and all calls will be returned. Alternatively email us on sips@soton.ac.uk 
 






The effects of oily fish in pregnancy on signs of allergic diseases in infants at high risk of developing allergies 
Salmon in Pregnancy Study Information Sheet for Parents of Babies 
 
Ethics Number: 07/Q1704/43  
 
Co-ordinator: Dr Liz Miles 
  
Chief Investigator: Prof Philip Calder 
 
Telephone: 023 8079 6925 or 023 8079 5252 or 07864 831283 
 
Email  sips@soton.ac.uk  
 
Version 3, 14
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   57
 
14 Consent form for follow-up infant at 6 months 
Thank you for reading the information about our research project. If you would 
like to take part, please read and sign this form. 
 
Title of study: The effects of oily fish in pregnancy on signs of allergic 
diseases in infants at high risk of developing allergies 
Ethics number: 07/Q1704/43    Study ID No…………………………………………… 
Chief Investigator: Professor Philip Calder, Tel: 023 8079 5250 
Contact details for research team: Dr Liz Miles, Tel: 023 8079 6925 or 023 
8079 5252 
PLEASE INITIAL THE BOXES IF YOU AGREE WITH EACH SECTION: 
 
I have read the information sheet dated 14th February (version 3) for the above study and 
have been given a copy to keep. I have had the opportunity to ask questions, understand 
why the research is being done and any possible risks which have been explained to me. 
 
I give permission for my child to be skin prick tested to common allergens, to have a 
sample of blood taken and for a clinical check (delete as appropriate). I understand how 
the skin test will be done, and how the blood sample will be collected and that this is 
voluntary and that I am free to withdraw my approval at any time without my or my baby’s 
medical treatment or legal rights being affected. 
 
I give permission for someone from the research team to look at my child’s medical notes 
to get information pertinent to the study. I understand that the information will be kept 
confidential. 
 
I understand that my Doctor and/or I may be informed of any of the results of tests 
done as part of the research. 
 
I understand that the research may not directly benefit my child’s health. 
 
 
____________________        ____________  ______________________ 




____________________        ____________  _______________________ 
Name of Person taking consent  Date      Signature 
 
1 for patient, 1 for researcher, 1 to be kept with hospital notes.   58




Volunteer Name   
 
Height    
 
Please read through the following notes and instructions for measuring your body composition 
with the Tanita UM-014S daily for your first 14 days after delivery. Thank you. If you have any 
questions please call the SIPS research team (tel: 023 8079 6925 or 023 8079 5252 or 07864 
831283). 
 
To make these measurements as accurate as you can please could you: 
1. Undress (or wear as few clothes as possible) before stepping on the Tanita machine. 
2.  Try  to  take  the  readings  at  the  same  time  of  day  (about  3  hours  after  rising  or  eating  or 
exercise). 
3.  Try  to  keep  body  water  levels  the  same  for  each  measurement  i.e.  try  to  drink  the  same 
amount before the measurement and try to empty your bladder just before you step on the 
Tanita machine. 
 
Instructions for using the Tanita UM-014S 
 
1. Turn on the Power 
Press the Set button to turn on the machine. It will beep to confirm activation, the Personal 
data number will be displayed, and the display will flash. 
 
2. Get pen and form 
Get your form for writing down your measurements and a pen and place them close to the 
Tanita machine 
 
3. Select a Personal data Number 
Press the Up/Down buttons to select a Personal data number. Once you reach the Personal 
data number you wish to use, press the Set button. The machine will beep once to confirm. 
 
4. Set Age 
Use the Up/Down buttons to scroll through numbers. When you reach your age, press the Set 
button. The machine will beep once to confirm. 
 
5. Select Female or Male 
Use the Up/Down buttons to scroll through Female (F), Male (M) settings, then press the Set 
button. The machine will beep once to confirm. 
6. Specify the Height 
Use the Up/Down buttons to specify Height (in centimetres) and then press the Set button 
(this is written on your body weight and composition recording form). The machine will beep 
once  to  confirm.  The  machine  will  beep  twice  and  the  display  will  flash  all  data 
(Male/Female, Age, Height) three times to confirm the programming.     59
7. Step on 
After programming your personal data you are ready to take a reading. The machine 
will beep again and the display will show “0.0”. Now step onto the platform. Note: 
Once the scales are programmed you can turn the machine on with the memory button 
and press set when the machine displays your personal data number (normally 1). The 
machine will then display your data then 0.0 and is ready for you to step on. 
 
8. Write down and keep record of your readings 
Your weight will be shown first. Continue to stand on the platform. “00000” will 
appear on the display and disappear one by one from left to right. Your body fat 
percentage will appear on the display screen. Do not step off until body fat percentage 
is shown. The display will then flash your weight and body fat percentage alternately 
three times. The unit will then shut down automatically. Please write your weight and 






Weight (Kg)  Body fat (%) 
day 1     
day 2     
day 3     
day 4     
day 5     
day 6     
day 7     
day 8     
day 9     
day 10     
day 11     
day 12     
day 13     
day 14     
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16   Infant clinical assessment: skin prick testing 
(standard operating procedure (SOP)) 
1. Expose the flexor aspect of the forearm. 
 
2. Do not sterilise the skin in any way since antiseptics or alcohol temporarily impair 
the ability of the skin to react. 
 
3. Starting 2 cm from the antecubital fossa, mark out sites about 2.5 cm apart with a 
Soluprick pen, with different symbols for the different allergens. 
 
4. Place one drop of each of the allergen solutions on the forearm skin. A positive 
control (histamine) and a negative control (the allergen diluent), must also be applied 
on the same arm. 
 
5. Push a lancet through the drop of allergen or control solution at 90° to the skin, 
without drawing blood. 
 
6. Repeat the procedure for each allergen and control using a new lancet each time. 
 
7. Carefully remove the surplus fluid from all sites simultaneously by placing a paper 
tissue over the forearm. Take care not to cross contaminate the sites with other 
allergen solutions. 
 
8. The size of the wheal and flare should be measured at the time of peak response. 
This will be at 15 minutes post skin puncture. 
 
9. Measurement should be made with a skin test reaction gauge and the maximum 
wheal diameters should be noted along with the perpendicular diameters. 
 
10. A wheal diameter of at least 3 mm greater than the negative control is considered 
to be positive. 
 
Clear records of the skin test should be made including the following information: 
 
-The date 
-The name of the patient/subject 
-The name of the investigator 
-The size of the response in millimetres 
 
The following may also be recorded: 
 
-Any recent medication (please note that certain medications e.g. anti-histamines, 
affect skin reactivity and any results obtained under these conditions should be 
interpreted with this in mind). 
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17  SOP containing additional information for 
paediatric SPT. 
 
Background:  SPT  is  performed  by  introducing  a  small  amount  of  allergen, 
approximately 0.1µl of extract, into the epidermis. The immediate, type one, response 
wheal and flare reaction is a consequence of allergen-specific IgE molecules being 
cross-linked by allergen. This results in signalling via Fcε receptors on mast cells 
which  leads  to  degranulation  and  release  of  histamine,  proteases,  proteoglycans, 
prostaglandin  D2  (PGD2),  leukotriene  C4  (LTC4)  and  platelet-activating  factor 
causing a wheal and flare reaction. Histamine is considered to be the major mediator 
in the allergic wheal reaction. The wheal is caused by extravasation of serum from 
capillaries in the skin, which results from a direct effect of histamine. Pruritis and a 
larger erythematous flare accompany the wheal.  
 
Skin  prick  testing  is  a  reliable  test  to  determine  sensitivity  and  subsequent 
conformation of allergy in susceptible individuals.  
 
Purpose: To ensure that this procedure is carried out in a consistent fashion.  
 
Scope:  To ensure that skin prick testing is performed in a consistent manner using the 
same solutions (ALK Abello) and equipment. This SOP applies to any members of 
the SIPS team or SWS team who may undertake skin prick testing on infants. 
 
Responsibility: It is the responsibility of the individual members of the SIPS team 
to read and ensue they have received the necessary training to undertake skin prick 
testing on infants on the SIPS. 
 
Procedure: The procedure will be carried out as detailed on the SUHT guideline for 
skin prick testing 
 
 
Supporting Documents:  Protocol for SIPS Version 1, dated 20/02/07 
        SOP for taking Informed Consent (No 001C) 
        SUHT Policy and Procedure for Hand Washing 
DoH  Consent  –  what  you  have  a  right  to  expect.  A 
guide for Adults 




NB:  ALL  SKIN  PRICK  TEST  SOLUTIONS  MUST  BE  ORDERED  VIA 
PHARMACY  AS  THEY  ARE  CLASSED  AS  A  “PATIENT  NAMED 
TREATMENT” 
Company Name & Address:    UniDrug Distribution Ltd 
Amber Park 
Berristow Lane 
South  Normanton 
Derbyshire, DE55 2FH   62
 
Skin Prick Test Solution  Concentration  Cost (2ml vials) 
Negative Control  Saline  £8.00 
Dermatophagoides pteronyssinus  Soluprick standard quality (SQ) 
10 HEP ((Histamine Equivalent 
in Prick testing) 
£27.00 
Felix domesticus  SQ 10 HEP  £27.00 
Dog  SQ 10 HEP  £27.00 
Grass pollen mix  SQ 10 HEP  £27.00 
Tree pollen mix  SQ 10 HEP  £27.00 
Cow’s milk raw  1:20 w/v  £27.00 
Whole hen’s egg  1:100 w/v  £27.00 
Histamine (positive) control  10 mg/ml  £8.00 
 
 
Lancets:   Via Linda Jackson (IIR Research Division) IDT for supplies  
(Cases 1000/ 5 boxes 200) 
 
18 SOP for  SCORAD 
Background 
The severity of atopic dermatitis can be quantified by using a clinical measuring tool Scoring 
Atopic Dermatitis (SCORAD). SCORAD has been previously validated in other studies  
SCORAD can be completed in 10 minutes and uses a body map proforma found in the six-
month questionnaire.  
 
Purpose 
To  ensure  that  correct  and  standardised  scoring  for  eczema  severity  is  undertaken.  The 
validated SCORAD system is to be used. 
 
Scope 
SCORAD is an international validated tool used for the assessment of eczema. The following 
SOP is to be used in conjunction with the validated tool and has been written to assist the 
novice in understanding the terms and to give knowledge on how to perform the calculation in 
determining the total score. This standard operating procedure is to be used for Salmon in 
Pregnancy Study, LREC No: 07/1704/43 and used in conjunction with the protocol. This SOP 
applies to all individuals undertaking the assessment of SCORAD. 
 
No advice is to be given to parent / carer if an infant has eczema. If required, suggest they 
contact their General Practitioner or health Visitor for further advice and treatment options. 
 
Responsibilities 
It is the responsibility of the individual members of the study team to read and ensure they 
have  received  sufficient  training  and  have  been  deemed  competent  to  undertake  the 
assessment of SCORAD by the Clinical Co-Investigator (Dr Mich Lajeunesse). If any new   63
member should join the study team they will need to be trained and validated against an 




1. Explain procedure to parents. 
 
2. Obtain informed written consent using supporting documentation. 
 
3. Wash hands in accordance with SUHT guideline on hand washing. 
 
4. Undress infant and examine for signs of eczema. If present, evaluate eczema using 
SCORAD using the proforma in the six month questionnaire.  
 
5. Start the SCORAD assessment with evaluation of the extent (see definition below). Draw 
the involved areas on the evaluation sheet. 
 
Extent the atopic dermatitis covers, 
SCORAD is based on the rule of nine’s. This principle was first used for  determining  the 
severity of burns to the human body. Each arm and the head constitute 9% of the body surface 
area. The front and back of the torso and each leg constitutes 18% of body surface area thus 
giving a total body surface area  expressed as a percentage. Within the first domain the extent 
of body surface is expressed by indicating the total area involved. The size of the volunteer’s 
palm is  equivalent to 1% of body surface area. 
 
1. Continue the SCORAD assessment with evaluation of the intensity (see definitions and 
grades below). Place figures in the boxes in the table on part B of the form. Add up the 
figures and place in box B. 
 
Intensity (severity), 
a. Erythema – A reddening of the skin that disappears under pressure. 
b. Oedema/papules – Raised bumps which can be felt under the skin. This element cannot be 
evaluated only by the eye, the rash needs to be felt to establish correct graduation. 
c. Oozing/crust – oozing lesions due to skin oedema and vesiculation. 
d. Excoriation/scratch marks - Abrasions, signs of scratching and/or rubbing caused by 
mechanical trauma. 
e.  Lichenification-  thickened  and  coarse  appearance  in  chronic  rashes.  Accentuation  of 
normal  wrinkling  which  separates  into  thinner  rhomboidal  areas.  Normally  grayish  or 
brownish in colour. This is generally seen in patients over the age of 2 years of age. 
f. Skin dryness – Dry skin should be better appraised away from the inflamed areas and 
without any application of emollients or moisturizers. The dry, scaly skin coming from the 
healing of previous rashes should not be considered. Palpation is important in evaluating the 
roughness of the skin. The presence of cracked skin is usually associated with marked dryness 
in the hands and feet. 
 
 Choose a representative area to calculate the intensity of eczema. Place your figures in the 
appropriate sections on the sheet provided. These parameters are graded on a scale of 0 – 3.  
    0 = Absent 
    1 = Mild 
    2 = Moderate 
    3 = Severe 
 
The following table of grades can be used to define intensity: 
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Erythema  1. Mild  Faintly detectable, very light pink 
  2. Moderate  Dull red, clearly distinguishable 
  3. Seve re  Deep dark red 
Papules  1. Mild  Barely perceptible elevation 
  2. Moderate  Clearly perceptible elevation 
  3. Severe  Marked and extensive 
Excoriations  1. Mild  Scant  evidence  with  no  signs  of  deeper  skin 
change. 
  2. Moderate  Several  linear  marks  of  skin  with  some  showing 
evidence of deeper skin injury. 
  3. Severe  Many erosive or crusty lesions. 
Lichenification  1. Mild  Slight thickening of the skin discernable only by 
touch  and  with  skin  markings  minimally 
exaggerated. 
  2. Moderate  Definite thickening of the skin with skin markings 
exaggerated  so  that  they  form  visible  criss-cross 
pattern 
  3. Severe  Thickened  indurated  skin  with  skin  markings 
visibly  portraying  an  exaggerated  criss-cross 
pattern 
 
1. Continue the SCORAD assessment with evaluation of the subjective criteria (see definition 
below). Draw on the visual analogue scale on the evaluation sheet. Place figure in box C. 
 
Subjective symptoms of pruritis and sleep loss.  
 
Subjective criteria 
The  third  domain  is  the  subjective  scores  of  pruritus  and  sleep  loss.  The  size  of  the 
participants’ palm is equivalent to 1% of body surface area. The subjective symptoms are 
measured on a visual analogue scale between zero and ten and are an average for the last three 
days or nights. These figures are used and calculated to give a final figure expressed as a 
percentage (Kunz et al.) 
1.Calculate the proportion of involved surface area segment by segment (extent). Place figure 
in box A. 
 
2.Complete SCORAD calculations as post visit administration.  
 
3.Post Visit Administration 
 
1.Complete SCORAD as follows. Total the results for all segments. 
 
2.Make calculations using the body map form (use example cited below), and a calculator 
if needed and record on form.  
SCORAD Calculation 
The calculation is derived in the following way: 
  Extent / 5 + Intensity x 7 / 2 + Subjective Score = total 
Example – if extent (A) - 5, intensity (B) - 10 and subjective score (C) - 3, total would 
equal 39.  
    A/5 = 1 
    7B/2 = 35 
    C = 3 
    Total = 39  
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19  SIPS Neonatal Anthropometry  
 
Maternal Volunteer Number                
Date  
 
Date informed consent given 
 












Telephone – home/work 
 




  Personal Details 
 
Date of Birth                                          Gender 
 





  Anthropometry 
12  INFANT EXAMINATION 
                                       d      d        m    m        y    y 
12.1  Measurement  Date                                                          
 
 
12.2  Time (24 hr clock)                   : 
 
 
12.3  Measurer                        
 
      66
12.4  Helpers (Parent 90)  
 
 
12.5  Occipito-frontal circumference                  .         cm 
                          Crying 
                                                                           .         cm         0. No 
                      1. 
Yes 
                .         cm 
 
 
12.6  Crown-heel length                                            .         cm 
       (left leg)                     Crying 
                                                                                    .         cm    0.  No 
                      1.  
Yes 
                          .         cm 
 
 
12.7  Minimum carriage reading                              mm      
 
12.8  Anthropometer used 
 
 
12.9  Baby weight                                                    .                 kg 
  (preferably nude) 
 
12.10  Weight of any clothes / nappy                        .                 kg 
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20 Infant health and food frequency questionnaire at 6 Months of Age 
 
 
Volunteer Number                        B               
Infant’s Name   (Forename, Surname)             
Mother’s Name   (Forename, Surname)             
 
Date informed consent given 
 
Check clinical cover is in place (tick if confirmed) 
 
[Clinical cover Dr Mich Lajeunesse or Dr Woolf Walker confirm by calling PA Chris Dyche xt 4335 2 hours prior to appointment 
time (if unable to get an answer xt 4829 or 8973)] 
 
 
6 month visit check list (please tick when sample/data collected): 
 
a  Completed baby feeding and health diary 
 
b  Skin test 
 
c  Blood sample 
 
 
Note to administrators.  Questions 1 to 4 are the FFQ question and must be asked by appropriately trained staff (Maria V and Stella K). 
The front sheet and questions 4 to 9 are to be completed by designated CRF nurses or SIPS research team staff. Clinical procedures to be 
carried out by designated CRF nurses. 
 
 
          d      d         m     m        y      y 
Infant's date of birth 
 
Sex     M=Male 
    F=Female 
 
          d      d         m     m        y      y 
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I would firstly like to ask you about your baby’s feeding.  I’ll start with questions about the type of milk or formula he/she has had. 
1. Milk or Formula Feeding 
 
1.1 Did you ever put your baby to the breast, even for a single feed? 
0.  No 
1.  Yes go to 1.3 
 
1.2 *Was this? : 
1.  Personal choice 
2.  Because you were unwell 
3.  Because the baby was too small or unwell 
8.  Any other reason (e.g. advised not to; problems with previous baby) 
 
Then go to 1.10 
 
1.3 Did you ever require antibiotic injections, tablets or surgery for mastitis or a breast abscess? 
0.  No 
1.  Yes 
 
1.4 Are you still breast feeding? 
0.  No 
1.  Yes go to 1.6 
 
1.5 How old was your baby when he/she last had a breast feed? Note: refer to volunteer’s infant feeding diary if possible. 
 
           mths          wks           days 
or 
On what date did he/she last have a breast feed?   d      d         m     m        y      y 
 
Go to 1.8 
 
 
1.6 *What is the main reason for continuing to breast feed? 
1 Enjoyment 
2 Best for baby / prevention of allergies 
3 Cheaper 
4 Baby prefers it or refuses other feeds 
5 Convenience 
6 Any other / multiple reasons, e.g. help lose weight, so sleeps through night 
 
1.7 Except for breast milk, has he/she ever had any other milk or formula in a bottle or cup or for mixing with solid foods, eg rusks? 
 
0.  No    go to section 2 

























1.8 How old was your baby when he/she started regularly having other milk or formula feeds from a bottle or cup or for mixing with 
solid foods? Note: refer to volunteer’s infant feeding diary if possible. 
 
 
mths          wks           days 
or 
On what date did he/she start regularly having milk or formula feeds?  




1.9 *What was the main reason for starting other milk or formula feeds? 
1.  Return to work 
2.  Breastfeeding took too long or was too tiring 
3.  Convenience or to allow others in the family to feed 
4.  To try and get him/her to sleep through the night 
5.  The right time/age to change 
6.  Insufficient milk to satisfy the baby 
7.  Baby wouldn’t suck because unwell or low birth weight 
8.  Baby wouldn’t suck or not interested – no apparent reason 
9.  Baby irritable or colicky, or not gaining weight 
10.  Painful breasts / sore nipples / mastitis / breast abscess 
11.  Milk dried up 
12.  To mix with cereals/dried foods 
88.  Any other reason / multiple reasons 
e.g. mother unwell, inverted nipples, not enjoying it, bitten by baby 
 
1.10*Please tell me which types of milk or formula you have used and what age your baby was when it was started and stopped or on 
what date it was started and stopped. Note: refer to volunteer’s infant feeding diary if possible. 
 
Use 88’s if still using 
Name of formula   Formula 
code 






Mths  wks  days  mths  wks  days 
                   
                   
                   
                   
                   
 Version 1, 7 May 2008     Page  of 86      Ethics Number: 07/Q1704/43 
 
70
2. Food Frequency Questionnaire 
 
I am now going to ask you about the milk or formula your baby has had in the past week. 
 
If no breast feeding in the past 7 days go to 2.5 
 
2.1 Not including expressed breast milk, can you tell me how many days out of the past 7 days he/she was breast fed?  On average, 
how many feeds per day did he/she receive on these days?  How long on average was he/she actively sucking per day on these days? 
Note: refer to volunteer’s infant feeding diary if possible. 
 
Number of days in the past 7 
days 
Number of feeds per day  Average time actively 
sucking per day 
 
 
          hrs                  mins 
 
2.2 In the past 7 days did he/she have any expressed breast milk? 
0.  No    go to 2.4 
1.  Yes 
 
2.3 How many days out of the past 7 days did he/she have expressed breast milk?  On average, how many times per day did he/she 
have expressed breast milk on these days?  What was the average amount of milk per day on these days? 
 
How many days out of the 
past 7 
How many times 
per day 
Volume per day 
oz  mls 
 
 
       
. 
           
 
 
2.4 In the past week did he/she have any other milk or formula except breast milk?  Include any milk used for mixing with food. 
Note: refer to volunteer’s infant feeding diary if possible. 
0.  No    go to 2.6 
1.  Yes 
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2.5*Can you tell me the types of milk or formula he/she has had in the past 7 days? How many days out of the past 7 days was type 
of milk given? How many times per day was type of milk given? What was the average amount of type of milk per day on these 
days? Note: refer to volunteer’s infant feeding diary if possible. Repeat for any other types of milk used. 
 




days out of 





Volume per day 
oz  mls 
 
 
           
. 
           
 
 
           
. 
           
 
 
           
. 
           
 
 
           
. 
           
Have you included any milk used for mixing with food?  If no, adjust table above. 
 
2.6 Now I am going to ask you about the foods your baby has eaten in the past week.  I will ask you how many times he/she has eaten 
certain foods and also the amount of food eaten.  You should only include food actually eaten, do not include food that was left over 
or spilled.  I have a list of foods, many of which may not have been eaten in the past week or ever.  You may also find that foods your 













Average amount on each 
occasion 
1  Pure baby rice, not including fruit 
flavoured rice 
      No. of 
tablespn 
dried 
  .     
      .     
      .     
2  Other dried baby cereals        No. of 
tablespn 
dried 
  .     
      .     
      .     
3  Rusks        No. of 
rusks 
  .     
      .     
      .     
  Were they  
1.  Original               3.  Savoury 
2.  Reduced sugar    4.  Gluten free 




*2.7 Did your baby eat any other dried baby foods in the past week?  0.  No  go to 2.9 














Average no. of 
tablespoons dried on 
each occasion 
4  Dried meat or fish based meals           .     
      .     
      .     
5  Dried vegetable, pasta or rice based meals          .     
      .     
      .     
6  Dried desserts          .     
      .     
      .     
 
2.9*Did your baby eat any jars, tins or pots of baby foods in the past week? 
0.  No  go to 2.11 













jar/tinΑ Α Α Α 
Average number of  
jars on each 
occasion 
7  Breakfast meals such as porridge            .     
        .     
        .     
8  Meat or fish based meals            .     
        .     
        .     
9  Vegetable, pasta or rice based 
savoury meals 
          .     
        .     
        .     
10  Milk or cereal based desserts            .     
        .     
        .     
11  Fruit based desserts, not including 
pure fruit puree 
          .     
        .     
        .     
12  Pure fruit puree            .     
        .     
        .     
1 = Small jars (100-150 g)  Usually from 4 months 
2 = Medium jars (160-200 g)  Usually from 7 months 
3 = Large jars (220-250 g)  Usually from 12 months (toddlers) 
 
2.11*Did your baby eat anything else apart from these ready made baby foods in the past week? 
0.  No    go to 2.13 



















Food  No. of 
times in 
past wk 
Average amount on each occasion 
13  Weetabix or other wheat bisks    No. of biscuits 
                                . 
14  Other cereals, not including Weetabix or baby cereals    No. of tbsp 




Food  No. of 
times in 
past wk 
Average number of 
tablespoons on each 
occasion 
15  Potatoes 
 
    .     
16  Rice 
 
    .     
17  Pasta including tinned spaghetti 
 
    .     
18  Meat 
 
    .     
19  Fish 
 
    .     
20  Beans and pulses, including baked beans, kidney beans, 
chick peas and lentils 
    .     
21  Other vegetables 
 




Food  No. of 
times in 
past wk 
Average amount on each occasion 
22  Yogurt and fromage frais 
 
  Weight (grams) 
small pot approx 50g 
avge pot approx 100g 
1)   Ordinary wholemilk 
2)   Low fat 
3)  Danone baby fromage frais with  
      follow on milk 
 
4)  Onky Blok fromage frais with  
Added vitamins  
5)   Tescos fromage frais with added vitamins 
88) Other (specify) 
…………………………………      for multiple types use 77 
23  Cooked fruit    No. of tbsp 
                                 . 
24  Banana 
 
  No. of bananas 
                                 . 
25  Other fresh fruit:(1 serving = 1 apple/peach/pear  2 
apricot/plum, 10 strawberry, 25 cherry/ grape) 
  No. of servings 
                                 . 
26  Bread or toast    No. of slices 
                                 . 
27  Crackers or breadsticks 
(Ritz size = 1            Cream cracker size = 2) 
(Baby breadstick = 0.3       Adult b’stick = 2) 
  No. of crackers 
or breadsticks           . 
 
28  Biscuits 
 
  No. of biscuits 
                                 . 









2.15*Did your baby have anything else to drink apart from milk or formula in the past week? 
0.  No    go to 2.15 












Volume  (oz) on each 
occasion 
29  Baby fruit juice 
(for concentrate, use vol. After standard 
dilution)) 
          .     
        .     
        .     
30  Baby herbal drinks            .     
        .     
        .     
31  Squash, not including diet drinks labelled 
low calorie or low sugar 
         
. 
   
  Was it    1.  Ribena or hi juice blackcurrant 
              8.  Other 
32  Diet squash labelled low calorie or low 
sugar 
        .     
  Was it         1.  Low sugar Ribena         8.  Other 
                   2.  Really Light Ribena 
33  Tea 
Volume of tea not including milk 
         
. 
   
34  Water 
Not including water used to mix with food or 
drink which must have water added, such as 
squash and dried baby food 
         
. 
   
 
2.17*Is there anything else he/she has had to eat or drink in the past week that we have not already included?  Here is a list to help 
remind you about foods which he/she may have had but if there are any others which are not on the list please let me know what 
these are. 
0.  No    go to section 3 
1.  Yes 
2.18 
Brand/Description  No. of 
times in 
past wk 
Portion size  Code  Weight 
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2.19 If fish consumed in question 2.12, record details of types and frequencies of fish below. 
 
Note: Check if number of times in past week entered below agrees with previous answer for this question i.e. question 2.12 food code 19. 
 
 NAME OF FOOD/DRINK  CODE 
Portion size  Number of 
times in past 
week 
       
       
       Version 2, 18 March 2008     Page 76 of 86      Ethics Number: 07/Q1704/43 
 
2.20 DIETARY QUESTIONS ON FOOD ITEMS FORTIFIED WITH ESSENTIAL FATTY ACIDS, PROBIOTICS, PREBIOTICS 
 
We are particularly interested in your baby’s consumption of food items with added omega-3, omega-6, probiotics or prebiotics.  I have a list of food items that have 
these things added to help you remember the specific products the baby might have consumed. Are any of there foods or drinks with added omega-3, omega-6, 
probiotics or prebiotics that the baby has eaten or drunk in the past week?  
 
                                  0.No/1. Yes 
   
If Yes 
NAME OF FOOD/DRINK  CODE 
Portion  Number of 
times in last 
week 
       
       
       
       
       




3. Introduction of foods and supplement use 
Now I’d like to ask you about when various foods were first introduced to your baby. Note: refer to 
volunteer’s infant feeding diary if possible. 
 
3.1 How old was he/she when solids were first regularly introduced?       
                    




On what date were solids first regularly introduced? 
 
 D      d       m     m           y      y 
 
3.2What was the first solid food he/she regularly ate? 
Use the FFQ list to prompt and code this 
Use 88 for multiple foods 
 
3.3During the past 3 months have you given him/her any vitamins or mineral drops, including iron 
and fluoride drops? 
0.  No    go to 3.5 
1.  Yes 
 
3.4 If yes, please state which: 
Supplement Name  Code  How 
many days 





Did he/she start this: 
1: Less than 1 mth ago 
2: 1-2 months ago 
3: More than 2 mths ago 
 
 
       
 
 
       
 
 
       
 
 
       
 
3.5 During the past three months have you taken any pills, tonics or tablets to supplement your diet?  
(e.g.  vitamins, minerals, iron tablets, folic acid, fish oils etc.) 
0.  No    go to section 4 
1.  Yes 
 













Did you start this: 
1: Less than 1 mth ago 
2: 1-2 months ago 
3: More than 2 mths ago 
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4. BABY’S ILLNESSES 
 
I would just like to ask a few questions about any illnesses the baby might have had at any stage since 
he/she was born.  (Prolonged period with <1 week break between bouts - enter 88) Note: refer to 
volunteer’s infant health diary if possible. 
 
4.1 Has he/she had any episodes of chestiness associated with wheezing or whistling in his/her 
chest?  (includes wheezy bronchitis, asthma)     
   No     0.     go to 4.3 
   Yes -  number of times  
        
4.2 How old was he/she at the start of the first episode?             mths          wks          days 
 
4.3 Other than during the first week of a cold has he/she ever woken at night with coughing for 3 or 
more nights in a row? 
  0.  No  
  1.  Yes                
 
4.4 *Over the last 3 months, (90 days) on roughly how many days has he/she had a cough, cold or 
runny nose?                           
0.  None 
1.  1-15 days 
2.  16-30 days 
3.  31-45 days 
4.  45 days or more (more than half the time)  
 
4.5 Has he/she ever been diagnosed by a doctor as having had pneumonia or bronchiolitis?  (don't 
include bronchitis or "chest infection") 
    No     0. 
    Yes – number of times 
 
4.6 Has he/she ever been diagnosed by a doctor as having had a chest infection or bronchitis ?   
(includes wheezy bronchitis) 
    No     0.     
    Yes – number of times   
 
4.7 Has he/she had any episodes of croup or a croupy cough ? 
  (i.e. a barking cough worse at night)      
    No     0. 
    Yes – number of episodes   
 
4. 8 Has he/she had any bouts of vomiting lasting 2 days or longer ? 
  (do not include possetting or regurgitation)  
    No     0.     
    Yes – number of bouts  
 
4.9 Has he/she had any bouts of diarrhoea lasting 2 days or longer? 
  (probe; diarrhoea=frequent unformed stools)   
    No     0. 
    Yes – number of bouts   
 
 
4.10 Has he/she ever been diagnosed by a doctor as having an ear infection? 
    No     0.          




4.11 Has he/she had an itchy skin condition at any time since birth - by itchy we mean scratching or 
rubbing the skin a lot?        (exclude chicken pox) 
0.  No   go to 4.14 
1.  Yes  
 
4.12 Has this skin condition ever affected the cheeks, the outer arms or legs, or the skin creases in the 
past - by skin creases we mean the folds of the elbows, behind the knees, the fronts of the ankles, or 
around the eyes?                      
0.  No  
1.  Yes   
 
4.13 How old was he/she when the rash first appeared?            mths            wks            days     
  
4.14 Has he/she suffered from a generally dry skin? 
(do not include a dry skin in the immediate postnatal period)    
0.  No  
1.  Yes  
8.  To a minor degree 
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4.15*Has he/she had a scaly, or red and weeping skin rash affecting any of the following areas at 
any time since birth: 
 
  A) the scalp or behind the ears (including "cradle cap") 
0.  No  
1.  Yes 
      
  B) around the neck                        
0.  No  
1.  Yes 
 
       C) the cheeks or forehead             
0.  No  
1.  Yes                   
 
       D) either the folds of the elbows or behind the knees 
0.  No  
1.  Yes 
 
       E) the forearms, wrists, shins or ankles 
0.  No  
1.  Yes 
        
  F) the shoulders, chest, tummy or back     
0.  No   
1.  Yes 
  
      G) in the armpits                             
0.  No  
1.  Yes 
 
      H) the nappy area (including nappy rash)  
0.  No 
1.  Yes 
If yes to (C), (D), (E), (F) or (G), 
have you ever been able to clearly link a rash on his/her face, trunk or limbs with teething 
0.  No 
1.  Yes      
     
or with specific foods        
0.  No go to 4.17 
1.  Yes   
 
4.16 If yes, which foods?_____________________________________________________ 
 
4.17 Was he/she born with any health problems or abnormalities? 
0.  No go to section 5 
1.  Yes 
 
4.18 What is the problem?  ____________________________________ 
       
      _____________________________________ 




One of the things we are trying to determine is 
why  some  children  become  allergic  to  cats  & 
dogs whereas many others don't. 
 
5.1I would first like to ask whether you have kept a cat 
at home at any time since your baby was born 
0.  No  go to 5.3 
1.  Yes 
 
5.2 If yes, and offered, is the cat kept:   if yes & 
not offered, go to 5.5 
1.  Only in a separate room   go 
to 5.5 
2.  Only outside the house 
  go to 5.5 
 
5.3 *How often has he/she visited homes that keep a 
cat or cats over the last 6 months. 
0.  Never 
1.  Infrequently (once a month or 
less) 
2.  Fairly  frequently  (several 
times a month) 
3.  Frequently  (several  times  a 
week) 
4.  Every day or almost every day 
 
5.4 If yes, and offered, is the cat kept: 
1.  Only in a separate room  
2.  Only outside the house 
 
5.5 And similarly, have you kept a dog at home at any 
time since your baby was born? 
0.    No    go to 5.7 
1.  Yes  
 
If yes, and offered, is the dog kept:    if 
yes & not offered, go to section 6 
1.  Only in a separate room   go 
to section 6 
2.  Only outside the house   go 
to section 6 
 
5.6*How often has he/she visited homes that keep a 
dog or dogs over the last 6 months. 
0.  Never 
1.  Infrequently (once a month or 
less) 
2.  Fairly  frequently  (several 
times month) 
3.  Frequently  (several  times  a 
week) 
4.  Every day or almost every day 
 
5.7If yes, and offered, is the dog kept: 
1.  Only in a separate room  
2.  Only outside the house 
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6. HOUSEHOLD HEATING 
 
6.1*How is your flat/house principally heated? 
1.  Gas central heating 
2.  Ducted central heating 
3.  Under floor heating 
4.  Night storage heaters 
5.  Coal/wood open fires 
6.  Coal/wood burners 
7.  Gas fires 
8.  Electric fires/heaters 
9.  Paraffin/kerosene heaters 
10. Oil central heating 
11. Other, specify 
 _______________________________ 
 
6.2  Is the room where your child usually sleeps 
heated in this way? 
0.  No 
1.  Yes   go to section 7 
 
6.3  *How is the room heated where your child 
usually sleeps? 
1.  Gas central heating 
2.  Ducted central heating 
3.  Under floor heating 
4.  Night storage heaters 
5.  Coal/wood open fires 
6.  Coal/wood burners 
7.  Gas fires 
8.  Electric fires/heaters 
9.  Paraffin/kerosene heaters 
10. Oil central heating 




7. SLEEPING ARRANGEMENTS 
 
7.1*Does he/she sleep mainly 
1.  in the same bedroom as brothers or sisters 
2.  in the same bedroom as parents 
3.  in his/her own bedroom   
8.  other, specify 
 ________________________________ 
 
7.2 How many times per night (between midnight and 
6am) does he/she generally wake for feeding or any 
other reason?Please answer this in relation to the last 
2 weeks?        .






8.1 Are you currently smoking? 
0.  No  go to 8.5   
1.  Yes  
 
If yes, and offered, is it: 
1.  Only in a separate room 
2.  Only outside the house 
 
How many per day? 
  
8.2What is your current brand?   
_______________________________  
 
8.3Does anyone else smoke in the flat/house, or is 
he/she ever looked after more 
  than once a week by anyone who smokes ?   
0.  No   
1.  Yes    
 
8.4 If yes, and offered, is it: 
1.  Only in a separate room 
2.  Only outside the house 
 
9. INFANT CLINICAL EXAMINATION 
 










Topical Steroid use: 
Potency (brand name)………………………….. 
 
Amount / month……………………………….. 
 
Number of flares / month ………………… 
 




CRITERIA  INTENSITY 
Erythema   
Oedema/Papulation   
Oozing/Crust   
Excoriation   
Lichenification   
Dryness (evaluated on uninvolved areas)   
 
 
Means of calculation 
Intensity Items 
(average representative area) 
0 = absence 
1 = mild 
2 = moderate 





C: Subjective symptoms. Pruritis + sleep loss 
 
 
Visual analogue scale (average for the last 3 days or nights) 
 
Pruritis  (1-10) 
 
Sleep Loss (1-10)   
0  10 
SCORAD A/5 + 7B/2 + C 
             
 
             
9.2  Baby length: ........ cm 
   
 
9.3  Baby weight : ........ kg 
   
 
 
9.4 Has your baby been given any medication, prescription (i.e. antibiotics) or non-
prescription (i.e. infacol, Calpol) used in the last 4 weeks? 
 






If yes to 9.4 please give details below 
Therapy  Dose route and regimen  Date started  Date stopped 
 
 
9.5 Has your baby had any injections or immunisations? 
0  No  





If yes to 9.5 please give details below 
 
     1st Immunisations    2nd Immunisations  3rd Immunisations 
 
Polio       
HIB/Diphtheria/Tetanus       
Whooping cough       
Meningitis       
Other – Name…………..       
Other – Name…………..       
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Skin Test Results 
 













House dust mite 













































Thank you for giving us this information 
 